Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases

ABSTRACT

The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for treatment of vasopressin-related disorders.

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a National Stage of International Patent Application No.PCT/EP2014/078699 filed on Dec. 19, 2014, which claims priority to U.S.Patent Application No. 61/919,281, filed on Dec. 20, 2013, the entirecontents of which are incorporated herein by reference.

The present invention relates to novel substituted oxindole derivatives,pharmaceutical compositions comprising them, and their use for thetreatment of vasopressin-related disorders.

Vasopressin is an endogenous hormone which exerts various effects onorgans and tissues. It is suspected that the vasopressin system isinvolved in various pathological states such as, for example, heartfailure and high blood pressure. At present, three receptors (V1a, V1bor V3 and V2) via which vasopressin mediates its numerous effects areknown. Antagonists of these receptors are therefore being investigatedas possible new therapeutic approaches for the treatment of diseases (M.Thibonnier, Exp. Opin. Invest. Drugs 1998, 7(5), 729-740; T. Ryckmans,Current Opinion in Drug Discovery & Development 13 (2010), 538-547; G.Decaux et al., Lancet 371 (2008), 1624-1632; R. Lemmens-Gruber, M.Kamyar, Cell. Mol. Life Sci. 63 (2006), 1766-1779).

1-(Het)Arylsulfonyl-1,3-dihydro-2H-indol-2-ones have previously beendescribed as ligands of vasopressin receptors, for example in WO2005/030755, WO 2006/005609, WO 2006/080574, WO 2008/080970, WO2008/080971, WO 2008/080972, WO 2008/080973, WO 2009/071687, WO2009/071689, WO 2009/071690, WO2009/071691, WO 2009/083559, WO2010/009775 or WO 2010/142739.

Besides the binding affinity for the vasopressin V1b receptor, furtherproperties may be advantageous for the treatment and/or prophylaxis ofvasopressin-related disorders, such as, for example:

1.) a selectivity for the vasopressin V1b receptor compared with thevasopressin V1a receptor, i.e. the quotient of the binding affinity forthe V1a receptor (Ki(V1a) (determined in the unit “nanomolar (nM)”) andthe binding affinity for the V1b receptor (Ki(V1b)) (determined in theunit “nanomolar (nM)”). A larger quotient Ki(V1a)/Ki(V1b) means agreater V1b selectivity;

2.) a selectivity for the vasopressin V1b receptor compared with thevasopressin V2 receptor, i.e. the quotient of the binding affinity forthe V2 receptor (Ki(V2) (determined in the unit “nanomolar (nM)”) andthe binding affinity for the V1b receptor (Ki(V1b)) (determined in theunit “nanomolar (nM)”). A larger quotient Ki(V2)/Ki(V1b) means a greaterV1b selectivity;

3.) a selectivity for the vasopressin V1b receptor compared with theoxytocin OT receptor, i.e. the quotient of the binding affinity for theOT receptor (Ki(OT) (determined in the unit “nanomolar (nM)”) and thebinding affinity for the V1b receptor (Ki(V1b)) (determined in the unit“nanomolar (nM)”). A larger quotient Ki(OT)/Ki(V1b) means a greater V1bselectivity.

4.) the metabolic stability, for example determined from the half-lives,measured in vitro, in liver microsomes from various species (e.g. rat orhuman);

5.) no or only low inhibition of cytochrome P450 (CYP) enzymes:cytochrome P450 (CYP) is the name for a superfamily of heme proteinshaving enzymatic activity (oxidase). They are also particularlyimportant for the degradation (metabolism) of foreign substances such asdrugs or xenobiotics in mammalian organisms. The principalrepresentatives of the types and subtypes of CYP in the human body are:CYP 1A2, CYP 2C9, CYP 2D6 and CYP 3A4. If CYP 3A4 inhibitors (e.g.grapefruit juice, cimetidine, erythromycin) are used at the same time asmedicinal substances which are degraded by this enzyme system and thuscompete for the same binding site on the enzyme, the degradation thereofmay be slowed down and thus effects and side effects of the administeredmedicinal substance may be undesirably enhanced;

6.) a suitable solubility in water (in mg/ml);

7.) suitable pharmacokinetics (time course of the concentration of thecompound of the invention in plasma or in tissue, for example brain).The pharmacokinetics can be described by the following parameters:half-life (in h), volume of distribution (in 1·kg−1), plasma clearance(in 1·h−1·kg−1), AUC (area under the curve, area under theconcentration-time curve, in ng·h·1−1), oral bioavailability (thedose-normalized ratio of AUC after oral administration and AUC afterintravenous administration), the so-called brain-plasma ratio (the ratioof AUC in brain tissue and AUC in plasma);

8.) no or only low blockade of the hERG channel: compounds which blockthe hERG channel may cause a prolongation of the QT interval and thuslead to serious disturbances of cardiac rhythm (for example so-called“torsade de pointes”). The potential of compounds to block the hERGchannel can be determined by means of the displacement assay withradiolabelled dofetilide which is described in the literature (G. J.Diaz et al., Journal of Pharmacological and Toxicological Methods, 50(2004), 187 199). A smaller IC50 in this dofetilide assay means agreater probability of potent hERG blockade. In addition, the blockadeof the hERG channel can be measured by electrophysiological experimentson cells which have been transfected with the hERG channel, by so-calledwhole-cell patch clamping (G. J. Diaz et al., Journal of Pharmacologicaland Toxicological Methods, 50 (2004), 187-199).

It was therefore an object of the present invention to provide compoundsfor the treatment or prophylaxis of various vasopressin-relateddiseases. The compounds were intended to have a high activity andselectivity, especially a high affinity and selectivity vis-à-vis thevasopressin V1b receptor. In addition, the substance of the inventionwas intended to have one or more of the aforementioned advantages 1.) to8.).

The object is achieved by compounds of the formula I

wherein

-   X¹ is N or CH;-   X² is C—R¹ or N;-   R¹ and R², independently of each other, are selected from hydrogen,    halogen, cyano, C₁-C₃-alkyl, fluorinated C₁-C₃-alkyl,    C₁-C₃-hydroxyalkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy;-   R³ is selected from hydrogen, halogen, cyano, hydroxyl, C₁-C₃-alkyl,    fluorinated C₁-C₃-alkyl, C₁-C₃-hydroxyalkyl, C₁-C₃-alkoxy and    fluorinated C₁-C₃-alkoxy;-   R⁴ is selected from C₁-C₃-alkoxy;-   R⁵ is selected from hydrogen and C₁-C₃-alkoxy;-   R⁶ is selected from cyano and halogen;-   R⁷ is selected from hydrogen, halogen and cyano;-   R⁸ is selected from hydrogen, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl,    C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl,    C₃-C₇-cycloalkyl, C₃-C₇-halocycloalkyl and phenyl which may carry 1,    2 or 3 substituents selected from halogen, hydroxyl, cyano,    C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy;-   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl,    C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,    C₃-C₇-cycloalkoxy, C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio,    C₁-C₄-haloalkylthio, C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl,    C₁-C₄-alkylsulfonyl, C₁-C₄-haloalkylsulfonyl, phenoxy, where the    phenyl moiety may carry 1, 2 or 3 substituents selected from    halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy    and C₁-C₄-haloalkoxy; and a 3-, 4-, 5-, 6- or 7-membered saturated,    partially unsaturated or maximally unsaturated heterocyclic ring    containing 1, 2 or 3 heteroatoms or heteroatom groups selected from    O, N, S, NO, SO and SO₂ as ring members, where the heterocyclic ring    may carry 1, 2 or 3 substituents selected from halogen, hydroxyl,    cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and    C₁-C₄-haloalkoxy; or    -   R⁸ and R⁹, together with the nitrogen atom they are bound to,        form a 3-, 4-, 5-, 6- or 7-membered saturated, partially        unsaturated or maximally unsaturated heterocyclic ring, where        the heterocyclic ring may contain 1 or 2 further heteroatoms or        heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring        members, and where the heterocyclic ring may carry 1 or 2        substituents R¹² and/or 1 or 2 substituents R¹³; where in case        that the heterocyclic ring does not contain 1 or 2 further        heteroatoms or heteroatom groups as ring members, the        heterocyclic ring carries 1 or 2 substituents R¹² and optionally        1 or 2 substituents R¹³;-   R¹⁰ and R¹¹, independently of each other and independently of each    occurrence, are selected from halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl,    C₁-C₄-alkoxy and C₁-C₄-haloalkoxy, with the proviso that R¹⁰ and R¹¹    are not halogen, C₁-C₄-alkoxy or C₁-C₄-haloalkoxy if they are bound    to a carbon atom in α-position to a nitrogen ring atom; or    -   two non-geminal radicals R¹⁰ form together a group —(CH₂)_(n)—,        where n is 1, 2, 3 or 4, where 1 or 2 hydrogen atoms in this        group may be replaced a methyl group; or    -   two non-geminal radicals R¹¹ form together a group —(CH₂)_(n)—,        where n is 1, 2, 3 or 4, where 1 or 2 hydrogen atoms in this        group may be replaced a methyl group;-   each R¹² is independently selected from halogen, hydroxyl,    C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₇-cycloalkoxy,    C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkylthio,    C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl, C₁-C₄-alkylsulfonyl,    C₁-C₄-haloalkylsulfonyl, phenoxy, benzyloxy, where the phenyl moiety    in the two last-mentioned radicals may carry 1, 2 or 3 substituents    selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,    C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; and a 3-, 4-,    5-, 6- or 7-membered saturated, partially unsaturated or maximally    unsaturated heterocyclic ring containing 1, 2 or 3 heteroatoms or    heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring    members, where the heterocyclic ring may carry 1, 2 or 3    substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,    C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy;    -   or    -   two radicals R¹², together with the atom(s) they are bound to,        form a 3-, 4-, 5-, 6- or 7-membered saturated, partially        unsaturated or maximally unsaturated heterocyclic ring        containing 1, 2 or 3 heteroatoms or heteroatom groups selected        from O, N, S, NO, SO and SO₂ as ring members, where the        heterocyclic ring may carry 1, 2 or 3 substituents selected from        halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl,        C₁-C₄-alkoxy and C₁-C₄-haloalkoxy;-   each R¹³ is independently selected from halogen, hydroxyl, cyano,    C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl,    C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₃-C₇-cycloalkyl,    C₃-C₇-halocycloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,    C₃-C₇-cycloalkoxy, C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio,    C₁-C₄-haloalkylthio, C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl,    C₁-C₄-alkylsulfonyl, C₁-C₄-haloalkylsulfonyl, C₁-C₄-alkylcarbonyl,    C₁-C₄-haloalkylcarbonyl, phenyl, phenoxy and a 3-, 4-, 5-, 6- or    7-membered saturated, partially unsaturated or maximally unsaturated    heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom    groups selected from O, N, S, NO, SO and SO₂ as ring members, where    the phenyl moieties or the heterocyclic ring may carry 1, 2 or 3    substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,    C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy;-   a is 0, 1 or 2; and-   b is 0, 1, 2, 3 or 4;    and the N-oxides, stereoisomers and pharmaceutically acceptable    salts thereof, and the compound of the formula I, wherein at least    one of the atoms has been replaced by its stable, non-radioactive    isotope.

Accordingly, the present invention relates to compounds of the formula I(also “compounds I” hereinafter) and the N-oxides, stereoisomers and thepharmaceutically acceptable salts of the compounds I of the compounds I.

In another aspect, the invention relates to a pharmaceutical compositioncomprising a therapeutically effective amount of at least one compoundof formula I or an N-oxide, a stereoisomer or a pharmaceuticallyacceptable salt thereof, or comprising at least one compound as definedabove or below wherein at least one of the atoms has been replaced byits stable, non-radioactive isotope, preferably wherein at least onehydrogen atom has been replaced by a deuterium atom, in combination withat least one pharmaceutically acceptable carrier and/or auxiliarysubstance.

In yet another aspect, the invention relates to a compound of formula Ior an N-oxide, a stereoisomer or a pharmaceutically acceptable saltthereof for use as a medicament.

In yet another aspect, the invention relates to a compound of formula Ior an N-oxide, a stereoisomer or a pharmaceutically acceptable saltthereof for the treatment and/or prophylaxis of vasopressin-relateddiseases, especially of disorders which respond to the modulation of thevasopressin receptor, in particular of the V1b receptor.

In yet another aspect, the invention relates to the use of a compound offormula I or of an N-oxide, a stereoisomer or a pharmaceuticallyacceptable salt thereof for the manufacture of a medicament for thetreatment and/or prophylaxis of vasopressin-related diseases; especiallyof disorders which respond to the modulation of the vasopressinreceptor, in particular of the V1b receptor.

The pharmaceutically acceptable salts of compounds of the formula I,which are also referred to as physiologically tolerated salts, areordinarily obtainable by reacting the free base of the compounds I ofthe invention (i.e. of the compounds I according to structural formulaI) with suitable acids. Examples of suitable acids are listed in“Fortschritte der Arzneimittelforschung”, 1966, Birkhauser Verlag, vol.10, pp. 224-285. These include for example hydrochloric acid, citricacid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid,acetic acid, trifluoroacetic acid, formic acid, maleic acid and fumaricacid.

Halogen in the terms of the present invention is fluorine, chlorine,bromine or iodine, preferably fluorine, chlorine or bromine andespecially fluorine or chlorine.

C₁-C₃-Alkyl is a linear or branched alkyl radical having 1 to 3 carbonatoms, such as methyl, ethyl, n-propyl or isopropyl. C₁-C₄-Alkyl is alinear or branched alkyl radical having 1 to 4 carbon atoms, such asmethyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl ortert-butyl.

Fluorinated alkyl is a straight-chain or branched alkyl group havingfrom 1 to 4 (=fluorinated C₁-C₄-alkyl), in particular 1 to 3 carbonatoms (=fluorinated C₁-C₃-alkyl), more preferably 1 or 2 carbon atoms(=fluorinated C₁-C₂-alkyl), wherein at least one, e.g. 1, 2, 3, 4 or allof the hydrogen atoms are replaced by fluorine atoms. Examples forfluorinated C₁-C₂-alkyl are fluoromethyl, difluoromethyl,trifluoromethyl, 1-fluoroethyl, (R)-1-fluoroethyl, (S)-1-fluoroethyl,2-fluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl,2,2,2-trifluoroethyl, pentafluoroethyl and the like. Examples forfluorinated C₁-C₃-alkyl are, apart those mentioned above for fluorinatedC₁-C₂-alkyl, 1-fluoropropyl, (R)-1-fluoropropyl, (S)-1-fluoropropyl,2-fluoropropyl, 3-fluoropropyl, 1,1-difluoropropyl, 2,2-difluoropropyl,3,3-difluoropropyl, 3,3,3-trifluoropropyl, 2-fluoropropyl,2-fluoro-1-methylethyl, (R)-2-fluoro-1-methylethyl,(S)-2-fluoro-1-methylethyl, 2,2-difluoro-1-methylethyl,(R)-2,2-difluoro-1-methylethyl, (S)-2,2-difluoro-1-methylethyl,1,2-difluoro-1-methylethyl, (R)-1,2-difluoro-1-methylethyl,(S)-1,2-difluoro-1-methylethyl, 2,2,2-trifluoro-1-methylethyl,(R)-2,2,2-trifluoro-1-methylethyl, (S)-2,2,2-trifluoro-1-methylethyl,2-fluoro-1-(fluoromethyl)ethyl, 1-(difluoromethyl)-2,2-difluoroethyl andthe like. Examples for fluorinated C₁-C₄-alkyl are, apart thosementioned above for fluorinated C₁-C₃-alkyl, 1-fluorobutyl,(R)-1-fluorobutyl, (S)-1-fluorobutyl, 2-fluorobutyl, 3-fluorobutyl,4-fluorobutyl, 1,1-difluorobutyl, 2,2-difluorobutyl, 3,3-difluorobutyl,4,4-difluorobutyl, 4,4,4-trifluorobutyl, and the like.

C₁-C₄-Haloalkyl is C₁-C₄-alkyl as defined above wherein at least one,e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by a halogenatom. Examples are, apart those mentioned above for fluorinatedC₁-C₄-alkyl, chloromethyl, bromomethyl, dichloromethyl, trichloromethyl,chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl,1-chloroethyl, 1-bromoethyl, 2-chloro-2-fluoroethyl,2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl,2,2,2-trichloroethyl, 3-chloropropyl, 4-chlorobutyl and the like.

C₁-C₃-Hydroxyalkyl is C₁-C₃-alkyl as defined above wherein one of thehydrogen atoms is replaced by a hydroxyl group. Examples arehydroxymethyl, 1- and 2-hydroxyethyl, 1-, 2- and 3-hydroxy-n-propyl,1-(hydroxymethyl)-ethyl and the like.

C₃-C₇-Cycloalkyl is a monocyclic saturated hydrocarbon radical having 3to 7, in particular 3 to 6 (“C₃-C₆-cycloalkyl”) or 3 to 5(“C₃-C₅-cycloalkyl”) or 3 to 4 (“C₃-C₄-cycloalkyl”) carbon atoms.Examples of C₃-C₄-cycloalkyl comprise cyclopropyl and cyclobutyl.Examples of C₃-C₅-cycloalkyl comprise cyclopropyl, cyclobutyl andcyclopentyl. Examples of C₃-C₆-cycloalkyl comprise cyclopropyl,cyclobutyl, cyclopentyl and cyclohexyl. Examples of C₃-C₇-cycloalkylcomprise cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl andcycloheptyl.

C₃-C₇-Halocycloalkyl is a monocyclic saturated hydrocarbon radicalhaving 3 to 7, in particular 3 to 6 (“C₃-C₆-halocycloalkyl”) or 3 to 5(“C₃-C₅-halocycloalkyl”) or 3 to 4 (“C₃-C₄-halocycloalkyl”) carbon ringmembers (as mentioned above) in which some or all of the hydrogen atomsare replaced by halogen atoms as mentioned above, in particularfluorine, chlorine and bromine.

C₁-C₃-Alkoxy is a linear or branched alkyl radical linked via an oxygenatom and having 1 to 3 carbon atoms. Examples are methoxy, ethoxy,n-propoxy and isopropoxy. C₁-C₄-Alkoxy is a linear or branched alkylradical linked via an oxygen atom and having 1 to 4 carbon atoms.Examples are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy,sec-butoxy, isobutoxy and tert-butoxy.

C₁-C₄-Haloalkoxy is C₁-C₄-alkoxy as defined above wherein at least one,e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced by a halogenatom. Preferably, C₁-C₄-haloalkoxy is fluorinated C₁-C₄-alkoxy. This isa straight-chain or branched alkoxy group having from 1 to 4, inparticular 1 to 3 carbon atoms (=fluorinated C₁-C₃-alkoxy), morepreferably 1 or 2 carbon atoms (=fluorinated C₁-C₂-alkoxy), wherein atleast one, e.g. 1, 2, 3, 4 or all of the hydrogen atoms are replaced byfluorine atoms, such as in fluoromethoxy, difluoromethoxy,trifluoromethoxy, 1-fluoroethoxy, (R)-1-fluoroethoxy,(S)-1-fluoroethoxy, 2-fluoroethoxy, 1,1-difluoroethoxy,2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 1-fluoropropoxy,(R)-1-fluoropropoxy, (S)-1-fluoropropoxy, 2-fluoropropoxy,3-fluoropropoxy, 1,1-difluoropropoxy, 2,2-difluoropropoxy,3,3-difluoropropoxy, 3,3,3-trifluoropropoxy, 2-fluoro-1-methylethoxy,(R)-2-fluoro-1-methylethoxy, (S)-2-fluoro-1-methylethoxy,2,2-difluoro-1-methylethoxy, (R)-2,2-difluoro-1-methylethoxy,(S)-2,2-difluoro-1-methylethoxy, 1,2-difluoro-1-methylethoxy,(R)-1,2-difluoro-1-methylethoxy, (S)-1,2-difluoro-1-methylethoxy,2,2,2-trifluoro-1-methylethoxy, (R)-2,2,2-trifluoro-1-methylethoxy,(S)-2,2,2-trifluoro-1-methylethoxy, 2-fluoro-1-(fluoromethyl)ethoxy,1-(difluoromethyl)-2,2-difluoroethoxy, (R)-1-fluorobutoxy,(S)-1-fluorobutoxy, 2-fluorobutoxy, 3-fluorobutoxy, 4-fluorobutoxy,1,1-difluorobutoxy, 2,2-difluorobutoxy, 3,3-difluorobutoxy,4,4-difluorobutoxy, 4,4,4-trifluorobutoxy, etc

C₃-C₇-Cycloalkoxy is a monocyclic saturated hydrocarbon radical linkedvia an oxygen atom and having 3 to 7, in particular 3 to 6(“C₃-C₆-cycloalkyl”) or 3 to 5 (“C₃-C₅-cycloalkyl”) or 3 to 4(“C₃-C₄-cycloalkyl”) carbon atoms. Examples of C₃-C₄-cycloalkoxycomprise cyclopropoxy and cyclobutoxy. Examples of C₃-C₅-cycloalkoxycomprise cyclopropoxy, cyclobutoxy and cyclopentoxy. Examples ofC₃-C₆-cycloalkoxy comprise cyclopropoxy, cyclobutoxy, cyclopentoxy andcyclohexoxy. Examples of C₃-C₇-cycloalkoxy comprise cyclopropoxy,cyclobutoxy, cyclopentoxy, cyclohexoxy and cycloheptoxy.

C₃-C₇-Halocycloalkoxy is a monocyclic saturated hydrocarbon radicallinked via an oxygen atom and having 3 to 7, in particular 3 to 6(“C₃-C₆-halocycloalkoxy”) or 3 to 5 (“C₃-C₅-halocycloalkoxy”) or 3 to 4(“C₃-C₄-halocycloalkoxy”) carbon ring members (as mentioned above) inwhich some or all of the hydrogen atoms are replaced by halogen atoms asmentioned above, in particular fluorine, chlorine and bromine.

“C₁-C₄-Alkoxy-C₁-C₄-alkyl” refers to a straight-chain or branched alkylgroup having 1 to 4 carbon atoms, as defined above, where one hydrogenatom is replaced by a C₁-C₄-alkoxy group, as defined above. Examples aremethoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl,n-butoxymethyl, sec-butoxymethyl, isobutoxymethyl, tert-butoxymethyl,1-methoxyethyl, 1-ethoxyethyl, 1-propoxyethyl, 1-isopropoxyethyl,1-n-butoxyethyl, 1-sec-butoxyethyl, 1-isobutoxyethyl,1-tert-butoxyethyl, 2-methoxyethyl, 2-ethoxyethyl, 2-propoxyethyl,2-isopropoxyethyl, 2-n-butoxyethyl, 2-sec-butoxyethyl, 2-isobutoxyethyl,2-tert-butoxyethyl, 1-methoxypropyl, 1-ethoxypropyl, 1-propoxypropyl,1-isopropoxypropyl, 1-n-butoxypropyl, 1-sec-butoxypropyl,1-isobutoxypropyl, 1-tert-butoxypropyl, 2-methoxypropyl, 2-ethoxypropyl,2-propoxypropyl, 2-isopropoxypropyl, 2-n-butoxypropyl,2-sec-butoxypropyl, 2-isobutoxypropyl, 2-tert-butoxypropyl,3-methoxypropyl, 3-ethoxypropyl, 3-propoxypropyl, 3-isopropoxypropyl,3-n-butoxypropyl, 3-sec-butoxypropyl, 3-isobutoxypropyl,3-tert-butoxypropyl and the like.

C₁-C₄-Haloalkoxy-C₁-C₄-alkyl is a straight-chain or branched alkyl grouphaving from 1 to 4 carbon atoms, wherein one of the hydrogen atoms isreplaced by a C₁-C₄-alkoxy group and wherein at least one, e.g. 1, 2, 3,4 or all of the remaining hydrogen atoms (either in the alkoxy moiety orin the alkyl moiety or in both) are replaced by halogen atoms. Examplesare difluoromethoxymethyl (CHF₂OCH₂), trifluoromethoxymethyl,1-difluoromethoxyethyl, 1-trifluoromethoxyethyl, 2-difluoromethoxyethyl,2-trifluoromethoxyethyl, difluoro-methoxy-methyl (CH₃OCF₂),1,1-difluoro-2-methoxyethyl, 2,2-difluoro-2-methoxyethyl and the like.

C₁-C₄-Alkylthio is a C₁-C₄-alkyl group, as defined above, attached via asulfur atom. Examples are methylthio, ethylthio, n-propylthio,1-methylethylthio (isopropylthio), butylthio, 1-methylpropylthio(sec-butylthio), 2-methylpropylthio (isobutylthio) or1,1-dimethylethylthio (tert-butylthio).

C₁-C₄-Haloalkylthio is a C₁-C₄-haloalkyl group, as defined above,attached via a sulfur atom. Examples are SCH₂F, SCHF₂, SCF₃, SCH₂Cl,SCHCl₂, SCCl₃, chlorofluoromethylthio, dichlorofluoromethylthio,chlorodifluoromethylthio, 2-fluoroethylthio, 2-chloroethylthio,2-bromoethylthio, 2-iodoethylthio, 2,2-difluoroethylthio,2,2,2-trifluoroethylthio, 2-chloro-2-fluoroethylthio,2-chloro-2,2-difluoroethylthio, 2,2-dichloro-2-fluoroethylthio,2,2,2-trichloroethylthio, SC₂F₅, 2-fluoropropylthio, 3-fluoropropylthio,2,2-difluoropropylthio, 2,3-difluoropropylthio, 2-chloropropylthio,3-chloropropylthio, 2,3-dichloropropylthio, 2-bromopropylthio,3-bromopropylthio, 3,3,3-trifluoropropylthio, 3,3,3-trichloropropylthio,SCH₂—C₂F₅, SCF₂—C₂F₅, 1-(CH₂F)-2-fluoroethylthio,1-(CH₂Cl)-2-chloroethylthio, 1-(CH₂Br)-2-bromoethylthio,4-fluorobutylthio, 4-chlorobutylthio, 4-bromobutylthio ornonafluorobutylthio.

C₁-C₄-Alkylsulfinyl is a C₁-C₁-alkyl group, as defined above, attachedvia a sulfinyl [S(O)] group. Examples are methylsulfinyl, ethylsulfinyl,n-propylsulfinyl, 1-methylethylsulfinyl (isopropylsulfinyl),butylsulfinyl, 1-methylpropylsulfinyl (sec-butylsulfinyl),2-methylpropylsulfinyl (isobutylsulfinyl) or 1,1-dimethylethylsulfinyl(tert-butylsulfinyl).

C₁-C₄-Haloalkylsulfinyl is a C₁-C₄-haloalkyl group, as defined above,attached via a sulfinyl [S(O)] group. Examples are S(O)CH₂F, S(O)CHF₂,S(O)CF₃, S(O)CH₂Cl, S(O)CHCl₂, S(O)CCl₃, chlorofluoromethylsulfinyl,dichlorofluoromethylsulfinyl, chlorodifluoromethylsulfinyl,2-fluoroethylsulfinyl, 2-chloroethylsulfinyl, 2-bromoethylsulfinyl,2-iodoethylsulfinyl, 2,2-difluoroethylsulfinyl,2,2,2-trifluoroethylsulfinyl, 2-chloro-2-fluoroethylsulfinyl,2-chloro-2,2-difluoroethylsulfinyl, 2,2-dichloro-2-fluoroethylsulfinyl,2,2,2-trichloroethylsulfinyl, S(O)C₂F₅, 2-fluoropropylsulfinyl,3-fluoropropylsulfinyl, 2,2-difluoropropylsulfinyl,2,3-difluoropropylsulfinyl, 2-chloropropylsulfinyl,3-chloropropylsulfinyl, 2,3-dichloropropylsulfinyl,2-bromopropylsulfinyl, 3-bromopropylsulfinyl,3,3,3-trifluoropropylsulfinyl, 3,3,3-trichloropropylsulfinyl,S(O)CH₂—C₂F₅, S(O)CF₂—C₂F₅, 1-(CH₂F)-2-fluoroethylsulfinyl,1-(CH₂Cl)-2-chloroethylsulfinyl, 1-(CH₂Br)-2-bromoethylsulfinyl,4-fluorobutylsulfinyl, 4-chlorobutylsulfinyl, 4-bromobutylsulfinyl ornonafluorobutylsulfinyl.

C₁-C₄-Alkylsulfonyl is a C₁-C₄-alkyl group, as defined above, attachedvia a sulfonyl [S(O)₂] group. Examples are methylsulfonyl,ethylsulfonyl, n-propylsulfonyl, 1-methylethylsulfonyl(isopropylsulfonyl), butylsulfonyl, 1-methylpropylsulfonyl(sec-butylsulfonyl), 2-methylpropylsulfonyl (isobutylsulfonyl) or1,1-dimethylethylsulfonyl (tert-butylsulfonyl).

C₁-C₄-Haloalkylsulfonyl is a C₁-C₄-haloalkyl group, as defined above,attached via a sulfonyl [S(O)₂] group. Examples are S(O)₂CH₂F,S(O)₂CHF₂, S(O)₂CF₃, S(O)₂CH₂Cl, S(O)₂CHCl₂, S(O)₂CCl₃,chlorofluoromethylsulfonyl, dichlorofluoromethylsulfonyl,chlorodifluoromethylsulfonyl, 2-fluoroethylsulfonyl,2-chloroethylsulfonyl, 2-bromoethylsulfonyl, 2-iodoethylsulfonyl,2,2-difluoroethylsulfonyl, 2,2,2-trifluoroethylsulfonyl,2-chloro-2-fluoroethylsulfonyl, 2-chloro-2,2-difluoroethylsulfonyl,2,2-dichloro-2-fluoroethylsulfonyl, 2,2,2-trichloroethylsulfonyl,S(O)₂C₂F₅, 2-fluoropropylsulfonyl, 3-fluoropropylsulfonyl,2,2-difluoropropylsulfonyl, 2,3-difluoropropylsulfonyl,2-chloropropylsulfonyl, 3-chloropropylsulfonyl,2,3-dichloropropylsulfonyl, 2-bromopropylsulfonyl,3-bromopropylsulfonyl, 3,3,3-trifluoropropylsulfonyl,3,3,3-trichloropropylsulfonyl, S(O)₂CH₂—C₂F₅, S(O)₂CF₂—C₂F₅,1-(CH₂F)-2-fluoroethylsulfonyl, 1-(CH₂Cl)-2-chloroethylsulfonyl,1-(CH₂Br)-2-bromoethylsulfonyl, 4-fluorobutylsulfonyl,4-chlorobutylsulfonyl, 4-bromobutylsulfonyl or nonafluorobutylsulfonyl.

C₁-C₄-Alkylcarbonyl is a C₁-C₄-alkyl group, as defined above, attachedvia a carbonyl [C(═O)] group. Examples are acetyl (methylcarbonyl),propionyl (ethylcarbonyl), propylcarbonyl, isopropylcarbonyl,n-butylcarbonyl and the like.

C₁-C₄-Haloalkylcarbonyl is a C₁-C₄-haloalkyl group, as defined above,attached via a carbonyl [C(═O)] group. Examples aretrifluoromethylcarbonyl, 2,2,2-trifluoroethylcarbonyl and the like.

The term “3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturatedor maximally unsaturated heterocyclic ring containing 1, 2 or 3heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂as ring members” denotes a 3-, 4-, 5-, 6- or 7-membered saturated,partially unsaturated or maximum unsaturated heteromonocyclic ringcontaining 1, 2 or 3 heteroatoms or heteroatom groups selected from O,N, S, NO, SO and SO₂, as ring members.

Unsaturated rings contain at least one C—C and/or C—N and/or N—N doublebond(s). Maximally unsaturated rings contain as many conjugated C—Cand/or C—N and/or N—N double bonds as allowed by the ring size.Maximally unsaturated 5- or 6-membered heterocyclic rings are aromatic.The heterocyclic ring may be attached to the remainder of the moleculevia a carbon ring member or via a nitrogen ring member. As a matter ofcourse, the heterocyclic ring contains at least one carbon ring atom. Ifthe ring contains more than one O ring atom, these are not adjacent.

The term “3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturatedor maximum unsaturated heterocyclic ring containing 1, 2 or 3heteroatoms or heteroatom groups selected from O, N, S, NO, SO and SO₂,as ring members” [wherein “maximum unsaturated” includes also“aromatic”] as used herein denotes monocyclic radicals, the monocyclicradicals being saturated, partially unsaturated or maximum unsaturated(including aromatic). 7-membered rings cannot be aromatic; they arehomoaromatic if maximally unsaturated (3 double bonds).

Examples of a 3-, 4-, 5-, 6- or 7-membered saturated heterocyclic ringinclude: Oxiranyl, thiiranyl, aziridinyl, oxetanyl, thietanyl,azetidinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl,tetrahydrothien-2-yl, tetrahydrothien-3-yl, pyrrolidin-1-yl,pyrrolidin-2-yl, pyrrolidin-3-yl, pyrazolidin-1-yl, pyrazolidin-3-yl,pyrazolidin-4-yl, pyrazolidin-5-yl, imidazolidin-1-yl,imidazolidin-2-yl, imidazolidin-4-yl, oxazolidin-2-yl, oxazolidin-3-yl,oxazolidin-4-yl, oxazolidin-5-yl, isoxazolidin-2-yl, isoxazolidin-3-yl,isoxazolidin-4-yl, isoxazolidin-5-yl, thiazolidin-2-yl,thiazolidin-3-yl, thiazolidin-4-yl, thiazolidin-5-yl,isothiazolidin-2-yl, isothiazolidin-3-yl, isothiazolidin-4-yl,isothiazolidin-5-yl, 1,2,4-oxadiazolidin-3-yl, 1,2,4-oxadiazolidin-5-yl,1,2,4-thiadiazolidin-3-yl, 1,2,4-thiadiazolidin-5-yl,1,2,4-triazolidin-3-yl, 1,3,4-oxadiazolidin-2-yl,1,3,4-thiadiazolidin-2-yl, 1,3,4-triazolidin-1-yl,1,3,4-triazolidin-2-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl,1,3-dioxan-5-yl, 1,4-dioxan-2-yl, piperidin-1-yl, piperidin-2-yl,piperidin-3-yl, piperidin-4-yl, hexahydropyridazin-3-yl,hexahydropyridazin-4-yl, hexahydropyrimidin-2-yl,hexahydropyrimidin-4-yl, hexahydropyrimidin-5-yl, piperazin-1-yl,piperazin-2-yl, 1,3,5-hexahydrotriazin-1-yl, 1,3,5-hexahydrotriazin-2-yland 1,2,4-hexahydrotriazin-3-yl, morpholin-2-yl, morpholin-3-yl,morpholin-4-yl, thiomorpholin-2-yl, thiomorpholin-3-yl,thiomorpholin-4-yl, 1-oxothiomorpholin-2-yl, 1-oxothiomorpholin-3-yl,1-oxothiomorpholin-4-yl, 1,1-dioxothiomorpholin-2-yl,1,1-dioxothiomorpholin-3-yl, 1,1-dioxothiomorpholin-4-yl, azepan-1-,-2-, -3- or -4-yl, oxepan-2-, -3-, -4- or -5-yl,hexahydro-1,3-diazepinyl, hexahydro-1,4-diazepinyl,hexahydro-1,3-oxazepinyl, hexahydro-1,4-oxazepinyl,hexahydro-1,3-dioxepinyl, hexahydro-1,4-dioxepinyl and the like.

Examples of a 3-, 4-, 5-, 6- or 7-membered partially unsaturatedheterocyclic ring include: 2,3-dihydrofur-2-yl, 2,3-dihydrofur-3-yl,2,4-dihydrofur-2-yl, 2,4-dihydrofur-3-yl, 2,3-dihydrothien-2-yl,2,3-dihydrothien-3-yl, 2,4-dihydrothien-2-yl, 2,4-dihydrothien-3-yl,2-pyrrolin-2-yl, 2-pyrrolin-3-yl, 3-pyrrolin-2-yl, 3-pyrrolin-3-yl,2-isoxazolin-3-yl, 3-isoxazolin-3-yl, 4-isoxazolin-3-yl,2-isoxazolin-4-yl, 3-isoxazolin-4-yl, 4-isoxazolin-4-yl,2-isoxazolin-5-yl, 3-isoxazolin-5-yl, 4-isoxazolin-5-yl,2-isothiazolin-3-yl, 3-isothiazolin-3-yl, 4-isothiazolin-3-yl,2-isothiazolin-4-yl, 3-isothiazolin-4-yl, 4-isothiazolin-4-yl,2-isothiazolin-5-yl, 3-isothiazolin-5-yl, 4-isothiazolin-5-yl,2,3-dihydropyrazol-1-yl, 2,3-dihydropyrazol-2-yl,2,3-dihydropyrazol-3-yl, 2,3-dihydropyrazol-4-yl,2,3-dihydropyrazol-5-yl, 3,4-dihydropyrazol-1-yl,3,4-dihydropyrazol-3-yl, 3,4-dihydropyrazol-4-yl,3,4-dihydropyrazol-5-yl, 4,5-dihydropyrazol-1-yl,4,5-dihydropyrazol-3-yl, 4,5-dihydropyrazol-4-yl,4,5-dihydropyrazol-5-yl, 2,3-dihydrooxazol-2-yl, 2,3-dihydrooxazol-3-yl,2,3-dihydrooxazol-4-yl, 2,3-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl,3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl, 3,4-dihydrooxazol-5-yl,3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl,2-, 3-, 4-, 5- or 6-di- or tetrahydropyridinyl, 3-di- ortetrahydropyridazinyl, 4-di- or tetrahydropyridazinyl, 2-di- ortetrahydropyrimidinyl, 4-di- or tetrahydropyrimidinyl, 5-di- ortetrahydropyrimidinyl, di- or tetrahydropyrazinyl, 1,3,5-di- ortetrahydrotriazin-2-yl, 1,2,4-di- or tetrahydrotriazin-3-yl,2,3,4,5-tetrahydro[1H]azepin-1-, -2-, -3-, -4-, -5-, -6- or -7-yl,3,4,5,6-tetrahydro[2H]azepin-2-, -3-, -4-, -5-, -6- or -7-yl-,-2,3,4,7-tetrahydro[1H]azepin-1-, -2-, -3-, -4-, -5-, -6- or -7-yl,2,3,6,7-tetrahydro[1H]azepin-1-, -2-, -3-, -4-, -5-, -6- or -7-yl,tetrahydrooxepinyl, such as 2,3,4,5-tetrahydro[1H]oxepin-2-, -3-, -4-,-5-, -6- or -7-yl, 2,3,4,7-tetrahydro[1H]oxepin-2-, -3-, -4-, -5-, -6-or -7-yl, 2,3,6,7-tetrahydro[1H]oxepin-2-, -3-, -4-, -5-, -6- or -7-yl,tetrahydro-1,3-diazepinyl, tetrahydro-1,4-diazepinyl,tetrahydro-1,3-oxazepinyl, tetrahydro-1,4-oxazepinyl,tetrahydro-1,3-dioxepinyl and tetrahydro-1,4-dioxepinyl.

Examples for a 3-, 4-, 5-, 6- or 7-membered maximally unsaturated(including aromatic) heterocyclic ring are 5- or 6-memberedheteroaromatic rings, such as 2-furyl, 3-furyl, 2-thienyl, 3-thienyl,1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrazolyl, 3-pyrazolyl,4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl,2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 1-imidazolyl, 2-imidazolyl,4-imidazolyl, 1,3,4-triazol-1-yl, 1,3,4-triazol-2-yl, 2-pyridinyl,3-pyridinyl, 4-pyridinyl, 1-oxopyridin-2-yl, 1-oxopyridin-3-yl,1-oxopyridin-4-yl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl,4-pyrimidinyl, 5-pyrimidinyl and 2-pyrazinyl, and also homoaromaticradicals, such as 1H-azepine, 1H-[1,3]-diazepine and 1H-[1,4]-diazepine.

The compounds of the invention of the formula I and their N-oxides,stereoisomers and pharmacologically acceptable salts may also be presentin the form of solvates or hydrates. Solvates mean in the context of thepresent invention crystalline forms of the compounds I or of theirpharmaceutically acceptable salts which comprise solvent moleculesincorporated in the crystal lattice. The solvent molecules arepreferably incorporated in stoichiometric ratios. Hydrates are aspecific form of solvates; the solvent in this case being water.

The statements made hereinafter concerning suitable and preferredfeatures of the invention, especially concerning the radicals R¹, R²,R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, X¹, X², a and b in thecompound I, but also concerning the features of the process of theinvention and of the use according to the invention apply both taken ontheir own as well as preferably in any possible combination with oneanother.

The compounds I are preferably provided in the form of the free base(i.e. according to structural formula I) or in the form of their acidaddition salts.

In a preferred embodiment, X² is C—R¹ and R¹, R² and R³, independentlyof each other, are selected from hydrogen, halogen, C₁-C₃-alkyl,fluorinated C₁-C₃-alkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy. Morepreferably, R¹, R² and R³, independently of each other, are selectedfrom hydrogen, fluorine and methoxy.

In particular, R¹ is selected from hydrogen, fluorine and methoxy.

In particular, R² is selected from hydrogen, fluorine and methoxy.

In particular, R³ is selected from hydrogen and fluorine.

R³ is preferably bound in 3- or 5-position, in particular in 5-position,relative to the 2- and 4-positions of R¹ and R².

In another preferred embodiment, X² is N and R² and R³, independently ofeach other, are selected from hydrogen, halogen, C₁-C₃-alkyl,fluorinated C₁-C₃-alkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy. Morepreferably, R¹, R² and R³, independently of each other, are selectedfrom hydrogen, fluorine and methoxy.

In this case, R² is preferably selected from hydrogen, fluorine andmethoxy, and is in particular methoxy.

In this case, R³ is preferably selected from hydrogen, fluorine andmethoxy, and is in particular hydrogen.

Preferably, R⁴ is selected from methoxy and ethoxy.

Preferably, R⁵ is hydrogen or methoxy, and in particular hydrogen.

Preferably, R⁶ is selected from cyano, fluorine and chlorine.

Preferably, R⁷ is selected from hydrogen and fluorine.

In a preferred embodiment,

-   R⁸ is selected from hydrogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl,    C₃-C₆-cycloalkyl and C₃-C₆-halocycloalkyl;-   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl,    C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,    C₃-C₆-cycloalkoxy, C₃-C₆-halocycloalkoxy, and a 3-, 4-, 5- or    6-membered saturated, partially unsaturated or maximally unsaturated    heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups    selected from O, N, S, NO, SO and SO₂ as ring members, where the    heterocyclic ring may carry 1, 2 or 3 substituents selected from    halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy    and C₁-C₄-haloalkoxy; or    -   R⁸ and R⁹, together with the nitrogen atom they are bound to,        form a 3-, 4-, 5- or 6-membered saturated, partially unsaturated        or maximally unsaturated heterocyclic ring, where the        heterocyclic ring may contain 1 or 2 further heteroatoms or        heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring        members, and where the heterocyclic ring may carry 1 or 2        substituents R¹² and/or 1 substituent R¹³; where in case that        the heterocyclic ring does not contain 1 or 2 further        heteroatoms or heteroatom groups as ring members, the        heterocyclic ring carries 1 or 2 substituents R¹² and optionally        1 substituent R¹³;-   each R¹² is independently selected from halogen, hydroxyl,    C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₆-cycloalkoxy,    C₃-C₆-halocycloalkoxy, and a 3-, 4-, 5- or 6-membered saturated,    partially unsaturated or maximally unsaturated heterocyclic ring    containing 1 or 2 heteroatoms or heteroatom groups selected from O,    N, S, NO, SO and SO₂ as ring members, where the heterocyclic ring    may carry 1, 2 or 3 substituents selected from halogen, hydroxyl,    cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and    C₁-C₄-haloalkoxy;    -   or    -   two radicals R¹², together with the atom(s) they are bound to,        form a 3-, 4-, 5- or 6-membered saturated, partially unsaturated        or maximally unsaturated heterocyclic ring containing 1 or 2        heteroatoms or heteroatom groups selected from O, N, S, NO, SO        and SO₂ as ring members, where the heterocyclic ring may carry        1, 2 or 3 substituents selected from halogen, hydroxyl, cyano,        C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy;        and-   R¹³ is selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,    C₁-C₄-haloalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl,    C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₃-C₆-cycloalkyl,    C₃-C₆-halocycloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,    C₃-C₇-cycloalkoxy, C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio,    C₁-C₄-haloalkylthio, C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl,    C₁-C₄-alkylsulfonyl, C₁-C₄-haloalkylsulfonyl, C₁-C₄-alkylcarbonyl,    C₁-C₄-haloalkylcarbonyl, phenyl, phenoxy and a 3-, 4-, 5- or    6-membered saturated, partially unsaturated or maximally unsaturated    heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom    groups selected from O, N, S, NO, SO and SO₂ as ring members, where    the phenyl moieties or the heterocyclic ring may carry 1, 2 or 3    substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,    C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy.

More preferably,

-   R⁸ is selected from hydrogen, C₁-C₄-alkyl, fluorinated C₁-C₄-alkyl,    C₃-C₆-cycloalkyl and fluorinated C₃-C₆-cycloalkyl;-   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated    C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy,    and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring    containing 1 or 2 heteroatoms or heteroatom groups selected from O,    N, S, NO, SO and SO₂ as ring members, where the heterocyclic ring    may carry 1, 2 or 3 substituents selected from halogen, hydroxyl,    cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and    C₁-C₄-haloalkoxy; or    -   R⁸ and R⁹, together with the nitrogen atom they are bound to,        form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring,        where the heterocyclic ring may contain 1 or 2 further        heteroatoms or heteroatom groups selected from O, N, S, NO, SO        and SO₂ as ring members, and where the heterocyclic ring may        carry 1 or 2 substituents R¹² and/or 1 substituent R¹³; where in        case that the heterocyclic ring does not contain 1 or 2 further        heteroatoms or heteroatom groups as ring members, the        heterocyclic ring carries 1 or 2 substituents R¹² and optionally        1 substituent R¹³;-   each R¹² is independently selected from halogen, hydroxyl,    C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-, 4-, 5- or    6-membered saturated heterocyclic ring containing 1 or 2 heteroatoms    or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring    members, where the heterocyclic ring may carry 1, 2 or 3    substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,    C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; or    -   two radicals R¹², together with the atom(s) they are bound to,        form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring        containing 1 or 2 heteroatoms or heteroatom groups selected from        O, N, S, NO, SO and SO₂ as ring members, where the heterocyclic        ring may carry 1, 2 or 3 substituents selected from halogen,        hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and        C₁-C₄-haloalkoxy; and-   R¹³ is selected halogen, hydroxyl, cyano, C₁-C₄-alkyl, fluorinated    C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated    C₁-C₄-alkoxy-C₁-C₄-alkyl, C₃-C₆-cycloalkyl, fluorinated    C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-,    4-, 5- or 6-membered saturated, partially unsaturated or maximally    unsaturated heterocyclic ring containing 1 or 2 heteroatoms or    heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring    members, where the heterocyclic ring may carry 1, 2 or 3    substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,    C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy.

In particular,

-   R⁸ is selected from hydrogen, C₁-C₄-alkyl and C₃-C₆-cycloalkyl;-   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated    C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy,    and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring    containing 1 oxygen atom as ring member; or    -   R⁸ and R⁹, together with the nitrogen atom they are bound to        form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring,        where the heterocyclic ring contains 1 further oxygen atom as        ring member, and where the heterocyclic ring may carry 1 or 2        substituents R¹²; or form a 3-, 4-, 5- or 6-membered saturated        heterocyclic ring which carries 1 or 2 substituents R¹²; and-   each R¹² is independently selected from halogen, hydroxyl,    C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated heterocyclic    ring containing 1 oxygen atom as ring member; or two radicals R¹²    bound to the same carbon ring atom, together with this carbon atom    they are bound to, form a 3-, 4-, 5- or 6-membered saturated    heterocyclic ring containing 1 oxygen atom as ring member.

The saturated heterocyclic ring formed by R⁸ and R⁹ together with thenitrogen atom they are bound to is preferably selected fromazetidin-1-yl carrying in the 3-position (relative to the 1-position ofthe nitrogen ring atom) 1 or 2 substituents R¹²; isoxazolidin-2-yl,piperidin-1-yl carrying in the 4-position (relative to the 1-position ofthe nitrogen ring atom) 1 or 2 substituents R¹²; and morpholin-1-yl,where R¹² is as defined above or, in particular, as defined below.

If two radicals R¹² bound to the same carbon ring atom together withthis carbon atom form a ring, this is preferably a spiro-boundoxetan-3-yl ring; i.e. preferably the two radicals R¹² bound to the samecarbon atom together form a group —CH₂—O—CH₂—.

Preferably, each R¹⁰ is independently selected from halogen andC₁-C₄-alkyl, preferably from F, Cl and CH₃, with the proviso that R¹⁰ isnot halogen if it is bound to a carbon atom in α-position to a nitrogenring atom; and is in particular CH₃.

Preferably, each R¹¹ is independently selected from halogen andC₁-C₄-alkyl, preferably from F, Cl and CH₃, with the proviso that R¹¹ isnot halogen if it is bound to a carbon atom in α-position to a nitrogenring atom; and is in particular CH₃;

or two non-geminal radicals R¹¹ form together a group —CH₂—.

In one embodiment, X¹ is N.

In another embodiment, X¹ is CH.

In one embodiment, X² is C—R¹.

In another embodiment, X² is N.

a is preferably 0 or 1, in particular 0.

b is preferably 0, 1 or 2, in particular 0.

The invention preferably relates to compounds of the formula I in which

-   R¹ (if present), R² and R³, independently of each other, are    selected from hydrogen, halogen, C₁-C₃-alkyl, fluorinated    C₁-C₃-alkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy;-   R⁴ is selected from methoxy and ethoxy;-   R⁵ is hydrogen or methoxy;-   R⁶ is selected from cyano, fluorine and chlorine;-   R⁷ is hydrogen or fluorine;-   R⁸ is selected from hydrogen, C₁-C₄-alkyl, fluorinated C₁-C₄-alkyl,    C₃-C₆-cycloalkyl and fluorinated C₃-C₆-cycloalkyl;-   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated    C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy,    and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring    containing 1 or 2 heteroatoms or heteroatom groups selected from O,    N, S, NO, SO and SO₂ as ring members, where the heterocyclic ring    may carry 1, 2 or 3 substituents selected from halogen, hydroxyl,    cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and    C₁-C₄-haloalkoxy; or    -   R⁸ and R⁹, together with the nitrogen atom they are bound to,        form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring,        where the heterocyclic ring may contain 1 or 2 further        heteroatoms or heteroatom groups selected from O, N, S, NO, SO        and SO₂ as ring members, and where the heterocyclic ring may        carry 1 or 2 substituents R¹² and/or 1 substituent R¹³; where in        case that the heterocyclic ring does not contain 1 or 2 further        heteroatoms or heteroatom groups as ring members, the        heterocyclic ring carries 1 or 2 substituents R¹² and optionally        1 substituent R¹³;-   each R¹² is independently selected from halogen, hydroxyl,    C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-, 4-, 5- or    6-membered saturated heterocyclic ring containing 1 or 2 heteroatoms    or heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring    members, where the heterocyclic ring may carry 1, 2 or 3    substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,    C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; or    -   two radicals R¹², together with the atom(s) they are bound to,        form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring        containing 1 or 2 heteroatoms or heteroatom groups selected from        O, N, S, NO, SO and SO₂ as ring members, where the heterocyclic        ring may carry 1, 2 or 3 substituents selected from halogen,        hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and        C₁-C₄-haloalkoxy; and-   R¹³ is selected halogen, hydroxyl, cyano, C₁-C₄-alkyl, fluorinated    C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated    C₁-C₄-alkoxy-C₁-C₄-alkyl, C₃-C₆-cycloalkyl, fluorinated    C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-,    4-, 5- or 6-membered saturated, partially unsaturated or maximally    unsaturated heterocyclic ring containing 1 or 2 heteroatoms or    heteroatom groups selected from O, N, S, NO, SO and SO₂ as ring    members, where the heterocyclic ring may carry 1, 2 or 3    substituents selected from halogen, hydroxyl, cyano, C₁-C₄-alkyl,    C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy;-   each R¹⁰ is independently selected from halogen and C₁-C₄-alkyl or    two non-geminal radicals R¹⁰ form together a group —CH₂— or    —CH₂CH₂—;-   each R¹¹ is independently selected from halogen and C₁-C₄-alkyl or    two non-geminal radicals R¹¹ form together a group —CH₂— or    —CH₂CH₂—;-   a is 0, 1 or 2;-   b is 0, 1 or 2;    and the pharmaceutically acceptable salts thereof.

The invention more preferably relates to compounds of the formula I inwhich

-   R¹ (if present), R² and R³, independently of each other, are    selected from hydrogen, fluorine and methoxy;-   R⁴ is selected from methoxy and ethoxy;-   R⁵ is hydrogen or methoxy;-   R⁶ is selected from cyano, fluorine and chlorine;-   R⁷ is hydrogen or fluorine;-   R⁸ is selected from hydrogen, C₁-C₄-alkyl and C₃-C₆-cycloalkyl;-   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated    C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy,    and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring    containing 1 oxygen atom as ring member; or    -   R⁸ and R⁹, together with the nitrogen atom they are bound to        form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring,        where the heterocyclic ring contains 1 further oxygen atom as        ring member, and where the heterocyclic ring may carry 1 or 2        substituents R¹²; or form a 3-, 4-, 5- or 6-membered saturated        heterocyclic ring which carries 1 or 2 substituents R¹²; and-   each R¹² is independently selected from halogen, hydroxyl,    C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated heterocyclic    ring containing 1 oxygen atom as ring member; or    -   two radicals R¹² bound to the same carbon ring atom, together        with this carbon atom they are bound to, form a 3-, 4-, 5- or        6-membered saturated heterocyclic ring containing 1 oxygen atom        as ring member;-   each R¹ is independently selected from F, Cl and methyl or two    non-geminal radicals R¹⁰ form together a group —CH₂—;-   each R¹¹ is independently selected from F, Cl and methyl or two    non-geminal radicals R¹¹ form together a group —CH₂—;-   X¹ is N or CH;-   X² is C—R¹ or N;-   a is 0, 1 or 2, preferably 0 or 1;-   b is 0, 1 or 2, preferably 0 or 2;    and the pharmaceutically acceptable salts thereof.

The invention even more preferably relates to compounds of the formula Iin which

-   R¹ (if present) is selected from hydrogen, fluorine and methoxy;-   R² is selected from hydrogen, fluorine and methoxy;-   R³ is selected from hydrogen and fluorine;-   R⁴ is selected from methoxy and ethoxy;-   R⁵ is hydrogen or methoxy;-   R⁶ is selected from cyano, fluorine and chlorine;-   R⁷ is hydrogen or fluorine;-   R⁸ is selected from hydrogen, C₁-C₄-alkyl and C₃-C₆-cycloalkyl;-   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, and a    3-, 4-, 5- or 6-membered saturated heterocyclic ring containing 1    oxygen atom as ring member;    -   or    -   R⁸ and R⁹, together with the nitrogen atom they are bound to        form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring,        where the heterocyclic ring contains 1 further oxygen atom as        ring member, and where the heterocyclic ring may carry 1 or 2        substituents R¹²; or form a 3-, 4-, 5- or 6-membered saturated        heterocyclic ring which carries 1 or 2 substituents R¹²; and-   each R¹² is independently selected from halogen, hydroxyl,    C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated heterocyclic    ring containing 1 oxygen atom as ring member; or    -   two radicals R¹² bound to the same carbon ring atom, together        with this carbon atom they are bound to, form a 3-, 4-, 5- or        6-membered saturated heterocyclic ring containing 1 oxygen atom        as ring member;-   X¹ is N or CH;-   X² is C—R¹ or N;-   a is 0;-   b is 0;    and the pharmaceutically acceptable salts thereof.

The invention even in particular relates to compounds of the formula Iin which

-   R¹ (if present) is selected from hydrogen, fluorine and methoxy;-   R² is selected from hydrogen, fluorine and methoxy;-   R³ is selected from hydrogen and fluorine;-   R⁴ is selected from methoxy and ethoxy;-   R⁵ is hydrogen or methoxy;-   R⁶ is selected from cyano, fluorine and chlorine;-   R⁷ is hydrogen or fluorine;-   R⁸ is selected from hydrogen, C₁-C₄-alkyl and C₃-C₆-cycloalkyl;-   R⁹ is selected from C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy,    oxetan-3-yl and tetrahydropyran-4-yl; or    -   R⁸ and R⁹, together with the nitrogen atom they are bound to        form a saturated heterocyclic ring selected from azetidin-1-yl        carrying in the 3-position (relative to the 1-position of the        nitrogen ring atom) 1 or 2 substituents R¹²; isoxazolidin-2-yl,        piperidin-1-yl carrying in the 4-position (relative to the        1-position of the nitrogen ring atom) 1 or 2 substituents R¹²;        and morpholin-1-yl; and-   each R¹² is independently selected from halogen, hydroxyl,    C₁-C₄-alkoxy, and oxetan-3-yl; or    -   two radicals R¹² bound to the same carbon ring atom together        form a group —CH₂—O—CH₂— (i.e. together with the carbon atom        they are bound to form a spiro-bound oxetan-3-yl ring);-   X¹ is N or CH;-   X² is C—R¹ or N;-   a is 0;-   b is 0;    and the pharmaceutically acceptable salts thereof.

Examples of preferred embodiment of the present invention are compoundsof the formulae I.1 to I.40 and the N-oxides, stereoisomers and thepharmaceutically acceptable salts thereof, in which the radicals R¹, R²,R³, R⁶, R⁷, R⁸ and R⁹ have one of the above general or preferredmeanings. In particular, preferred compounds are the individualcompounds compiled in the tables 1 to 28600 below. Moreover, themeanings mentioned below for the individual variables in the tables areper se, independently of the combination in which they are mentioned, aparticularly preferred embodiment of the substituents in question.

Table 1

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is methoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 2

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is ethoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 3

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is n-propoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 4

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is isopropoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 5

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is n-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 6

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is sec-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 7

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is isobutoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 8

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is tert-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 9

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isfluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 10

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isdifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 11

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ istrifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 12

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 13

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 14

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 15

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ ispentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 16

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ ismethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 17

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 18

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isn-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 19

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isisopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 20

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ ismethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 21

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 22

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isn-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 23

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isisopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 24

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ ismethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 25

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 26

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isn-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 27

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isisopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 28

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ ismethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 29

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 30

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isn-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 31

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isisopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 32

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ ismethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 33

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 34

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isn-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 35

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isisopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 36

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ ismethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 37

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 38

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isn-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 39

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isisopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 40

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is oxetan-2-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 41

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is oxetan-3-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 42

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ istetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 43

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ istetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 44

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ istetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 45

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ istetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 46

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ istetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 47

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isthietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 48

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ isthietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 49

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 50

Compounds of the formula I.1 in which R⁸ is hydrogen, R⁹ is1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 51

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is methoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 52

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is ethoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 53

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is n-propoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 54

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is isopropoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 55

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is n-butoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 56

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is sec-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 57

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is isobutoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 58

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is tert-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 59

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is fluoromethoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 60

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isdifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 61

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ istrifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 62

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 63

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 64

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 65

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ ispentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 66

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is methoxymethyl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 67

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is ethoxymethyl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 68

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isn-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 69

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isisopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 70

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ ismethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 71

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 72

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isn-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 73

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isisopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 74

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ ismethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 75

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 76

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isn-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 77

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isisopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 78

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ ismethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 79

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 80

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isn-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 81

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isisopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 82

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ ismethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 83

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 84

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isn-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 85

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isisopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 86

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ ismethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 87

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 88

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isn-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 89

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ isisopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 90

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is oxetan-2-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 91

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is oxetan-3-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 92

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ istetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 93

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ istetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 94

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ istetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 95

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ istetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 96

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ istetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 97

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is thietan-2-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 98

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is thietan-3-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 99

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 100

Compounds of the formula I.1 in which R⁸ is methyl, R⁹ is1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 101

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is methoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 102

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is ethoxy, and R¹,R², R³, R⁶ and R⁷ for a compound corresponds in each case to one row ofTable A

Table 103

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is n-propoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 104

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is isopropoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 105

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is n-butoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 106

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is sec-butoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 107

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is isobutoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 108

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is tert-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 109

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is fluoromethoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 110

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isdifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 111

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ istrifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 112

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is 2-fluoroethoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 113

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 114

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 115

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ ispentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 116

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is methoxymethyl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 117

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is ethoxymethyl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 118

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isn-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 119

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isisopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 120

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ ismethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 121

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is ethoxy-1-ethyl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 122

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isn-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 123

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isisopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 124

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ ismethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 125

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is ethoxy-2-ethyl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 126

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isn-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 127

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isisopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 128

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ ismethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 129

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 130

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isn-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 131

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isisopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 132

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ ismethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 133

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 134

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isn-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 135

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isisopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 136

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ ismethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 137

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 138

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isn-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 139

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ isisopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 140

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is oxetan-2-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 141

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is oxetan-3-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 142

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ istetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 143

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ istetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 144

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ istetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 145

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ istetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 146

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ istetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 147

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is thietan-2-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 148

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is thietan-3-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 149

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 150

Compounds of the formula I.1 in which R⁸ is ethyl, R⁹ is1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 151

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is methoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 152

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is ethoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 153

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is n-propoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 154

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is isopropoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 155

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is n-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 156

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is sec-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 157

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is isobutoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 158

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is tert-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 159

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isfluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 160

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isdifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 161

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ istrifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 162

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 163

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 164

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 165

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ ispentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 166

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ ismethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 167

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 168

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isn-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 169

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isisopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 170

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ ismethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 171

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 172

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isn-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 173

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isisopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 174

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ ismethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 175

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 176

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isn-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 177

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isisopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 178

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ ismethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 179

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 180

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isn-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 181

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isisopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 182

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ ismethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 183

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 184

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isn-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 185

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isisopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 186

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ ismethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 187

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 188

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isn-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 189

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isisopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 190

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is oxetan-2-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 191

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is oxetan-3-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 192

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ istetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 193

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ istetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 194

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ istetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 195

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ istetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 196

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ istetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 197

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isthietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 198

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ isthietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 199

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 200

Compounds of the formula I.1 in which R⁸ is n-propyl, R⁹ is1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 201

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is methoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 202

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is ethoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 203

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is n-propoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 204

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is isopropoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 205

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is n-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 206

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is sec-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 207

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is isobutoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 208

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ istert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 209

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isfluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 210

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isdifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 211

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ istrifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 212

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 213

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 214

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 215

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ ispentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 216

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ ismethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 217

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 218

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isn-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 219

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isisopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 220

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ ismethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 221

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 222

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isn-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 223

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isisopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 224

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ ismethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 225

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 226

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isn-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 227

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isisopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 228

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ ismethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 229

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 230

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isn-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 231

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isisopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 232

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ ismethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 233

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 234

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isn-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 235

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isisopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 236

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ ismethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 237

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 238

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isn-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 239

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isisopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 240

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isoxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 241

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isoxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 242

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ istetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 243

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ istetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 244

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ istetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 245

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ istetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 246

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ istetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 247

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isthietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 248

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ isthietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 249

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 250

Compounds of the formula I.1 in which R⁸ is isopropyl, R⁹ is1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 251

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is methoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 252

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is ethoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 253

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is n-propoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 254

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is isopropoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 255

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is n-butoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 256

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is sec-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 257

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is isobutoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 258

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is tert-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 259

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isfluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 260

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isdifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 261

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ istrifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 262

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 263

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 264

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 265

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ ispentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 266

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ ismethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 267

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is ethoxymethyl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 268

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isn-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 269

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isisopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 270

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ ismethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 271

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 272

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isn-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 273

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isisopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 274

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ ismethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 275

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 276

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isn-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 277

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isisopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 278

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ ismethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 279

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 280

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isn-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 281

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isisopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 282

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ ismethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 283

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 284

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isn-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 285

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isisopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 286

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ ismethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 287

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 288

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isn-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 289

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ isisopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 290

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is oxetan-2-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 291

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is oxetan-3-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 292

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ istetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 293

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ istetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 294

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ istetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 295

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ istetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 296

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ istetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 297

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is thietan-2-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 298

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is thietan-3-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 299

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 300

Compounds of the formula I.1 in which R⁸ is n-butyl, R⁹ is1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 301

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is methoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 302

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is ethoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 303

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is n-propoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 304

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is isopropoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 305

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is n-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 306

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is sec-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 307

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is isobutoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 308

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ istert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 309

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isfluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 310

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isdifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 311

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ istrifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 312

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 313

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 314

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 315

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ ispentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 316

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ ismethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 317

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 318

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isn-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 319

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isisopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 320

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ ismethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 321

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 322

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isn-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 323

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isisopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 324

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ ismethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 325

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 326

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isn-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 327

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isisopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 328

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ ismethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 329

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 330

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isn-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 331

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isisopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 332

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ ismethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 333

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 334

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isn-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 335

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isisopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 336

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ ismethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 337

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 338

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isn-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 339

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isisopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 340

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isoxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 341

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isoxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 342

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ istetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 343

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ istetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 344

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ istetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 345

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ istetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 346

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ istetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 347

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isthietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 348

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ isthietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 349

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 350

Compounds of the formula I.1 in which R⁸ is sec-butyl, R⁹ is1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 351

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is methoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 352

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is ethoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 353

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is n-propoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 354

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is isopropoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 355

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is n-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 356

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is sec-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 357

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is isobutoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 358

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is tert-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 359

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isfluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 360

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isdifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 361

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ istrifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 362

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 363

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 364

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 365

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ ispentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 366

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ ismethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 367

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 368

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isn-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 369

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isisopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 370

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ ismethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 371

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 372

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isn-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 373

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isisopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 374

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ ismethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 375

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 376

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isn-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 377

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isisopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 378

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ ismethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 379

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 380

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isn-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 381

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isisopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 382

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ ismethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 383

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 384

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isn-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 385

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isisopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 386

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ ismethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 387

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 388

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isn-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 389

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isisopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 390

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is oxetan-2-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 391

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is oxetan-3-yl,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 392

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ istetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 393

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ istetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 394

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ istetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 395

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ istetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 396

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ istetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 397

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isthietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 398

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ isthietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 399

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 400

Compounds of the formula I.1 in which R⁸ is isobutyl, R⁹ is1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 401

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is methoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 402

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is ethoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 403

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is n-propoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 404

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isisopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in eachcase to one row of Table A

Table 405

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is n-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 406

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ issec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in eachcase to one row of Table A

Table 407

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is isobutoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 408

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ istert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 409

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isfluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 410

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isdifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 411

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ istrifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 412

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 413

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 414

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 415

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ ispentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 416

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ ismethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 417

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 418

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isn-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 419

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isisopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 420

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ ismethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 421

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 422

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isn-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 423

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isisopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 424

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ ismethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 425

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 426

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isn-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 427

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isisopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 428

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ ismethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 429

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 430

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isn-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 431

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isisopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 432

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ ismethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 433

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 434

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isn-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 435

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isisopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 436

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ ismethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 437

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 438

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isn-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 439

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isisopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 440

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isoxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 441

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isoxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 442

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ istetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 443

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ istetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 444

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ istetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 445

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ istetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 446

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ istetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 447

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isthietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 448

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ isthietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 449

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 450

Compounds of the formula I.1 in which R⁸ is tert-butyl, R⁹ is1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 451

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is methoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 452

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is ethoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 453

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isn-propoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in eachcase to one row of Table A

Table 454

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isisopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in eachcase to one row of Table A

Table 455

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is n-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 456

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ issec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in eachcase to one row of Table A

Table 457

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isisobutoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in eachcase to one row of Table A

Table 458

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ istert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 459

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isfluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 460

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isdifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 461

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ istrifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 462

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 463

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 464

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 465

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ ispentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 466

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ ismethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 467

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 468

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isn-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 469

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isisopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 470

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ ismethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 471

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 472

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isn-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 473

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isisopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 474

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ ismethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 475

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 476

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isn-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 477

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isisopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 478

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ ismethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 479

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 480

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isn-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 481

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isisopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 482

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ ismethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 483

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 484

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isn-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 485

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isisopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 486

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ ismethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 487

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 488

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isn-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 489

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isisopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 490

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isoxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 491

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isoxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 492

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ istetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 493

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ istetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 494

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ istetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 495

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ istetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 496

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ istetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 497

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isthietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 498

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ isthietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 499

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 500

Compounds of the formula I.1 in which R⁸ is cyclopropyl, R⁹ is1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 501

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is methoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 502

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is ethoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 503

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is n-propoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 504

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isisopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in eachcase to one row of Table A

Table 505

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is n-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 506

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ issec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in eachcase to one row of Table A

Table 507

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is isobutoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 508

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ istert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 509

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isfluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 510

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isdifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 511

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ istrifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 512

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 513

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 514

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 515

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ ispentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 516

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ ismethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 517

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 518

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isn-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 519

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isisopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 520

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ ismethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 521

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 522

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isn-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 523

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isisopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 524

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ ismethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 525

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 526

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isn-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 527

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isisopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 528

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ ismethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 529

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 530

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isn-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 531

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isisopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 532

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ ismethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 533

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 534

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isn-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 535

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isisopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 536

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ ismethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 537

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 538

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isn-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 539

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isisopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 540

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isoxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 541

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isoxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 542

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ istetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 543

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ istetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 544

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ istetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 545

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ istetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 546

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ istetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 547

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isthietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 548

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ isthietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 549

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 550

Compounds of the formula I.1 in which R⁸ is cyclobutyl, R⁹ is1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 551

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is methoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 552

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is ethoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 553

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isn-propoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in eachcase to one row of Table A

Table 554

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isisopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in eachcase to one row of Table A

Table 555

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is n-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 556

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ issec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in eachcase to one row of Table A

Table 557

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isisobutoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in eachcase to one row of Table A

Table 558

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ istert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 559

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isfluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 560

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isdifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 561

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ istrifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 562

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 563

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 564

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 565

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ ispentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 566

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ ismethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 567

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 568

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isn-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 569

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isisopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 570

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ ismethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 571

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 572

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isn-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 573

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isisopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 574

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ ismethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 575

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 576

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isn-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 577

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isisopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 578

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ ismethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 579

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 580

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isn-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 581

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isisopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 582

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ ismethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 583

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 584

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isn-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 585

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isisopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 586

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ ismethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 587

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 588

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isn-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 589

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isisopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 590

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isoxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 591

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isoxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 592

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ istetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 593

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ istetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 594

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ istetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 595

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ istetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 596

Compounds of the formula II in which R⁸ is cyclopentyl, R⁹ istetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 597

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isthietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 598

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ isthietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 599

Compounds of the formula II in which R⁸ is cyclopentyl, R⁹ is1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 600

Compounds of the formula I.1 in which R⁸ is cyclopentyl, R⁹ is1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 601

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is methoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 602

Compounds of the formula II in which R⁸ is cyclohexyl, R⁹ is ethoxy, andR¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to one rowof Table A

Table 603

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is n-propoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 604

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isisopropoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in eachcase to one row of Table A

Table 605

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is n-butoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 606

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ issec-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in eachcase to one row of Table A

Table 607

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is isobutoxy,and R¹, R², R³, R⁶ and R⁷ for a compound corresponds in each case to onerow of Table A

Table 608

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ istert-butoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 609

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isfluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 610

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isdifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 611

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ istrifluoromethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 612

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is2-fluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 613

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is2,2-difluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 614

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is2,2,2-trifluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 615

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ ispentafluoroethoxy, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 616

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ ismethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 617

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isethoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 618

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isn-propoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 619

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isisopropoxymethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 620

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ ismethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 621

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isethoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 622

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isn-propoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 623

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isisopropoxy-1-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 624

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ ismethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 625

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isethoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 626

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isn-propoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 627

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isisopropoxy-2-ethyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 628

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ ismethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 629

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isethoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 630

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isn-propoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 631

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isisopropoxy-1-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 632

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ ismethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 633

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isethoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 634

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isn-propoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 635

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isisopropoxy-2-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 636

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ ismethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 637

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isethoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 638

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isn-propoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 639

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isisopropoxy-3-propyl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 640

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isoxetan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 641

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isoxetan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 642

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ istetrahydrofuran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 643

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ istetrahydrofuran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 644

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ istetrahydropyran-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 645

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ istetrahydropyran-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 646

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ istetrahydropyran-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 647

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isthietan-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 648

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ isthietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 649

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is1-oxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compound correspondsin each case to one row of Table A

Table 650

Compounds of the formula I.1 in which R⁸ is cyclohexyl, R⁹ is1,1-dioxothietan-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 651

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-fluoroaziridin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 652

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2,2-difluoroaziridin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 653

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-methoxyaziridin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 654

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-fluoroazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 655

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2,2-difluoroazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 656

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-fluoroazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 657

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3,3-difluoroazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 658

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-hydroxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 659

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-hydroxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 660

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-methoxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 661

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-methoxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 662

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-ethoxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 663

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-ethoxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 664

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-trifluoromethoxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Table 665

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-trifluoromethoxyazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Table 666

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-(oxetan-3-yl)-azetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 667

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-(oxetan-3-yl)-azetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 668

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)[1,3]oxazetidin-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 669

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)[1,3]diazetidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 670

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-oxa-6-aza-spiro[3.3]hept-6-yl, and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Table 671

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2,6-diaza-spiro[3.3]hept-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 672

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-fluoropyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 673

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2,2-difluoropyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 674

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-fluoropyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 675

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3,3-difluoropyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 676

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-hydroxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 677

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-hydroxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 678

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-methoxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 679

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-methoxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 680

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-ethoxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 681

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-ethoxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 682

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-trifluoromethoxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Table 683

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-trifluoromethoxypyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Table 684

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-(oxetan-3-yl)-pyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Table 685

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-(oxetan-3-yl)-pyrrolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Table 686

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)tetrahydroisoxazolidin-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 687

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)tetrahydroxazolidin-3-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 688

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)tetrahydropyrazolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 689

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)tetrahydroimidazolidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 690

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-fluoropiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 691

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2,2-difluoropiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 692

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-fluoropiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 693

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3,3-difluoropiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 694

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)4-fluoropiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 695

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)4,4-difluoropiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 696

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-hydroxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 697

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-hydroxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 698

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)4-hydroxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 699

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-methoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 700

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-methoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 701

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)4-methoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 702

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-ethoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 703

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-ethoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 704

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)4-ethoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 705

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-trifluoromethoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Table 706

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-trifluoromethoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Table 707

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)4-trifluoromethoxypiperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Table 708

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-(oxetan-3-yl)-piperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 709

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)3-(oxetan-3-yl)-piperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 710

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)4-(oxetan-3-yl)-piperidin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 711

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)morpholin-4-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 712

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)piperazin-1-yl, and R¹, R², R³, R⁶ and R⁷ for a compound corresponds ineach case to one row of Table A

Table 713

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2-oxa-7-aza-spiro[3.5]non-7-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 714

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2,7-diaza-spiro[3.5]non-7-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Table 715

Compounds of the formula I.1 in which R⁸ and R⁹, together with thenitrogen atom they are bound to, form (or in other words: NR⁸R⁹ is)2,7-diaza-spiro[3.5]non-2-yl, and R¹, R², R³, R⁶ and R⁷ for a compoundcorresponds in each case to one row of Table A

Tables 716 to 1430

Compounds of the formula I.2, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 1431 to 2145

Compounds of the formula I.3, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 2146 to 2860

Compounds of the formula I.4, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 2861 to 3575

Compounds of the formula I.5, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 3576 to 4290

Compounds of the formula I.6, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 4291 to 5005

Compounds of the formula I.7, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 5006 to 5720

Compounds of the formula I.8, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 5721 to 6435

Compounds of the formula I.9, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 6436 to 7150

Compounds of the formula I.10, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 7151 to 7865

Compounds of the formula I.11, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 7866 to 8580

Compounds of the formula I.12, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 8581 to 9295

Compounds of the formula I.13, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 9296 to 10010

Compounds of the formula I.14, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 10011 to 10725

Compounds of the formula I.15, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 10726 to 11440

Compounds of the formula I.16, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 11441 to 12155

Compounds of the formula I.17, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 12156 to 12870

Compounds of the formula I.18, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 12871 to 13585

Compounds of the formula I.19, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 13586 to 14300

Compounds of the formula I.20, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R¹, R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table A

Tables 14301 to 15015

Compounds of the formula I.21, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 15016 to 15730

Compounds of the formula I.22, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 15731 to 16445

Compounds of the formula I.23, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 16646 to 17160

Compounds of the formula I.24, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 17161 to 17875

Compounds of the formula I.25, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 17876 to 18590

Compounds of the formula I.26, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 18591 to 19305

Compounds of the formula I.27, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 19306 to 20020

Compounds of the formula I.28, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 20021 to 20735

Compounds of the formula I.29, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 20736 to 21450

Compounds of the formula I.30, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 21451 to 22165

Compounds of the formula I.31, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 22166 to 22880

Compounds of the formula I.32, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 22881 to 23595

Compounds of the formula I.33, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 23596 to 24310

Compounds of the formula I.34, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 24311 to 25025

Compounds of the formula I.35, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 25026 to 25740

Compounds of the formula I.36, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 25741 to 26455

Compounds of the formula I.37, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 26456 to 27170

Compounds of the formula I.38, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 27171 to 27885

Compounds of the formula I.39, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

Tables 27886 to 28600

Compounds of the formula I.40, in which the combination of R⁸ and R⁹ isas defined in any one of Tables 1 to 715 and R², R³, R⁶ and R⁷ for acompound corresponds in each case to one row of Table B

TABLE A Example No. R¹ R² R³ R⁶ R⁷ A-1. H H H CN H A-2. F H H CN H A-3.CH₃ H H CN H A-4. OCH₃ H H CN H A-5. CH₂F H H CN H A-6. CHF₂ H H CN HA-7. CF₃ H H CN H A-8. OCH₂F H H CN H A-9. OCHF₂ H H CN H A-10. OCF₃ H HCN H A-11. H F H CN H A-12. H CH₃ H CN H A-13. H OCH₃ H CN H A-14. H CNH CN H A-15. H CH₂F H CN H A-16. H CHF₂ H CN H A-17. H CF₃ H CN H A-18.H OCH₂F H CN H A-19. H OCHF₂ H CN H A-20. H OCF₃ H CN H A-21. H H 3-F CNH A-22. H H 3-CH₃ CN H A-23. H H 3-OCH₃ CN H A-24. H H 5-F CN H A-25. HH 5-CH₃ CN H A-26. H H 5-OCH₃ CN H A-27. F F H CN H A-28. F CH₃ H CN HA-29. F OCH₃ H CN H A-30. F CN H CN H A-31. F CH₂F H CN H A-32. F CHF₂ HCN H A-33. F CF₃ H CN H A-34. F OCH₂F H CN H A-35. F OCHF₂ H CN H A-36.F OCF₃ H CN H A-37. F H 3-F CN H A-38. F H 3-CH₃ CN H A-39. F H 3-OCH₃CN H A-40. F H 5-F CN H A-41. F H 5-CH₃ CN H A-42. F H 5-OCH₃ CN H A-43.CH₃ F H CN H A-44. CH₃ CH₃ H CN H A-45. CH₃ OCH₃ H CN H A-46. CH₃ CN HCN H A-47. CH₃ CH₂F H CN H A-48. CH₃ CHF₂ H CN H A-49. CH₃ CF₃ H CN HA-50. CH₃ OCH₂F H CN H A-51. CH₃ OCHF₂ H CN H A-52. CH₃ OCF₃ H CN HA-53. CH₃ H 3-F CN H A-54. CH₃ H 3-CH₃ CN H A-55. CH₃ H 3-OCH₃ CN HA-56. CH₃ H 5-F CN H A-57. CH₃ H 5-CH₃ CN H A-58. CH₃ H 5-OCH₃ CN HA-59. OCH₃ F H CN H A-60. OCH₃ CH₃ H CN H A-61. OCH₃ OCH₃ H CN H A-62.OCH₃ CN H CN H A-63. OCH₃ CH₂F H CN H A-64. OCH₃ CHF₂ H CN H A-65. OCH₃CF₃ H CN H A-66. OCH₃ OCH₂F H CN H A-67. OCH₃ OCHF₂ H CN H A-68. OCH₃OCF₃ H CN H A-69. OCH₃ H 3-F CN H A-70. OCH₃ H 3-CH₃ CN H A-71. OCH₃ H3-OCH₃ CN H A-72. OCH₃ H 5-F CN H A-73. OCH₃ H 5-CH₃ CN H A-74. OCH₃ H5-OCH₃ CN H A-75. H F 3-F CN H A-76. H F 3-CH₃ CN H A-77. H F 3-OCH₃ CNH A-78. H F 5-F CN H A-79. H F 5-CH₃ CN H A-80. H F 5-OCH₃ CN H A-81. HCH₃ 3-F CN H A-82. H CH₃ 3-CH₃ CN H A-83. H CH₃ 3-OCH₃ CN H A-84. H CH₃5-F CN H A-85. H CH₃ 5-CH₃ CN H A-86. H CH₃ 5-OCH₃ CN H A-87. H OCH₃ 3-FCN H A-88. H OCH₃ 3-CH₃ CN H A-89. H OCH₃ 3-OCH₃ CN H A-90. H OCH₃ 5-FCN H A-91. H OCH₃ 5-CH₃ CN H A-92. H OCH₃ 5-OCH₃ CN H A-93. H CN 3-F CNH A-94. H CN 3-CH₃ CN H A-95. H CN 3-OCH₃ CN H A-96. H CN 5-F CN H A-97.H CN 5-CH₃ CN H A-98. H CN 5-OCH₃ CN H A-99. H CH₂F 3-F CN H A-100. HCH₂F 3-CH₃ CN H A-101. H CH₂F 3-OCH₃ CN H A-102. H CH₂F 5-F CN H A-103.H CH₂F 5-CH₃ CN H A-104. H CH₂F 5-OCH₃ CN H A-105. H CHF₂ 3-F CN HA-106. H CHF₂ 3-CH₃ CN H A-107. H CHF₂ 3-OCH₃ CN H A-108. H CHF₂ 5-F CNH A-109. H CHF₂ 5-CH₃ CN H A-110. H CHF₂ 5-OCH₃ CN H A-111. H CF₃ 3-F CNH A-112. H CF₃ 3-CH₃ CN H A-113. H CF₃ 3-OCH₃ CN H A-114. H CF₃ 5-F CN HA-115. H CF₃ 5-CH₃ CN H A-116. H CF₃ 5-OCH₃ CN H A-117. H OCH₂F 3-F CN HA-118. H OCH₂F 3-CH₃ CN H A-119. H OCH₂F 3-OCH₃ CN H A-120. H OCH₂F 5-FCN H A-121. H OCH₂F 5-CH₃ CN H A-122. H OCH₂F 5-OCH₃ CN H A-123. H OCHF₂3-F CN H A-124. H OCHF₂ 3-CH₃ CN H A-125. H OCHF₂ 3-OCH₃ CN H A-126. HOCHF₂ 5-F CN H A-127. H OCHF₂ 5-CH₃ CN H A-128. H OCHF₂ 5-OCH₃ CN HA-129. H OCF₃ 3-F CN H A-130. H OCF₃ 3-CH₃ CN H A-131. H OCF₃ 3-OCH₃ CNH A-132. H OCF₃ 5-F CN H A-133. H OCF₃ 5-CH₃ CN H A-134. H OCF₃ 5-OCH₃CN H A-135. F F 3-F CN H A-136. F F 3-CH₃ CN H A-137. F F 3-OCH₃ CN HA-138. F F 5-F CN H A-139. F F 5-CH₃ CN H A-140. F F 5-OCH₃ CN H A-141.F CH₃ 3-F CN H A-142. F CH₃ 3-CH₃ CN H A-143. F CH₃ 3-OCH₃ CN H A-144. FCH₃ 5-F CN H A-145. F CH₃ 5-CH₃ CN H A-146. F CH₃ 5-OCH₃ CN H A-147. FOCH₃ 3-F CN H A-148. F OCH₃ 3-CH₃ CN H A-149. F OCH₃ 3-OCH₃ CN H A-150.F OCH₃ 5-F CN H A-151. F OCH₃ 5-CH₃ CN H A-152. F OCH₃ 5-OCH₃ CN HA-153. F CN 3-F CN H A-154. F CN 3-CH₃ CN H A-155. F CN 3-OCH₃ CN HA-156. F CN 5-F CN H A-157. F CN 5-CH₃ CN H A-158. F CN 5-OCH₃ CN HA-159. F CH₂F 3-F CN H A-160. F CH₂F 3-CH₃ CN H A-161. F CH₂F 3-OCH₃ CNH A-162. F CH₂F 5-F CN H A-163. F CH₂F 5-CH₃ CN H A-164. F CH₂F 5-OCH₃CN H A-165. F CHF₂ 3-F CN H A-166. F CHF₂ 3-CH₃ CN H A-167. F CHF₂3-OCH₃ CN H A-168. F CHF₂ 5-F CN H A-169. F CHF₂ 5-CH₃ CN H A-170. FCHF₂ 5-OCH₃ CN H A-171. F CF₃ 3-F CN H A-172. F CF₃ 3-CH₃ CN H A-173. FCF₃ 3-OCH₃ CN H A-174. F CF₃ 5-F CN H A-175. F CF₃ 5-CH₃ CN H A-176. FCF₃ 5-OCH₃ CN H A-177. F OCH₂F 3-F CN H A-178. F OCH₂F 3-CH₃ CN H A-179.F OCH₂F 3-OCH₃ CN H A-180. F OCH₂F 5-F CN H A-181. F OCH₂F 5-CH₃ CN HA-182. F OCH₂F 5-OCH₃ CN H A-183. F OCHF₂ 3-F CN H A-184. F OCHF₂ 3-CH₃CN H A-185. F OCHF₂ 3-OCH₃ CN H A-186. F OCHF₂ 5-F CN H A-187. F OCHF₂5-CH₃ CN H A-188. F OCHF₂ 5-OCH₃ CN H A-189. F OCF₃ 3-F CN H A-190. FOCF₃ 3-CH₃ CN H A-191. F OCF₃ 3-OCH₃ CN H A-192. F OCF₃ 5-F CN H A-193.F OCF₃ 5-CH₃ CN H A-194. F OCF₃ 5-OCH₃ CN H A-195. CH₃ F 3-F CN H A-196.CH₃ F 3-CH₃ CN H A-197. CH₃ F 3-OCH₃ CN H A-198. CH₃ F 5-F CN H A-199.CH₃ F 5-CH₃ CN H A-200. CH₃ F 5-OCH₃ CN H A-201. CH₃ CH₃ 3-F CN H A-202.CH₃ CH₃ 3-CH₃ CN H A-203. CH₃ CH₃ 3-OCH₃ CN H A-204. CH₃ CH₃ 5-F CN HA-205. CH₃ CH₃ 5-CH₃ CN H A-206. CH₃ CH₃ 5-OCH₃ CN H A-207. CH₃ OCH₃ 3-FCN H A-208. CH₃ OCH₃ 3-CH₃ CN H A-209. CH₃ OCH₃ 3-OCH₃ CN H A-210. CH₃OCH₃ 5-F CN H A-211. CH₃ OCH₃ 5-CH₃ CN H A-212. CH₃ OCH₃ 5-OCH₃ CN HA-213. CH₃ CN 3-F CN H A-214. CH₃ CN 3-CH₃ CN H A-215. CH₃ CN 3-OCH₃ CNH A-216. CH₃ CN 5-F CN H A-217. CH₃ CN 5-CH₃ CN H A-218. CH₃ CN 5-OCH₃CN H A-219. CH₃ CH₂F 3-F CN H A-220. CH₃ CH₂F 3-CH₃ CN H A-221. CH₃ CH₂F3-OCH₃ CN H A-222. CH₃ CH₂F 5-F CN H A-223. CH₃ CH₂F 5-CH₃ CN H A-224.CH₃ CH₂F 5-OCH₃ CN H A-225. CH₃ CHF₂ 3-F CN H A-226. CH₃ CHF₂ 3-CH₃ CN HA-227. CH₃ CHF₂ 3-OCH₃ CN H A-228. CH₃ CHF₂ 5-F CN H A-229. CH₃ CHF₂5-CH₃ CN H A-230. CH₃ CHF₂ 5-OCH₃ CN H A-231. CH₃ CF₃ 3-F CN H A-232.CH₃ CF₃ 3-CH₃ CN H A-233. CH₃ CF₃ 3-OCH₃ CN H A-234. CH₃ CF₃ 5-F CN HA-235. CH₃ CF₃ 5-CH₃ CN H A-236. CH₃ CF₃ 5-OCH₃ CN H A-237. CH₃ OCH₂F3-F CN H A-238. CH₃ OCH₂F 3-CH₃ CN H A-239. CH₃ OCH₂F 3-OCH₃ CN H A-240.CH₃ OCH₂F 5-F CN H A-241. CH₃ OCH₂F 5-CH₃ CN H A-242. CH₃ OCH₂F 5-OCH₃CN H A-243. CH₃ OCHF₂ 3-F CN H A-244. CH₃ OCHF₂ 3-CH₃ CN H A-245. CH₃OCHF₂ 3-OCH₃ CN H A-246. CH₃ OCHF₂ 5-F CN H A-247. CH₃ OCHF₂ 5-CH₃ CN HA-248. CH₃ OCHF₂ 5-OCH₃ CN H A-249. CH₃ OCF₃ 3-F CN H A-250. CH₃ OCF₃3-CH₃ CN H A-251. CH₃ OCF₃ 3-OCH₃ CN H A-252. CH₃ OCF₃ 5-F CN H A-253.CH₃ OCF₃ 5-CH₃ CN H A-254. CH₃ OCF₃ 5-OCH₃ CN H A-255. OCH₃ F 3-F CN HA-256. OCH₃ F 3-CH₃ CN H A-257. OCH₃ F 3-OCH₃ CN H A-258. OCH₃ F 5-F CNH A-259. OCH₃ F 5-CH₃ CN H A-260. OCH₃ F 5-OCH₃ CN H A-261. OCH₃ CH₃ 3-FCN H A-262. OCH₃ CH₃ 3-CH₃ CN H A-263. OCH₃ CH₃ 3-OCH₃ CN H A-264. OCH₃CH₃ 5-F CN H A-265. OCH₃ CH₃ 5-CH₃ CN H A-266. OCH₃ CH₃ 5-OCH₃ CN HA-267. OCH₃ OCH₃ 3-F CN H A-268. OCH₃ OCH₃ 3-CH₃ CN H A-269. OCH₃ OCH₃3-OCH₃ CN H A-270. OCH₃ OCH₃ 5-F CN H A-271. OCH₃ OCH₃ 5-CH₃ CN H A-272.OCH₃ OCH₃ 5-OCH₃ CN H A-273. OCH₃ CN 3-F CN H A-274. OCH₃ CN 3-CH₃ CN HA-275. OCH₃ CN 3-OCH₃ CN H A-276. OCH₃ CN 5-F CN H A-277. OCH₃ CN 5-CH₃CN H A-278. OCH₃ CN 5-OCH₃ CN H A-279. OCH₃ CH₂F 3-F CN H A-280. OCH₃CH₂F 3-CH₃ CN H A-281. OCH₃ CH₂F 3-OCH₃ CN H A-282. OCH₃ CH₂F 5-F CN HA-283. OCH₃ CH₂F 5-CH₃ CN H A-284. OCH₃ CH₂F 5-OCH₃ CN H A-285. OCH₃CHF₂ 3-F CN H A-286. OCH₃ CHF₂ 3-CH₃ CN H A-287. OCH₃ CHF₂ 3-OCH₃ CN HA-288. OCH₃ CHF₂ 5-F CN H A-289. OCH₃ CHF₂ 5-CH₃ CN H A-290. OCH₃ CHF₂5-OCH₃ CN H A-291. OCH₃ CF₃ 3-F CN H A-292. OCH₃ CF₃ 3-CH₃ CN H A-293.OCH₃ CF₃ 3-OCH₃ CN H A-294. OCH₃ CF₃ 5-F CN H A-295. OCH₃ CF₃ 5-CH₃ CN HA-296. OCH₃ CF₃ 5-OCH₃ CN H A-297. OCH₃ OCH₂F 3-F CN H A-298. OCH₃ OCH₂F3-CH₃ CN H A-299. OCH₃ OCH₂F 3-OCH₃ CN H A-300. OCH₃ OCH₂F 5-F CN HA-301. OCH₃ OCH₂F 5-CH₃ CN H A-302. OCH₃ OCH₂F 5-OCH₃ CN H A-303. OCH₃OCHF₂ 3-F CN H A-304. OCH₃ OCHF₂ 3-CH₃ CN H A-305. OCH₃ OCHF₂ 3-OCH₃ CNH A-306. OCH₃ OCHF₂ 5-F CN H A-307. OCH₃ OCHF₂ 5-CH₃ CN H A-308. OCH₃OCHF₂ 5-OCH₃ CN H A-309. OCH₃ OCF₃ 3-F CN H A-310. OCH₃ OCF₃ 3-CH₃ CN HA-311. OCH₃ OCF₃ 3-OCH₃ CN H A-312. OCH₃ OCF₃ 5-F CN H A-313. OCH₃ OCF₃5-CH₃ CN H A-314. OCH₃ OCF₃ 5-OCH₃ CN H A-315. CH₂F F 3-F CN H A-316.CH₂F F 3-CH₃ CN H A-317. CH₂F F 3-OCH₃ CN H A-318. CH₂F F 5-F CN HA-319. CH₂F F 5-CH₃ CN H A-320. CH₂F F 5-OCH₃ CN H A-321. CH₂F CH₃ 3-FCN H A-322. CH₂F CH₃ 3-CH₃ CN H A-323. CH₂F CH₃ 3-OCH₃ CN H A-324. CH₂FCH₃ 5-F CN H A-325. CH₂F CH₃ 5-CH₃ CN H A-326. CH₂F CH₃ 5-OCH₃ CN HA-327. CH₂F OCH₃ 3-F CN H A-328. CH₂F OCH₃ 3-CH₃ CN H A-329. CH₂F OCH₃3-OCH₃ CN H A-330. CH₂F OCH₃ 5-F CN H A-331. CH₂F OCH₃ 5-CH₃ CN H A-332.CH₂F OCH₃ 5-OCH₃ CN H A-333. CH₂F CN 3-F CN H A-334. CH₂F CN 3-CH₃ CN HA-335. CH₂F CN 3-OCH₃ CN H A-336. CH₂F CN 5-F CN H A-337. CH₂F CN 5-CH₃CN H A-338. CH₂F CN 5-OCH₃ CN H A-339. CH₂F CH₂F 3-F CN H A-340. CH₂FCH₂F 3-CH₃ CN H A-341. CH₂F CH₂F 3-OCH₃ CN H A-342. CH₂F CH₂F 5-F CN HA-343. CH₂F CH₂F 5-CH₃ CN H A-344. CH₂F CH₂F 5-OCH₃ CN H A-345. CH₂FCHF₂ 3-F CN H A-346. CH₂F CHF₂ 3-CH₃ CN H A-347. CH₂F CHF₂ 3-OCH₃ CN HA-348. CH₂F CHF₂ 5-F CN H A-349. CH₂F CHF₂ 5-CH₃ CN H A-350. CH₂F CHF₂5-OCH₃ CN H A-351. CH₂F CF₃ 3-F CN H A-352. CH₂F CF₃ 3-CH₃ CN H A-353.CH₂F CF₃ 3-OCH₃ CN H A-354. CH₂F CF₃ 5-F CN H A-355. CH₂F CF₃ 5-CH₃ CN HA-356. CH₂F CF₃ 5-OCH₃ CN H A-357. CH₂F OCH₂F 3-F CN H A-358. CH₂F OCH₂F3-CH₃ CN H A-359. CH₂F OCH₂F 3-OCH₃ CN H A-360. CH₂F OCH₂F 5-F CN HA-361. CH₂F OCH₂F 5-CH₃ CN H A-362. CH₂F OCH₂F 5-OCH₃ CN H A-363. CH₂FOCHF₂ 3-F CN H A-364. CH₂F OCHF₂ 3-CH₃ CN H A-365. CH₂F OCHF₂ 3-OCH₃ CNH A-366. CH₂F OCHF₂ 5-F CN H A-367. CH₂F OCHF₂ 5-CH₃ CN H A-368. CH₂FOCHF₂ 5-OCH₃ CN H A-369. CH₂F OCF₃ 3-F CN H A-370. CH₂F OCF₃ 3-CH₃ CN HA-371. CH₂F OCF₃ 3-OCH₃ CN H A-372. CH₂F OCF₃ 5-F CN H A-373. CH₂F OCF₃5-CH₃ CN H A-374. CH₂F OCF₃ 5-OCH₃ CN H A-375. CHF₂ F 3-F CN H A-376.CHF₂ F 3-CH₃ CN H A-377. CHF₂ F 3-OCH₃ CN H A-378. CHF₂ F 5-F CN HA-379. CHF₂ F 5-CH₃ CN H A-380. CHF₂ F 5-OCH₃ CN H A-381. CHF₂ CH₃ 3-FCN H A-382. CHF₂ CH₃ 3-CH₃ CN H A-383. CHF₂ CH₃ 3-OCH₃ CN H A-384. CHF₂CH₃ 5-F CN H A-385. CHF₂ CH₃ 5-CH₃ CN H A-386. CHF₂ CH₃ 5-OCH₃ CN HA-387. CHF₂ OCH₃ 3-F CN H A-388. CHF₂ OCH₃ 3-CH₃ CN H A-389. CHF₂ OCH₃3-OCH₃ CN H A-390. CHF₂ OCH₃ 5-F CN H A-391. CHF₂ OCH₃ 5-CH₃ CN H A-392.CHF₂ OCH₃ 5-OCH₃ CN H A-393. CHF₂ CN 3-F CN H A-394. CHF₂ CN 3-CH₃ CN HA-395. CHF₂ CN 3-OCH₃ CN H A-396. CHF₂ CN 5-F CN H A-397. CHF₂ CN 5-CH₃CN H A-398. CHF₂ CN 5-OCH₃ CN H A-399. CHF₂ CH₂F 3-F CN H A-400. CHF₂CH₂F 3-CH₃ CN H A-401. CHF₂ CH₂F 3-OCH₃ CN H A-402. CHF₂ CH₂F 5-F CN HA-403. CHF₂ CH₂F 5-CH₃ CN H A-404. CHF₂ CH₂F 5-OCH₃ CN H A-405. CHF₂CHF₂ 3-F CN H A-406. CHF₂ CHF₂ 3-CH₃ CN H A-407. CHF₂ CHF₂ 3-OCH₃ CN HA-408. CHF₂ CHF₂ 5-F CN H A-409. CHF₂ CHF₂ 5-CH₃ CN H A-410. CHF₂ CHF₂5-OCH₃ CN H A-411. CHF₂ CF₃ 3-F CN H A-412. CHF₂ CF₃ 3-CH₃ CN H A-413.CHF₂ CF₃ 3-OCH₃ CN H A-414. CHF₂ CF₃ 5-F CN H A-415. CHF₂ CF₃ 5-CH₃ CN HA-416. CHF₂ CF₃ 5-OCH₃ CN H A-417. CHF₂ OCH₂F 3-F CN H A-418. CHF₂ OCH₂F3-CH₃ CN H A-419. CHF₂ OCH₂F 3-OCH₃ CN H A-420. CHF₂ OCH₂F 5-F CN HA-421. CHF₂ OCH₂F 5-CH₃ CN H A-422. CHF₂ OCH₂F 5-OCH₃ CN H A-423. CHF₂OCHF₂ 3-F CN H A-424. CHF₂ OCHF₂ 3-CH₃ CN H A-425. CHF₂ OCHF₂ 3-OCH₃ CNH A-426. CHF₂ OCHF₂ 5-F CN H A-427. CHF₂ OCHF₂ 5-CH₃ CN H A-428. CHF₂OCHF₂ 5-OCH₃ CN H A-429. CHF₂ OCF₃ 3-F CN H A-430. CHF₂ OCF₃ 3-CH₃ CN HA-431. CHF₂ OCF₃ 3-OCH₃ CN H A-432. CHF₂ OCF₃ 5-F CN H A-433. CHF₂ OCF₃5-CH₃ CN H A-434. CHF₂ OCF₃ 5-OCH₃ CN H A-435. CF₃ F 3-F CN H A-436. CF₃F 3-CH₃ CN H A-437. CF₃ F 3-OCH₃ CN H A-438. CF₃ F 5-F CN H A-439. CF₃ F5-CH₃ CN H A-440. CF₃ F 5-OCH₃ CN H A-441. CF₃ CH₃ 3-F CN H A-442. CF₃CH₃ 3-CH₃ CN H A-443. CF₃ CH₃ 3-OCH₃ CN H A-444. CF₃ CH₃ 5-F CN H A-445.CF₃ CH₃ 5-CH₃ CN H A-446. CF₃ CH₃ 5-OCH₃ CN H A-447. CF₃ OCH₃ 3-F CN HA-448. CF₃ OCH₃ 3-CH₃ CN H A-449. CF₃ OCH₃ 3-OCH₃ CN H A-450. CF₃ OCH₃5-F CN H A-451. CF₃ OCH₃ 5-CH₃ CN H A-452. CF₃ OCH₃ 5-OCH₃ CN H A-453.CF₃ CN 3-F CN H A-454. CF₃ CN 3-CH₃ CN H A-455. CF₃ CN 3-OCH₃ CN HA-456. CF₃ CN 5-F CN H A-457. CF₃ CN 5-CH₃ CN H A-458. CF₃ CN 5-OCH₃ CNH A-459. CF₃ CH₂F 3-F CN H A-460. CF₃ CH₂F 3-CH₃ CN H A-461. CF₃ CH₂F3-OCH₃ CN H A-462. CF₃ CH₂F 5-F CN H A-463. CF₃ CH₂F 5-CH₃ CN H A-464.CF₃ CH₂F 5-OCH₃ CN H A-465. CF₃ CHF₂ 3-F CN H A-466. CF₃ CHF₂ 3-CH₃ CN HA-467. CF₃ CHF₂ 3-OCH₃ CN H A-468. CF₃ CHF₂ 5-F CN H A-469. CF₃ CHF₂5-CH₃ CN H A-470. CF₃ CHF₂ 5-OCH₃ CN H A-471. CF₃ CF₃ 3-F CN H A-472.CF₃ CF₃ 3-CH₃ CN H A-473. CF₃ CF₃ 3-OCH₃ CN H A-474. CF₃ CF₃ 5-F CN HA-475. CF₃ CF₃ 5-CH₃ CN H A-476. CF₃ CF₃ 5-OCH₃ CN H A-477. CF₃ OCH₂F3-F CN H A-478. CF₃ OCH₂F 3-CH₃ CN H A-479. CF₃ OCH₂F 3-OCH₃ CN H A-480.CF₃ OCH₂F 5-F CN H A-481. CF₃ OCH₂F 5-CH₃ CN H A-482. CF₃ OCH₂F 5-OCH₃CN H A-483. CF₃ OCHF₂ 3-F CN H A-484. CF₃ OCHF₂ 3-CH₃ CN H A-485. CF₃OCHF₂ 3-OCH₃ CN H A-486. CF₃ OCHF₂ 5-F CN H A-487. CF₃ OCHF₂ 5-CH₃ CN HA-488. CF₃ OCHF₂ 5-OCH₃ CN H A-489. CF₃ OCF₃ 3-F CN H A-490. CF₃ OCF₃3-CH₃ CN H A-491. CF₃ OCF₃ 3-OCH₃ CN H A-492. CF₃ OCF₃ 5-F CN H A-493.CF₃ OCF₃ 5-CH₃ CN H A-494. CF₃ OCF₃ 5-OCH₃ CN H A-495. OCH₂F F 3-F CN HA-496. OCH₂F F 3-CH₃ CN H A-497. OCH₂F F 3-OCH₃ CN H A-498. OCH₂F F 5-FCN H A-499. OCH₂F F 5-CH₃ CN H A-500. OCH₂F F 5-OCH₃ CN H A-501. OCH₂FCH₃ 3-F CN H A-502. OCH₂F CH₃ 3-CH₃ CN H A-503. OCH₂F CH₃ 3-OCH₃ CN HA-504. OCH₂F CH₃ 5-F CN H A-505. OCH₂F CH₃ 5-CH₃ CN H A-506. OCH₂F CH₃5-OCH₃ CN H A-507. OCH₂F OCH₃ 3-F CN H A-508. OCH₂F OCH₃ 3-CH₃ CN HA-509. OCH₂F OCH₃ 3-OCH₃ CN H A-510. OCH₂F OCH₃ 5-F CN H A-511. OCH₂FOCH₃ 5-CH₃ CN H A-512. OCH₂F OCH₃ 5-OCH₃ CN H A-513. OCH₂F CN 3-F CN HA-514. OCH₂F CN 3-CH₃ CN H A-515. OCH₂F CN 3-OCH₃ CN H A-516. OCH₂F CN5-F CN H A-517. OCH₂F CN 5-CH₃ CN H A-518. OCH₂F CN 5-OCH₃ CN H A-519.OCH₂F CH₂F 3-F CN H A-520. OCH₂F CH₂F 3-CH₃ CN H A-521. OCH₂F CH₂F3-OCH₃ CN H A-522. OCH₂F CH₂F 5-F CN H A-523. OCH₂F CH₂F 5-CH₃ CN HA-524. OCH₂F CH₂F 5-OCH₃ CN H A-525. OCH₂F CHF₂ 3-F CN H A-526. OCH₂FCHF₂ 3-CH₃ CN H A-527. OCH₂F CHF₂ 3-OCH₃ CN H A-528. OCH₂F CHF₂ 5-F CN HA-529. OCH₂F CHF₂ 5-CH₃ CN H A-530. OCH₂F CHF₂ 5-OCH₃ CN H A-531. OCH₂FCF₃ 3-F CN H A-532. OCH₂F CF₃ 3-CH₃ CN H A-533. OCH₂F CF₃ 3-OCH₃ CN HA-534. OCH₂F CF₃ 5-F CN H A-535. OCH₂F CF₃ 5-CH₃ CN H A-536. OCH₂F CF₃5-OCH₃ CN H A-537. OCH₂F OCH₂F 3-F CN H A-538. OCH₂F OCH₂F 3-CH₃ CN HA-539. OCH₂F OCH₂F 3-OCH₃ CN H A-540. OCH₂F OCH₂F 5-F CN H A-541. OCH₂FOCH₂F 5-CH₃ CN H A-542. OCH₂F OCH₂F 5-OCH₃ CN H A-543. OCH₂F OCHF₂ 3-FCN H A-544. OCH₂F OCHF₂ 3-CH₃ CN H A-545. OCH₂F OCHF₂ 3-OCH₃ CN H A-546.OCH₂F OCHF₂ 5-F CN H A-547. OCH₂F OCHF₂ 5-CH₃ CN H A-548. OCH₂F OCHF₂5-OCH₃ CN H A-549. OCH₂F OCF₃ 3-F CN H A-550. OCH₂F OCF₃ 3-CH₃ CN HA-551. OCH₂F OCF₃ 3-OCH₃ CN H A-552. OCH₂F OCF₃ 5-F CN H A-553. OCH₂FOCF₃ 5-CH₃ CN H A-554. OCH₂F OCF₃ 5-OCH₃ CN H A-555. OCHF₂ F 3-F CN HA-556. OCHF₂ F 3-CH₃ CN H A-557. OCHF₂ F 3-OCH₃ CN H A-558. OCHF₂ F 5-FCN H A-559. OCHF₂ F 5-CH₃ CN H A-560. OCHF₂ F 5-OCH₃ CN H A-561. OCHF₂CH₃ 3-F CN H A-562. OCHF₂ CH₃ 3-CH₃ CN H A-563. OCHF₂ CH₃ 3-OCH₃ CN HA-564. OCHF₂ CH₃ 5-F CN H A-565. OCHF₂ CH₃ 5-CH₃ CN H A-566. OCHF₂ CH₃5-OCH₃ CN H A-567. OCHF₂ OCH₃ 3-F CN H A-568. OCHF₂ OCH₃ 3-CH₃ CN HA-569. OCHF₂ OCH₃ 3-OCH₃ CN H A-570. OCHF₂ OCH₃ 5-F CN H A-571. OCHF₂OCH₃ 5-CH₃ CN H A-572. OCHF₂ OCH₃ 5-OCH₃ CN H A-573. OCHF₂ CN 3-F CN HA-574. OCHF₂ CN 3-CH₃ CN H A-575. OCHF₂ CN 3-OCH₃ CN H A-576. OCHF₂ CN5-F CN H A-577. OCHF₂ CN 5-CH₃ CN H A-578. OCHF₂ CN 5-OCH₃ CN H A-579.OCHF₂ CH₂F 3-F CN H A-580. OCHF₂ CH₂F 3-CH₃ CN H A-581. OCHF₂ CH₂F3-OCH₃ CN H A-582. OCHF₂ CH₂F 5-F CN H A-583. OCHF₂ CH₂F 5-CH₃ CN HA-584. OCHF₂ CH₂F 5-OCH₃ CN H A-585. OCHF₂ CHF₂ 3-F CN H A-586. OCHF₂CHF₂ 3-CH₃ CN H A-587. OCHF₂ CHF₂ 3-OCH₃ CN H A-588. OCHF₂ CHF₂ 5-F CN HA-589. OCHF₂ CHF₂ 5-CH₃ CN H A-590. OCHF₂ CHF₂ 5-OCH₃ CN H A-591. OCHF₂CF₃ 3-F CN H A-592. OCHF₂ CF₃ 3-CH₃ CN H A-593. OCHF₂ CF₃ 3-OCH₃ CN HA-594. OCHF₂ CF₃ 5-F CN H A-595. OCHF₂ CF₃ 5-CH₃ CN H A-596. OCHF₂ CF₃5-OCH₃ CN H A-597. OCHF₂ OCH₂F 3-F CN H A-598. OCHF₂ OCH₂F 3-CH₃ CN HA-599. OCHF₂ OCH₂F 3-OCH₃ CN H A-600. OCHF₂ OCH₂F 5-F CN H A-601. OCHF₂OCH₂F 5-CH₃ CN H A-602. OCHF₂ OCH₂F 5-OCH₃ CN H A-603. OCHF₂ OCHF₂ 3-FCN H A-604. OCHF₂ OCHF₂ 3-CH₃ CN H A-605. OCHF₂ OCHF₂ 3-OCH₃ CN H A-606.OCHF₂ OCHF₂ 5-F CN H A-607. OCHF₂ OCHF₂ 5-CH₃ CN H A-608. OCHF₂ OCHF₂5-OCH₃ CN H A-609. OCHF₂ OCF₃ 3-F CN H A-610. OCHF₂ OCF₃ 3-CH₃ CN HA-611. OCHF₂ OCF₃ 3-OCH₃ CN H A-612. OCHF₂ OCF₃ 5-F CN H A-613. OCHF₂OCF₃ 5-CH₃ CN H A-614. OCHF₂ OCF₃ 5-OCH₃ CN H A-615. OCF₃ F 3-F CN HA-616. OCF₃ F 3-CH₃ CN H A-617. OCF₃ F 3-OCH₃ CN H A-618. OCF₃ F 5-F CNH A-619. OCF₃ F 5-CH₃ CN H A-620. OCF₃ F 5-OCH₃ CN H A-621. OCF₃ CH₃ 3-FCN H A-622. OCF₃ CH₃ 3-CH₃ CN H A-623. OCF₃ CH₃ 3-OCH₃ CN H A-624. OCF₃CH₃ 5-F CN H A-625. OCF₃ CH₃ 5-CH₃ CN H A-626. OCF₃ CH₃ 5-OCH₃ CN HA-627. OCF₃ OCH₃ 3-F CN H A-628. OCF₃ OCH₃ 3-CH₃ CN H A-629. OCF₃ OCH₃3-OCH₃ CN H A-630. OCF₃ OCH₃ 5-F CN H A-631. OCF₃ OCH₃ 5-CH₃ CN H A-632.OCF₃ OCH₃ 5-OCH₃ CN H A-633. OCF₃ CN 3-F CN H A-634. OCF₃ CN 3-CH₃ CN HA-635. OCF₃ CN 3-OCH₃ CN H A-636. OCF₃ CN 5-F CN H A-637. OCF₃ CN 5-CH₃CN H A-638. OCF₃ CN 5-OCH₃ CN H A-639. OCF₃ CH₂F 3-F CN H A-640. OCF₃CH₂F 3-CH₃ CN H A-641. OCF₃ CH₂F 3-OCH₃ CN H A-642. OCF₃ CH₂F 5-F CN HA-643. OCF₃ CH₂F 5-CH₃ CN H A-644. OCF₃ CH₂F 5-OCH₃ CN H A-645. OCF₃CHF₂ 3-F CN H A-646. OCF₃ CHF₂ 3-CH₃ CN H A-647. OCF₃ CHF₂ 3-OCH₃ CN HA-648. OCF₃ CHF₂ 5-F CN H A-649. OCF₃ CHF₂ 5-CH₃ CN H A-650. OCF₃ CHF₂5-OCH₃ CN H A-651. OCF₃ CF₃ 3-F CN H A-652. OCF₃ CF₃ 3-CH₃ CN H A-653.OCF₃ CF₃ 3-OCH₃ CN H A-654. OCF₃ CF₃ 5-F CN H A-655. OCF₃ CF₃ 5-CH₃ CN HA-656. OCF₃ CF₃ 5-OCH₃ CN H A-657. OCF₃ OCH₂F 3-F CN H A-658. OCF₃ OCH₂F3-CH₃ CN H A-659. OCF₃ OCH₂F 3-OCH₃ CN H A-660. OCF₃ OCH₂F 5-F CN HA-661. OCF₃ OCH₂F 5-CH₃ CN H A-662. OCF₃ OCH₂F 5-OCH₃ CN H A-663. OCF₃OCHF₂ 3-F CN H A-664. OCF₃ OCHF₂ 3-CH₃ CN H A-665. OCF₃ OCHF₂ 3-OCH₃ CNH A-666. OCF₃ OCHF₂ 5-F CN H A-667. OCF₃ OCHF₂ 5-CH₃ CN H A-668. OCF₃OCHF₂ 5-OCH₃ CN H A-669. OCF₃ OCF₃ 3-F CN H A-670. OCF₃ OCF₃ 3-CH₃ CN HA-671. OCF₃ OCF₃ 3-OCH₃ CN H A-672. OCF₃ OCF₃ 5-F CN H A-673. OCF₃ OCF₃5-CH₃ CN H A-674. OCF₃ OCF₃ 5-OCH₃ CN H A-675. H H H F H A-676. F H H FH A-677. CH₃ H H F H A-678. OCH₃ H H F H A-679. CH₂F H H F H A-680. CHF₂H H F H A-681. CF₃ H H F H A-682. OCH₂F H H F H A-683. OCHF₂ H H F HA-684. OCF₃ H H F H A-685. H F H F H A-686. H CH₃ H F H A-687. H OCH₃ HF H A-688. H CN H F H A-689. H CH₂F H F H A-690. H CHF₂ H F H A-691. HCF₃ H F H A-692. H OCH₂F H F H A-693. H OCHF₂ H F H A-694. H OCF₃ H F HA-695. H H 3-F F H A-696. H H 3-CH₃ F H A-697. H H 3-OCH₃ F H A-698. H H5-F F H A-699. H H 5-CH₃ F H A-700. H H 5-OCH₃ F H A-701. F F H F HA-702. F CH₃ H F H A-703. F OCH₃ H F H A-704. F CN H F H A-705. F CH₂F HF H A-706. F CHF₂ H F H A-707. F CF₃ H F H A-708. F OCH₂F H F H A-709. FOCHF₂ H F H A-710. F OCF₃ H F H A-711. F H 3-F F H A-712. F H 3-CH₃ F HA-713. F H 3-OCH₃ F H A-714. F H 5-F F H A-715. F H 5-CH₃ F H A-716. F H5-OCH₃ F H A-717. CH₃ F H F H A-718. CH₃ CH₃ H F H A-719. CH₃ OCH₃ H F HA-720. CH₃ CN H F H A-721. CH₃ CH₂F H F H A-722. CH₃ CHF₂ H F H A-723.CH₃ CF₃ H F H A-724. CH₃ OCH₂F H F H A-725. CH₃ OCHF₂ H F H A-726. CH₃OCF₃ H F H A-727. CH₃ H 3-F F H A-728. CH₃ H 3-CH₃ F H A-729. CH₃ H3-OCH₃ F H A-730. CH₃ H 5-F F H A-731. CH₃ H 5-CH₃ F H A-732. CH₃ H5-OCH₃ F H A-733. OCH₃ F H F H A-734. OCH₃ CH₃ H F H A-735. OCH₃ OCH₃ HF H A-736. OCH₃ CN H F H A-737. OCH₃ CH₂F H F H A-738. OCH₃ CHF₂ H F HA-739. OCH₃ CF₃ H F H A-740. OCH₃ OCH₂F H F H A-741. OCH₃ OCHF₂ H F HA-742. OCH₃ OCF₃ H F H A-743. OCH₃ H 3-F F H A-744. OCH₃ H 3-CH₃ F HA-745. OCH₃ H 3-OCH₃ F H A-746. OCH₃ H 5-F F H A-747. OCH₃ H 5-CH₃ F HA-748. OCH₃ H 5-OCH₃ F H A-749. H F 3-F F H A-750. H F 3-CH₃ F H A-751.H F 3-OCH₃ F H A-752. H F 5-F F H A-753. H F 5-CH₃ F H A-754. H F 5-OCH₃F H A-755. H CH₃ 3-F F H A-756. H CH₃ 3-CH₃ F H A-757. H CH₃ 3-OCH₃ F HA-758. H CH₃ 5-F F H A-759. H CH₃ 5-CH₃ F H A-760. H CH₃ 5-OCH₃ F HA-761. H OCH₃ 3-F F H A-762. H OCH₃ 3-CH₃ F H A-763. H OCH₃ 3-OCH₃ F HA-764. H OCH₃ 5-F F H A-765. H OCH₃ 5-CH₃ F H A-766. H OCH₃ 5-OCH₃ F HA-767. H CN 3-F F H A-768. H CN 3-CH₃ F H A-769. H CN 3-OCH₃ F H A-770.H CN 5-F F H A-771. H CN 5-CH₃ F H A-772. H CN 5-OCH₃ F H A-773. H CH₂F3-F F H A-774. H CH₂F 3-CH₃ F H A-775. H CH₂F 3-OCH₃ F H A-776. H CH₂F5-F F H A-777. H CH₂F 5-CH₃ F H A-778. H CH₂F 5-OCH₃ F H A-779. H CHF₂3-F F H A-780. H CHF₂ 3-CH₃ F H A-781. H CHF₂ 3-OCH₃ F H A-782. H CHF₂5-F F H A-783. H CHF₂ 5-CH₃ F H A-784. H CHF₂ 5-OCH₃ F H A-785. H CF₃3-F F H A-786. H CF₃ 3-CH₃ F H A-787. H CF₃ 3-OCH₃ F H A-788. H CF₃ 5-FF H A-789. H CF₃ 5-CH₃ F H A-790. H CF₃ 5-OCH₃ F H A-791. H OCH₂F 3-F FH A-792. H OCH₂F 3-CH₃ F H A-793. H OCH₂F 3-OCH₃ F H A-794. H OCH₂F 5-FF H A-795. H OCH₂F 5-CH₃ F H A-796. H OCH₂F 5-OCH₃ F H A-797. H OCHF₂3-F F H A-798. H OCHF₂ 3-CH₃ F H A-799. H OCHF₂ 3-OCH₃ F H A-800. HOCHF₂ 5-F F H A-801. H OCHF₂ 5-CH₃ F H A-802. H OCHF₂ 5-OCH₃ F H A-803.H OCF₃ 3-F F H A-804. H OCF₃ 3-CH₃ F H A-805. H OCF₃ 3-OCH₃ F H A-806. HOCF₃ 5-F F H A-807. H OCF₃ 5-CH₃ F H A-808. H OCF₃ 5-OCH₃ F H A-809. F F3-F F H A-810. F F 3-CH₃ F H A-811. F F 3-OCH₃ F H A-812. F F 5-F F HA-813. F F 5-CH₃ F H A-814. F F 5-OCH₃ F H A-815. F CH₃ 3-F F H A-816. FCH₃ 3-CH₃ F H A-817. F CH₃ 3-OCH₃ F H A-818. F CH₃ 5-F F H A-819. F CH₃5-CH₃ F H A-820. F CH₃ 5-OCH₃ F H A-821. F OCH₃ 3-F F H A-822. F OCH₃3-CH₃ F H A-823. F OCH₃ 3-OCH₃ F H A-824. F OCH₃ 5-F F H A-825. F OCH₃5-CH₃ F H A-826. F OCH₃ 5-OCH₃ F H A-827. F CN 3-F F H A-828. F CN 3-CH₃F H A-829. F CN 3-OCH₃ F H A-830. F CN 5-F F H A-831. F CN 5-CH₃ F HA-832. F CN 5-OCH₃ F H A-833. F CH₂F 3-F F H A-834. F CH₂F 3-CH₃ F HA-835. F CH₂F 3-OCH₃ F H A-836. F CH₂F 5-F F H A-837. F CH₂F 5-CH₃ F HA-838. F CH₂F 5-OCH₃ F H A-839. F CHF₂ 3-F F H A-840. F CHF₂ 3-CH₃ F HA-841. F CHF₂ 3-OCH₃ F H A-842. F CHF₂ 5-F F H A-843. F CHF₂ 5-CH₃ F HA-844. F CHF₂ 5-OCH₃ F H A-845. F CF₃ 3-F F H A-846. F CF₃ 3-CH₃ F HA-847. F CF₃ 3-OCH₃ F H A-848. F CF₃ 5-F F H A-849. F CF₃ 5-CH₃ F HA-850. F CF₃ 5-OCH₃ F H A-851. F OCH₂F 3-F F H A-852. F OCH₂F 3-CH₃ F HA-853. F OCH₂F 3-OCH₃ F H A-854. F OCH₂F 5-F F H A-855. F OCH₂F 5-CH₃ FH A-856. F OCH₂F 5-OCH₃ F H A-857. F OCHF₂ 3-F F H A-858. F OCHF₂ 3-CH₃F H A-859. F OCHF₂ 3-OCH₃ F H A-860. F OCHF₂ 5-F F H A-861. F OCHF₂5-CH₃ F H A-862. F OCHF₂ 5-OCH₃ F H A-863. F OCF₃ 3-F F H A-864. F OCF₃3-CH₃ F H A-865. F OCF₃ 3-OCH₃ F H A-866. F OCF₃ 5-F F H A-867. F OCF₃5-CH₃ F H A-868. F OCF₃ 5-OCH₃ F H A-869. CH₃ F 3-F F H A-870. CH₃ F3-CH₃ F H A-871. CH₃ F 3-OCH₃ F H A-872. CH₃ F 5-F F H A-873. CH₃ F5-CH₃ F H A-874. CH₃ F 5-OCH₃ F H A-875. CH₃ CH₃ 3-F F H A-876. CH₃ CH₃3-CH₃ F H A-877. CH₃ CH₃ 3-OCH₃ F H A-878. CH₃ CH₃ 5-F F H A-879. CH₃CH₃ 5-CH₃ F H A-880. CH₃ CH₃ 5-OCH₃ F H A-881. CH₃ OCH₃ 3-F F H A-882.CH₃ OCH₃ 3-CH₃ F H A-883. CH₃ OCH₃ 3-OCH₃ F H A-884. CH₃ OCH₃ 5-F F HA-885. CH₃ OCH₃ 5-CH₃ F H A-886. CH₃ OCH₃ 5-OCH₃ F H A-887. CH₃ CN 3-F FH A-888. CH₃ CN 3-CH₃ F H A-889. CH₃ CN 3-OCH₃ F H A-890. CH₃ CN 5-F F HA-891. CH₃ CN 5-CH₃ F H A-892. CH₃ CN 5-OCH₃ F H A-893. CH₃ CH₂F 3-F F HA-894. CH₃ CH₂F 3-CH₃ F H A-895. CH₃ CH₂F 3-OCH₃ F H A-896. CH₃ CH₂F 5-FF H A-897. CH₃ CH₂F 5-CH₃ F H A-898. CH₃ CH₂F 5-OCH₃ F H A-899. CH₃ CHF₂3-F F H A-900. CH₃ CHF₂ 3-CH₃ F H A-901. CH₃ CHF₂ 3-OCH₃ F H A-902. CH₃CHF₂ 5-F F H A-903. CH₃ CHF₂ 5-CH₃ F H A-904. CH₃ CHF₂ 5-OCH₃ F H A-905.CH₃ CF₃ 3-F F H A-906. CH₃ CF₃ 3-CH₃ F H A-907. CH₃ CF₃ 3-OCH₃ F HA-908. CH₃ CF₃ 5-F F H A-909. CH₃ CF₃ 5-CH₃ F H A-910. CH₃ CF₃ 5-OCH₃ FH A-911. CH₃ OCH₂F 3-F F H A-912. CH₃ OCH₂F 3-CH₃ F H A-913. CH₃ OCH₂F3-OCH₃ F H A-914. CH₃ OCH₂F 5-F F H A-915. CH₃ OCH₂F 5-CH₃ F H A-916.CH₃ OCH₂F 5-OCH₃ F H A-917. CH₃ OCHF₂ 3-F F H A-918. CH₃ OCHF₂ 3-CH₃ F HA-919. CH₃ OCHF₂ 3-OCH₃ F H A-920. CH₃ OCHF₂ 5-F F H A-921. CH₃ OCHF₂5-CH₃ F H A-922. CH₃ OCHF₂ 5-OCH₃ F H A-923. CH₃ OCF₃ 3-F F H A-924. CH₃OCF₃ 3-CH₃ F H A-925. CH₃ OCF₃ 3-OCH₃ F H A-926. CH₃ OCF₃ 5-F F H A-927.CH₃ OCF₃ 5-CH₃ F H A-928. CH₃ OCF₃ 5-OCH₃ F H A-929. OCH₃ F 3-F F HA-930. OCH₃ F 3-CH₃ F H A-931. OCH₃ F 3-OCH₃ F H A-932. OCH₃ F 5-F F HA-933. OCH₃ F 5-CH₃ F H A-934. OCH₃ F 5-OCH₃ F H A-935. OCH₃ CH₃ 3-F F HA-936. OCH₃ CH₃ 3-CH₃ F H A-937. OCH₃ CH₃ 3-OCH₃ F H A-938. OCH₃ CH₃ 5-FF H A-939. OCH₃ CH₃ 5-CH₃ F H A-940. OCH₃ CH₃ 5-OCH₃ F H A-941. OCH₃OCH₃ 3-F F H A-942. OCH₃ OCH₃ 3-CH₃ F H A-943. OCH₃ OCH₃ 3-OCH₃ F HA-944. OCH₃ OCH₃ 5-F F H A-945. OCH₃ OCH₃ 5-CH₃ F H A-946. OCH₃ OCH₃5-OCH₃ F H A-947. OCH₃ CN 3-F F H A-948. OCH₃ CN 3-CH₃ F H A-949. OCH₃CN 3-OCH₃ F H A-950. OCH₃ CN 5-F F H A-951. OCH₃ CN 5-CH₃ F H A-952.OCH₃ CN 5-OCH₃ F H A-953. OCH₃ CH₂F 3-F F H A-954. OCH₃ CH₂F 3-CH₃ F HA-955. OCH₃ CH₂F 3-OCH₃ F H A-956. OCH₃ CH₂F 5-F F H A-957. OCH₃ CH₂F5-CH₃ F H A-958. OCH₃ CH₂F 5-OCH₃ F H A-959. OCH₃ CHF₂ 3-F F H A-960.OCH₃ CHF₂ 3-CH₃ F H A-961. OCH₃ CHF₂ 3-OCH₃ F H A-962. OCH₃ CHF₂ 5-F F HA-963. OCH₃ CHF₂ 5-CH₃ F H A-964. OCH₃ CHF₂ 5-OCH₃ F H A-965. OCH₃ CF₃3-F F H A-966. OCH₃ CF₃ 3-CH₃ F H A-967. OCH₃ CF₃ 3-OCH₃ F H A-968. OCH₃CF₃ 5-F F H A-969. OCH₃ CF₃ 5-CH₃ F H A-970. OCH₃ CF₃ 5-OCH₃ F H A-971.OCH₃ OCH₂F 3-F F H A-972. OCH₃ OCH₂F 3-CH₃ F H A-973. OCH₃ OCH₂F 3-OCH₃F H A-974. OCH₃ OCH₂F 5-F F H A-975. OCH₃ OCH₂F 5-CH₃ F H A-976. OCH₃OCH₂F 5-OCH₃ F H A-977. OCH₃ OCHF₂ 3-F F H A-978. OCH₃ OCHF₂ 3-CH₃ F HA-979. OCH₃ OCHF₂ 3-OCH₃ F H A-980. OCH₃ OCHF₂ 5-F F H A-981. OCH₃ OCHF₂5-CH₃ F H A-982. OCH₃ OCHF₂ 5-OCH₃ F H A-983. OCH₃ OCF₃ 3-F F H A-984.OCH₃ OCF₃ 3-CH₃ F H A-985. OCH₃ OCF₃ 3-OCH₃ F H A-986. OCH₃ OCF₃ 5-F F HA-987. OCH₃ OCF₃ 5-CH₃ F H A-988. OCH₃ OCF₃ 5-OCH₃ F H A-989. CH₂F F 3-FF H A-990. CH₂F F 3-CH₃ F H A-991. CH₂F F 3-OCH₃ F H A-992. CH₂F F 5-F FH A-993. CH₂F F 5-CH₃ F H A-994. CH₂F F 5-OCH₃ F H A-995. CH₂F CH₃ 3-F FH A-996. CH₂F CH₃ 3-CH₃ F H A-997. CH₂F CH₃ 3-OCH₃ F H A-998. CH₂F CH₃5-F F H A-999. CH₂F CH₃ 5-CH₃ F H A-1000. CH₂F CH₃ 5-OCH₃ F H A-1001.CH₂F OCH₃ 3-F F H A-1002. CH₂F OCH₃ 3-CH₃ F H A-1003. CH₂F OCH₃ 3-OCH₃ FH A-1004. CH₂F OCH₃ 5-F F H A-1005. CH₂F OCH₃ 5-CH₃ F H A-1006. CH₂FOCH₃ 5-OCH₃ F H A-1007. CH₂F CN 3-F F H A-1008. CH₂F CN 3-CH₃ F HA-1009. CH₂F CN 3-OCH₃ F H A-1010. CH₂F CN 5-F F H A-1011. CH₂F CN 5-CH₃F H A-1012. CH₂F CN 5-OCH₃ F H A-1013. CH₂F CH₂F 3-F F H A-1014. CH₂FCH₂F 3-CH₃ F H A-1015. CH₂F CH₂F 3-OCH₃ F H A-1016. CH₂F CH₂F 5-F F HA-1017. CH₂F CH₂F 5-CH₃ F H A-1018. CH₂F CH₂F 5-OCH₃ F H A-1019. CH₂FCHF₂ 3-F F H A-1020. CH₂F CHF₂ 3-CH₃ F H A-1021. CH₂F CHF₂ 3-OCH₃ F HA-1022. CH₂F CHF₂ 5-F F H A-1023. CH₂F CHF₂ 5-CH₃ F H A-1024. CH₂F CHF₂5-OCH₃ F H A-1025. CH₂F CF₃ 3-F F H A-1026. CH₂F CF₃ 3-CH₃ F H A-1027.CH₂F CF₃ 3-OCH₃ F H A-1028. CH₂F CF₃ 5-F F H A-1029. CH₂F CF₃ 5-CH₃ F HA-1030. CH₂F CF₃ 5-OCH₃ F H A-1031. CH₂F OCH₂F 3-F F H A-1032. CH₂FOCH₂F 3-CH₃ F H A-1033. CH₂F OCH₂F 3-OCH₃ F H A-1034. CH₂F OCH₂F 5-F F HA-1035. CH₂F OCH₂F 5-CH₃ F H A-1036. CH₂F OCH₂F 5-OCH₃ F H A-1037. CH₂FOCHF₂ 3-F F H A-1038. CH₂F OCHF₂ 3-CH₃ F H A-1039. CH₂F OCHF₂ 3-OCH₃ F HA-1040. CH₂F OCHF₂ 5-F F H A-1041. CH₂F OCHF₂ 5-CH₃ F H A-1042. CH₂FOCHF₂ 5-OCH₃ F H A-1043. CH₂F OCF₃ 3-F F H A-1044. CH₂F OCF₃ 3-CH₃ F HA-1045. CH₂F OCF₃ 3-OCH₃ F H A-1046. CH₂F OCF₃ 5-F F H A-1047. CH₂F OCF₃5-CH₃ F H A-1048. CH₂F OCF₃ 5-OCH₃ F H A-1049. CHF₂ F 3-F F H A-1050.CHF₂ F 3-CH₃ F H A-1051. CHF₂ F 3-OCH₃ F H A-1052. CHF₂ F 5-F F HA-1053. CHF₂ F 5-CH₃ F H A-1054. CHF₂ F 5-OCH₃ F H A-1055. CHF₂ CH₃ 3-FF H A-1056. CHF₂ CH₃ 3-CH₃ F H A-1057. CHF₂ CH₃ 3-OCH₃ F H A-1058. CHF₂CH₃ 5-F F H A-1059. CHF₂ CH₃ 5-CH₃ F H A-1060. CHF₂ CH₃ 5-OCH₃ F HA-1061. CHF₂ OCH₃ 3-F F H A-1062. CHF₂ OCH₃ 3-CH₃ F H A-1063. CHF₂ OCH₃3-OCH₃ F H A-1064. CHF₂ OCH₃ 5-F F H A-1065. CHF₂ OCH₃ 5-CH₃ F H A-1066.CHF₂ OCH₃ 5-OCH₃ F H A-1067. CHF₂ CN 3-F F H A-1068. CHF₂ CN 3-CH₃ F HA-1069. CHF₂ CN 3-OCH₃ F H A-1070. CHF₂ CN 5-F F H A-1071. CHF₂ CN 5-CH₃F H A-1072. CHF₂ CN 5-OCH₃ F H A-1073. CHF₂ CH₂F 3-F F H A-1074. CHF₂CH₂F 3-CH₃ F H A-1075. CHF₂ CH₂F 3-OCH₃ F H A-1076. CHF₂ CH₂F 5-F F HA-1077. CHF₂ CH₂F 5-CH₃ F H A-1078. CHF₂ CH₂F 5-OCH₃ F H A-1079. CHF₂CHF₂ 3-F F H A-1080. CHF₂ CHF₂ 3-CH₃ F H A-1081. CHF₂ CHF₂ 3-OCH₃ F HA-1082. CHF₂ CHF₂ 5-F F H A-1083. CHF₂ CHF₂ 5-CH₃ F H A-1084. CHF₂ CHF₂5-OCH₃ F H A-1085. CHF₂ CF₃ 3-F F H A-1086. CHF₂ CF₃ 3-CH₃ F H A-1087.CHF₂ CF₃ 3-OCH₃ F H A-1088. CHF₂ CF₃ 5-F F H A-1089. CHF₂ CF₃ 5-CH₃ F HA-1090. CHF₂ CF₃ 5-OCH₃ F H A-1091. CHF₂ OCH₂F 3-F F H A-1092. CHF₂OCH₂F 3-CH₃ F H A-1093. CHF₂ OCH₂F 3-OCH₃ F H A-1094. CHF₂ OCH₂F 5-F F HA-1095. CHF₂ OCH₂F 5-CH₃ F H A-1096. CHF₂ OCH₂F 5-OCH₃ F H A-1097. CHF₂OCHF₂ 3-F F H A-1098. CHF₂ OCHF₂ 3-CH₃ F H A-1099. CHF₂ OCHF₂ 3-OCH₃ F HA-1100. CHF₂ OCHF₂ 5-F F H A-1101. CHF₂ OCHF₂ 5-CH₃ F H A-1102. CHF₂OCHF₂ 5-OCH₃ F H A-1103. CHF₂ OCF₃ 3-F F H A-1104. CHF₂ OCF₃ 3-CH₃ F HA-1105. CHF₂ OCF₃ 3-OCH₃ F H A-1106. CHF₂ OCF₃ 5-F F H A-1107. CHF₂ OCF₃5-CH₃ F H A-1108. CHF₂ OCF₃ 5-OCH₃ F H A-1109. CF₃ F 3-F F H A-1110. CF₃F 3-CH₃ F H A-1111. CF₃ F 3-OCH₃ F H A-1112. CF₃ F 5-F F H A-1113. CF₃ F5-CH₃ F H A-1114. CF₃ F 5-OCH₃ F H A-1115. CF₃ CH₃ 3-F F H A-1116. CF₃CH₃ 3-CH₃ F H A-1117. CF₃ CH₃ 3-OCH₃ F H A-1118. CF₃ CH₃ 5-F F H A-1119.CF₃ CH₃ 5-CH₃ F H A-1120. CF₃ CH₃ 5-OCH₃ F H A-1121. CF₃ OCH₃ 3-F F HA-1122. CF₃ OCH₃ 3-CH₃ F H A-1123. CF₃ OCH₃ 3-OCH₃ F H A-1124. CF₃ OCH₃5-F F H A-1125. CF₃ OCH₃ 5-CH₃ F H A-1126. CF₃ OCH₃ 5-OCH₃ F H A-1127.CF₃ CN 3-F F H A-1128. CF₃ CN 3-CH₃ F H A-1129. CF₃ CN 3-OCH₃ F HA-1130. CF₃ CN 5-F F H A-1131. CF₃ CN 5-CH₃ F H A-1132. CF₃ CN 5-OCH₃ FH A-1133. CF₃ CH₂F 3-F F H A-1134. CF₃ CH₂F 3-CH₃ F H A-1135. CF₃ CH₂F3-OCH₃ F H A-1136. CF₃ CH₂F 5-F F H A-1137. CF₃ CH₂F 5-CH₃ F H A-1138.CF₃ CH₂F 5-OCH₃ F H A-1139. CF₃ CHF₂ 3-F F H A-1140. CF₃ CHF₂ 3-CH₃ F HA-1141. CF₃ CHF₂ 3-OCH₃ F H A-1142. CF₃ CHF₂ 5-F F H A-1143. CF₃ CHF₂5-CH₃ F H A-1144. CF₃ CHF₂ 5-OCH₃ F H A-1145. CF₃ CF₃ 3-F F H A-1146.CF₃ CF₃ 3-CH₃ F H A-1147. CF₃ CF₃ 3-OCH₃ F H A-1148. CF₃ CF₃ 5-F F HA-1149. CF₃ CF₃ 5-CH₃ F H A-1150. CF₃ CF₃ 5-OCH₃ F H A-1151. CF₃ OCH₂F3-F F H A-1152. CF₃ OCH₂F 3-CH₃ F H A-1153. CF₃ OCH₂F 3-OCH₃ F H A-1154.CF₃ OCH₂F 5-F F H A-1155. CF₃ OCH₂F 5-CH₃ F H A-1156. CF₃ OCH₂F 5-OCH₃ FH A-1157. CF₃ OCHF₂ 3-F F H A-1158. CF₃ OCHF₂ 3-CH₃ F H A-1159. CF₃OCHF₂ 3-OCH₃ F H A-1160. CF₃ OCHF₂ 5-F F H A-1161. CF₃ OCHF₂ 5-CH₃ F HA-1162. CF₃ OCHF₂ 5-OCH₃ F H A-1163. CF₃ OCF₃ 3-F F H A-1164. CF₃ OCF₃3-CH₃ F H A-1165. CF₃ OCF₃ 3-OCH₃ F H A-1166. CF₃ OCF₃ 5-F F H A-1167.CF₃ OCF₃ 5-CH₃ F H A-1168. CF₃ OCF₃ 5-OCH₃ F H A-1169. OCH₂F F 3-F F HA-1170. OCH₂F F 3-CH₃ F H A-1171. OCH₂F F 3-OCH₃ F H A-1172. OCH₂F F 5-FF H A-1173. OCH₂F F 5-CH₃ F H A-1174. OCH₂F F 5-OCH₃ F H A-1175. OCH₂FCH₃ 3-F F H A-1176. OCH₂F CH₃ 3-CH₃ F H A-1177. OCH₂F CH₃ 3-OCH₃ F HA-1178. OCH₂F CH₃ 5-F F H A-1179. OCH₂F CH₃ 5-CH₃ F H A-1180. OCH₂F CH₃5-OCH₃ F H A-1181. OCH₂F OCH₃ 3-F F H A-1182. OCH₂F OCH₃ 3-CH₃ F HA-1183. OCH₂F OCH₃ 3-OCH₃ F H A-1184. OCH₂F OCH₃ 5-F F H A-1185. OCH₂FOCH₃ 5-CH₃ F H A-1186. OCH₂F OCH₃ 5-OCH₃ F H A-1187. OCH₂F CN 3-F F HA-1188. OCH₂F CN 3-CH₃ F H A-1189. OCH₂F CN 3-OCH₃ F H A-1190. OCH₂F CN5-F F H A-1191. OCH₂F CN 5-CH₃ F H A-1192. OCH₂F CN 5-OCH₃ F H A-1193.OCH₂F CH₂F 3-F F H A-1194. OCH₂F CH₂F 3-CH₃ F H A-1195. OCH₂F CH₂F3-OCH₃ F H A-1196. OCH₂F CH₂F 5-F F H A-1197. OCH₂F CH₂F 5-CH₃ F HA-1198. OCH₂F CH₂F 5-OCH₃ F H A-1199. OCH₂F CHF₂ 3-F F H A-1200. OCH₂FCHF₂ 3-CH₃ F H A-1201. OCH₂F CHF₂ 3-OCH₃ F H A-1202. OCH₂F CHF₂ 5-F F HA-1203. OCH₂F CHF₂ 5-CH₃ F H A-1204. OCH₂F CHF₂ 5-OCH₃ F H A-1205. OCH₂FCF₃ 3-F F H A-1206. OCH₂F CF₃ 3-CH₃ F H A-1207. OCH₂F CF₃ 3-OCH₃ F HA-1208. OCH₂F CF₃ 5-F F H A-1209. OCH₂F CF₃ 5-CH₃ F H A-1210. OCH₂F CF₃5-OCH₃ F H A-1211. OCH₂F OCH₂F 3-F F H A-1212. OCH₂F OCH₂F 3-CH₃ F HA-1213. OCH₂F OCH₂F 3-OCH₃ F H A-1214. OCH₂F OCH₂F 5-F F H A-1215. OCH₂FOCH₂F 5-CH₃ F H A-1216. OCH₂F OCH₂F 5-OCH₃ F H A-1217. OCH₂F OCHF₂ 3-F FH A-1218. OCH₂F OCHF₂ 3-CH₃ F H A-1219. OCH₂F OCHF₂ 3-OCH₃ F H A-1220.OCH₂F OCHF₂ 5-F F H A-1221. OCH₂F OCHF₂ 5-CH₃ F H A-1222. OCH₂F OCHF₂5-OCH₃ F H A-1223. OCH₂F OCF₃ 3-F F H A-1224. OCH₂F OCF₃ 3-CH₃ F HA-1225. OCH₂F OCF₃ 3-OCH₃ F H A-1226. OCH₂F OCF₃ 5-F F H A-1227. OCH₂FOCF₃ 5-CH₃ F H A-1228. OCH₂F OCF₃ 5-OCH₃ F H A-1229. OCHF₂ F 3-F F HA-1230. OCHF₂ F 3-CH₃ F H A-1231. OCHF₂ F 3-OCH₃ F H A-1232. OCHF₂ F 5-FF H A-1233. OCHF₂ F 5-CH₃ F H A-1234. OCHF₂ F 5-OCH₃ F H A-1235. OCHF₂CH₃ 3-F F H A-1236. OCHF₂ CH₃ 3-CH₃ F H A-1237. OCHF₂ CH₃ 3-OCH₃ F HA-1238. OCHF₂ CH₃ 5-F F H A-1239. OCHF₂ CH₃ 5-CH₃ F H A-1240. OCHF₂ CH₃5-OCH₃ F H A-1241. OCHF₂ OCH₃ 3-F F H A-1242. OCHF₂ OCH₃ 3-CH₃ F HA-1243. OCHF₂ OCH₃ 3-OCH₃ F H A-1244. OCHF₂ OCH₃ 5-F F H A-1245. OCHF₂OCH₃ 5-CH₃ F H A-1246. OCHF₂ OCH₃ 5-OCH₃ F H A-1247. OCHF₂ CN 3-F F HA-1248. OCHF₂ CN 3-CH₃ F H A-1249. OCHF₂ CN 3-OCH₃ F H A-1250. OCHF₂ CN5-F F H A-1251. OCHF₂ CN 5-CH₃ F H A-1252. OCHF₂ CN 5-OCH₃ F H A-1253.OCHF₂ CH₂F 3-F F H A-1254. OCHF₂ CH₂F 3-CH₃ F H A-1255. OCHF₂ CH₂F3-OCH₃ F H A-1256. OCHF₂ CH₂F 5-F F H A-1257. OCHF₂ CH₂F 5-CH₃ F HA-1258. OCHF₂ CH₂F 5-OCH₃ F H A-1259. OCHF₂ CHF₂ 3-F F H A-1260. OCHF₂CHF₂ 3-CH₃ F H A-1261. OCHF₂ CHF₂ 3-OCH₃ F H A-1262. OCHF₂ CHF₂ 5-F F HA-1263. OCHF₂ CHF₂ 5-CH₃ F H A-1264. OCHF₂ CHF₂ 5-OCH₃ F H A-1265. OCHF₂CF₃ 3-F F H A-1266. OCHF₂ CF₃ 3-CH₃ F H A-1267. OCHF₂ CF₃ 3-OCH₃ F HA-1268. OCHF₂ CF₃ 5-F F H A-1269. OCHF₂ CF₃ 5-CH₃ F H A-1270. OCHF₂ CF₃5-OCH₃ F H A-1271. OCHF₂ OCH₂F 3-F F H A-1272. OCHF₂ OCH₂F 3-CH₃ F HA-1273. OCHF₂ OCH₂F 3-OCH₃ F H A-1274. OCHF₂ OCH₂F 5-F F H A-1275. OCHF₂OCH₂F 5-CH₃ F H A-1276. OCHF₂ OCH₂F 5-OCH₃ F H A-1277. OCHF₂ OCHF₂ 3-F FH A-1278. OCHF₂ OCHF₂ 3-CH₃ F H A-1279. OCHF₂ OCHF₂ 3-OCH₃ F H A-1280.OCHF₂ OCHF₂ 5-F F H A-1281. OCHF₂ OCHF₂ 5-CH₃ F H A-1282. OCHF₂ OCHF₂5-OCH₃ F H A-1283. OCHF₂ OCF₃ 3-F F H A-1284. OCHF₂ OCF₃ 3-CH₃ F HA-1285. OCHF₂ OCF₃ 3-OCH₃ F H A-1286. OCHF₂ OCF₃ 5-F F H A-1287. OCHF₂OCF₃ 5-CH₃ F H A-1288. OCHF₂ OCF₃ 5-OCH₃ F H A-1289. OCF₃ F 3-F F HA-1290. OCF₃ F 3-CH₃ F H A-1291. OCF₃ F 3-OCH₃ F H A-1292. OCF₃ F 5-F FH A-1293. OCF₃ F 5-CH₃ F H A-1294. OCF₃ F 5-OCH₃ F H A-1295. OCF₃ CH₃3-F F H A-1296. OCF₃ CH₃ 3-CH₃ F H A-1297. OCF₃ CH₃ 3-OCH₃ F H A-1298.OCF₃ CH₃ 5-F F H A-1299. OCF₃ CH₃ 5-CH₃ F H A-1300. OCF₃ CH₃ 5-OCH₃ F HA-1301. OCF₃ OCH₃ 3-F F H A-1302. OCF₃ OCH₃ 3-CH₃ F H A-1303. OCF₃ OCH₃3-OCH₃ F H A-1304. OCF₃ OCH₃ 5-F F H A-1305. OCF₃ OCH₃ 5-CH₃ F H A-1306.OCF₃ OCH₃ 5-OCH₃ F H A-1307. OCF₃ CN 3-F F H A-1308. OCF₃ CN 3-CH₃ F HA-1309. OCF₃ CN 3-OCH₃ F H A-1310. OCF₃ CN 5-F F H A-1311. OCF₃ CN 5-CH₃F H A-1312. OCF₃ CN 5-OCH₃ F H A-1313. OCF₃ CH₂F 3-F F H A-1314. OCF₃CH₂F 3-CH₃ F H A-1315. OCF₃ CH₂F 3-OCH₃ F H A-1316. OCF₃ CH₂F 5-F F HA-1317. OCF₃ CH₂F 5-CH₃ F H A-1318. OCF₃ CH₂F 5-OCH₃ F H A-1319. OCF₃CHF₂ 3-F F H A-1320. OCF₃ CHF₂ 3-CH₃ F H A-1321. OCF₃ CHF₂ 3-OCH₃ F HA-1322. OCF₃ CHF₂ 5-F F H A-1323. OCF₃ CHF₂ 5-CH₃ F H A-1324. OCF₃ CHF₂5-OCH₃ F H A-1325. OCF₃ CF₃ 3-F F H A-1326. OCF₃ CF₃ 3-CH₃ F H A-1327.OCF₃ CF₃ 3-OCH₃ F H A-1328. OCF₃ CF₃ 5-F F H A-1329. OCF₃ CF₃ 5-CH₃ F HA-1330. OCF₃ CF₃ 5-OCH₃ F H A-1331. OCF₃ OCH₂F 3-F F H A-1332. OCF₃OCH₂F 3-CH₃ F H A-1333. OCF₃ OCH₂F 3-OCH₃ F H A-1334. OCF₃ OCH₂F 5-F F HA-1335. OCF₃ OCH₂F 5-CH₃ F H A-1336. OCF₃ OCH₂F 5-OCH₃ F H A-1337. OCF₃OCHF₂ 3-F F H A-1338. OCF₃ OCHF₂ 3-CH₃ F H A-1339. OCF₃ OCHF₂ 3-OCH₃ F HA-1340. OCF₃ OCHF₂ 5-F F H A-1341. OCF₃ OCHF₂ 5-CH₃ F H A-1342. OCF₃OCHF₂ 5-OCH₃ F H A-1343. OCF₃ OCF₃ 3-F F H A-1344. OCF₃ OCF₃ 3-CH₃ F HA-1345. OCF₃ OCF₃ 3-OCH₃ F H A-1346. OCF₃ OCF₃ 5-F F H A-1347. OCF₃ OCF₃5-CH₃ F H A-1348. OCF₃ OCF₃ 5-OCH₃ F H A-1349. H H H Cl H A-1350. F H HCl H A-1351. CH₃ H H Cl H A-1352. OCH₃ H H Cl H A-1353. CH₂F H H Cl HA-1354. CHF₂ H H Cl H A-1355. CF₃ H H Cl H A-1356. OCH₂F H H Cl HA-1357. OCHF₂ H H Cl H A-1358. OCF₃ H H Cl H A-1359. H F H Cl H A-1360.H CH₃ H Cl H A-1361. H OCH₃ H Cl H A-1362. H CN H Cl H A-1363. H CH₂F HCl H A-1364. H CHF₂ H Cl H A-1365. H CF₃ H Cl H A-1366. H OCH₂F H Cl HA-1367. H OCHF₂ H Cl H A-1368. H OCF₃ H Cl H A-1369. H H 3-F Cl HA-1370. H H 3-CH₃ Cl H A-1371. H H 3-OCH₃ Cl H A-1372. H H 5-F Cl HA-1373. H H 5-CH₃ Cl H A-1374. H H 5-OCH₃ Cl H A-1375. F F H Cl HA-1376. F CH₃ H Cl H A-1377. F OCH₃ H Cl H A-1378. F CN H Cl H A-1379. FCH₂F H Cl H A-1380. F CHF₂ H Cl H A-1381. F CF₃ H Cl H A-1382. F OCH₂F HCl H A-1383. F OCHF₂ H Cl H A-1384. F OCF₃ H Cl H A-1385. F H 3-F Cl HA-1386. F H 3-CH₃ Cl H A-1387. F H 3-OCH₃ Cl H A-1388. F H 5-F Cl HA-1389. F H 5-CH₃ Cl H A-1390. F H 5-OCH₃ Cl H A-1391. CH₃ F H Cl HA-1392. CH₃ CH₃ H Cl H A-1393. CH₃ OCH₃ H Cl H A-1394. CH₃ CN H Cl HA-1395. CH₃ CH₂F H Cl H A-1396. CH₃ CHF₂ H Cl H A-1397. CH₃ CF₃ H Cl HA-1398. CH₃ OCH₂F H Cl H A-1399. CH₃ OCHF₂ H Cl H A-1400. CH₃ OCF₃ H ClH A-1401. CH₃ H 3-F Cl H A-1402. CH₃ H 3-CH₃ Cl H A-1403. CH₃ H 3-OCH₃Cl H A-1404. CH₃ H 5-F Cl H A-1405. CH₃ H 5-CH₃ Cl H A-1406. CH₃ H5-OCH₃ Cl H A-1407. OCH₃ F H Cl H A-1408. OCH₃ CH₃ H Cl H A-1409. OCH₃OCH₃ H Cl H A-1410. OCH₃ CN H Cl H A-1411. OCH₃ CH₂F H Cl H A-1412. OCH₃CHF₂ H Cl H A-1413. OCH₃ CF₃ H Cl H A-1414. OCH₃ OCH₂F H Cl H A-1415.OCH₃ OCHF₂ H Cl H A-1416. OCH₃ OCF₃ H Cl H A-1417. OCH₃ H 3-F Cl HA-1418. OCH₃ H 3-CH₃ Cl H A-1419. OCH₃ H 3-OCH₃ Cl H A-1420. OCH₃ H 5-FCl H A-1421. OCH₃ H 5-CH₃ Cl H A-1422. OCH₃ H 5-OCH₃ Cl H A-1423. H F3-F Cl H A-1424. H F 3-CH₃ Cl H A-1425. H F 3-OCH₃ Cl H A-1426. H F 5-FCl H A-1427. H F 5-CH₃ Cl H A-1428. H F 5-OCH₃ Cl H A-1429. H CH₃ 3-F ClH A-1430. H CH₃ 3-CH₃ Cl H A-1431. H CH₃ 3-OCH₃ Cl H A-1432. H CH₃ 5-FCl H A-1433. H CH₃ 5-CH₃ Cl H A-1434. H CH₃ 5-OCH₃ Cl H A-1435. H OCH₃3-F Cl H A-1436. H OCH₃ 3-CH₃ Cl H A-1437. H OCH₃ 3-OCH₃ Cl H A-1438. HOCH₃ 5-F Cl H A-1439. H OCH₃ 5-CH₃ Cl H A-1440. H OCH₃ 5-OCH₃ Cl HA-1441. H CN 3-F Cl H A-1442. H CN 3-CH₃ Cl H A-1443. H CN 3-OCH₃ Cl HA-1444. H CN 5-F Cl H A-1445. H CN 5-CH₃ Cl H A-1446. H CN 5-OCH₃ Cl HA-1447. H CH₂F 3-F Cl H A-1448. H CH₂F 3-CH₃ Cl H A-1449. H CH₂F 3-OCH₃Cl H A-1450. H CH₂F 5-F Cl H A-1451. H CH₂F 5-CH₃ Cl H A-1452. H CH₂F5-OCH₃ Cl H A-1453. H CHF₂ 3-F Cl H A-1454. H CHF₂ 3-CH₃ Cl H A-1455. HCHF₂ 3-OCH₃ Cl H A-1456. H CHF₂ 5-F Cl H A-1457. H CHF₂ 5-CH₃ Cl HA-1458. H CHF₂ 5-OCH₃ Cl H A-1459. H CF₃ 3-F Cl H A-1460. H CF₃ 3-CH₃ ClH A-1461. H CF₃ 3-OCH₃ Cl H A-1462. H CF₃ 5-F Cl H A-1463. H CF₃ 5-CH₃Cl H A-1464. H CF₃ 5-OCH₃ Cl H A-1465. H OCH₂F 3-F Cl H A-1466. H OCH₂F3-CH₃ Cl H A-1467. H OCH₂F 3-OCH₃ Cl H A-1468. H OCH₂F 5-F Cl H A-1469.H OCH₂F 5-CH₃ Cl H A-1470. H OCH₂F 5-OCH₃ Cl H A-1471. H OCHF₂ 3-F Cl HA-1472. H OCHF₂ 3-CH₃ Cl H A-1473. H OCHF₂ 3-OCH₃ Cl H A-1474. H OCHF₂5-F Cl H A-1475. H OCHF₂ 5-CH₃ Cl H A-1476. H OCHF₂ 5-OCH₃ Cl H A-1477.H OCF₃ 3-F Cl H A-1478. H OCF₃ 3-CH₃ Cl H A-1479. H OCF₃ 3-OCH₃ Cl HA-1480. H OCF₃ 5-F Cl H A-1481. H OCF₃ 5-CH₃ Cl H A-1482. H OCF₃ 5-OCH₃Cl H A-1483. F F 3-F Cl H A-1484. F F 3-CH₃ Cl H A-1485. F F 3-OCH₃ Cl HA-1486. F F 5-F Cl H A-1487. F F 5-CH₃ Cl H A-1488. F F 5-OCH₃ Cl HA-1489. F CH₃ 3-F Cl H A-1490. F CH₃ 3-CH₃ Cl H A-1491. F CH₃ 3-OCH₃ ClH A-1492. F CH₃ 5-F Cl H A-1493. F CH₃ 5-CH₃ Cl H A-1494. F CH₃ 5-OCH₃Cl H A-1495. F OCH₃ 3-F Cl H A-1496. F OCH₃ 3-CH₃ Cl H A-1497. F OCH₃3-OCH₃ Cl H A-1498. F OCH₃ 5-F Cl H A-1499. F OCH₃ 5-CH₃ Cl H A-1500. FOCH₃ 5-OCH₃ Cl H A-1501. F CN 3-F Cl H A-1502. F CN 3-CH₃ Cl H A-1503. FCN 3-OCH₃ Cl H A-1504. F CN 5-F Cl H A-1505. F CN 5-CH₃ Cl H A-1506. FCN 5-OCH₃ Cl H A-1507. F CH₂F 3-F Cl H A-1508. F CH₂F 3-CH₃ Cl H A-1509.F CH₂F 3-OCH₃ Cl H A-1510. F CH₂F 5-F Cl H A-1511. F CH₂F 5-CH₃ Cl HA-1512. F CH₂F 5-OCH₃ Cl H A-1513. F CHF₂ 3-F Cl H A-1514. F CHF₂ 3-CH₃Cl H A-1515. F CHF₂ 3-OCH₃ Cl H A-1516. F CHF₂ 5-F Cl H A-1517. F CHF₂5-CH₃ Cl H A-1518. F CHF₂ 5-OCH₃ Cl H A-1519. F CF₃ 3-F Cl H A-1520. FCF₃ 3-CH₃ Cl H A-1521. F CF₃ 3-OCH₃ Cl H A-1522. F CF₃ 5-F Cl H A-1523.F CF₃ 5-CH₃ Cl H A-1524. F CF₃ 5-OCH₃ Cl H A-1525. F OCH₂F 3-F Cl HA-1526. F OCH₂F 3-CH₃ Cl H A-1527. F OCH₂F 3-OCH₃ Cl H A-1528. F OCH₂F5-F Cl H A-1529. F OCH₂F 5-CH₃ Cl H A-1530. F OCH₂F 5-OCH₃ Cl H A-1531.F OCHF₂ 3-F Cl H A-1532. F OCHF₂ 3-CH₃ Cl H A-1533. F OCHF₂ 3-OCH₃ Cl HA-1534. F OCHF₂ 5-F Cl H A-1535. F OCHF₂ 5-CH₃ Cl H A-1536. F OCHF₂5-OCH₃ Cl H A-1537. F OCF₃ 3-F Cl H A-1538. F OCF₃ 3-CH₃ Cl H A-1539. FOCF₃ 3-OCH₃ Cl H A-1540. F OCF₃ 5-F Cl H A-1541. F OCF₃ 5-CH₃ Cl HA-1542. F OCF₃ 5-OCH₃ Cl H A-1543. CH₃ F 3-F Cl H A-1544. CH₃ F 3-CH₃ ClH A-1545. CH₃ F 3-OCH₃ Cl H A-1546. CH₃ F 5-F Cl H A-1547. CH₃ F 5-CH₃Cl H A-1548. CH₃ F 5-OCH₃ Cl H A-1549. CH₃ CH₃ 3-F Cl H A-1550. CH₃ CH₃3-CH₃ Cl H A-1551. CH₃ CH₃ 3-OCH₃ Cl H A-1552. CH₃ CH₃ 5-F Cl H A-1553.CH₃ CH₃ 5-CH₃ Cl H A-1554. CH₃ CH₃ 5-OCH₃ Cl H A-1555. CH₃ OCH₃ 3-F Cl HA-1556. CH₃ OCH₃ 3-CH₃ Cl H A-1557. CH₃ OCH₃ 3-OCH₃ Cl H A-1558. CH₃OCH₃ 5-F Cl H A-1559. CH₃ OCH₃ 5-CH₃ Cl H A-1560. CH₃ OCH₃ 5-OCH₃ Cl HA-1561. CH₃ CN 3-F Cl H A-1562. CH₃ CN 3-CH₃ Cl H A-1563. CH₃ CN 3-OCH₃Cl H A-1564. CH₃ CN 5-F Cl H A-1565. CH₃ CN 5-CH₃ Cl H A-1566. CH₃ CN5-OCH₃ Cl H A-1567. CH₃ CH₂F 3-F Cl H A-1568. CH₃ CH₂F 3-CH₃ Cl HA-1569. CH₃ CH₂F 3-OCH₃ Cl H A-1570. CH₃ CH₂F 5-F Cl H A-1571. CH₃ CH₂F5-CH₃ Cl H A-1572. CH₃ CH₂F 5-OCH₃ Cl H A-1573. CH₃ CHF₂ 3-F Cl HA-1574. CH₃ CHF₂ 3-CH₃ Cl H A-1575. CH₃ CHF₂ 3-OCH₃ Cl H A-1576. CH₃CHF₂ 5-F Cl H A-1577. CH₃ CHF₂ 5-CH₃ Cl H A-1578. CH₃ CHF₂ 5-OCH₃ Cl HA-1579. CH₃ CF₃ 3-F Cl H A-1580. CH₃ CF₃ 3-CH₃ Cl H A-1581. CH₃ CF₃3-OCH₃ Cl H A-1582. CH₃ CF₃ 5-F Cl H A-1583. CH₃ CF₃ 5-CH₃ Cl H A-1584.CH₃ CF₃ 5-OCH₃ Cl H A-1585. CH₃ OCH₂F 3-F Cl H A-1586. CH₃ OCH₂F 3-CH₃Cl H A-1587. CH₃ OCH₂F 3-OCH₃ Cl H A-1588. CH₃ OCH₂F 5-F Cl H A-1589.CH₃ OCH₂F 5-CH₃ Cl H A-1590. CH₃ OCH₂F 5-OCH₃ Cl H A-1591. CH₃ OCHF₂ 3-FCl H A-1592. CH₃ OCHF₂ 3-CH₃ Cl H A-1593. CH₃ OCHF₂ 3-OCH₃ Cl H A-1594.CH₃ OCHF₂ 5-F Cl H A-1595. CH₃ OCHF₂ 5-CH₃ Cl H A-1596. CH₃ OCHF₂ 5-OCH₃Cl H A-1597. CH₃ OCF₃ 3-F Cl H A-1598. CH₃ OCF₃ 3-CH₃ Cl H A-1599. CH₃OCF₃ 3-OCH₃ Cl H A-1600. CH₃ OCF₃ 5-F Cl H A-1601. CH₃ OCF₃ 5-CH₃ Cl HA-1602. CH₃ OCF₃ 5-OCH₃ Cl H A-1603. OCH₃ F 3-F Cl H A-1604. OCH₃ F3-CH₃ Cl H A-1605. OCH₃ F 3-OCH₃ Cl H A-1606. OCH₃ F 5-F Cl H A-1607.OCH₃ F 5-CH₃ Cl H A-1608. OCH₃ F 5-OCH₃ Cl H A-1609. OCH₃ CH₃ 3-F Cl HA-1610. OCH₃ CH₃ 3-CH₃ Cl H A-1611. OCH₃ CH₃ 3-OCH₃ Cl H A-1612. OCH₃CH₃ 5-F Cl H A-1613. OCH₃ CH₃ 5-CH₃ Cl H A-1614. OCH₃ CH₃ 5-OCH₃ Cl HA-1615. OCH₃ OCH₃ 3-F Cl H A-1616. OCH₃ OCH₃ 3-CH₃ Cl H A-1617. OCH₃OCH₃ 3-OCH₃ Cl H A-1618. OCH₃ OCH₃ 5-F Cl H A-1619. OCH₃ OCH₃ 5-CH₃ Cl HA-1620. OCH₃ OCH₃ 5-OCH₃ Cl H A-1621. OCH₃ CN 3-F Cl H A-1622. OCH₃ CN3-CH₃ Cl H A-1623. OCH₃ CN 3-OCH₃ Cl H A-1624. OCH₃ CN 5-F Cl H A-1625.OCH₃ CN 5-CH₃ Cl H A-1626. OCH₃ CN 5-OCH₃ Cl H A-1627. OCH₃ CH₂F 3-F ClH A-1628. OCH₃ CH₂F 3-CH₃ Cl H A-1629. OCH₃ CH₂F 3-OCH₃ Cl H A-1630.OCH₃ CH₂F 5-F Cl H A-1631. OCH₃ CH₂F 5-CH₃ Cl H A-1632. OCH₃ CH₂F 5-OCH₃Cl H A-1633. OCH₃ CHF₂ 3-F Cl H A-1634. OCH₃ CHF₂ 3-CH₃ Cl H A-1635.OCH₃ CHF₂ 3-OCH₃ Cl H A-1636. OCH₃ CHF₂ 5-F Cl H A-1637. OCH₃ CHF₂ 5-CH₃Cl H A-1638. OCH₃ CHF₂ 5-OCH₃ Cl H A-1639. OCH₃ CF₃ 3-F Cl H A-1640.OCH₃ CF₃ 3-CH₃ Cl H A-1641. OCH₃ CF₃ 3-OCH₃ Cl H A-1642. OCH₃ CF₃ 5-F ClH A-1643. OCH₃ CF₃ 5-CH₃ Cl H A-1644. OCH₃ CF₃ 5-OCH₃ Cl H A-1645. OCH₃OCH₂F 3-F Cl H A-1646. OCH₃ OCH₂F 3-CH₃ Cl H A-1647. OCH₃ OCH₂F 3-OCH₃Cl H A-1648. OCH₃ OCH₂F 5-F Cl H A-1649. OCH₃ OCH₂F 5-CH₃ Cl H A-1650.OCH₃ OCH₂F 5-OCH₃ Cl H A-1651. OCH₃ OCHF₂ 3-F Cl H A-1652. OCH₃ OCHF₂3-CH₃ Cl H A-1653. OCH₃ OCHF₂ 3-OCH₃ Cl H A-1654. OCH₃ OCHF₂ 5-F Cl HA-1655. OCH₃ OCHF₂ 5-CH₃ Cl H A-1656. OCH₃ OCHF₂ 5-OCH₃ Cl H A-1657.OCH₃ OCF₃ 3-F Cl H A-1658. OCH₃ OCF₃ 3-CH₃ Cl H A-1659. OCH₃ OCF₃ 3-OCH₃Cl H A-1660. OCH₃ OCF₃ 5-F Cl H A-1661. OCH₃ OCF₃ 5-CH₃ Cl H A-1662.OCH₃ OCF₃ 5-OCH₃ Cl H A-1663. CH₂F F 3-F Cl H A-1664. CH₂F F 3-CH₃ Cl HA-1665. CH₂F F 3-OCH₃ Cl H A-1666. CH₂F F 5-F Cl H A-1667. CH₂F F 5-CH₃Cl H A-1668. CH₂F F 5-OCH₃ Cl H A-1669. CH₂F CH₃ 3-F Cl H A-1670. CH₂FCH₃ 3-CH₃ Cl H A-1671. CH₂F CH₃ 3-OCH₃ Cl H A-1672. CH₂F CH₃ 5-F Cl HA-1673. CH₂F CH₃ 5-CH₃ Cl H A-1674. CH₂F CH₃ 5-OCH₃ Cl H A-1675. CH₂FOCH₃ 3-F Cl H A-1676. CH₂F OCH₃ 3-CH₃ Cl H A-1677. CH₂F OCH₃ 3-OCH₃ Cl HA-1678. CH₂F OCH₃ 5-F Cl H A-1679. CH₂F OCH₃ 5-CH₃ Cl H A-1680. CH₂FOCH₃ 5-OCH₃ Cl H A-1681. CH₂F CN 3-F Cl H A-1682. CH₂F CN 3-CH₃ Cl HA-1683. CH₂F CN 3-OCH₃ Cl H A-1684. CH₂F CN 5-F Cl H A-1685. CH₂F CN5-CH₃ Cl H A-1686. CH₂F CN 5-OCH₃ Cl H A-1687. CH₂F CH₂F 3-F Cl HA-1688. CH₂F CH₂F 3-CH₃ Cl H A-1689. CH₂F CH₂F 3-OCH₃ Cl H A-1690. CH₂FCH₂F 5-F Cl H A-1691. CH₂F CH₂F 5-CH₃ Cl H A-1692. CH₂F CH₂F 5-OCH₃ Cl HA-1693. CH₂F CHF₂ 3-F Cl H A-1694. CH₂F CHF₂ 3-CH₃ Cl H A-1695. CH₂FCHF₂ 3-OCH₃ Cl H A-1696. CH₂F CHF₂ 5-F Cl H A-1697. CH₂F CHF₂ 5-CH₃ Cl HA-1698. CH₂F CHF₂ 5-OCH₃ Cl H A-1699. CH₂F CF₃ 3-F Cl H A-1700. CH₂F CF₃3-CH₃ Cl H A-1701. CH₂F CF₃ 3-OCH₃ Cl H A-1702. CH₂F CF₃ 5-F Cl HA-1703. CH₂F CF₃ 5-CH₃ Cl H A-1704. CH₂F CF₃ 5-OCH₃ Cl H A-1705. CH₂FOCH₂F 3-F Cl H A-1706. CH₂F OCH₂F 3-CH₃ Cl H A-1707. CH₂F OCH₂F 3-OCH₃Cl H A-1708. CH₂F OCH₂F 5-F Cl H A-1709. CH₂F OCH₂F 5-CH₃ Cl H A-1710.CH₂F OCH₂F 5-OCH₃ Cl H A-1711. CH₂F OCHF₂ 3-F Cl H A-1712. CH₂F OCHF₂3-CH₃ Cl H A-1713. CH₂F OCHF₂ 3-OCH₃ Cl H A-1714. CH₂F OCHF₂ 5-F Cl HA-1715. CH₂F OCHF₂ 5-CH₃ Cl H A-1716. CH₂F OCHF₂ 5-OCH₃ Cl H A-1717.CH₂F OCF₃ 3-F Cl H A-1718. CH₂F OCF₃ 3-CH₃ Cl H A-1719. CH₂F OCF₃ 3-OCH₃Cl H A-1720. CH₂F OCF₃ 5-F Cl H A-1721. CH₂F OCF₃ 5-CH₃ Cl H A-1722.CH₂F OCF₃ 5-OCH₃ Cl H A-1723. CHF₂ F 3-F Cl H A-1724. CHF₂ F 3-CH₃ Cl HA-1725. CHF₂ F 3-OCH₃ Cl H A-1726. CHF₂ F 5-F Cl H A-1727. CHF₂ F 5-CH₃Cl H A-1728. CHF₂ F 5-OCH₃ Cl H A-1729. CHF₂ CH₃ 3-F Cl H A-1730. CHF₂CH₃ 3-CH₃ Cl H A-1731. CHF₂ CH₃ 3-OCH₃ Cl H A-1732. CHF₂ CH₃ 5-F Cl HA-1733. CHF₂ CH₃ 5-CH₃ Cl H A-1734. CHF₂ CH₃ 5-OCH₃ Cl H A-1735. CHF₂OCH₃ 3-F Cl H A-1736. CHF₂ OCH₃ 3-CH₃ Cl H A-1737. CHF₂ OCH₃ 3-OCH₃ Cl HA-1738. CHF₂ OCH₃ 5-F Cl H A-1739. CHF₂ OCH₃ 5-CH₃ Cl H A-1740. CHF₂OCH₃ 5-OCH₃ Cl H A-1741. CHF₂ CN 3-F Cl H A-1742. CHF₂ CN 3-CH₃ Cl HA-1743. CHF₂ CN 3-OCH₃ Cl H A-1744. CHF₂ CN 5-F Cl H A-1745. CHF₂ CN5-CH₃ Cl H A-1746. CHF₂ CN 5-OCH₃ Cl H A-1747. CHF₂ CH₂F 3-F Cl HA-1748. CHF₂ CH₂F 3-CH₃ Cl H A-1749. CHF₂ CH₂F 3-OCH₃ Cl H A-1750. CHF₂CH₂F 5-F Cl H A-1751. CHF₂ CH₂F 5-CH₃ Cl H A-1752. CHF₂ CH₂F 5-OCH₃ Cl HA-1753. CHF₂ CHF₂ 3-F Cl H A-1754. CHF₂ CHF₂ 3-CH₃ Cl H A-1755. CHF₂CHF₂ 3-OCH₃ Cl H A-1756. CHF₂ CHF₂ 5-F Cl H A-1757. CHF₂ CHF₂ 5-CH₃ Cl HA-1758. CHF₂ CHF₂ 5-OCH₃ Cl H A-1759. CHF₂ CF₃ 3-F Cl H A-1760. CHF₂ CF₃3-CH₃ Cl H A-1761. CHF₂ CF₃ 3-OCH₃ Cl H A-1762. CHF₂ CF₃ 5-F Cl HA-1763. CHF₂ CF₃ 5-CH₃ Cl H A-1764. CHF₂ CF₃ 5-OCH₃ Cl H A-1765. CHF₂OCH₂F 3-F Cl H A-1766. CHF₂ OCH₂F 3-CH₃ Cl H A-1767. CHF₂ OCH₂F 3-OCH₃Cl H A-1768. CHF₂ OCH₂F 5-F Cl H A-1769. CHF₂ OCH₂F 5-CH₃ Cl H A-1770.CHF₂ OCH₂F 5-OCH₃ Cl H A-1771. CHF₂ OCHF₂ 3-F Cl H A-1772. CHF₂ OCHF₂3-CH₃ Cl H A-1773. CHF₂ OCHF₂ 3-OCH₃ Cl H A-1774. CHF₂ OCHF₂ 5-F Cl HA-1775. CHF₂ OCHF₂ 5-CH₃ Cl H A-1776. CHF₂ OCHF₂ 5-OCH₃ Cl H A-1777.CHF₂ OCF₃ 3-F Cl H A-1778. CHF₂ OCF₃ 3-CH₃ Cl H A-1779. CHF₂ OCF₃ 3-OCH₃Cl H A-1780. CHF₂ OCF₃ 5-F Cl H A-1781. CHF₂ OCF₃ 5-CH₃ Cl H A-1782.CHF₂ OCF₃ 5-OCH₃ Cl H A-1783. CF₃ F 3-F Cl H A-1784. CF₃ F 3-CH₃ Cl HA-1785. CF₃ F 3-OCH₃ Cl H A-1786. CF₃ F 5-F Cl H A-1787. CF₃ F 5-CH₃ ClH A-1788. CF₃ F 5-OCH₃ Cl H A-1789. CF₃ CH₃ 3-F Cl H A-1790. CF₃ CH₃3-CH₃ Cl H A-1791. CF₃ CH₃ 3-OCH₃ Cl H A-1792. CF₃ CH₃ 5-F Cl H A-1793.CF₃ CH₃ 5-CH₃ Cl H A-1794. CF₃ CH₃ 5-OCH₃ Cl H A-1795. CF₃ OCH₃ 3-F Cl HA-1796. CF₃ OCH₃ 3-CH₃ Cl H A-1797. CF₃ OCH₃ 3-OCH₃ Cl H A-1798. CF₃OCH₃ 5-F Cl H A-1799. CF₃ OCH₃ 5-CH₃ Cl H A-1800. CF₃ OCH₃ 5-OCH₃ Cl HA-1801. CF₃ CN 3-F Cl H A-1802. CF₃ CN 3-CH₃ Cl H A-1803. CF₃ CN 3-OCH₃Cl H A-1804. CF₃ CN 5-F Cl H A-1805. CF₃ CN 5-CH₃ Cl H A-1806. CF₃ CN5-OCH₃ Cl H A-1807. CF₃ CH₂F 3-F Cl H A-1808. CF₃ CH₂F 3-CH₃ Cl HA-1809. CF₃ CH₂F 3-OCH₃ Cl H A-1810. CF₃ CH₂F 5-F Cl H A-1811. CF₃ CH₂F5-CH₃ Cl H A-1812. CF₃ CH₂F 5-OCH₃ Cl H A-1813. CF₃ CHF₂ 3-F Cl HA-1814. CF₃ CHF₂ 3-CH₃ Cl H A-1815. CF₃ CHF₂ 3-OCH₃ Cl H A-1816. CF₃CHF₂ 5-F Cl H A-1817. CF₃ CHF₂ 5-CH₃ Cl H A-1818. CF₃ CHF₂ 5-OCH₃ Cl HA-1819. CF₃ CF₃ 3-F Cl H A-1820. CF₃ CF₃ 3-CH₃ Cl H A-1821. CF₃ CF₃3-OCH₃ Cl H A-1822. CF₃ CF₃ 5-F Cl H A-1823. CF₃ CF₃ 5-CH₃ Cl H A-1824.CF₃ CF₃ 5-OCH₃ Cl H A-1825. CF₃ OCH₂F 3-F Cl H A-1826. CF₃ OCH₂F 3-CH₃Cl H A-1827. CF₃ OCH₂F 3-OCH₃ Cl H A-1828. CF₃ OCH₂F 5-F Cl H A-1829.CF₃ OCH₂F 5-CH₃ Cl H A-1830. CF₃ OCH₂F 5-OCH₃ Cl H A-1831. CF₃ OCHF₂ 3-FCl H A-1832. CF₃ OCHF₂ 3-CH₃ Cl H A-1833. CF₃ OCHF₂ 3-OCH₃ Cl H A-1834.CF₃ OCHF₂ 5-F Cl H A-1835. CF₃ OCHF₂ 5-CH₃ Cl H A-1836. CF₃ OCHF₂ 5-OCH₃Cl H A-1837. CF₃ OCF₃ 3-F Cl H A-1838. CF₃ OCF₃ 3-CH₃ Cl H A-1839. CF₃OCF₃ 3-OCH₃ Cl H A-1840. CF₃ OCF₃ 5-F Cl H A-1841. CF₃ OCF₃ 5-CH₃ Cl HA-1842. CF₃ OCF₃ 5-OCH₃ Cl H A-1843. OCH₂F F 3-F Cl H A-1844. OCH₂F F3-CH₃ Cl H A-1845. OCH₂F F 3-OCH₃ Cl H A-1846. OCH₂F F 5-F Cl H A-1847.OCH₂F F 5-CH₃ Cl H A-1848. OCH₂F F 5-OCH₃ Cl H A-1849. OCH₂F CH₃ 3-F ClH A-1850. OCH₂F CH₃ 3-CH₃ Cl H A-1851. OCH₂F CH₃ 3-OCH₃ Cl H A-1852.OCH₂F CH₃ 5-F Cl H A-1853. OCH₂F CH₃ 5-CH₃ Cl H A-1854. OCH₂F CH₃ 5-OCH₃Cl H A-1855. OCH₂F OCH₃ 3-F Cl H A-1856. OCH₂F OCH₃ 3-CH₃ Cl H A-1857.OCH₂F OCH₃ 3-OCH₃ Cl H A-1858. OCH₂F OCH₃ 5-F Cl H A-1859. OCH₂F OCH₃5-CH₃ Cl H A-1860. OCH₂F OCH₃ 5-OCH₃ Cl H A-1861. OCH₂F CN 3-F Cl HA-1862. OCH₂F CN 3-CH₃ Cl H A-1863. OCH₂F CN 3-OCH₃ Cl H A-1864. OCH₂FCN 5-F Cl H A-1865. OCH₂F CN 5-CH₃ Cl H A-1866. OCH₂F CN 5-OCH₃ Cl HA-1867. OCH₂F CH₂F 3-F Cl H A-1868. OCH₂F CH₂F 3-CH₃ Cl H A-1869. OCH₂FCH₂F 3-OCH₃ Cl H A-1870. OCH₂F CH₂F 5-F Cl H A-1871. OCH₂F CH₂F 5-CH₃ ClH A-1872. OCH₂F CH₂F 5-OCH₃ Cl H A-1873. OCH₂F CHF₂ 3-F Cl H A-1874.OCH₂F CHF₂ 3-CH₃ Cl H A-1875. OCH₂F CHF₂ 3-OCH₃ Cl H A-1876. OCH₂F CHF₂5-F Cl H A-1877. OCH₂F CHF₂ 5-CH₃ Cl H A-1878. OCH₂F CHF₂ 5-OCH₃ Cl HA-1879. OCH₂F CF₃ 3-F Cl H A-1880. OCH₂F CF₃ 3-CH₃ Cl H A-1881. OCH₂FCF₃ 3-OCH₃ Cl H A-1882. OCH₂F CF₃ 5-F Cl H A-1883. OCH₂F CF₃ 5-CH₃ Cl HA-1884. OCH₂F CF₃ 5-OCH₃ Cl H A-1885. OCH₂F OCH₂F 3-F Cl H A-1886. OCH₂FOCH₂F 3-CH₃ Cl H A-1887. OCH₂F OCH₂F 3-OCH₃ Cl H A-1888. OCH₂F OCH₂F 5-FCl H A-1889. OCH₂F OCH₂F 5-CH₃ Cl H A-1890. OCH₂F OCH₂F 5-OCH₃ Cl HA-1891. OCH₂F OCHF₂ 3-F Cl H A-1892. OCH₂F OCHF₂ 3-CH₃ Cl H A-1893.OCH₂F OCHF₂ 3-OCH₃ Cl H A-1894. OCH₂F OCHF₂ 5-F Cl H A-1895. OCH₂F OCHF₂5-CH₃ Cl H A-1896. OCH₂F OCHF₂ 5-OCH₃ Cl H A-1897. OCH₂F OCF₃ 3-F Cl HA-1898. OCH₂F OCF₃ 3-CH₃ Cl H A-1899. OCH₂F OCF₃ 3-OCH₃ Cl H A-1900.OCH₂F OCF₃ 5-F Cl H A-1901. OCH₂F OCF₃ 5-CH₃ Cl H A-1902. OCH₂F OCF₃5-OCH₃ Cl H A-1903. OCHF₂ F 3-F Cl H A-1904. OCHF₂ F 3-CH₃ Cl H A-1905.OCHF₂ F 3-OCH₃ Cl H A-1906. OCHF₂ F 5-F Cl H A-1907. OCHF₂ F 5-CH₃ Cl HA-1908. OCHF₂ F 5-OCH₃ Cl H A-1909. OCHF₂ CH₃ 3-F Cl H A-1910. OCHF₂ CH₃3-CH₃ Cl H A-1911. OCHF₂ CH₃ 3-OCH₃ Cl H A-1912. OCHF₂ CH₃ 5-F Cl HA-1913. OCHF₂ CH₃ 5-CH₃ Cl H A-1914. OCHF₂ CH₃ 5-OCH₃ Cl H A-1915. OCHF₂OCH₃ 3-F Cl H A-1916. OCHF₂ OCH₃ 3-CH₃ Cl H A-1917. OCHF₂ OCH₃ 3-OCH₃ ClH A-1918. OCHF₂ OCH₃ 5-F Cl H A-1919. OCHF₂ OCH₃ 5-CH₃ Cl H A-1920.OCHF₂ OCH₃ 5-OCH₃ Cl H A-1921. OCHF₂ CN 3-F Cl H A-1922. OCHF₂ CN 3-CH₃Cl H A-1923. OCHF₂ CN 3-OCH₃ Cl H A-1924. OCHF₂ CN 5-F Cl H A-1925.OCHF₂ CN 5-CH₃ Cl H A-1926. OCHF₂ CN 5-OCH₃ Cl H A-1927. OCHF₂ CH₂F 3-FCl H A-1928. OCHF₂ CH₂F 3-CH₃ Cl H A-1929. OCHF₂ CH₂F 3-OCH₃ Cl HA-1930. OCHF₂ CH₂F 5-F Cl H A-1931. OCHF₂ CH₂F 5-CH₃ Cl H A-1932. OCHF₂CH₂F 5-OCH₃ Cl H A-1933. OCHF₂ CHF₂ 3-F Cl H A-1934. OCHF₂ CHF₂ 3-CH₃ ClH A-1935. OCHF₂ CHF₂ 3-OCH₃ Cl H A-1936. OCHF₂ CHF₂ 5-F Cl H A-1937.OCHF₂ CHF₂ 5-CH₃ Cl H A-1938. OCHF₂ CHF₂ 5-OCH₃ Cl H A-1939. OCHF₂ CF₃3-F Cl H A-1940. OCHF₂ CF₃ 3-CH₃ Cl H A-1941. OCHF₂ CF₃ 3-OCH₃ Cl HA-1942. OCHF₂ CF₃ 5-F Cl H A-1943. OCHF₂ CF₃ 5-CH₃ Cl H A-1944. OCHF₂CF₃ 5-OCH₃ Cl H A-1945. OCHF₂ OCH₂F 3-F Cl H A-1946. OCHF₂ OCH₂F 3-CH₃Cl H A-1947. OCHF₂ OCH₂F 3-OCH₃ Cl H A-1948. OCHF₂ OCH₂F 5-F Cl HA-1949. OCHF₂ OCH₂F 5-CH₃ Cl H A-1950. OCHF₂ OCH₂F 5-OCH₃ Cl H A-1951.OCHF₂ OCHF₂ 3-F Cl H A-1952. OCHF₂ OCHF₂ 3-CH₃ Cl H A-1953. OCHF₂ OCHF₂3-OCH₃ Cl H A-1954. OCHF₂ OCHF₂ 5-F Cl H A-1955. OCHF₂ OCHF₂ 5-CH₃ Cl HA-1956. OCHF₂ OCHF₂ 5-OCH₃ Cl H A-1957. OCHF₂ OCF₃ 3-F Cl H A-1958.OCHF₂ OCF₃ 3-CH₃ Cl H A-1959. OCHF₂ OCF₃ 3-OCH₃ Cl H A-1960. OCHF₂ OCF₃5-F Cl H A-1961. OCHF₂ OCF₃ 5-CH₃ Cl H A-1962. OCHF₂ OCF₃ 5-OCH₃ Cl HA-1963. OCF₃ F 3-F Cl H A-1964. OCF₃ F 3-CH₃ Cl H A-1965. OCF₃ F 3-OCH₃Cl H A-1966. OCF₃ F 5-F Cl H A-1967. OCF₃ F 5-CH₃ Cl H A-1968. OCF₃ F5-OCH₃ Cl H A-1969. OCF₃ CH₃ 3-F Cl H A-1970. OCF₃ CH₃ 3-CH₃ Cl HA-1971. OCF₃ CH₃ 3-OCH₃ Cl H A-1972. OCF₃ CH₃ 5-F Cl H A-1973. OCF₃ CH₃5-CH₃ Cl H A-1974. OCF₃ CH₃ 5-OCH₃ Cl H A-1975. OCF₃ OCH₃ 3-F Cl HA-1976. OCF₃ OCH₃ 3-CH₃ Cl H A-1977. OCF₃ OCH₃ 3-OCH₃ Cl H A-1978. OCF₃OCH₃ 5-F Cl H A-1979. OCF₃ OCH₃ 5-CH₃ Cl H A-1980. OCF₃ OCH₃ 5-OCH₃ Cl HA-1981. OCF₃ CN 3-F Cl H A-1982. OCF₃ CN 3-CH₃ Cl H A-1983. OCF₃ CN3-OCH₃ Cl H A-1984. OCF₃ CN 5-F Cl H A-1985. OCF₃ CN 5-CH₃ Cl H A-1986.OCF₃ CN 5-OCH₃ Cl H A-1987. OCF₃ CH₂F 3-F Cl H A-1988. OCF₃ CH₂F 3-CH₃Cl H A-1989. OCF₃ CH₂F 3-OCH₃ Cl H A-1990. OCF₃ CH₂F 5-F Cl H A-1991.OCF₃ CH₂F 5-CH₃ Cl H A-1992. OCF₃ CH₂F 5-OCH₃ Cl H A-1993. OCF₃ CHF₂ 3-FCl H A-1994. OCF₃ CHF₂ 3-CH₃ Cl H A-1995. OCF₃ CHF₂ 3-OCH₃ Cl H A-1996.OCF₃ CHF₂ 5-F Cl H A-1997. OCF₃ CHF₂ 5-CH₃ Cl H A-1998. OCF₃ CHF₂ 5-OCH₃Cl H A-1999. OCF₃ CF₃ 3-F Cl H A-2000. OCF₃ CF₃ 3-CH₃ Cl H A-2001. OCF₃CF₃ 3-OCH₃ Cl H A-2002. OCF₃ CF₃ 5-F Cl H A-2003. OCF₃ CF₃ 5-CH₃ Cl HA-2004. OCF₃ CF₃ 5-OCH₃ Cl H A-2005. OCF₃ OCH₂F 3-F Cl H A-2006. OCF₃OCH₂F 3-CH₃ Cl H A-2007. OCF₃ OCH₂F 3-OCH₃ Cl H A-2008. OCF₃ OCH₂F 5-FCl H A-2009. OCF₃ OCH₂F 5-CH₃ Cl H A-2010. OCF₃ OCH₂F 5-OCH₃ Cl HA-2011. OCF₃ OCHF₂ 3-F Cl H A-2012. OCF₃ OCHF₂ 3-CH₃ Cl H A-2013. OCF₃OCHF₂ 3-OCH₃ Cl H A-2014. OCF₃ OCHF₂ 5-F Cl H A-2015. OCF₃ OCHF₂ 5-CH₃Cl H A-2016. OCF₃ OCHF₂ 5-OCH₃ Cl H A-2017. OCF₃ OCF₃ 3-F Cl H A-2018.OCF₃ OCF₃ 3-CH₃ Cl H A-2019. OCF₃ OCF₃ 3-OCH₃ Cl H A-2020. OCF₃ OCF₃ 5-FCl H A-2021. OCF₃ OCF₃ 5-CH₃ Cl H A-2022. OCF₃ OCF₃ 5-OCH₃ Cl H A-2023.H H H CN F A-2024. F H H CN F A-2025. CH₃ H H CN F A-2026. OCH₃ H H CN FA-2027. CH₂F H H CN F A-2028. CHF₂ H H CN F A-2029. CF₃ H H CN F A-2030.OCH₂F H H CN F A-2031. OCHF₂ H H CN F A-2032. OCF₃ H H CN F A-2033. H FH CN F A-2034. H CH₃ H CN F A-2035. H OCH₃ H CN F A-2036. H CN H CN FA-2037. H CH₂F H CN F A-2038. H CHF₂ H CN F A-2039. H CF₃ H CN F A-2040.H OCH₂F H CN F A-2041. H OCHF₂ H CN F A-2042. H OCF₃ H CN F A-2043. H H3-F CN F A-2044. H H 3-CH₃ CN F A-2045. H H 3-OCH₃ CN F A-2046. H H 5-FCN F A-2047. H H 5-CH₃ CN F A-2048. H H 5-OCH₃ CN F A-2049. F F H CN FA-2050. F CH₃ H CN F A-2051. F OCH₃ H CN F A-2052. F CN H CN F A-2053. FCH₂F H CN F A-2054. F CHF₂ H CN F A-2055. F CF₃ H CN F A-2056. F OCH₂F HCN F A-2057. F OCHF₂ H CN F A-2058. F OCF₃ H CN F A-2059. F H 3-F CN FA-2060. F H 3-CH₃ CN F A-2061. F H 3-OCH₃ CN F A-2062. F H 5-F CN FA-2063. F H 5-CH₃ CN F A-2064. F H 5-OCH₃ CN F A-2065. CH₃ F H CN FA-2066. CH₃ CH₃ H CN F A-2067. CH₃ OCH₃ H CN F A-2068. CH₃ CN H CN FA-2069. CH₃ CH₂F H CN F A-2070. CH₃ CHF₂ H CN F A-2071. CH₃ CF₃ H CN FA-2072. CH₃ OCH₂F H CN F A-2073. CH₃ OCHF₂ H CN F A-2074. CH₃ OCF₃ H CNF A-2075. CH₃ H 3-F CN F A-2076. CH₃ H 3-CH₃ CN F A-2077. CH₃ H 3-OCH₃CN F A-2078. CH₃ H 5-F CN F A-2079. CH₃ H 5-CH₃ CN F A-2080. CH₃ H5-OCH₃ CN F A-2081. OCH₃ F H CN F A-2082. OCH₃ CH₃ H CN F A-2083. OCH₃OCH₃ H CN F A-2084. OCH₃ CN H CN F A-2085. OCH₃ CH₂F H CN F A-2086. OCH₃CHF₂ H CN F A-2087. OCH₃ CF₃ H CN F A-2088. OCH₃ OCH₂F H CN F A-2089.OCH₃ OCHF₂ H CN F A-2090. OCH₃ OCF₃ H CN F A-2091. OCH₃ H 3-F CN FA-2092. OCH₃ H 3-CH₃ CN F A-2093. OCH₃ H 3-OCH₃ CN F A-2094. OCH₃ H 5-FCN F A-2095. OCH₃ H 5-CH₃ CN F A-2096. OCH₃ H 5-OCH₃ CN F A-2097. H F3-F CN F A-2098. H F 3-CH₃ CN F A-2099. H F 3-OCH₃ CN F A-2100. H F 5-FCN F A-2101. H F 5-CH₃ CN F A-2102. H F 5-OCH₃ CN F A-2103. H CH₃ 3-F CNF A-2104. H CH₃ 3-CH₃ CN F A-2105. H CH₃ 3-OCH₃ CN F A-2106. H CH₃ 5-FCN F A-2107. H CH₃ 5-CH₃ CN F A-2108. H CH₃ 5-OCH₃ CN F A-2109. H OCH₃3-F CN F A-2110. H OCH₃ 3-CH₃ CN F A-2111. H OCH₃ 3-OCH₃ CN F A-2112. HOCH₃ 5-F CN F A-2113. H OCH₃ 5-CH₃ CN F A-2114. H OCH₃ 5-OCH₃ CN FA-2115. H CN 3-F CN F A-2116. H CN 3-CH₃ CN F A-2117. H CN 3-OCH₃ CN FA-2118. H CN 5-F CN F A-2119. H CN 5-CH₃ CN F A-2120. H CN 5-OCH₃ CN FA-2121. H CH₂F 3-F CN F A-2122. H CH₂F 3-CH₃ CN F A-2123. H CH₂F 3-OCH₃CN F A-2124. H CH₂F 5-F CN F A-2125. H CH₂F 5-CH₃ CN F A-2126. H CH₂F5-OCH₃ CN F A-2127. H CHF₂ 3-F CN F A-2128. H CHF₂ 3-CH₃ CN F A-2129. HCHF₂ 3-OCH₃ CN F A-2130. H CHF₂ 5-F CN F A-2131. H CHF₂ 5-CH₃ CN FA-2132. H CHF₂ 5-OCH₃ CN F A-2133. H CF₃ 3-F CN F A-2134. H CF₃ 3-CH₃ CNF A-2135. H CF₃ 3-OCH₃ CN F A-2136. H CF₃ 5-F CN F A-2137. H CF₃ 5-CH₃CN F A-2138. H CF₃ 5-OCH₃ CN F A-2139. H OCH₂F 3-F CN F A-2140. H OCH₂F3-CH₃ CN F A-2141. H OCH₂F 3-OCH₃ CN F A-2142. H OCH₂F 5-F CN F A-2143.H OCH₂F 5-CH₃ CN F A-2144. H OCH₂F 5-OCH₃ CN F A-2145. H OCHF₂ 3-F CN FA-2146. H OCHF₂ 3-CH₃ CN F A-2147. H OCHF₂ 3-OCH₃ CN F A-2148. H OCHF₂5-F CN F A-2149. H OCHF₂ 5-CH₃ CN F A-2150. H OCHF₂ 5-OCH₃ CN F A-2151.H OCF₃ 3-F CN F A-2152. H OCF₃ 3-CH₃ CN F A-2153. H OCF₃ 3-OCH₃ CN FA-2154. H OCF₃ 5-F CN F A-2155. H OCF₃ 5-CH₃ CN F A-2156. H OCF₃ 5-OCH₃CN F A-2157. F F 3-F CN F A-2158. F F 3-CH₃ CN F A-2159. F F 3-OCH₃ CN FA-2160. F F 5-F CN F A-2161. F F 5-CH₃ CN F A-2162. F F 5-OCH₃ CN FA-2163. F CH₃ 3-F CN F A-2164. F CH₃ 3-CH₃ CN F A-2165. F CH₃ 3-OCH₃ CNF A-2166. F CH₃ 5-F CN F A-2167. F CH₃ 5-CH₃ CN F A-2168. F CH₃ 5-OCH₃CN F A-2169. F OCH₃ 3-F CN F A-2170. F OCH₃ 3-CH₃ CN F A-2171. F OCH₃3-OCH₃ CN F A-2172. F OCH₃ 5-F CN F A-2173. F OCH₃ 5-CH₃ CN F A-2174. FOCH₃ 5-OCH₃ CN F A-2175. F CN 3-F CN F A-2176. F CN 3-CH₃ CN F A-2177. FCN 3-OCH₃ CN F A-2178. F CN 5-F CN F A-2179. F CN 5-CH₃ CN F A-2180. FCN 5-OCH₃ CN F A-2181. F CH₂F 3-F CN F A-2182. F CH₂F 3-CH₃ CN F A-2183.F CH₂F 3-OCH₃ CN F A-2184. F CH₂F 5-F CN F A-2185. F CH₂F 5-CH₃ CN FA-2186. F CH₂F 5-OCH₃ CN F A-2187. F CHF₂ 3-F CN F A-2188. F CHF₂ 3-CH₃CN F A-2189. F CHF₂ 3-OCH₃ CN F A-2190. F CHF₂ 5-F CN F A-2191. F CHF₂5-CH₃ CN F A-2192. F CHF₂ 5-OCH₃ CN F A-2193. F CF₃ 3-F CN F A-2194. FCF₃ 3-CH₃ CN F A-2195. F CF₃ 3-OCH₃ CN F A-2196. F CF₃ 5-F CN F A-2197.F CF₃ 5-CH₃ CN F A-2198. F CF₃ 5-OCH₃ CN F A-2199. F OCH₂F 3-F CN FA-2200. F OCH₂F 3-CH₃ CN F A-2201. F OCH₂F 3-OCH₃ CN F A-2202. F OCH₂F5-F CN F A-2203. F OCH₂F 5-CH₃ CN F A-2204. F OCH₂F 5-OCH₃ CN F A-2205.F OCHF₂ 3-F CN F A-2206. F OCHF₂ 3-CH₃ CN F A-2207. F OCHF₂ 3-OCH₃ CN FA-2208. F OCHF₂ 5-F CN F A-2209. F OCHF₂ 5-CH₃ CN F A-2210. F OCHF₂5-OCH₃ CN F A-2211. F OCF₃ 3-F CN F A-2212. F OCF₃ 3-CH₃ CN F A-2213. FOCF₃ 3-OCH₃ CN F A-2214. F OCF₃ 5-F CN F A-2215. F OCF₃ 5-CH₃ CN FA-2216. F OCF₃ 5-OCH₃ CN F A-2217. CH₃ F 3-F CN F A-2218. CH₃ F 3-CH₃ CNF A-2219. CH₃ F 3-OCH₃ CN F A-2220. CH₃ F 5-F CN F A-2221. CH₃ F 5-CH₃CN F A-2222. CH₃ F 5-OCH₃ CN F A-2223. CH₃ CH₃ 3-F CN F A-2224. CH₃ CH₃3-CH₃ CN F A-2225. CH₃ CH₃ 3-OCH₃ CN F A-2226. CH₃ CH₃ 5-F CN F A-2227.CH₃ CH₃ 5-CH₃ CN F A-2228. CH₃ CH₃ 5-OCH₃ CN F A-2229. CH₃ OCH₃ 3-F CN FA-2230. CH₃ OCH₃ 3-CH₃ CN F A-2231. CH₃ OCH₃ 3-OCH₃ CN F A-2232. CH₃OCH₃ 5-F CN F A-2233. CH₃ OCH₃ 5-CH₃ CN F A-2234. CH₃ OCH₃ 5-OCH₃ CN FA-2235. CH₃ CN 3-F CN F A-2236. CH₃ CN 3-CH₃ CN F A-2237. CH₃ CN 3-OCH₃CN F A-2238. CH₃ CN 5-F CN F A-2239. CH₃ CN 5-CH₃ CN F A-2240. CH₃ CN5-OCH₃ CN F A-2241. CH₃ CH₂F 3-F CN F A-2242. CH₃ CH₂F 3-CH₃ CN FA-2243. CH₃ CH₂F 3-OCH₃ CN F A-2244. CH₃ CH₂F 5-F CN F A-2245. CH₃ CH₂F5-CH₃ CN F A-2246. CH₃ CH₂F 5-OCH₃ CN F A-2247. CH₃ CHF₂ 3-F CN FA-2248. CH₃ CHF₂ 3-CH₃ CN F A-2249. CH₃ CHF₂ 3-OCH₃ CN F A-2250. CH₃CHF₂ 5-F CN F A-2251. CH₃ CHF₂ 5-CH₃ CN F A-2252. CH₃ CHF₂ 5-OCH₃ CN FA-2253. CH₃ CF₃ 3-F CN F A-2254. CH₃ CF₃ 3-CH₃ CN F A-2255. CH₃ CF₃3-OCH₃ CN F A-2256. CH₃ CF₃ 5-F CN F A-2257. CH₃ CF₃ 5-CH₃ CN F A-2258.CH₃ CF₃ 5-OCH₃ CN F A-2259. CH₃ OCH₂F 3-F CN F A-2260. CH₃ OCH₂F 3-CH₃CN F A-2261. CH₃ OCH₂F 3-OCH₃ CN F A-2262. CH₃ OCH₂F 5-F CN F A-2263.CH₃ OCH₂F 5-CH₃ CN F A-2264. CH₃ OCH₂F 5-OCH₃ CN F A-2265. CH₃ OCHF₂ 3-FCN F A-2266. CH₃ OCHF₂ 3-CH₃ CN F A-2267. CH₃ OCHF₂ 3-OCH₃ CN F A-2268.CH₃ OCHF₂ 5-F CN F A-2269. CH₃ OCHF₂ 5-CH₃ CN F A-2270. CH₃ OCHF₂ 5-OCH₃CN F A-2271. CH₃ OCF₃ 3-F CN F A-2272. CH₃ OCF₃ 3-CH₃ CN F A-2273. CH₃OCF₃ 3-OCH₃ CN F A-2274. CH₃ OCF₃ 5-F CN F A-2275. CH₃ OCF₃ 5-CH₃ CN FA-2276. CH₃ OCF₃ 5-OCH₃ CN F A-2277. OCH₃ F 3-F CN F A-2278. OCH₃ F3-CH₃ CN F A-2279. OCH₃ F 3-OCH₃ CN F A-2280. OCH₃ F 5-F CN F A-2281.OCH₃ F 5-CH₃ CN F A-2282. OCH₃ F 5-OCH₃ CN F A-2283. OCH₃ CH₃ 3-F CN FA-2284. OCH₃ CH₃ 3-CH₃ CN F A-2285. OCH₃ CH₃ 3-OCH₃ CN F A-2286. OCH₃CH₃ 5-F CN F A-2287. OCH₃ CH₃ 5-CH₃ CN F A-2288. OCH₃ CH₃ 5-OCH₃ CN FA-2289. OCH₃ OCH₃ 3-F CN F A-2290. OCH₃ OCH₃ 3-CH₃ CN F A-2291. OCH₃OCH₃ 3-OCH₃ CN F A-2292. OCH₃ OCH₃ 5-F CN F A-2293. OCH₃ OCH₃ 5-CH₃ CN FA-2294. OCH₃ OCH₃ 5-OCH₃ CN F A-2295. OCH₃ CN 3-F CN F A-2296. OCH₃ CN3-CH₃ CN F A-2297. OCH₃ CN 3-OCH₃ CN F A-2298. OCH₃ CN 5-F CN F A-2299.OCH₃ CN 5-CH₃ CN F A-2300. OCH₃ CN 5-OCH₃ CN F A-2301. OCH₃ CH₂F 3-F CNF A-2302. OCH₃ CH₂F 3-CH₃ CN F A-2303. OCH₃ CH₂F 3-OCH₃ CN F A-2304.OCH₃ CH₂F 5-F CN F A-2305. OCH₃ CH₂F 5-CH₃ CN F A-2306. OCH₃ CH₂F 5-OCH₃CN F A-2307. OCH₃ CHF₂ 3-F CN F A-2308. OCH₃ CHF₂ 3-CH₃ CN F A-2309.OCH₃ CHF₂ 3-OCH₃ CN F A-2310. OCH₃ CHF₂ 5-F CN F A-2311. OCH₃ CHF₂ 5-CH₃CN F A-2312. OCH₃ CHF₂ 5-OCH₃ CN F A-2313. OCH₃ CF₃ 3-F CN F A-2314.OCH₃ CF₃ 3-CH₃ CN F A-2315. OCH₃ CF₃ 3-OCH₃ CN F A-2316. OCH₃ CF₃ 5-F CNF A-2317. OCH₃ CF₃ 5-CH₃ CN F A-2318. OCH₃ CF₃ 5-OCH₃ CN F A-2319. OCH₃OCH₂F 3-F CN F A-2320. OCH₃ OCH₂F 3-CH₃ CN F A-2321. OCH₃ OCH₂F 3-OCH₃CN F A-2322. OCH₃ OCH₂F 5-F CN F A-2323. OCH₃ OCH₂F 5-CH₃ CN F A-2324.OCH₃ OCH₂F 5-OCH₃ CN F A-2325. OCH₃ OCHF₂ 3-F CN F A-2326. OCH₃ OCHF₂3-CH₃ CN F A-2327. OCH₃ OCHF₂ 3-OCH₃ CN F A-2328. OCH₃ OCHF₂ 5-F CN FA-2329. OCH₃ OCHF₂ 5-CH₃ CN F A-2330. OCH₃ OCHF₂ 5-OCH₃ CN F A-2331.OCH₃ OCF₃ 3-F CN F A-2332. OCH₃ OCF₃ 3-CH₃ CN F A-2333. OCH₃ OCF₃ 3-OCH₃CN F A-2334. OCH₃ OCF₃ 5-F CN F A-2335. OCH₃ OCF₃ 5-CH₃ CN F A-2336.OCH₃ OCF₃ 5-OCH₃ CN F A-2337. CH₂F F 3-F CN F A-2338. CH₂F F 3-CH₃ CN FA-2339. CH₂F F 3-OCH₃ CN F A-2340. CH₂F F 5-F CN F A-2341. CH₂F F 5-CH₃CN F A-2342. CH₂F F 5-OCH₃ CN F A-2343. CH₂F CH₃ 3-F CN F A-2344. CH₂FCH₃ 3-CH₃ CN F A-2345. CH₂F CH₃ 3-OCH₃ CN F A-2346. CH₂F CH₃ 5-F CN FA-2347. CH₂F CH₃ 5-CH₃ CN F A-2348. CH₂F CH₃ 5-OCH₃ CN F A-2349. CH₂FOCH₃ 3-F CN F A-2350. CH₂F OCH₃ 3-CH₃ CN F A-2351. CH₂F OCH₃ 3-OCH₃ CN FA-2352. CH₂F OCH₃ 5-F CN F A-2353. CH₂F OCH₃ 5-CH₃ CN F A-2354. CH₂FOCH₃ 5-OCH₃ CN F A-2355. CH₂F CN 3-F CN F A-2356. CH₂F CN 3-CH₃ CN FA-2357. CH₂F CN 3-OCH₃ CN F A-2358. CH₂F CN 5-F CN F A-2359. CH₂F CN5-CH₃ CN F A-2360. CH₂F CN 5-OCH₃ CN F A-2361. CH₂F CH₂F 3-F CN FA-2362. CH₂F CH₂F 3-CH₃ CN F A-2363. CH₂F CH₂F 3-OCH₃ CN F A-2364. CH₂FCH₂F 5-F CN F A-2365. CH₂F CH₂F 5-CH₃ CN F A-2366. CH₂F CH₂F 5-OCH₃ CN FA-2367. CH₂F CHF₂ 3-F CN F A-2368. CH₂F CHF₂ 3-CH₃ CN F A-2369. CH₂FCHF₂ 3-OCH₃ CN F A-2370. CH₂F CHF₂ 5-F CN F A-2371. CH₂F CHF₂ 5-CH₃ CN FA-2372. CH₂F CHF₂ 5-OCH₃ CN F A-2373. CH₂F CF₃ 3-F CN F A-2374. CH₂F CF₃3-CH₃ CN F A-2375. CH₂F CF₃ 3-OCH₃ CN F A-2376. CH₂F CF₃ 5-F CN FA-2377. CH₂F CF₃ 5-CH₃ CN F A-2378. CH₂F CF₃ 5-OCH₃ CN F A-2379. CH₂FOCH₂F 3-F CN F A-2380. CH₂F OCH₂F 3-CH₃ CN F A-2381. CH₂F OCH₂F 3-OCH₃CN F A-2382. CH₂F OCH₂F 5-F CN F A-2383. CH₂F OCH₂F 5-CH₃ CN F A-2384.CH₂F OCH₂F 5-OCH₃ CN F A-2385. CH₂F OCHF₂ 3-F CN F A-2386. CH₂F OCHF₂3-CH₃ CN F A-2387. CH₂F OCHF₂ 3-OCH₃ CN F A-2388. CH₂F OCHF₂ 5-F CN FA-2389. CH₂F OCHF₂ 5-CH₃ CN F A-2390. CH₂F OCHF₂ 5-OCH₃ CN F A-2391.CH₂F OCF₃ 3-F CN F A-2392. CH₂F OCF₃ 3-CH₃ CN F A-2393. CH₂F OCF₃ 3-OCH₃CN F A-2394. CH₂F OCF₃ 5-F CN F A-2395. CH₂F OCF₃ 5-CH₃ CN F A-2396.CH₂F OCF₃ 5-OCH₃ CN F A-2397. CHF₂ F 3-F CN F A-2398. CHF₂ F 3-CH₃ CN FA-2399. CHF₂ F 3-OCH₃ CN F A-2400. CHF₂ F 5-F CN F A-2401. CHF₂ F 5-CH₃CN F A-2402. CHF₂ F 5-OCH₃ CN F A-2403. CHF₂ CH₃ 3-F CN F A-2404. CHF₂CH₃ 3-CH₃ CN F A-2405. CHF₂ CH₃ 3-OCH₃ CN F A-2406. CHF₂ CH₃ 5-F CN FA-2407. CHF₂ CH₃ 5-CH₃ CN F A-2408. CHF₂ CH₃ 5-OCH₃ CN F A-2409. CHF₂OCH₃ 3-F CN F A-2410. CHF₂ OCH₃ 3-CH₃ CN F A-2411. CHF₂ OCH₃ 3-OCH₃ CN FA-2412. CHF₂ OCH₃ 5-F CN F A-2413. CHF₂ OCH₃ 5-CH₃ CN F A-2414. CHF₂OCH₃ 5-OCH₃ CN F A-2415. CHF₂ CN 3-F CN F A-2416. CHF₂ CN 3-CH₃ CN FA-2417. CHF₂ CN 3-OCH₃ CN F A-2418. CHF₂ CN 5-F CN F A-2419. CHF₂ CN5-CH₃ CN F A-2420. CHF₂ CN 5-OCH₃ CN F A-2421. CHF₂ CH₂F 3-F CN FA-2422. CHF₂ CH₂F 3-CH₃ CN F A-2423. CHF₂ CH₂F 3-OCH₃ CN F A-2424. CHF₂CH₂F 5-F CN F A-2425. CHF₂ CH₂F 5-CH₃ CN F A-2426. CHF₂ CH₂F 5-OCH₃ CN FA-2427. CHF₂ CHF₂ 3-F CN F A-2428. CHF₂ CHF₂ 3-CH₃ CN F A-2429. CHF₂CHF₂ 3-OCH₃ CN F A-2430. CHF₂ CHF₂ 5-F CN F A-2431. CHF₂ CHF₂ 5-CH₃ CN FA-2432. CHF₂ CHF₂ 5-OCH₃ CN F A-2433. CHF₂ CF₃ 3-F CN F A-2434. CHF₂ CF₃3-CH₃ CN F A-2435. CHF₂ CF₃ 3-OCH₃ CN F A-2436. CHF₂ CF₃ 5-F CN FA-2437. CHF₂ CF₃ 5-CH₃ CN F A-2438. CHF₂ CF₃ 5-OCH₃ CN F A-2439. CHF₂OCH₂F 3-F CN F A-2440. CHF₂ OCH₂F 3-CH₃ CN F A-2441. CHF₂ OCH₂F 3-OCH₃CN F A-2442. CHF₂ OCH₂F 5-F CN F A-2443. CHF₂ OCH₂F 5-CH₃ CN F A-2444.CHF₂ OCH₂F 5-OCH₃ CN F A-2445. CHF₂ OCHF₂ 3-F CN F A-2446. CHF₂ OCHF₂3-CH₃ CN F A-2447. CHF₂ OCHF₂ 3-OCH₃ CN F A-2448. CHF₂ OCHF₂ 5-F CN FA-2449. CHF₂ OCHF₂ 5-CH₃ CN F A-2450. CHF₂ OCHF₂ 5-OCH₃ CN F A-2451.CHF₂ OCF₃ 3-F CN F A-2452. CHF₂ OCF₃ 3-CH₃ CN F A-2453. CHF₂ OCF₃ 3-OCH₃CN F A-2454. CHF₂ OCF₃ 5-F CN F A-2455. CHF₂ OCF₃ 5-CH₃ CN F A-2456.CHF₂ OCF₃ 5-OCH₃ CN F A-2457. CF₃ F 3-F CN F A-2458. CF₃ F 3-CH₃ CN FA-2459. CF₃ F 3-OCH₃ CN F A-2460. CF₃ F 5-F CN F A-2461. CF₃ F 5-CH₃ CNF A-2462. CF₃ F 5-OCH₃ CN F A-2463. CF₃ CH₃ 3-F CN F A-2464. CF₃ CH₃3-CH₃ CN F A-2465. CF₃ CH₃ 3-OCH₃ CN F A-2466. CF₃ CH₃ 5-F CN F A-2467.CF₃ CH₃ 5-CH₃ CN F A-2468. CF₃ CH₃ 5-OCH₃ CN F A-2469. CF₃ OCH₃ 3-F CN FA-2470. CF₃ OCH₃ 3-CH₃ CN F A-2471. CF₃ OCH₃ 3-OCH₃ CN F A-2472. CF₃OCH₃ 5-F CN F A-2473. CF₃ OCH₃ 5-CH₃ CN F A-2474. CF₃ OCH₃ 5-OCH₃ CN FA-2475. CF₃ CN 3-F CN F A-2476. CF₃ CN 3-CH₃ CN F A-2477. CF₃ CN 3-OCH₃CN F A-2478. CF₃ CN 5-F CN F A-2479. CF₃ CN 5-CH₃ CN F A-2480. CF₃ CN5-OCH₃ CN F A-2481. CF₃ CH₂F 3-F CN F A-2482. CF₃ CH₂F 3-CH₃ CN FA-2483. CF₃ CH₂F 3-OCH₃ CN F A-2484. CF₃ CH₂F 5-F CN F A-2485. CF₃ CH₂F5-CH₃ CN F A-2486. CF₃ CH₂F 5-OCH₃ CN F A-2487. CF₃ CHF₂ 3-F CN FA-2488. CF₃ CHF₂ 3-CH₃ CN F A-2489. CF₃ CHF₂ 3-OCH₃ CN F A-2490. CF₃CHF₂ 5-F CN F A-2491. CF₃ CHF₂ 5-CH₃ CN F A-2492. CF₃ CHF₂ 5-OCH₃ CN FA-2493. CF₃ CF₃ 3-F CN F A-2494. CF₃ CF₃ 3-CH₃ CN F A-2495. CF₃ CF₃3-OCH₃ CN F A-2496. CF₃ CF₃ 5-F CN F A-2497. CF₃ CF₃ 5-CH₃ CN F A-2498.CF₃ CF₃ 5-OCH₃ CN F A-2499. CF₃ OCH₂F 3-F CN F A-2500. CF₃ OCH₂F 3-CH₃CN F A-2501. CF₃ OCH₂F 3-OCH₃ CN F A-2502. CF₃ OCH₂F 5-F CN F A-2503.CF₃ OCH₂F 5-CH₃ CN F A-2504. CF₃ OCH₂F 5-OCH₃ CN F A-2505. CF₃ OCHF₂ 3-FCN F A-2506. CF₃ OCHF₂ 3-CH₃ CN F A-2507. CF₃ OCHF₂ 3-OCH₃ CN F A-2508.CF₃ OCHF₂ 5-F CN F A-2509. CF₃ OCHF₂ 5-CH₃ CN F A-2510. CF₃ OCHF₂ 5-OCH₃CN F A-2511. CF₃ OCF₃ 3-F CN F A-2512. CF₃ OCF₃ 3-CH₃ CN F A-2513. CF₃OCF₃ 3-OCH₃ CN F A-2514. CF₃ OCF₃ 5-F CN F A-2515. CF₃ OCF₃ 5-CH₃ CN FA-2516. CF₃ OCF₃ 5-OCH₃ CN F A-2517. OCH₂F F 3-F CN F A-2518. OCH₂F F3-CH₃ CN F A-2519. OCH₂F F 3-OCH₃ CN F A-2520. OCH₂F F 5-F CN F A-2521.OCH₂F F 5-CH₃ CN F A-2522. OCH₂F F 5-OCH₃ CN F A-2523. OCH₂F CH₃ 3-F CNF A-2524. OCH₂F CH₃ 3-CH₃ CN F A-2525. OCH₂F CH₃ 3-OCH₃ CN F A-2526.OCH₂F CH₃ 5-F CN F A-2527. OCH₂F CH₃ 5-CH₃ CN F A-2528. OCH₂F CH₃ 5-OCH₃CN F A-2529. OCH₂F OCH₃ 3-F CN F A-2530. OCH₂F OCH₃ 3-CH₃ CN F A-2531.OCH₂F OCH₃ 3-OCH₃ CN F A-2532. OCH₂F OCH₃ 5-F CN F A-2533. OCH₂F OCH₃5-CH₃ CN F A-2534. OCH₂F OCH₃ 5-OCH₃ CN F A-2535. OCH₂F CN 3-F CN FA-2536. OCH₂F CN 3-CH₃ CN F A-2537. OCH₂F CN 3-OCH₃ CN F A-2538. OCH₂FCN 5-F CN F A-2539. OCH₂F CN 5-CH₃ CN F A-2540. OCH₂F CN 5-OCH₃ CN FA-2541. OCH₂F CH₂F 3-F CN F A-2542. OCH₂F CH₂F 3-CH₃ CN F A-2543. OCH₂FCH₂F 3-OCH₃ CN F A-2544. OCH₂F CH₂F 5-F CN F A-2545. OCH₂F CH₂F 5-CH₃ CNF A-2546. OCH₂F CH₂F 5-OCH₃ CN F A-2547. OCH₂F CHF₂ 3-F CN F A-2548.OCH₂F CHF₂ 3-CH₃ CN F A-2549. OCH₂F CHF₂ 3-OCH₃ CN F A-2550. OCH₂F CHF₂5-F CN F A-2551. OCH₂F CHF₂ 5-CH₃ CN F A-2552. OCH₂F CHF₂ 5-OCH₃ CN FA-2553. OCH₂F CF₃ 3-F CN F A-2554. OCH₂F CF₃ 3-CH₃ CN F A-2555. OCH₂FCF₃ 3-OCH₃ CN F A-2556. OCH₂F CF₃ 5-F CN F A-2557. OCH₂F CF₃ 5-CH₃ CN FA-2558. OCH₂F CF₃ 5-OCH₃ CN F A-2559. OCH₂F OCH₂F 3-F CN F A-2560. OCH₂FOCH₂F 3-CH₃ CN F A-2561. OCH₂F OCH₂F 3-OCH₃ CN F A-2562. OCH₂F OCH₂F 5-FCN F A-2563. OCH₂F OCH₂F 5-CH₃ CN F A-2564. OCH₂F OCH₂F 5-OCH₃ CN FA-2565. OCH₂F OCHF₂ 3-F CN F A-2566. OCH₂F OCHF₂ 3-CH₃ CN F A-2567.OCH₂F OCHF₂ 3-OCH₃ CN F A-2568. OCH₂F OCHF₂ 5-F CN F A-2569. OCH₂F OCHF₂5-CH₃ CN F A-2570. OCH₂F OCHF₂ 5-OCH₃ CN F A-2571. OCH₂F OCF₃ 3-F CN FA-2572. OCH₂F OCF₃ 3-CH₃ CN F A-2573. OCH₂F OCF₃ 3-OCH₃ CN F A-2574.OCH₂F OCF₃ 5-F CN F A-2575. OCH₂F OCF₃ 5-CH₃ CN F A-2576. OCH₂F OCF₃5-OCH₃ CN F A-2577. OCHF₂ F 3-F CN F A-2578. OCHF₂ F 3-CH₃ CN F A-2579.OCHF₂ F 3-OCH₃ CN F A-2580. OCHF₂ F 5-F CN F A-2581. OCHF₂ F 5-CH₃ CN FA-2582. OCHF₂ F 5-OCH₃ CN F A-2583. OCHF₂ CH₃ 3-F CN F A-2584. OCHF₂ CH₃3-CH₃ CN F A-2585. OCHF₂ CH₃ 3-OCH₃ CN F A-2586. OCHF₂ CH₃ 5-F CN FA-2587. OCHF₂ CH₃ 5-CH₃ CN F A-2588. OCHF₂ CH₃ 5-OCH₃ CN F A-2589. OCHF₂OCH₃ 3-F CN F A-2590. OCHF₂ OCH₃ 3-CH₃ CN F A-2591. OCHF₂ OCH₃ 3-OCH₃ CNF A-2592. OCHF₂ OCH₃ 5-F CN F A-2593. OCHF₂ OCH₃ 5-CH₃ CN F A-2594.OCHF₂ OCH₃ 5-OCH₃ CN F A-2595. OCHF₂ CN 3-F CN F A-2596. OCHF₂ CN 3-CH₃CN F A-2597. OCHF₂ CN 3-OCH₃ CN F A-2598. OCHF₂ CN 5-F CN F A-2599.OCHF₂ CN 5-CH₃ CN F A-2600. OCHF₂ CN 5-OCH₃ CN F A-2601. OCHF₂ CH₂F 3-FCN F A-2602. OCHF₂ CH₂F 3-CH₃ CN F A-2603. OCHF₂ CH₂F 3-OCH₃ CN FA-2604. OCHF₂ CH₂F 5-F CN F A-2605. OCHF₂ CH₂F 5-CH₃ CN F A-2606. OCHF₂CH₂F 5-OCH₃ CN F A-2607. OCHF₂ CHF₂ 3-F CN F A-2608. OCHF₂ CHF₂ 3-CH₃ CNF A-2609. OCHF₂ CHF₂ 3-OCH₃ CN F A-2610. OCHF₂ CHF₂ 5-F CN F A-2611.OCHF₂ CHF₂ 5-CH₃ CN F A-2612. OCHF₂ CHF₂ 5-OCH₃ CN F A-2613. OCHF₂ CF₃3-F CN F A-2614. OCHF₂ CF₃ 3-CH₃ CN F A-2615. OCHF₂ CF₃ 3-OCH₃ CN FA-2616. OCHF₂ CF₃ 5-F CN F A-2617. OCHF₂ CF₃ 5-CH₃ CN F A-2618. OCHF₂CF₃ 5-OCH₃ CN F A-2619. OCHF₂ OCH₂F 3-F CN F A-2620. OCHF₂ OCH₂F 3-CH₃CN F A-2621. OCHF₂ OCH₂F 3-OCH₃ CN F A-2622. OCHF₂ OCH₂F 5-F CN FA-2623. OCHF₂ OCH₂F 5-CH₃ CN F A-2624. OCHF₂ OCH₂F 5-OCH₃ CN F A-2625.OCHF₂ OCHF₂ 3-F CN F A-2626. OCHF₂ OCHF₂ 3-CH₃ CN F A-2627. OCHF₂ OCHF₂3-OCH₃ CN F A-2628. OCHF₂ OCHF₂ 5-F CN F A-2629. OCHF₂ OCHF₂ 5-CH₃ CN FA-2630. OCHF₂ OCHF₂ 5-OCH₃ CN F A-2631. OCHF₂ OCF₃ 3-F CN F A-2632.OCHF₂ OCF₃ 3-CH₃ CN F A-2633. OCHF₂ OCF₃ 3-OCH₃ CN F A-2634. OCHF₂ OCF₃5-F CN F A-2635. OCHF₂ OCF₃ 5-CH₃ CN F A-2636. OCHF₂ OCF₃ 5-OCH₃ CN FA-2637. OCF₃ F 3-F CN F A-2638. OCF₃ F 3-CH₃ CN F A-2639. OCF₃ F 3-OCH₃CN F A-2640. OCF₃ F 5-F CN F A-2641. OCF₃ F 5-CH₃ CN F A-2642. OCF₃ F5-OCH₃ CN F A-2643. OCF₃ CH₃ 3-F CN F A-2644. OCF₃ CH₃ 3-CH₃ CN FA-2645. OCF₃ CH₃ 3-OCH₃ CN F A-2646. OCF₃ CH₃ 5-F CN F A-2647. OCF₃ CH₃5-CH₃ CN F A-2648. OCF₃ CH₃ 5-OCH₃ CN F A-2649. OCF₃ OCH₃ 3-F CN FA-2650. OCF₃ OCH₃ 3-CH₃ CN F A-2651. OCF₃ OCH₃ 3-OCH₃ CN F A-2652. OCF₃OCH₃ 5-F CN F A-2653. OCF₃ OCH₃ 5-CH₃ CN F A-2654. OCF₃ OCH₃ 5-OCH₃ CN FA-2655. OCF₃ CN 3-F CN F A-2656. OCF₃ CN 3-CH₃ CN F A-2657. OCF₃ CN3-OCH₃ CN F A-2658. OCF₃ CN 5-F CN F A-2659. OCF₃ CN 5-CH₃ CN F A-2660.OCF₃ CN 5-OCH₃ CN F A-2661. OCF₃ CH₂F 3-F CN F A-2662. OCF₃ CH₂F 3-CH₃CN F A-2663. OCF₃ CH₂F 3-OCH₃ CN F A-2664. OCF₃ CH₂F 5-F CN F A-2665.OCF₃ CH₂F 5-CH₃ CN F A-2666. OCF₃ CH₂F 5-OCH₃ CN F A-2667. OCF₃ CHF₂ 3-FCN F A-2668. OCF₃ CHF₂ 3-CH₃ CN F A-2669. OCF₃ CHF₂ 3-OCH₃ CN F A-2670.OCF₃ CHF₂ 5-F CN F A-2671. OCF₃ CHF₂ 5-CH₃ CN F A-2672. OCF₃ CHF₂ 5-OCH₃CN F A-2673. OCF₃ CF₃ 3-F CN F A-2674. OCF₃ CF₃ 3-CH₃ CN F A-2675. OCF₃CF₃ 3-OCH₃ CN F A-2676. OCF₃ CF₃ 5-F CN F A-2677. OCF₃ CF₃ 5-CH₃ CN FA-2678. OCF₃ CF₃ 5-OCH₃ CN F A-2679. OCF₃ OCH₂F 3-F CN F A-2680. OCF₃OCH₂F 3-CH₃ CN F A-2681. OCF₃ OCH₂F 3-OCH₃ CN F A-2682. OCF₃ OCH₂F 5-FCN F A-2683. OCF₃ OCH₂F 5-CH₃ CN F A-2684. OCF₃ OCH₂F 5-OCH₃ CN FA-2685. OCF₃ OCHF₂ 3-F CN F A-2686. OCF₃ OCHF₂ 3-CH₃ CN F A-2687. OCF₃OCHF₂ 3-OCH₃ CN F A-2688. OCF₃ OCHF₂ 5-F CN F A-2689. OCF₃ OCHF₂ 5-CH₃CN F A-2690. OCF₃ OCHF₂ 5-OCH₃ CN F A-2691. OCF₃ OCF₃ 3-F CN F A-2692.OCF₃ OCF₃ 3-CH₃ CN F A-2693. OCF₃ OCF₃ 3-OCH₃ CN F A-2694. OCF₃ OCF₃ 5-FCN F A-2695. OCF₃ OCF₃ 5-CH₃ CN F A-2696. OCF₃ OCF₃ 5-OCH₃ CN F A-2697.H H H F F A-2698. F H H F F A-2699. CH₃ H H F F A-2700. OCH₃ H H F FA-2701. CH₂F H H F F A-2702. CHF₂ H H F F A-2703. CF₃ H H F F A-2704.OCH₂F H H F F A-2705. OCHF₂ H H F F A-2706. OCF₃ H H F F A-2707. H F H FF A-2708. H CH₃ H F F A-2709. H OCH₃ H F F A-2710. H CN H F F A-2711. HCH₂F H F F A-2712. H CHF₂ H F F A-2713. H CF₃ H F F A-2714. H OCH₂F H FF A-2715. H OCHF₂ H F F A-2716. H OCF₃ H F F A-2717. H H 3-F F F A-2718.H H 3-CH₃ F F A-2719. H H 3-OCH₃ F F A-2720. H H 5-F F F A-2721. H H5-CH₃ F F A-2722. H H 5-OCH₃ F F A-2723. F F H F F A-2724. F CH₃ H F FA-2725. F OCH₃ H F F A-2726. F CN H F F A-2727. F CH₂F H F F A-2728. FCHF₂ H F F A-2729. F CF₃ H F F A-2730. F OCH₂F H F F A-2731. F OCHF₂ H FF A-2732. F OCF₃ H F F A-2733. F H 3-F F F A-2734. F H 3-CH₃ F F A-2735.F H 3-OCH₃ F F A-2736. F H 5-F F F A-2737. F H 5-CH₃ F F A-2738. F H5-OCH₃ F F A-2739. CH₃ F H F F A-2740. CH₃ CH₃ H F F A-2741. CH₃ OCH₃ HF F A-2742. CH₃ CN H F F A-2743. CH₃ CH₂F H F F A-2744. CH₃ CHF₂ H F FA-2745. CH₃ CF₃ H F F A-2746. CH₃ OCH₂F H F F A-2747. CH₃ OCHF₂ H F FA-2748. CH₃ OCF₃ H F F A-2749. CH₃ H 3-F F F A-2750. CH₃ H 3-CH₃ F FA-2751. CH₃ H 3-OCH₃ F F A-2752. CH₃ H 5-F F F A-2753. CH₃ H 5-CH₃ F FA-2754. CH₃ H 5-OCH₃ F F A-2755. OCH₃ F H F F A-2756. OCH₃ CH₃ H F FA-2757. OCH₃ OCH₃ H F F A-2758. OCH₃ CN H F F A-2759. OCH₃ CH₂F H F FA-2760. OCH₃ CHF₂ H F F A-2761. OCH₃ CF₃ H F F A-2762. OCH₃ OCH₂F H F FA-2763. OCH₃ OCHF₂ H F F A-2764. OCH₃ OCF₃ H F F A-2765. OCH₃ H 3-F F FA-2766. OCH₃ H 3-CH₃ F F A-2767. OCH₃ H 3-OCH₃ F F A-2768. OCH₃ H 5-F FF A-2769. OCH₃ H 5-CH₃ F F A-2770. OCH₃ H 5-OCH₃ F F A-2771. H F 3-F F FA-2772. H F 3-CH₃ F F A-2773. H F 3-OCH₃ F F A-2774. H F 5-F F F A-2775.H F 5-CH₃ F F A-2776. H F 5-OCH₃ F F A-2777. H CH₃ 3-F F F A-2778. H CH₃3-CH₃ F F A-2779. H CH₃ 3-OCH₃ F F A-2780. H CH₃ 5-F F F A-2781. H CH₃5-CH₃ F F A-2782. H CH₃ 5-OCH₃ F F A-2783. H OCH₃ 3-F F F A-2784. H OCH₃3-CH₃ F F A-2785. H OCH₃ 3-OCH₃ F F A-2786. H OCH₃ 5-F F F A-2787. HOCH₃ 5-CH₃ F F A-2788. H OCH₃ 5-OCH₃ F F A-2789. H CN 3-F F F A-2790. HCN 3-CH₃ F F A-2791. H CN 3-OCH₃ F F A-2792. H CN 5-F F F A-2793. H CN5-CH₃ F F A-2794. H CN 5-OCH₃ F F A-2795. H CH₂F 3-F F F A-2796. H CH₂F3-CH₃ F F A-2797. H CH₂F 3-OCH₃ F F A-2798. H CH₂F 5-F F F A-2799. HCH₂F 5-CH₃ F F A-2800. H CH₂F 5-OCH₃ F F A-2801. H CHF₂ 3-F F F A-2802.H CHF₂ 3-CH₃ F F A-2803. H CHF₂ 3-OCH₃ F F A-2804. H CHF₂ 5-F F FA-2805. H CHF₂ 5-CH₃ F F A-2806. H CHF₂ 5-OCH₃ F F A-2807. H CF₃ 3-F F FA-2808. H CF₃ 3-CH₃ F F A-2809. H CF₃ 3-OCH₃ F F A-2810. H CF₃ 5-F F FA-2811. H CF₃ 5-CH₃ F F A-2812. H CF₃ 5-OCH₃ F F A-2813. H OCH₂F 3-F F FA-2814. H OCH₂F 3-CH₃ F F A-2815. H OCH₂F 3-OCH₃ F F A-2816. H OCH₂F 5-FF F A-2817. H OCH₂F 5-CH₃ F F A-2818. H OCH₂F 5-OCH₃ F F A-2819. H OCHF₂3-F F F A-2820. H OCHF₂ 3-CH₃ F F A-2821. H OCHF₂ 3-OCH₃ F F A-2822. HOCHF₂ 5-F F F A-2823. H OCHF₂ 5-CH₃ F F A-2824. H OCHF₂ 5-OCH₃ F FA-2825. H OCF₃ 3-F F F A-2826. H OCF₃ 3-CH₃ F F A-2827. H OCF₃ 3-OCH₃ FF A-2828. H OCF₃ 5-F F F A-2829. H OCF₃ 5-CH₃ F F A-2830. H OCF₃ 5-OCH₃F F A-2831. F F 3-F F F A-2832. F F 3-CH₃ F F A-2833. F F 3-OCH₃ F FA-2834. F F 5-F F F A-2835. F F 5-CH₃ F F A-2836. F F 5-OCH₃ F F A-2837.F CH₃ 3-F F F A-2838. F CH₃ 3-CH₃ F F A-2839. F CH₃ 3-OCH₃ F F A-2840. FCH₃ 5-F F F A-2841. F CH₃ 5-CH₃ F F A-2842. F CH₃ 5-OCH₃ F F A-2843. FOCH₃ 3-F F F A-2844. F OCH₃ 3-CH₃ F F A-2845. F OCH₃ 3-OCH₃ F F A-2846.F OCH₃ 5-F F F A-2847. F OCH₃ 5-CH₃ F F A-2848. F OCH₃ 5-OCH₃ F FA-2849. F CN 3-F F F A-2850. F CN 3-CH₃ F F A-2851. F CN 3-OCH₃ F FA-2852. F CN 5-F F F A-2853. F CN 5-CH₃ F F A-2854. F CN 5-OCH₃ F FA-2855. F CH₂F 3-F F F A-2856. F CH₂F 3-CH₃ F F A-2857. F CH₂F 3-OCH₃ FF A-2858. F CH₂F 5-F F F A-2859. F CH₂F 5-CH₃ F F A-2860. F CH₂F 5-OCH₃F F A-2861. F CHF₂ 3-F F F A-2862. F CHF₂ 3-CH₃ F F A-2863. F CHF₂3-OCH₃ F F A-2864. F CHF₂ 5-F F F A-2865. F CHF₂ 5-CH₃ F F A-2866. FCHF₂ 5-OCH₃ F F A-2867. F CF₃ 3-F F F A-2868. F CF₃ 3-CH₃ F F A-2869. FCF₃ 3-OCH₃ F F A-2870. F CF₃ 5-F F F A-2871. F CF₃ 5-CH₃ F F A-2872. FCF₃ 5-OCH₃ F F A-2873. F OCH₂F 3-F F F A-2874. F OCH₂F 3-CH₃ F F A-2875.F OCH₂F 3-OCH₃ F F A-2876. F OCH₂F 5-F F F A-2877. F OCH₂F 5-CH₃ F FA-2878. F OCH₂F 5-OCH₃ F F A-2879. F OCHF₂ 3-F F F A-2880. F OCHF₂ 3-CH₃F F A-2881. F OCHF₂ 3-OCH₃ F F A-2882. F OCHF₂ 5-F F F A-2883. F OCHF₂5-CH₃ F F A-2884. F OCHF₂ 5-OCH₃ F F A-2885. F OCF₃ 3-F F F A-2886. FOCF₃ 3-CH₃ F F A-2887. F OCF₃ 3-OCH₃ F F A-2888. F OCF₃ 5-F F F A-2889.F OCF₃ 5-CH₃ F F A-2890. F OCF₃ 5-OCH₃ F F A-2891. CH₃ F 3-F F F A-2892.CH₃ F 3-CH₃ F F A-2893. CH₃ F 3-OCH₃ F F A-2894. CH₃ F 5-F F F A-2895.CH₃ F 5-CH₃ F F A-2896. CH₃ F 5-OCH₃ F F A-2897. CH₃ CH₃ 3-F F F A-2898.CH₃ CH₃ 3-CH₃ F F A-2899. CH₃ CH₃ 3-OCH₃ F F A-2900. CH₃ CH₃ 5-F F FA-2901. CH₃ CH₃ 5-CH₃ F F A-2902. CH₃ CH₃ 5-OCH₃ F F A-2903. CH₃ OCH₃3-F F F A-2904. CH₃ OCH₃ 3-CH₃ F F A-2905. CH₃ OCH₃ 3-OCH₃ F F A-2906.CH₃ OCH₃ 5-F F F A-2907. CH₃ OCH₃ 5-CH₃ F F A-2908. CH₃ OCH₃ 5-OCH₃ F FA-2909. CH₃ CN 3-F F F A-2910. CH₃ CN 3-CH₃ F F A-2911. CH₃ CN 3-OCH₃ FF A-2912. CH₃ CN 5-F F F A-2913. CH₃ CN 5-CH₃ F F A-2914. CH₃ CN 5-OCH₃F F A-2915. CH₃ CH₂F 3-F F F A-2916. CH₃ CH₂F 3-CH₃ F F A-2917. CH₃ CH₂F3-OCH₃ F F A-2918. CH₃ CH₂F 5-F F F A-2919. CH₃ CH₂F 5-CH₃ F F A-2920.CH₃ CH₂F 5-OCH₃ F F A-2921. CH₃ CHF₂ 3-F F F A-2922. CH₃ CHF₂ 3-CH₃ F FA-2923. CH₃ CHF₂ 3-OCH₃ F F A-2924. CH₃ CHF₂ 5-F F F A-2925. CH₃ CHF₂5-CH₃ F F A-2926. CH₃ CHF₂ 5-OCH₃ F F A-2927. CH₃ CF₃ 3-F F F A-2928.CH₃ CF₃ 3-CH₃ F F A-2929. CH₃ CF₃ 3-OCH₃ F F A-2930. CH₃ CF₃ 5-F F FA-2931. CH₃ CF₃ 5-CH₃ F F A-2932. CH₃ CF₃ 5-OCH₃ F F A-2933. CH₃ OCH₂F3-F F F A-2934. CH₃ OCH₂F 3-CH₃ F F A-2935. CH₃ OCH₂F 3-OCH₃ F F A-2936.CH₃ OCH₂F 5-F F F A-2937. CH₃ OCH₂F 5-CH₃ F F A-2938. CH₃ OCH₂F 5-OCH₃ FF A-2939. CH₃ OCHF₂ 3-F F F A-2940. CH₃ OCHF₂ 3-CH₃ F F A-2941. CH₃OCHF₂ 3-OCH₃ F F A-2942. CH₃ OCHF₂ 5-F F F A-2943. CH₃ OCHF₂ 5-CH₃ F FA-2944. CH₃ OCHF₂ 5-OCH₃ F F A-2945. CH₃ OCF₃ 3-F F F A-2946. CH₃ OCF₃3-CH₃ F F A-2947. CH₃ OCF₃ 3-OCH₃ F F A-2948. CH₃ OCF₃ 5-F F F A-2949.CH₃ OCF₃ 5-CH₃ F F A-2950. CH₃ OCF₃ 5-OCH₃ F F A-2951. OCH₃ F 3-F F FA-2952. OCH₃ F 3-CH₃ F F A-2953. OCH₃ F 3-OCH₃ F F A-2954. OCH₃ F 5-F FF A-2955. OCH₃ F 5-CH₃ F F A-2956. OCH₃ F 5-OCH₃ F F A-2957. OCH₃ CH₃3-F F F A-2958. OCH₃ CH₃ 3-CH₃ F F A-2959. OCH₃ CH₃ 3-OCH₃ F F A-2960.OCH₃ CH₃ 5-F F F A-2961. OCH₃ CH₃ 5-CH₃ F F A-2962. OCH₃ CH₃ 5-OCH₃ F FA-2963. OCH₃ OCH₃ 3-F F F A-2964. OCH₃ OCH₃ 3-CH₃ F F A-2965. OCH₃ OCH₃3-OCH₃ F F A-2966. OCH₃ OCH₃ 5-F F F A-2967. OCH₃ OCH₃ 5-CH₃ F F A-2968.OCH₃ OCH₃ 5-OCH₃ F F A-2969. OCH₃ CN 3-F F F A-2970. OCH₃ CN 3-CH₃ F FA-2971. OCH₃ CN 3-OCH₃ F F A-2972. OCH₃ CN 5-F F F A-2973. OCH₃ CN 5-CH₃F F A-2974. OCH₃ CN 5-OCH₃ F F A-2975. OCH₃ CH₂F 3-F F F A-2976. OCH₃CH₂F 3-CH₃ F F A-2977. OCH₃ CH₂F 3-OCH₃ F F A-2978. OCH₃ CH₂F 5-F F FA-2979. OCH₃ CH₂F 5-CH₃ F F A-2980. OCH₃ CH₂F 5-OCH₃ F F A-2981. OCH₃CHF₂ 3-F F F A-2982. OCH₃ CHF₂ 3-CH₃ F F A-2983. OCH₃ CHF₂ 3-OCH₃ F FA-2984. OCH₃ CHF₂ 5-F F F A-2985. OCH₃ CHF₂ 5-CH₃ F F A-2986. OCH₃ CHF₂5-OCH₃ F F A-2987. OCH₃ CF₃ 3-F F F A-2988. OCH₃ CF₃ 3-CH₃ F F A-2989.OCH₃ CF₃ 3-OCH₃ F F A-2990. OCH₃ CF₃ 5-F F F A-2991. OCH₃ CF₃ 5-CH₃ F FA-2992. OCH₃ CF₃ 5-OCH₃ F F A-2993. OCH₃ OCH₂F 3-F F F A-2994. OCH₃OCH₂F 3-CH₃ F F A-2995. OCH₃ OCH₂F 3-OCH₃ F F A-2996. OCH₃ OCH₂F 5-F F FA-2997. OCH₃ OCH₂F 5-CH₃ F F A-2998. OCH₃ OCH₂F 5-OCH₃ F F A-2999. OCH₃OCHF₂ 3-F F F A-3000. OCH₃ OCHF₂ 3-CH₃ F F A-3001. OCH₃ OCHF₂ 3-OCH₃ F FA-3002. OCH₃ OCHF₂ 5-F F F A-3003. OCH₃ OCHF₂ 5-CH₃ F F A-3004. OCH₃OCHF₂ 5-OCH₃ F F A-3005. OCH₃ OCF₃ 3-F F F A-3006. OCH₃ OCF₃ 3-CH₃ F FA-3007. OCH₃ OCF₃ 3-OCH₃ F F A-3008. OCH₃ OCF₃ 5-F F F A-3009. OCH₃ OCF₃5-CH₃ F F A-3010. OCH₃ OCF₃ 5-OCH₃ F F A-3011. CH₂F F 3-F F F A-3012.CH₂F F 3-CH₃ F F A-3013. CH₂F F 3-OCH₃ F F A-3014. CH₂F F 5-F F FA-3015. CH₂F F 5-CH₃ F F A-3016. CH₂F F 5-OCH₃ F F A-3017. CH₂F CH₃ 3-FF F A-3018. CH₂F CH₃ 3-CH₃ F F A-3019. CH₂F CH₃ 3-OCH₃ F F A-3020. CH₂FCH₃ 5-F F F A-3021. CH₂F CH₃ 5-CH₃ F F A-3022. CH₂F CH₃ 5-OCH₃ F FA-3023. CH₂F OCH₃ 3-F F F A-3024. CH₂F OCH₃ 3-CH₃ F F A-3025. CH₂F OCH₃3-OCH₃ F F A-3026. CH₂F OCH₃ 5-F F F A-3027. CH₂F OCH₃ 5-CH₃ F F A-3028.CH₂F OCH₃ 5-OCH₃ F F A-3029. CH₂F CN 3-F F F A-3030. CH₂F CN 3-CH₃ F FA-3031. CH₂F CN 3-OCH₃ F F A-3032. CH₂F CN 5-F F F A-3033. CH₂F CN 5-CH₃F F A-3034. CH₂F CN 5-OCH₃ F F A-3035. CH₂F CH₂F 3-F F F A-3036. CH₂FCH₂F 3-CH₃ F F A-3037. CH₂F CH₂F 3-OCH₃ F F A-3038. CH₂F CH₂F 5-F F FA-3039. CH₂F CH₂F 5-CH₃ F F A-3040. CH₂F CH₂F 5-OCH₃ F F A-3041. CH₂FCHF₂ 3-F F F A-3042. CH₂F CHF₂ 3-CH₃ F F A-3043. CH₂F CHF₂ 3-OCH₃ F FA-3044. CH₂F CHF₂ 5-F F F A-3045. CH₂F CHF₂ 5-CH₃ F F A-3046. CH₂F CHF₂5-OCH₃ F F A-3047. CH₂F CF₃ 3-F F F A-3048. CH₂F CF₃ 3-CH₃ F F A-3049.CH₂F CF₃ 3-OCH₃ F F A-3050. CH₂F CF₃ 5-F F F A-3051. CH₂F CF₃ 5-CH₃ F FA-3052. CH₂F CF₃ 5-OCH₃ F F A-3053. CH₂F OCH₂F 3-F F F A-3054. CH₂FOCH₂F 3-CH₃ F F A-3055. CH₂F OCH₂F 3-OCH₃ F F A-3056. CH₂F OCH₂F 5-F F FA-3057. CH₂F OCH₂F 5-CH₃ F F A-3058. CH₂F OCH₂F 5-OCH₃ F F A-3059. CH₂FOCHF₂ 3-F F F A-3060. CH₂F OCHF₂ 3-CH₃ F F A-3061. CH₂F OCHF₂ 3-OCH₃ F FA-3062. CH₂F OCHF₂ 5-F F F A-3063. CH₂F OCHF₂ 5-CH₃ F F A-3064. CH₂FOCHF₂ 5-OCH₃ F F A-3065. CH₂F OCF₃ 3-F F F A-3066. CH₂F OCF₃ 3-CH₃ F FA-3067. CH₂F OCF₃ 3-OCH₃ F F A-3068. CH₂F OCF₃ 5-F F F A-3069. CH₂F OCF₃5-CH₃ F F A-3070. CH₂F OCF₃ 5-OCH₃ F F A-3071. CHF₂ F 3-F F F A-3072.CHF₂ F 3-CH₃ F F A-3073. CHF₂ F 3-OCH₃ F F A-3074. CHF₂ F 5-F F FA-3075. CHF₂ F 5-CH₃ F F A-3076. CHF₂ F 5-OCH₃ F F A-3077. CHF₂ CH₃ 3-FF F A-3078. CHF₂ CH₃ 3-CH₃ F F A-3079. CHF₂ CH₃ 3-OCH₃ F F A-3080. CHF₂CH₃ 5-F F F A-3081. CHF₂ CH₃ 5-CH₃ F F A-3082. CHF₂ CH₃ 5-OCH₃ F FA-3083. CHF₂ OCH₃ 3-F F F A-3084. CHF₂ OCH₃ 3-CH₃ F F A-3085. CHF₂ OCH₃3-OCH₃ F F A-3086. CHF₂ OCH₃ 5-F F F A-3087. CHF₂ OCH₃ 5-CH₃ F F A-3088.CHF₂ OCH₃ 5-OCH₃ F F A-3089. CHF₂ CN 3-F F F A-3090. CHF₂ CN 3-CH₃ F FA-3091. CHF₂ CN 3-OCH₃ F F A-3092. CHF₂ CN 5-F F F A-3093. CHF₂ CN 5-CH₃F F A-3094. CHF₂ CN 5-OCH₃ F F A-3095. CHF₂ CH₂F 3-F F F A-3096. CHF₂CH₂F 3-CH₃ F F A-3097. CHF₂ CH₂F 3-OCH₃ F F A-3098. CHF₂ CH₂F 5-F F FA-3099. CHF₂ CH₂F 5-CH₃ F F A-3100. CHF₂ CH₂F 5-OCH₃ F F A-3101. CHF₂CHF₂ 3-F F F A-3102. CHF₂ CHF₂ 3-CH₃ F F A-3103. CHF₂ CHF₂ 3-OCH₃ F FA-3104. CHF₂ CHF₂ 5-F F F A-3105. CHF₂ CHF₂ 5-CH₃ F F A-3106. CHF₂ CHF₂5-OCH₃ F F A-3107. CHF₂ CF₃ 3-F F F A-3108. CHF₂ CF₃ 3-CH₃ F F A-3109.CHF₂ CF₃ 3-OCH₃ F F A-3110. CHF₂ CF₃ 5-F F F A-3111. CHF₂ CF₃ 5-CH₃ F FA-3112. CHF₂ CF₃ 5-OCH₃ F F A-3113. CHF₂ OCH₂F 3-F F F A-3114. CHF₂OCH₂F 3-CH₃ F F A-3115. CHF₂ OCH₂F 3-OCH₃ F F A-3116. CHF₂ OCH₂F 5-F F FA-3117. CHF₂ OCH₂F 5-CH₃ F F A-3118. CHF₂ OCH₂F 5-OCH₃ F F A-3119. CHF₂OCHF₂ 3-F F F A-3120. CHF₂ OCHF₂ 3-CH₃ F F A-3121. CHF₂ OCHF₂ 3-OCH₃ F FA-3122. CHF₂ OCHF₂ 5-F F F A-3123. CHF₂ OCHF₂ 5-CH₃ F F A-3124. CHF₂OCHF₂ 5-OCH₃ F F A-3125. CHF₂ OCF₃ 3-F F F A-3126. CHF₂ OCF₃ 3-CH₃ F FA-3127. CHF₂ OCF₃ 3-OCH₃ F F A-3128. CHF₂ OCF₃ 5-F F F A-3129. CHF₂ OCF₃5-CH₃ F F A-3130. CHF₂ OCF₃ 5-OCH₃ F F A-3131. CF₃ F 3-F F F A-3132. CF₃F 3-CH₃ F F A-3133. CF₃ F 3-OCH₃ F F A-3134. CF₃ F 5-F F F A-3135. CF₃ F5-CH₃ F F A-3136. CF₃ F 5-OCH₃ F F A-3137. CF₃ CH₃ 3-F F F A-3138. CF₃CH₃ 3-CH₃ F F A-3139. CF₃ CH₃ 3-OCH₃ F F A-3140. CF₃ CH₃ 5-F F F A-3141.CF₃ CH₃ 5-CH₃ F F A-3142. CF₃ CH₃ 5-OCH₃ F F A-3143. CF₃ OCH₃ 3-F F FA-3144. CF₃ OCH₃ 3-CH₃ F F A-3145. CF₃ OCH₃ 3-OCH₃ F F A-3146. CF₃ OCH₃5-F F F A-3147. CF₃ OCH₃ 5-CH₃ F F A-3148. CF₃ OCH₃ 5-OCH₃ F F A-3149.CF₃ CN 3-F F F A-3150. CF₃ CN 3-CH₃ F F A-3151. CF₃ CN 3-OCH₃ F FA-3152. CF₃ CN 5-F F F A-3153. CF₃ CN 5-CH₃ F F A-3154. CF₃ CN 5-OCH₃ FF A-3155. CF₃ CH₂F 3-F F F A-3156. CF₃ CH₂F 3-CH₃ F F A-3157. CF₃ CH₂F3-OCH₃ F F A-3158. CF₃ CH₂F 5-F F F A-3159. CF₃ CH₂F 5-CH₃ F F A-3160.CF₃ CH₂F 5-OCH₃ F F A-3161. CF₃ CHF₂ 3-F F F A-3162. CF₃ CHF₂ 3-CH₃ F FA-3163. CF₃ CHF₂ 3-OCH₃ F F A-3164. CF₃ CHF₂ 5-F F F A-3165. CF₃ CHF₂5-CH₃ F F A-3166. CF₃ CHF₂ 5-OCH₃ F F A-3167. CF₃ CF₃ 3-F F F A-3168.CF₃ CF₃ 3-CH₃ F F A-3169. CF₃ CF₃ 3-OCH₃ F F A-3170. CF₃ CF₃ 5-F F FA-3171. CF₃ CF₃ 5-CH₃ F F A-3172. CF₃ CF₃ 5-OCH₃ F F A-3173. CF₃ OCH₂F3-F F F A-3174. CF₃ OCH₂F 3-CH₃ F F A-3175. CF₃ OCH₂F 3-OCH₃ F F A-3176.CF₃ OCH₂F 5-F F F A-3177. CF₃ OCH₂F 5-CH₃ F F A-3178. CF₃ OCH₂F 5-OCH₃ FF A-3179. CF₃ OCHF₂ 3-F F F A-3180. CF₃ OCHF₂ 3-CH₃ F F A-3181. CF₃OCHF₂ 3-OCH₃ F F A-3182. CF₃ OCHF₂ 5-F F F A-3183. CF₃ OCHF₂ 5-CH₃ F FA-3184. CF₃ OCHF₂ 5-OCH₃ F F A-3185. CF₃ OCF₃ 3-F F F A-3186. CF₃ OCF₃3-CH₃ F F A-3187. CF₃ OCF₃ 3-OCH₃ F F A-3188. CF₃ OCF₃ 5-F F F A-3189.CF₃ OCF₃ 5-CH₃ F F A-3190. CF₃ OCF₃ 5-OCH₃ F F A-3191. OCH₂F F 3-F F FA-3192. OCH₂F F 3-CH₃ F F A-3193. OCH₂F F 3-OCH₃ F F A-3194. OCH₂F F 5-FF F A-3195. OCH₂F F 5-CH₃ F F A-3196. OCH₂F F 5-OCH₃ F F A-3197. OCH₂FCH₃ 3-F F F A-3198. OCH₂F CH₃ 3-CH₃ F F A-3199. OCH₂F CH₃ 3-OCH₃ F FA-3200. OCH₂F CH₃ 5-F F F A-3201. OCH₂F CH₃ 5-CH₃ F F A-3202. OCH₂F CH₃5-OCH₃ F F A-3203. OCH₂F OCH₃ 3-F F F A-3204. OCH₂F OCH₃ 3-CH₃ F FA-3205. OCH₂F OCH₃ 3-OCH₃ F F A-3206. OCH₂F OCH₃ 5-F F F A-3207. OCH₂FOCH₃ 5-CH₃ F F A-3208. OCH₂F OCH₃ 5-OCH₃ F F A-3209. OCH₂F CN 3-F F FA-3210. OCH₂F CN 3-CH₃ F F A-3211. OCH₂F CN 3-OCH₃ F F A-3212. OCH₂F CN5-F F F A-3213. OCH₂F CN 5-CH₃ F F A-3214. OCH₂F CN 5-OCH₃ F F A-3215.OCH₂F CH₂F 3-F F F A-3216. OCH₂F CH₂F 3-CH₃ F F A-3217. OCH₂F CH₂F3-OCH₃ F F A-3218. OCH₂F CH₂F 5-F F F A-3219. OCH₂F CH₂F 5-CH₃ F FA-3220. OCH₂F CH₂F 5-OCH₃ F F A-3221. OCH₂F CHF₂ 3-F F F A-3222. OCH₂FCHF₂ 3-CH₃ F F A-3223. OCH₂F CHF₂ 3-OCH₃ F F A-3224. OCH₂F CHF₂ 5-F F FA-3225. OCH₂F CHF₂ 5-CH₃ F F A-3226. OCH₂F CHF₂ 5-OCH₃ F F A-3227. OCH₂FCF₃ 3-F F F A-3228. OCH₂F CF₃ 3-CH₃ F F A-3229. OCH₂F CF₃ 3-OCH₃ F FA-3230. OCH₂F CF₃ 5-F F F A-3231. OCH₂F CF₃ 5-CH₃ F F A-3232. OCH₂F CF₃5-OCH₃ F F A-3233. OCH₂F OCH₂F 3-F F F A-3234. OCH₂F OCH₂F 3-CH₃ F FA-3235. OCH₂F OCH₂F 3-OCH₃ F F A-3236. OCH₂F OCH₂F 5-F F F A-3237. OCH₂FOCH₂F 5-CH₃ F F A-3238. OCH₂F OCH₂F 5-OCH₃ F F A-3239. OCH₂F OCHF₂ 3-F FF A-3240. OCH₂F OCHF₂ 3-CH₃ F F A-3241. OCH₂F OCHF₂ 3-OCH₃ F F A-3242.OCH₂F OCHF₂ 5-F F F A-3243. OCH₂F OCHF₂ 5-CH₃ F F A-3244. OCH₂F OCHF₂5-OCH₃ F F A-3245. OCH₂F OCF₃ 3-F F F A-3246. OCH₂F OCF₃ 3-CH₃ F FA-3247. OCH₂F OCF₃ 3-OCH₃ F F A-3248. OCH₂F OCF₃ 5-F F F A-3249. OCH₂FOCF₃ 5-CH₃ F F A-3250. OCH₂F OCF₃ 5-OCH₃ F F A-3251. OCHF₂ F 3-F F FA-3252. OCHF₂ F 3-CH₃ F F A-3253. OCHF₂ F 3-OCH₃ F F A-3254. OCHF₂ F 5-FF F A-3255. OCHF₂ F 5-CH₃ F F A-3256. OCHF₂ F 5-OCH₃ F F A-3257. OCHF₂CH₃ 3-F F F A-3258. OCHF₂ CH₃ 3-CH₃ F F A-3259. OCHF₂ CH₃ 3-OCH₃ F FA-3260. OCHF₂ CH₃ 5-F F F A-3261. OCHF₂ CH₃ 5-CH₃ F F A-3262. OCHF₂ CH₃5-OCH₃ F F A-3263. OCHF₂ OCH₃ 3-F F F A-3264. OCHF₂ OCH₃ 3-CH₃ F FA-3265. OCHF₂ OCH₃ 3-OCH₃ F F A-3266. OCHF₂ OCH₃ 5-F F F A-3267. OCHF₂OCH₃ 5-CH₃ F F A-3268. OCHF₂ OCH₃ 5-OCH₃ F F A-3269. OCHF₂ CN 3-F F FA-3270. OCHF₂ CN 3-CH₃ F F A-3271. OCHF₂ CN 3-OCH₃ F F A-3272. OCHF₂ CN5-F F F A-3273. OCHF₂ CN 5-CH₃ F F A-3274. OCHF₂ CN 5-OCH₃ F F A-3275.OCHF₂ CH₂F 3-F F F A-3276. OCHF₂ CH₂F 3-CH₃ F F A-3277. OCHF₂ CH₂F3-OCH₃ F F A-3278. OCHF₂ CH₂F 5-F F F A-3279. OCHF₂ CH₂F 5-CH₃ F FA-3280. OCHF₂ CH₂F 5-OCH₃ F F A-3281. OCHF₂ CHF₂ 3-F F F A-3282. OCHF₂CHF₂ 3-CH₃ F F A-3283. OCHF₂ CHF₂ 3-OCH₃ F F A-3284. OCHF₂ CHF₂ 5-F F FA-3285. OCHF₂ CHF₂ 5-CH₃ F F A-3286. OCHF₂ CHF₂ 5-OCH₃ F F A-3287. OCHF₂CF₃ 3-F F F A-3288. OCHF₂ CF₃ 3-CH₃ F F A-3289. OCHF₂ CF₃ 3-OCH₃ F FA-3290. OCHF₂ CF₃ 5-F F F A-3291. OCHF₂ CF₃ 5-CH₃ F F A-3292. OCHF₂ CF₃5-OCH₃ F F A-3293. OCHF₂ OCH₂F 3-F F F A-3294. OCHF₂ OCH₂F 3-CH₃ F FA-3295. OCHF₂ OCH₂F 3-OCH₃ F F A-3296. OCHF₂ OCH₂F 5-F F F A-3297. OCHF₂OCH₂F 5-CH₃ F F A-3298. OCHF₂ OCH₂F 5-OCH₃ F F A-3299. OCHF₂ OCHF₂ 3-F FF A-3300. OCHF₂ OCHF₂ 3-CH₃ F F A-3301. OCHF₂ OCHF₂ 3-OCH₃ F F A-3302.OCHF₂ OCHF₂ 5-F F F A-3303. OCHF₂ OCHF₂ 5-CH₃ F F A-3304. OCHF₂ OCHF₂5-OCH₃ F F A-3305. OCHF₂ OCF₃ 3-F F F A-3306. OCHF₂ OCF₃ 3-CH₃ F FA-3307. OCHF₂ OCF₃ 3-OCH₃ F F A-3308. OCHF₂ OCF₃ 5-F F F A-3309. OCHF₂OCF₃ 5-CH₃ F F A-3310. OCHF₂ OCF₃ 5-OCH₃ F F A-3311. OCF₃ F 3-F F FA-3312. OCF₃ F 3-CH₃ F F A-3313. OCF₃ F 3-OCH₃ F F A-3314. OCF₃ F 5-F FF A-3315. OCF₃ F 5-CH₃ F F A-3316. OCF₃ F 5-OCH₃ F F A-3317. OCF₃ CH₃3-F F F A-3318. OCF₃ CH₃ 3-CH₃ F F A-3319. OCF₃ CH₃ 3-OCH₃ F F A-3320.OCF₃ CH₃ 5-F F F A-3321. OCF₃ CH₃ 5-CH₃ F F A-3322. OCF₃ CH₃ 5-OCH₃ F FA-3323. OCF₃ OCH₃ 3-F F F A-3324. OCF₃ OCH₃ 3-CH₃ F F A-3325. OCF₃ OCH₃3-OCH₃ F F A-3326. OCF₃ OCH₃ 5-F F F A-3327. OCF₃ OCH₃ 5-CH₃ F F A-3328.OCF₃ OCH₃ 5-OCH₃ F F A-3329. OCF₃ CN 3-F F F A-3330. OCF₃ CN 3-CH₃ F FA-3331. OCF₃ CN 3-OCH₃ F F A-3332. OCF₃ CN 5-F F F A-3333. OCF₃ CN 5-CH₃F F A-3334. OCF₃ CN 5-OCH₃ F F A-3335. OCF₃ CH₂F 3-F F F A-3336. OCF₃CH₂F 3-CH₃ F F A-3337. OCF₃ CH₂F 3-OCH₃ F F A-3338. OCF₃ CH₂F 5-F F FA-3339. OCF₃ CH₂F 5-CH₃ F F A-3340. OCF₃ CH₂F 5-OCH₃ F F A-3341. OCF₃CHF₂ 3-F F F A-3342. OCF₃ CHF₂ 3-CH₃ F F A-3343. OCF₃ CHF₂ 3-OCH₃ F FA-3344. OCF₃ CHF₂ 5-F F F A-3345. OCF₃ CHF₂ 5-CH₃ F F A-3346. OCF₃ CHF₂5-OCH₃ F F A-3347. OCF₃ CF₃ 3-F F F A-3348. OCF₃ CF₃ 3-CH₃ F F A-3349.OCF₃ CF₃ 3-OCH₃ F F A-3350. OCF₃ CF₃ 5-F F F A-3351. OCF₃ CF₃ 5-CH₃ F FA-3352. OCF₃ CF₃ 5-OCH₃ F F A-3353. OCF₃ OCH₂F 3-F F F A-3354. OCF₃OCH₂F 3-CH₃ F F A-3355. OCF₃ OCH₂F 3-OCH₃ F F A-3356. OCF₃ OCH₂F 5-F F FA-3357. OCF₃ OCH₂F 5-CH₃ F F A-3358. OCF₃ OCH₂F 5-OCH₃ F F A-3359. OCF₃OCHF₂ 3-F F F A-3360. OCF₃ OCHF₂ 3-CH₃ F F A-3361. OCF₃ OCHF₂ 3-OCH₃ F FA-3362. OCF₃ OCHF₂ 5-F F F A-3363. OCF₃ OCHF₂ 5-CH₃ F F A-3364. OCF₃OCHF₂ 5-OCH₃ F F A-3365. OCF₃ OCF₃ 3-F F F A-3366. OCF₃ OCF₃ 3-CH₃ F FA-3367. OCF₃ OCF₃ 3-OCH₃ F F A-3368. OCF₃ OCF₃ 5-F F F A-3369. OCF₃ OCF₃5-CH₃ F F A-3370. OCF₃ OCF₃ 5-OCH₃ F F A-3371. H H H Cl F A-3372. F H HCl F A-3373. CH₃ H H Cl F A-3374. OCH₃ H H Cl F A-3375. CH₂F H H Cl FA-3376. CHF₂ H H Cl F A-3377. CF₃ H H Cl F A-3378. OCH₂F H H Cl FA-3379. OCHF₂ H H Cl F A-3380. OCF₃ H H Cl F A-3381. H F H Cl F A-3382.H CH₃ H Cl F A-3383. H OCH₃ H Cl F A-3384. H CN H Cl F A-3385. H CH₂F HCl F A-3386. H CHF₂ H Cl F A-3387. H CF₃ H Cl F A-3388. H OCH₂F H Cl FA-3389. H OCHF₂ H Cl F A-3390. H OCF₃ H Cl F A-3391. H H 3-F Cl FA-3392. H H 3-CH₃ Cl F A-3393. H H 3-OCH₃ Cl F A-3394. H H 5-F Cl FA-3395. H H 5-CH₃ Cl F A-3396. H H 5-OCH₃ Cl F A-3397. F F H Cl FA-3398. F CH₃ H Cl F A-3399. F OCH₃ H Cl F A-3400. F CN H Cl F A-3401. FCH₂F H Cl F A-3402. F CHF₂ H Cl F A-3403. F CF₃ H Cl F A-3404. F OCH₂F HCl F A-3405. F OCHF₂ H Cl F A-3406. F OCF₃ H Cl F A-3407. F H 3-F Cl FA-3408. F H 3-CH₃ Cl F A-3409. F H 3-OCH₃ Cl F A-3410. F H 5-F Cl FA-3411. F H 5-CH₃ Cl F A-3412. F H 5-OCH₃ Cl F A-3413. CH₃ F H Cl FA-3414. CH₃ CH₃ H Cl F A-3415. CH₃ OCH₃ H Cl F A-3416. CH₃ CN H Cl FA-3417. CH₃ CH₂F H Cl F A-3418. CH₃ CHF₂ H Cl F A-3419. CH₃ CF₃ H Cl FA-3420. CH₃ OCH₂F H Cl F A-3421. CH₃ OCHF₂ H Cl F A-3422. CH₃ OCF₃ H ClF A-3423. CH₃ H 3-F Cl F A-3424. CH₃ H 3-CH₃ Cl F A-3425. CH₃ H 3-OCH₃Cl F A-3426. CH₃ H 5-F Cl F A-3427. CH₃ H 5-CH₃ Cl F A-3428. CH₃ H5-OCH₃ Cl F A-3429. OCH₃ F H Cl F A-3430. OCH₃ CH₃ H Cl F A-3431. OCH₃OCH₃ H Cl F A-3432. OCH₃ CN H Cl F A-3433. OCH₃ CH₂F H Cl F A-3434. OCH₃CHF₂ H Cl F A-3435. OCH₃ CF₃ H Cl F A-3436. OCH₃ OCH₂F H Cl F A-3437.OCH₃ OCHF₂ H Cl F A-3438. OCH₃ OCF₃ H Cl F A-3439. OCH₃ H 3-F Cl FA-3440. OCH₃ H 3-CH₃ Cl F A-3441. OCH₃ H 3-OCH₃ Cl F A-3442. OCH₃ H 5-FCl F A-3443. OCH₃ H 5-CH₃ Cl F A-3444. OCH₃ H 5-OCH₃ Cl F A-3445. H F3-F Cl F A-3446. H F 3-CH₃ Cl F A-3447. H F 3-OCH₃ Cl F A-3448. H F 5-FCl F A-3449. H F 5-CH₃ Cl F A-3450. H F 5-OCH₃ Cl F A-3451. H CH₃ 3-F ClF A-3452. H CH₃ 3-CH₃ Cl F A-3453. H CH₃ 3-OCH₃ Cl F A-3454. H CH₃ 5-FCl F A-3455. H CH₃ 5-CH₃ Cl F A-3456. H CH₃ 5-OCH₃ Cl F A-3457. H OCH₃3-F Cl F A-3458. H OCH₃ 3-CH₃ Cl F A-3459. H OCH₃ 3-OCH₃ Cl F A-3460. HOCH₃ 5-F Cl F A-3461. H OCH₃ 5-CH₃ Cl F A-3462. H OCH₃ 5-OCH₃ Cl FA-3463. H CN 3-F Cl F A-3464. H CN 3-CH₃ Cl F A-3465. H CN 3-OCH₃ Cl FA-3466. H CN 5-F Cl F A-3467. H CN 5-CH₃ Cl F A-3468. H CN 5-OCH₃ Cl FA-3469. H CH₂F 3-F Cl F A-3470. H CH₂F 3-CH₃ Cl F A-3471. H CH₂F 3-OCH₃Cl F A-3472. H CH₂F 5-F Cl F A-3473. H CH₂F 5-CH₃ Cl F A-3474. H CH₂F5-OCH₃ Cl F A-3475. H CHF₂ 3-F Cl F A-3476. H CHF₂ 3-CH₃ Cl F A-3477. HCHF₂ 3-OCH₃ Cl F A-3478. H CHF₂ 5-F Cl F A-3479. H CHF₂ 5-CH₃ Cl FA-3480. H CHF₂ 5-OCH₃ Cl F A-3481. H CF₃ 3-F Cl F A-3482. H CF₃ 3-CH₃ ClF A-3483. H CF₃ 3-OCH₃ Cl F A-3484. H CF₃ 5-F Cl F A-3485. H CF₃ 5-CH₃Cl F A-3486. H CF₃ 5-OCH₃ Cl F A-3487. H OCH₂F 3-F Cl F A-3488. H OCH₂F3-CH₃ Cl F A-3489. H OCH₂F 3-OCH₃ Cl F A-3490. H OCH₂F 5-F Cl F A-3491.H OCH₂F 5-CH₃ Cl F A-3492. H OCH₂F 5-OCH₃ Cl F A-3493. H OCHF₂ 3-F Cl FA-3494. H OCHF₂ 3-CH₃ Cl F A-3495. H OCHF₂ 3-OCH₃ Cl F A-3496. H OCHF₂5-F Cl F A-3497. H OCHF₂ 5-CH₃ Cl F A-3498. H OCHF₂ 5-OCH₃ Cl F A-3499.H OCF₃ 3-F Cl F A-3500. H OCF₃ 3-CH₃ Cl F A-3501. H OCF₃ 3-OCH₃ Cl FA-3502. H OCF₃ 5-F Cl F A-3503. H OCF₃ 5-CH₃ Cl F A-3504. H OCF₃ 5-OCH₃Cl F A-3505. F F 3-F Cl F A-3506. F F 3-CH₃ Cl F A-3507. F F 3-OCH₃ Cl FA-3508. F F 5-F Cl F A-3509. F F 5-CH₃ Cl F A-3510. F F 5-OCH₃ Cl FA-3511. F CH₃ 3-F Cl F A-3512. F CH₃ 3-CH₃ Cl F A-3513. F CH₃ 3-OCH₃ ClF A-3514. F CH₃ 5-F Cl F A-3515. F CH₃ 5-CH₃ Cl F A-3516. F CH₃ 5-OCH₃Cl F A-3517. F OCH₃ 3-F Cl F A-3518. F OCH₃ 3-CH₃ Cl F A-3519. F OCH₃3-OCH₃ Cl F A-3520. F OCH₃ 5-F Cl F A-3521. F OCH₃ 5-CH₃ Cl F A-3522. FOCH₃ 5-OCH₃ Cl F A-3523. F CN 3-F Cl F A-3524. F CN 3-CH₃ Cl F A-3525. FCN 3-OCH₃ Cl F A-3526. F CN 5-F Cl F A-3527. F CN 5-CH₃ Cl F A-3528. FCN 5-OCH₃ Cl F A-3529. F CH₂F 3-F Cl F A-3530. F CH₂F 3-CH₃ Cl F A-3531.F CH₂F 3-OCH₃ Cl F A-3532. F CH₂F 5-F Cl F A-3533. F CH₂F 5-CH₃ Cl FA-3534. F CH₂F 5-OCH₃ Cl F A-3535. F CHF₂ 3-F Cl F A-3536. F CHF₂ 3-CH₃Cl F A-3537. F CHF₂ 3-OCH₃ Cl F A-3538. F CHF₂ 5-F Cl F A-3539. F CHF₂5-CH₃ Cl F A-3540. F CHF₂ 5-OCH₃ Cl F A-3541. F CF₃ 3-F Cl F A-3542. FCF₃ 3-CH₃ Cl F A-3543. F CF₃ 3-OCH₃ Cl F A-3544. F CF₃ 5-F Cl F A-3545.F CF₃ 5-CH₃ Cl F A-3546. F CF₃ 5-OCH₃ Cl F A-3547. F OCH₂F 3-F Cl FA-3548. F OCH₂F 3-CH₃ Cl F A-3549. F OCH₂F 3-OCH₃ Cl F A-3550. F OCH₂F5-F Cl F A-3551. F OCH₂F 5-CH₃ Cl F A-3552. F OCH₂F 5-OCH₃ Cl F A-3553.F OCHF₂ 3-F Cl F A-3554. F OCHF₂ 3-CH₃ Cl F A-3555. F OCHF₂ 3-OCH₃ Cl FA-3556. F OCHF₂ 5-F Cl F A-3557. F OCHF₂ 5-CH₃ Cl F A-3558. F OCHF₂5-OCH₃ Cl F A-3559. F OCF₃ 3-F Cl F A-3560. F OCF₃ 3-CH₃ Cl F A-3561. FOCF₃ 3-OCH₃ Cl F A-3562. F OCF₃ 5-F Cl F A-3563. F OCF₃ 5-CH₃ Cl FA-3564. F OCF₃ 5-OCH₃ Cl F A-3565. CH₃ F 3-F Cl F A-3566. CH₃ F 3-CH₃ ClF A-3567. CH₃ F 3-OCH₃ Cl F A-3568. CH₃ F 5-F Cl F A-3569. CH₃ F 5-CH₃Cl F A-3570. CH₃ F 5-OCH₃ Cl F A-3571. CH₃ CH₃ 3-F Cl F A-3572. CH₃ CH₃3-CH₃ Cl F A-3573. CH₃ CH₃ 3-OCH₃ Cl F A-3574. CH₃ CH₃ 5-F Cl F A-3575.CH₃ CH₃ 5-CH₃ Cl F A-3576. CH₃ CH₃ 5-OCH₃ Cl F A-3577. CH₃ OCH₃ 3-F Cl FA-3578. CH₃ OCH₃ 3-CH₃ Cl F A-3579. CH₃ OCH₃ 3-OCH₃ Cl F A-3580. CH₃OCH₃ 5-F Cl F A-3581. CH₃ OCH₃ 5-CH₃ Cl F A-3582. CH₃ OCH₃ 5-OCH₃ Cl FA-3583. CH₃ CN 3-F Cl F A-3584. CH₃ CN 3-CH₃ Cl F A-3585. CH₃ CN 3-OCH₃Cl F A-3586. CH₃ CN 5-F Cl F A-3587. CH₃ CN 5-CH₃ Cl F A-3588. CH₃ CN5-OCH₃ Cl F A-3589. CH₃ CH₂F 3-F Cl F A-3590. CH₃ CH₂F 3-CH₃ Cl FA-3591. CH₃ CH₂F 3-OCH₃ Cl F A-3592. CH₃ CH₂F 5-F Cl F A-3593. CH₃ CH₂F5-CH₃ Cl F A-3594. CH₃ CH₂F 5-OCH₃ Cl F A-3595. CH₃ CHF₂ 3-F Cl FA-3596. CH₃ CHF₂ 3-CH₃ Cl F A-3597. CH₃ CHF₂ 3-OCH₃ Cl F A-3598. CH₃CHF₂ 5-F Cl F A-3599. CH₃ CHF₂ 5-CH₃ Cl F A-3600. CH₃ CHF₂ 5-OCH₃ Cl FA-3601. CH₃ CF₃ 3-F Cl F A-3602. CH₃ CF₃ 3-CH₃ Cl F A-3603. CH₃ CF₃3-OCH₃ Cl F A-3604. CH₃ CF₃ 5-F Cl F A-3605. CH₃ CF₃ 5-CH₃ Cl F A-3606.CH₃ CF₃ 5-OCH₃ Cl F A-3607. CH₃ OCH₂F 3-F Cl F A-3608. CH₃ OCH₂F 3-CH₃Cl F A-3609. CH₃ OCH₂F 3-OCH₃ Cl F A-3610. CH₃ OCH₂F 5-F Cl F A-3611.CH₃ OCH₂F 5-CH₃ Cl F A-3612. CH₃ OCH₂F 5-OCH₃ Cl F A-3613. CH₃ OCHF₂ 3-FCl F A-3614. CH₃ OCHF₂ 3-CH₃ Cl F A-3615. CH₃ OCHF₂ 3-OCH₃ Cl F A-3616.CH₃ OCHF₂ 5-F Cl F A-3617. CH₃ OCHF₂ 5-CH₃ Cl F A-3618. CH₃ OCHF₂ 5-OCH₃Cl F A-3619. CH₃ OCF₃ 3-F Cl F A-3620. CH₃ OCF₃ 3-CH₃ Cl F A-3621. CH₃OCF₃ 3-OCH₃ Cl F A-3622. CH₃ OCF₃ 5-F Cl F A-3623. CH₃ OCF₃ 5-CH₃ Cl FA-3624. CH₃ OCF₃ 5-OCH₃ Cl F A-3625. OCH₃ F 3-F Cl F A-3626. OCH₃ F3-CH₃ Cl F A-3627. OCH₃ F 3-OCH₃ Cl F A-3628. OCH₃ F 5-F Cl F A-3629.OCH₃ F 5-CH₃ Cl F A-3630. OCH₃ F 5-OCH₃ Cl F A-3631. OCH₃ CH₃ 3-F Cl FA-3632. OCH₃ CH₃ 3-CH₃ Cl F A-3633. OCH₃ CH₃ 3-OCH₃ Cl F A-3634. OCH₃CH₃ 5-F Cl F A-3635. OCH₃ CH₃ 5-CH₃ Cl F A-3636. OCH₃ CH₃ 5-OCH₃ Cl FA-3637. OCH₃ OCH₃ 3-F Cl F A-3638. OCH₃ OCH₃ 3-CH₃ Cl F A-3639. OCH₃OCH₃ 3-OCH₃ Cl F A-3640. OCH₃ OCH₃ 5-F Cl F A-3641. OCH₃ OCH₃ 5-CH₃ Cl FA-3642. OCH₃ OCH₃ 5-OCH₃ Cl F A-3643. OCH₃ CN 3-F Cl F A-3644. OCH₃ CN3-CH₃ Cl F A-3645. OCH₃ CN 3-OCH₃ Cl F A-3646. OCH₃ CN 5-F Cl F A-3647.OCH₃ CN 5-CH₃ Cl F A-3648. OCH₃ CN 5-OCH₃ Cl F A-3649. OCH₃ CH₂F 3-F ClF A-3650. OCH₃ CH₂F 3-CH₃ Cl F A-3651. OCH₃ CH₂F 3-OCH₃ Cl F A-3652.OCH₃ CH₂F 5-F Cl F A-3653. OCH₃ CH₂F 5-CH₃ Cl F A-3654. OCH₃ CH₂F 5-OCH₃Cl F A-3655. OCH₃ CHF₂ 3-F Cl F A-3656. OCH₃ CHF₂ 3-CH₃ Cl F A-3657.OCH₃ CHF₂ 3-OCH₃ Cl F A-3658. OCH₃ CHF₂ 5-F Cl F A-3659. OCH₃ CHF₂ 5-CH₃Cl F A-3660. OCH₃ CHF₂ 5-OCH₃ Cl F A-3661. OCH₃ CF₃ 3-F Cl F A-3662.OCH₃ CF₃ 3-CH₃ Cl F A-3663. OCH₃ CF₃ 3-OCH₃ Cl F A-3664. OCH₃ CF₃ 5-F ClF A-3665. OCH₃ CF₃ 5-CH₃ Cl F A-3666. OCH₃ CF₃ 5-OCH₃ Cl F A-3667. OCH₃OCH₂F 3-F Cl F A-3668. OCH₃ OCH₂F 3-CH₃ Cl F A-3669. OCH₃ OCH₂F 3-OCH₃Cl F A-3670. OCH₃ OCH₂F 5-F Cl F A-3671. OCH₃ OCH₂F 5-CH₃ Cl F A-3672.OCH₃ OCH₂F 5-OCH₃ Cl F A-3673. OCH₃ OCHF₂ 3-F Cl F A-3674. OCH₃ OCHF₂3-CH₃ Cl F A-3675. OCH₃ OCHF₂ 3-OCH₃ Cl F A-3676. OCH₃ OCHF₂ 5-F Cl FA-3677. OCH₃ OCHF₂ 5-CH₃ Cl F A-3678. OCH₃ OCHF₂ 5-OCH₃ Cl F A-3679.OCH₃ OCF₃ 3-F Cl F A-3680. OCH₃ OCF₃ 3-CH₃ Cl F A-3681. OCH₃ OCF₃ 3-OCH₃Cl F A-3682. OCH₃ OCF₃ 5-F Cl F A-3683. OCH₃ OCF₃ 5-CH₃ Cl F A-3684.OCH₃ OCF₃ 5-OCH₃ Cl F A-3685. CH₂F F 3-F Cl F A-3686. CH₂F F 3-CH₃ Cl FA-3687. CH₂F F 3-OCH₃ Cl F A-3688. CH₂F F 5-F Cl F A-3689. CH₂F F 5-CH₃Cl F A-3690. CH₂F F 5-OCH₃ Cl F A-3691. CH₂F CH₃ 3-F Cl F A-3692. CH₂FCH₃ 3-CH₃ Cl F A-3693. CH₂F CH₃ 3-OCH₃ Cl F A-3694. CH₂F CH₃ 5-F Cl FA-3695. CH₂F CH₃ 5-CH₃ Cl F A-3696. CH₂F CH₃ 5-OCH₃ Cl F A-3697. CH₂FOCH₃ 3-F Cl F A-3698. CH₂F OCH₃ 3-CH₃ Cl F A-3699. CH₂F OCH₃ 3-OCH₃ Cl FA-3700. CH₂F OCH₃ 5-F Cl F A-3701. CH₂F OCH₃ 5-CH₃ Cl F A-3702. CH₂FOCH₃ 5-OCH₃ Cl F A-3703. CH₂F CN 3-F Cl F A-3704. CH₂F CN 3-CH₃ Cl FA-3705. CH₂F CN 3-OCH₃ Cl F A-3706. CH₂F CN 5-F Cl F A-3707. CH₂F CN5-CH₃ Cl F A-3708. CH₂F CN 5-OCH₃ Cl F A-3709. CH₂F CH₂F 3-F Cl FA-3710. CH₂F CH₂F 3-CH₃ Cl F A-3711. CH₂F CH₂F 3-OCH₃ Cl F A-3712. CH₂FCH₂F 5-F Cl F A-3713. CH₂F CH₂F 5-CH₃ Cl F A-3714. CH₂F CH₂F 5-OCH₃ Cl FA-3715. CH₂F CHF₂ 3-F Cl F A-3716. CH₂F CHF₂ 3-CH₃ Cl F A-3717. CH₂FCHF₂ 3-OCH₃ Cl F A-3718. CH₂F CHF₂ 5-F Cl F A-3719. CH₂F CHF₂ 5-CH₃ Cl FA-3720. CH₂F CHF₂ 5-OCH₃ Cl F A-3721. CH₂F CF₃ 3-F Cl F A-3722. CH₂F CF₃3-CH₃ Cl F A-3723. CH₂F CF₃ 3-OCH₃ Cl F A-3724. CH₂F CF₃ 5-F Cl FA-3725. CH₂F CF₃ 5-CH₃ Cl F A-3726. CH₂F CF₃ 5-OCH₃ Cl F A-3727. CH₂FOCH₂F 3-F Cl F A-3728. CH₂F OCH₂F 3-CH₃ Cl F A-3729. CH₂F OCH₂F 3-OCH₃Cl F A-3730. CH₂F OCH₂F 5-F Cl F A-3731. CH₂F OCH₂F 5-CH₃ Cl F A-3732.CH₂F OCH₂F 5-OCH₃ Cl F A-3733. CH₂F OCHF₂ 3-F Cl F A-3734. CH₂F OCHF₂3-CH₃ Cl F A-3735. CH₂F OCHF₂ 3-OCH₃ Cl F A-3736. CH₂F OCHF₂ 5-F Cl FA-3737. CH₂F OCHF₂ 5-CH₃ Cl F A-3738. CH₂F OCHF₂ 5-OCH₃ Cl F A-3739.CH₂F OCF₃ 3-F Cl F A-3740. CH₂F OCF₃ 3-CH₃ Cl F A-3741. CH₂F OCF₃ 3-OCH₃Cl F A-3742. CH₂F OCF₃ 5-F Cl F A-3743. CH₂F OCF₃ 5-CH₃ Cl F A-3744.CH₂F OCF₃ 5-OCH₃ Cl F A-3745. CHF₂ F 3-F Cl F A-3746. CHF₂ F 3-CH₃ Cl FA-3747. CHF₂ F 3-OCH₃ Cl F A-3748. CHF₂ F 5-F Cl F A-3749. CHF₂ F 5-CH₃Cl F A-3750. CHF₂ F 5-OCH₃ Cl F A-3751. CHF₂ CH₃ 3-F Cl F A-3752. CHF₂CH₃ 3-CH₃ Cl F A-3753. CHF₂ CH₃ 3-OCH₃ Cl F A-3754. CHF₂ CH₃ 5-F Cl FA-3755. CHF₂ CH₃ 5-CH₃ Cl F A-3756. CHF₂ CH₃ 5-OCH₃ Cl F A-3757. CHF₂OCH₃ 3-F Cl F A-3758. CHF₂ OCH₃ 3-CH₃ Cl F A-3759. CHF₂ OCH₃ 3-OCH₃ Cl FA-3760. CHF₂ OCH₃ 5-F Cl F A-3761. CHF₂ OCH₃ 5-CH₃ Cl F A-3762. CHF₂OCH₃ 5-OCH₃ Cl F A-3763. CHF₂ CN 3-F Cl F A-3764. CHF₂ CN 3-CH₃ Cl FA-3765. CHF₂ CN 3-OCH₃ Cl F A-3766. CHF₂ CN 5-F Cl F A-3767. CHF₂ CN5-CH₃ Cl F A-3768. CHF₂ CN 5-OCH₃ Cl F A-3769. CHF₂ CH₂F 3-F Cl FA-3770. CHF₂ CH₂F 3-CH₃ Cl F A-3771. CHF₂ CH₂F 3-OCH₃ Cl F A-3772. CHF₂CH₂F 5-F Cl F A-3773. CHF₂ CH₂F 5-CH₃ Cl F A-3774. CHF₂ CH₂F 5-OCH₃ Cl FA-3775. CHF₂ CHF₂ 3-F Cl F A-3776. CHF₂ CHF₂ 3-CH₃ Cl F A-3777. CHF₂CHF₂ 3-OCH₃ Cl F A-3778. CHF₂ CHF₂ 5-F Cl F A-3779. CHF₂ CHF₂ 5-CH₃ Cl FA-3780. CHF₂ CHF₂ 5-OCH₃ Cl F A-3781. CHF₂ CF₃ 3-F Cl F A-3782. CHF₂ CF₃3-CH₃ Cl F A-3783. CHF₂ CF₃ 3-OCH₃ Cl F A-3784. CHF₂ CF₃ 5-F Cl FA-3785. CHF₂ CF₃ 5-CH₃ Cl F A-3786. CHF₂ CF₃ 5-OCH₃ Cl F A-3787. CHF₂OCH₂F 3-F Cl F A-3788. CHF₂ OCH₂F 3-CH₃ Cl F A-3789. CHF₂ OCH₂F 3-OCH₃Cl F A-3790. CHF₂ OCH₂F 5-F Cl F A-3791. CHF₂ OCH₂F 5-CH₃ Cl F A-3792.CHF₂ OCH₂F 5-OCH₃ Cl F A-3793. CHF₂ OCHF₂ 3-F Cl F A-3794. CHF₂ OCHF₂3-CH₃ Cl F A-3795. CHF₂ OCHF₂ 3-OCH₃ Cl F A-3796. CHF₂ OCHF₂ 5-F Cl FA-3797. CHF₂ OCHF₂ 5-CH₃ Cl F A-3798. CHF₂ OCHF₂ 5-OCH₃ Cl F A-3799.CHF₂ OCF₃ 3-F Cl F A-3800. CHF₂ OCF₃ 3-CH₃ Cl F A-3801. CHF₂ OCF₃ 3-OCH₃Cl F A-3802. CHF₂ OCF₃ 5-F Cl F A-3803. CHF₂ OCF₃ 5-CH₃ Cl F A-3804.CHF₂ OCF₃ 5-OCH₃ Cl F A-3805. CF₃ F 3-F Cl F A-3806. CF₃ F 3-CH₃ Cl FA-3807. CF₃ F 3-OCH₃ Cl F A-3808. CF₃ F 5-F Cl F A-3809. CF₃ F 5-CH₃ ClF A-3810. CF₃ F 5-OCH₃ Cl F A-3811. CF₃ CH₃ 3-F Cl F A-3812. CF₃ CH₃3-CH₃ Cl F A-3813. CF₃ CH₃ 3-OCH₃ Cl F A-3814. CF₃ CH₃ 5-F Cl F A-3815.CF₃ CH₃ 5-CH₃ Cl F A-3816. CF₃ CH₃ 5-OCH₃ Cl F A-3817. CF₃ OCH₃ 3-F Cl FA-3818. CF₃ OCH₃ 3-CH₃ Cl F A-3819. CF₃ OCH₃ 3-OCH₃ Cl F A-3820. CF₃OCH₃ 5-F Cl F A-3821. CF₃ OCH₃ 5-CH₃ Cl F A-3822. CF₃ OCH₃ 5-OCH₃ Cl FA-3823. CF₃ CN 3-F Cl F A-3824. CF₃ CN 3-CH₃ Cl F A-3825. CF₃ CN 3-OCH₃Cl F A-3826. CF₃ CN 5-F Cl F A-3827. CF₃ CN 5-CH₃ Cl F A-3828. CF₃ CN5-OCH₃ Cl F A-3829. CF₃ CH₂F 3-F Cl F A-3830. CF₃ CH₂F 3-CH₃ Cl FA-3831. CF₃ CH₂F 3-OCH₃ Cl F A-3832. CF₃ CH₂F 5-F Cl F A-3833. CF₃ CH₂F5-CH₃ Cl F A-3834. CF₃ CH₂F 5-OCH₃ Cl F A-3835. CF₃ CHF₂ 3-F Cl FA-3836. CF₃ CHF₂ 3-CH₃ Cl F A-3837. CF₃ CHF₂ 3-OCH₃ Cl F A-3838. CF₃CHF₂ 5-F Cl F A-3839. CF₃ CHF₂ 5-CH₃ Cl F A-3840. CF₃ CHF₂ 5-OCH₃ Cl FA-3841. CF₃ CF₃ 3-F Cl F A-3842. CF₃ CF₃ 3-CH₃ Cl F A-3843. CF₃ CF₃3-OCH₃ Cl F A-3844. CF₃ CF₃ 5-F Cl F A-3845. CF₃ CF₃ 5-CH₃ Cl F A-3846.CF₃ CF₃ 5-OCH₃ Cl F A-3847. CF₃ OCH₂F 3-F Cl F A-3848. CF₃ OCH₂F 3-CH₃Cl F A-3849. CF₃ OCH₂F 3-OCH₃ Cl F A-3850. CF₃ OCH₂F 5-F Cl F A-3851.CF₃ OCH₂F 5-CH₃ Cl F A-3852. CF₃ OCH₂F 5-OCH₃ Cl F A-3853. CF₃ OCHF₂ 3-FCl F A-3854. CF₃ OCHF₂ 3-CH₃ Cl F A-3855. CF₃ OCHF₂ 3-OCH₃ Cl F A-3856.CF₃ OCHF₂ 5-F Cl F A-3857. CF₃ OCHF₂ 5-CH₃ Cl F A-3858. CF₃ OCHF₂ 5-OCH₃Cl F A-3859. CF₃ OCF₃ 3-F Cl F A-3860. CF₃ OCF₃ 3-CH₃ Cl F A-3861. CF₃OCF₃ 3-OCH₃ Cl F A-3862. CF₃ OCF₃ 5-F Cl F A-3863. CF₃ OCF₃ 5-CH₃ Cl FA-3864. CF₃ OCF₃ 5-OCH₃ Cl F A-3865. OCH₂F F 3-F Cl F A-3866. OCH₂F F3-CH₃ Cl F A-3867. OCH₂F F 3-OCH₃ Cl F A-3868. OCH₂F F 5-F Cl F A-3869.OCH₂F F 5-CH₃ Cl F A-3870. OCH₂F F 5-OCH₃ Cl F A-3871. OCH₂F CH₃ 3-F ClF A-3872. OCH₂F CH₃ 3-CH₃ Cl F A-3873. OCH₂F CH₃ 3-OCH₃ Cl F A-3874.OCH₂F CH₃ 5-F Cl F A-3875. OCH₂F CH₃ 5-CH₃ Cl F A-3876. OCH₂F CH₃ 5-OCH₃Cl F A-3877. OCH₂F OCH₃ 3-F Cl F A-3878. OCH₂F OCH₃ 3-CH₃ Cl F A-3879.OCH₂F OCH₃ 3-OCH₃ Cl F A-3880. OCH₂F OCH₃ 5-F Cl F A-3881. OCH₂F OCH₃5-CH₃ Cl F A-3882. OCH₂F OCH₃ 5-OCH₃ Cl F A-3883. OCH₂F CN 3-F Cl FA-3884. OCH₂F CN 3-CH₃ Cl F A-3885. OCH₂F CN 3-OCH₃ Cl F A-3886. OCH₂FCN 5-F Cl F A-3887. OCH₂F CN 5-CH₃ Cl F A-3888. OCH₂F CN 5-OCH₃ Cl FA-3889. OCH₂F CH₂F 3-F Cl F A-3890. OCH₂F CH₂F 3-CH₃ Cl F A-3891. OCH₂FCH₂F 3-OCH₃ Cl F A-3892. OCH₂F CH₂F 5-F Cl F A-3893. OCH₂F CH₂F 5-CH₃ ClF A-3894. OCH₂F CH₂F 5-OCH₃ Cl F A-3895. OCH₂F CHF₂ 3-F Cl F A-3896.OCH₂F CHF₂ 3-CH₃ Cl F A-3897. OCH₂F CHF₂ 3-OCH₃ Cl F A-3898. OCH₂F CHF₂5-F Cl F A-3899. OCH₂F CHF₂ 5-CH₃ Cl F A-3900. OCH₂F CHF₂ 5-OCH₃ Cl FA-3901. OCH₂F CF₃ 3-F Cl F A-3902. OCH₂F CF₃ 3-CH₃ Cl F A-3903. OCH₂FCF₃ 3-OCH₃ Cl F A-3904. OCH₂F CF₃ 5-F Cl F A-3905. OCH₂F CF₃ 5-CH₃ Cl FA-3906. OCH₂F CF₃ 5-OCH₃ Cl F A-3907. OCH₂F OCH₂F 3-F Cl F A-3908. OCH₂FOCH₂F 3-CH₃ Cl F A-3909. OCH₂F OCH₂F 3-OCH₃ Cl F A-3910. OCH₂F OCH₂F 5-FCl F A-3911. OCH₂F OCH₂F 5-CH₃ Cl F A-3912. OCH₂F OCH₂F 5-OCH₃ Cl FA-3913. OCH₂F OCHF₂ 3-F Cl F A-3914. OCH₂F OCHF₂ 3-CH₃ Cl F A-3915.OCH₂F OCHF₂ 3-OCH₃ Cl F A-3916. OCH₂F OCHF₂ 5-F Cl F A-3917. OCH₂F OCHF₂5-CH₃ Cl F A-3918. OCH₂F OCHF₂ 5-OCH₃ Cl F A-3919. OCH₂F OCF₃ 3-F Cl FA-3920. OCH₂F OCF₃ 3-CH₃ Cl F A-3921. OCH₂F OCF₃ 3-OCH₃ Cl F A-3922.OCH₂F OCF₃ 5-F Cl F A-3923. OCH₂F OCF₃ 5-CH₃ Cl F A-3924. OCH₂F OCF₃5-OCH₃ Cl F A-3925. OCHF₂ F 3-F Cl F A-3926. OCHF₂ F 3-CH₃ Cl F A-3927.OCHF₂ F 3-OCH₃ Cl F A-3928. OCHF₂ F 5-F Cl F A-3929. OCHF₂ F 5-CH₃ Cl FA-3930. OCHF₂ F 5-OCH₃ Cl F A-3931. OCHF₂ CH₃ 3-F Cl F A-3932. OCHF₂ CH₃3-CH₃ Cl F A-3933. OCHF₂ CH₃ 3-OCH₃ Cl F A-3934. OCHF₂ CH₃ 5-F Cl FA-3935. OCHF₂ CH₃ 5-CH₃ Cl F A-3936. OCHF₂ CH₃ 5-OCH₃ Cl F A-3937. OCHF₂OCH₃ 3-F Cl F A-3938. OCHF₂ OCH₃ 3-CH₃ Cl F A-3939. OCHF₂ OCH₃ 3-OCH₃ ClF A-3940. OCHF₂ OCH₃ 5-F Cl F A-3941. OCHF₂ OCH₃ 5-CH₃ Cl F A-3942.OCHF₂ OCH₃ 5-OCH₃ Cl F A-3943. OCHF₂ CN 3-F Cl F A-3944. OCHF₂ CN 3-CH₃Cl F A-3945. OCHF₂ CN 3-OCH₃ Cl F A-3946. OCHF₂ CN 5-F Cl F A-3947.OCHF₂ CN 5-CH₃ Cl F A-3948. OCHF₂ CN 5-OCH₃ Cl F A-3949. OCHF₂ CH₂F 3-FCl F A-3950. OCHF₂ CH₂F 3-CH₃ Cl F A-3951. OCHF₂ CH₂F 3-OCH₃ Cl FA-3952. OCHF₂ CH₂F 5-F Cl F A-3953. OCHF₂ CH₂F 5-CH₃ Cl F A-3954. OCHF₂CH₂F 5-OCH₃ Cl F A-3955. OCHF₂ CHF₂ 3-F Cl F A-3956. OCHF₂ CHF₂ 3-CH₃ ClF A-3957. OCHF₂ CHF₂ 3-OCH₃ Cl F A-3958. OCHF₂ CHF₂ 5-F Cl F A-3959.OCHF₂ CHF₂ 5-CH₃ Cl F A-3960. OCHF₂ CHF₂ 5-OCH₃ Cl F A-3961. OCHF₂ CF₃3-F Cl F A-3962. OCHF₂ CF₃ 3-CH₃ Cl F A-3963. OCHF₂ CF₃ 3-OCH₃ Cl FA-3964. OCHF₂ CF₃ 5-F Cl F A-3965. OCHF₂ CF₃ 5-CH₃ Cl F A-3966. OCHF₂CF₃ 5-OCH₃ Cl F A-3967. OCHF₂ OCH₂F 3-F Cl F A-3968. OCHF₂ OCH₂F 3-CH₃Cl F A-3969. OCHF₂ OCH₂F 3-OCH₃ Cl F A-3970. OCHF₂ OCH₂F 5-F Cl FA-3971. OCHF₂ OCH₂F 5-CH₃ Cl F A-3972. OCHF₂ OCH₂F 5-OCH₃ Cl F A-3973.OCHF₂ OCHF₂ 3-F Cl F A-3974. OCHF₂ OCHF₂ 3-CH₃ Cl F A-3975. OCHF₂ OCHF₂3-OCH₃ Cl F A-3976. OCHF₂ OCHF₂ 5-F Cl F A-3977. OCHF₂ OCHF₂ 5-CH₃ Cl FA-3978. OCHF₂ OCHF₂ 5-OCH₃ Cl F A-3979. OCHF₂ OCF₃ 3-F Cl F A-3980.OCHF₂ OCF₃ 3-CH₃ Cl F A-3981. OCHF₂ OCF₃ 3-OCH₃ Cl F A-3982. OCHF₂ OCF₃5-F Cl F A-3983. OCHF₂ OCF₃ 5-CH₃ Cl F A-3984. OCHF₂ OCF₃ 5-OCH₃ Cl FA-3985. OCF₃ F 3-F Cl F A-3986. OCF₃ F 3-CH₃ Cl F A-3987. OCF₃ F 3-OCH₃Cl F A-3988. OCF₃ F 5-F Cl F A-3989. OCF₃ F 5-CH₃ Cl F A-3990. OCF₃ F5-OCH₃ Cl F A-3991. OCF₃ CH₃ 3-F Cl F A-3992. OCF₃ CH₃ 3-CH₃ Cl FA-3993. OCF₃ CH₃ 3-OCH₃ Cl F A-3994. OCF₃ CH₃ 5-F Cl F A-3995. OCF₃ CH₃5-CH₃ Cl F A-3996. OCF₃ CH₃ 5-OCH₃ Cl F A-3997. OCF₃ OCH₃ 3-F Cl FA-3998. OCF₃ OCH₃ 3-CH₃ Cl F A-3999. OCF₃ OCH₃ 3-OCH₃ Cl F A-4000. OCF₃OCH₃ 5-F Cl F A-4001. OCF₃ OCH₃ 5-CH₃ Cl F A-4002. OCF₃ OCH₃ 5-OCH₃ Cl FA-4003. OCF₃ CN 3-F Cl F A-4004. OCF₃ CN 3-CH₃ Cl F A-4005. OCF₃ CN3-OCH₃ Cl F A-4006. OCF₃ CN 5-F Cl F A-4007. OCF₃ CN 5-CH₃ Cl F A-4008.OCF₃ CN 5-OCH₃ Cl F A-4009. OCF₃ CH₂F 3-F Cl F A-4010. OCF₃ CH₂F 3-CH₃Cl F A-4011. OCF₃ CH₂F 3-OCH₃ Cl F A-4012. OCF₃ CH₂F 5-F Cl F A-4013.OCF₃ CH₂F 5-CH₃ Cl F A-4014. OCF₃ CH₂F 5-OCH₃ Cl F A-4015. OCF₃ CHF₂ 3-FCl F A-4016. OCF₃ CHF₂ 3-CH₃ Cl F A-4017. OCF₃ CHF₂ 3-OCH₃ Cl F A-4018.OCF₃ CHF₂ 5-F Cl F A-4019. OCF₃ CHF₂ 5-CH₃ Cl F A-4020. OCF₃ CHF₂ 5-OCH₃Cl F A-4021. OCF₃ CF₃ 3-F Cl F A-4022. OCF₃ CF₃ 3-CH₃ Cl F A-4023. OCF₃CF₃ 3-OCH₃ Cl F A-4024. OCF₃ CF₃ 5-F Cl F A-4025. OCF₃ CF₃ 5-CH₃ Cl FA-4026. OCF₃ CF₃ 5-OCH₃ Cl F A-4027. OCF₃ OCH₂F 3-F Cl F A-4028. OCF₃OCH₂F 3-CH₃ Cl F A-4029. OCF₃ OCH₂F 3-OCH₃ Cl F A-4030. OCF₃ OCH₂F 5-FCl F A-4031. OCF₃ OCH₂F 5-CH₃ Cl F A-4032. OCF₃ OCH₂F 5-OCH₃ Cl FA-4033. OCF₃ OCHF₂ 3-F Cl F A-4034. OCF₃ OCHF₂ 3-CH₃ Cl F A-4035. OCF₃OCHF₂ 3-OCH₃ Cl F A-4036. OCF₃ OCHF₂ 5-F Cl F A-4037. OCF₃ OCHF₂ 5-CH₃Cl F A-4038. OCF₃ OCHF₂ 5-OCH₃ Cl F A-4039. OCF₃ OCF₃ 3-F Cl F A-4040.OCF₃ OCF₃ 3-CH₃ Cl F A-4041. OCF₃ OCF₃ 3-OCH₃ Cl F A-4042. OCF₃ OCF₃ 5-FCl F A-4043. OCF₃ OCF₃ 5-CH₃ Cl F A-4044. OCF₃ OCF₃ 5-OCH₃ Cl F

TABLE B Example No. R² R³ R⁶ R⁷ B-1. H H CN H B-2. F H CN H B-3. CH₃ HCN H B-4. OCH₃ H CN H B-5. CN H CN H B-6. CH₂F H CN H B-7. CHF₂ H CN HB-8. CF₃ H CN H B-9. OCH₂F H CN H B-10. OCHF₂ H CN H B-11. OCF₃ H CN HB-12. H 3-F CN H B-13. H 3-CH₃ CN H B-14. H 3-OCH₃ CN H B-15. H 5-F CN HB-16. H 5-CH₃ CN H B-17. H 5-OCH₃ CN H B-18. H 6-F CN H B-19. H 6-CH₃ CNH B-20. H 6-OCH₃ CN H B-21. F 3-F CN H B-22. F 3-CH₃ CN H B-23. F 3-OCH₃CN H B-24. F 5-F CN H B-25. F 5-CH₃ CN H B-26. F 5-OCH₃ CN H B-27. F 6-FCN H B-28. F 6-CH₃ CN H B-29. F 6-OCH₃ CN H B-30. CH₃ 3-F CN H B-31. CH₃3-CH₃ CN H B-32. CH₃ 3-OCH₃ CN H B-33. CH₃ 5-F CN H B-34. CH₃ 5-CH₃ CN HB-35. CH₃ 5-OCH₃ CN H B-36. CH₃ 6-F CN H B-37. CH₃ 6-CH₃ CN H B-38. CH₃6-OCH₃ CN H B-39. OCH₃ 3-F CN H B-40. OCH₃ 3-CH₃ CN H B-41. OCH₃ 3-OCH₃CN H B-42. OCH₃ 5-F CN H B-43. OCH₃ 5-CH₃ CN H B-44. OCH₃ 5-OCH₃ CN HB-45. OCH₃ 6-F CN H B-46. OCH₃ 6-CH₃ CN H B-47. OCH₃ 6-OCH₃ CN H B-48.CN 3-F CN H B-49. CN 3-CH₃ CN H B-50. CN 3-OCH₃ CN H B-51. CN 5-F CN HB-52. CN 5-CH₃ CN H B-53. CN 5-OCH₃ CN H B-54. CN 6-F CN H B-55. CN6-CH₃ CN H B-56. CN 6-OCH₃ CN H B-57. CH₂F 3-F CN H B-58. CH₂F 3-CH₃ CNH B-59. CH₂F 3-OCH₃ CN H B-60. CH₂F 5-F CN H B-61. CH₂F 5-CH₃ CN H B-62.CH₂F 5-OCH₃ CN H B-63. CH₂F 6-F CN H B-64. CH₂F 6-CH₃ CN H B-65. CH₂F6-OCH₃ CN H B-66. CHF₂ 3-F CN H B-67. CHF₂ 3-CH₃ CN H B-68. CHF₂ 3-OCH₃CN H B-69. CHF₂ 5-F CN H B-70. CHF₂ 5-CH₃ CN H B-71. CHF₂ 5-OCH₃ CN HB-72. CHF₂ 6-F CN H B-73. CHF₂ 6-CH₃ CN H B-74. CHF₂ 6-OCH₃ CN H B-75.CF₃ 3-F CN H B-76. CF₃ 3-CH₃ CN H B-77. CF₃ 3-OCH₃ CN H B-78. CF₃ 5-F CNH B-79. CF₃ 5-CH₃ CN H B-80. CF₃ 5-OCH₃ CN H B-81. CF₃ 6-F CN H B-82.CF₃ 6-CH₃ CN H B-83. CF₃ 6-OCH₃ CN H B-84. OCH₂F 3-F CN H B-85. OCH₂F3-CH₃ CN H B-86. OCH₂F 3-OCH₃ CN H B-87. OCH₂F 5-F CN H B-88. OCH₂F5-CH₃ CN H B-89. OCH₂F 5-OCH₃ CN H B-90. OCH₂F 6-F CN H B-91. OCH₂F6-CH₃ CN H B-92. OCH₂F 6-OCH₃ CN H B-93. OCHF₂ 3-F CN H B-94. OCHF₂3-CH₃ CN H B-95. OCHF₂ 3-OCH₃ CN H B-96. OCHF₂ 5-F CN H B-97. OCHF₂5-CH₃ CN H B-98. OCHF₂ 5-OCH₃ CN H B-99. OCHF₂ 6-F CN H B-100. OCHF₂6-CH₃ CN H B-101. OCHF₂ 6-OCH₃ CN H B-102. OCF₃ 3-F CN H B-103. OCF₃3-CH₃ CN H B-104. OCF₃ 3-OCH₃ CN H B-105. OCF₃ 5-F CN H B-106. OCF₃5-CH₃ CN H B-107. OCF₃ 5-OCH₃ CN H B-108. OCF₃ 6-F CN H B-109. OCF₃6-CH₃ CN H B-110. OCF₃ 6-OCH₃ CN H B-111. H H F H B-112. F H F H B-113.CH₃ H F H B-114. OCH₃ H F H B-115. CN H F H B-116. CH₂F H F H B-117.CHF₂ H F H B-118. CF₃ H F H B-119. OCH₂F H F H B-120. OCHF₂ H F H B-121.OCF₃ H F H B-122. H 3-F F H B-123. H 3-CH₃ F H B-124. H 3-OCH₃ F HB-125. H 5-F F H B-126. H 5-CH₃ F H B-127. H 5-OCH₃ F H B-128. H 6-F F HB-129. H 6-CH₃ F H B-130. H 6-OCH₃ F H B-131. F 3-F F H B-132. F 3-CH₃ FH B-133. F 3-OCH₃ F H B-134. F 5-F F H B-135. F 5-CH₃ F H B-136. F5-OCH₃ F H B-137. F 6-F F H B-138. F 6-CH₃ F H B-139. F 6-OCH₃ F HB-140. CH₃ 3-F F H B-141. CH₃ 3-CH₃ F H B-142. CH₃ 3-OCH₃ F H B-143. CH₃5-F F H B-144. CH₃ 5-CH₃ F H B-145. CH₃ 5-OCH₃ F H B-146. CH₃ 6-F F HB-147. CH₃ 6-CH₃ F H B-148. CH₃ 6-OCH₃ F H B-149. OCH₃ 3-F F H B-150.OCH₃ 3-CH₃ F H B-151. OCH₃ 3-OCH₃ F H B-152. OCH₃ 5-F F H B-153. OCH₃5-CH₃ F H B-154. OCH₃ 5-OCH₃ F H B-155. OCH₃ 6-F F H B-156. OCH₃ 6-CH₃ FH B-157. OCH₃ 6-OCH₃ F H B-158. CN 3-F F H B-159. CN 3-CH₃ F H B-160. CN3-OCH₃ F H B-161. CN 5-F F H B-162. CN 5-CH₃ F H B-163. CN 5-OCH₃ F HB-164. CN 6-F F H B-165. CN 6-CH₃ F H B-166. CN 6-OCH₃ F H B-167. CH₂F3-F F H B-168. CH₂F 3-CH₃ F H B-169. CH₂F 3-OCH₃ F H B-170. CH₂F 5-F F HB-171. CH₂F 5-CH₃ F H B-172. CH₂F 5-OCH₃ F H B-173. CH₂F 6-F F H B-174.CH₂F 6-CH₃ F H B-175. CH₂F 6-OCH₃ F H B-176. CHF₂ 3-F F H B-177. CHF₂3-CH₃ F H B-178. CHF₂ 3-OCH₃ F H B-179. CHF₂ 5-F F H B-180. CHF₂ 5-CH₃ FH B-181. CHF₂ 5-OCH₃ F H B-182. CHF₂ 6-F F H B-183. CHF₂ 6-CH₃ F HB-184. CHF₂ 6-OCH₃ F H B-185. CF₃ 3-F F H B-186. CF₃ 3-CH₃ F H B-187.CF₃ 3-OCH₃ F H B-188. CF₃ 5-F F H B-189. CF₃ 5-CH₃ F H B-190. CF₃ 5-OCH₃F H B-191. CF₃ 6-F F H B-192. CF₃ 6-CH₃ F H B-193. CF₃ 6-OCH₃ F H B-194.OCH₂F 3-F F H B-195. OCH₂F 3-CH₃ F H B-196. OCH₂F 3-OCH₃ F H B-197.OCH₂F 5-F F H B-198. OCH₂F 5-CH₃ F H B-199. OCH₂F 5-OCH₃ F H B-200.OCH₂F 6-F F H B-201. OCH₂F 6-CH₃ F H B-202. OCH₂F 6-OCH₃ F H B-203.OCHF₂ 3-F F H B-204. OCHF₂ 3-CH₃ F H B-205. OCHF₂ 3-OCH₃ F H B-206.OCHF₂ 5-F F H B-207. OCHF₂ 5-CH₃ F H B-208. OCHF₂ 5-OCH₃ F H B-209.OCHF₂ 6-F F H B-210. OCHF₂ 6-CH₃ F H B-211. OCHF₂ 6-OCH₃ F H B-212. OCF₃3-F F H B-213. OCF₃ 3-CH₃ F H B-214. OCF₃ 3-OCH₃ F H B-215. OCF₃ 5-F F HB-216. OCF₃ 5-CH₃ F H B-217. OCF₃ 5-OCH₃ F H B-218. OCF₃ 6-F F H B-219.OCF₃ 6-CH₃ F H B-220. OCF₃ 6-OCH₃ F H B-221. H H Cl H B-222. F H Cl HB-223. CH₃ H Cl H B-224. OCH₃ H Cl H B-225. CN H Cl H B-226. CH₂F H Cl HB-227. CHF₂ H Cl H B-228. CF₃ H Cl H B-229. OCH₂F H Cl H B-230. OCHF₂ HCl H B-231. OCF₃ H Cl H B-232. H 3-F Cl H B-233. H 3-CH₃ Cl H B-234. H3-OCH₃ Cl H B-235. H 5-F Cl H B-236. H 5-CH₃ Cl H B-237. H 5-OCH₃ Cl HB-238. H 6-F Cl H B-239. H 6-CH₃ Cl H B-240. H 6-OCH₃ Cl H B-241. F 3-FCl H B-242. F 3-CH₃ Cl H B-243. F 3-OCH₃ Cl H B-244. F 5-F Cl H B-245. F5-CH₃ Cl H B-246. F 5-OCH₃ Cl H B-247. F 6-F Cl H B-248. F 6-CH₃ Cl HB-249. F 6-OCH₃ Cl H B-250. CH₃ 3-F Cl H B-251. CH₃ 3-CH₃ Cl H B-252.CH₃ 3-OCH₃ Cl H B-253. CH₃ 5-F Cl H B-254. CH₃ 5-CH₃ Cl H B-255. CH₃5-OCH₃ Cl H B-256. CH₃ 6-F Cl H B-257. CH₃ 6-CH₃ Cl H B-258. CH₃ 6-OCH₃Cl H B-259. OCH₃ 3-F Cl H B-260. OCH₃ 3-CH₃ Cl H B-261. OCH₃ 3-OCH₃ Cl HB-262. OCH₃ 5-F Cl H B-263. OCH₃ 5-CH₃ Cl H B-264. OCH₃ 5-OCH₃ Cl HB-265. OCH₃ 6-F Cl H B-266. OCH₃ 6-CH₃ Cl H B-267. OCH₃ 6-OCH₃ Cl HB-268. CN 3-F Cl H B-269. CN 3-CH₃ Cl H B-270. CN 3-OCH₃ Cl H B-271. CN5-F Cl H B-272. CN 5-CH₃ Cl H B-273. CN 5-OCH₃ Cl H B-274. CN 6-F Cl HB-275. CN 6-CH₃ Cl H B-276. CN 6-OCH₃ Cl H B-277. CH₂F 3-F Cl H B-278.CH₂F 3-CH₃ Cl H B-279. CH₂F 3-OCH₃ Cl H B-280. CH₂F 5-F Cl H B-281. CH₂F5-CH₃ Cl H B-282. CH₂F 5-OCH₃ Cl H B-283. CH₂F 6-F Cl H B-284. CH₂F6-CH₃ Cl H B-285. CH₂F 6-OCH₃ Cl H B-286. CHF₂ 3-F Cl H B-287. CHF₂3-CH₃ Cl H B-288. CHF₂ 3-OCH₃ Cl H B-289. CHF₂ 5-F Cl H B-290. CHF₂5-CH₃ Cl H B-291. CHF₂ 5-OCH₃ Cl H B-292. CHF₂ 6-F Cl H B-293. CHF₂6-CH₃ Cl H B-294. CHF₂ 6-OCH₃ Cl H B-295. CF₃ 3-F Cl H B-296. CF₃ 3-CH₃Cl H B-297. CF₃ 3-OCH₃ Cl H B-298. CF₃ 5-F Cl H B-299. CF₃ 5-CH₃ Cl HB-300. CF₃ 5-OCH₃ Cl H B-301. CF₃ 6-F Cl H B-302. CF₃ 6-CH₃ Cl H B-303.CF₃ 6-OCH₃ Cl H B-304. OCH₂F 3-F Cl H B-305. OCH₂F 3-CH₃ Cl H B-306.OCH₂F 3-OCH₃ Cl H B-307. OCH₂F 5-F Cl H B-308. OCH₂F 5-CH₃ Cl H B-309.OCH₂F 5-OCH₃ Cl H B-310. OCH₂F 6-F Cl H B-311. OCH₂F 6-CH₃ Cl H B-312.OCH₂F 6-OCH₃ Cl H B-313. OCHF₂ 3-F Cl H B-314. OCHF₂ 3-CH₃ Cl H B-315.OCHF₂ 3-OCH₃ Cl H B-316. OCHF₂ 5-F Cl H B-317. OCHF₂ 5-CH₃ Cl H B-318.OCHF₂ 5-OCH₃ Cl H B-319. OCHF₂ 6-F Cl H B-320. OCHF₂ 6-CH₃ Cl H B-321.OCHF₂ 6-OCH₃ Cl H B-322. OCF₃ 3-F Cl H B-323. OCF₃ 3-CH₃ Cl H B-324.OCF₃ 3-OCH₃ Cl H B-325. OCF₃ 5-F Cl H B-326. OCF₃ 5-CH₃ Cl H B-327. OCF₃5-OCH₃ Cl H B-328. OCF₃ 6-F Cl H B-329. OCF₃ 6-CH₃ Cl H B-330. OCF₃6-OCH₃ Cl H B-331. H H CN F B-332. F H CN F B-333. CH₃ H CN F B-334.OCH₃ H CN F B-335. CN H CN F B-336. CH₂F H CN F B-337. CHF₂ H CN FB-338. CF₃ H CN F B-339. OCH₂F H CN F B-340. OCHF₂ H CN F B-341. OCF₃ HCN F B-342. H 3-F CN F B-343. H 3-CH₃ CN F B-344. H 3-OCH₃ CN F B-345. H5-F CN F B-346. H 5-CH₃ CN F B-347. H 5-OCH₃ CN F B-348. H 6-F CN FB-349. H 6-CH₃ CN F B-350. H 6-OCH₃ CN F B-351. F 3-F CN F B-352. F3-CH₃ CN F B-353. F 3-OCH₃ CN F B-354. F 5-F CN F B-355. F 5-CH₃ CN FB-356. F 5-OCH₃ CN F B-357. F 6-F CN F B-358. F 6-CH₃ CN F B-359. F6-OCH₃ CN F B-360. CH₃ 3-F CN F B-361. CH₃ 3-CH₃ CN F B-362. CH₃ 3-OCH₃CN F B-363. CH₃ 5-F CN F B-364. CH₃ 5-CH₃ CN F B-365. CH₃ 5-OCH₃ CN FB-366. CH₃ 6-F CN F B-367. CH₃ 6-CH₃ CN F B-368. CH₃ 6-OCH₃ CN F B-369.OCH₃ 3-F CN F B-370. OCH₃ 3-CH₃ CN F B-371. OCH₃ 3-OCH₃ CN F B-372. OCH₃5-F CN F B-373. OCH₃ 5-CH₃ CN F B-374. OCH₃ 5-OCH₃ CN F B-375. OCH₃ 6-FCN F B-376. OCH₃ 6-CH₃ CN F B-377. OCH₃ 6-OCH₃ CN F B-378. CN 3-F CN FB-379. CN 3-CH₃ CN F B-380. CN 3-OCH₃ CN F B-381. CN 5-F CN F B-382. CN5-CH₃ CN F B-383. CN 5-OCH₃ CN F B-384. CN 6-F CN F B-385. CN 6-CH₃ CN FB-386. CN 6-OCH₃ CN F B-387. CH₂F 3-F CN F B-388. CH₂F 3-CH₃ CN F B-389.CH₂F 3-OCH₃ CN F B-390. CH₂F 5-F CN F B-391. CH₂F 5-CH₃ CN F B-392. CH₂F5-OCH₃ CN F B-393. CH₂F 6-F CN F B-394. CH₂F 6-CH₃ CN F B-395. CH₂F6-OCH₃ CN F B-396. CHF₂ 3-F CN F B-397. CHF₂ 3-CH₃ CN F B-398. CHF₂3-OCH₃ CN F B-399. CHF₂ 5-F CN F B-400. CHF₂ 5-CH₃ CN F B-401. CHF₂5-OCH₃ CN F B-402. CHF₂ 6-F CN F B-403. CHF₂ 6-CH₃ CN F B-404. CHF₂6-OCH₃ CN F B-405. CF₃ 3-F CN F B-406. CF₃ 3-CH₃ CN F B-407. CF₃ 3-OCH₃CN F B-408. CF₃ 5-F CN F B-409. CF₃ 5-CH₃ CN F B-410. CF₃ 5-OCH₃ CN FB-411. CF₃ 6-F CN F B-412. CF₃ 6-CH₃ CN F B-413. CF₃ 6-OCH₃ CN F B-414.OCH₂F 3-F CN F B-415. OCH₂F 3-CH₃ CN F B-416. OCH₂F 3-OCH₃ CN F B-417.OCH₂F 5-F CN F B-418. OCH₂F 5-CH₃ CN F B-419. OCH₂F 5-OCH₃ CN F B-420.OCH₂F 6-F CN F B-421. OCH₂F 6-CH₃ CN F B-422. OCH₂F 6-OCH₃ CN F B-423.OCHF₂ 3-F CN F B-424. OCHF₂ 3-CH₃ CN F B-425. OCHF₂ 3-OCH₃ CN F B-426.OCHF₂ 5-F CN F B-427. OCHF₂ 5-CH₃ CN F B-428. OCHF₂ 5-OCH₃ CN F B-429.OCHF₂ 6-F CN F B-430. OCHF₂ 6-CH₃ CN F B-431. OCHF₂ 6-OCH₃ CN F B-432.OCF₃ 3-F CN F B-433. OCF₃ 3-CH₃ CN F B-434. OCF₃ 3-OCH₃ CN F B-435. OCF₃5-F CN F B-436. OCF₃ 5-CH₃ CN F B-437. OCF₃ 5-OCH₃ CN F B-438. OCF₃ 6-FCN F B-439. OCF₃ 6-CH₃ CN F B-440. OCF₃ 6-OCH₃ CN F B-441. H H F FB-442. F H F F B-443. CH₃ H F F B-444. OCH₃ H F F B-445. CN H F F B-446.CH₂F H F F B-447. CHF₂ H F F B-448. CF₃ H F F B-449. OCH₂F H F F B-450.OCHF₂ H F F B-451. OCF₃ H F F B-452. H 3-F F F B-453. H 3-CH₃ F F B-454.H 3-OCH₃ F F B-455. H 5-F F F B-456. H 5-CH₃ F F B-457. H 5-OCH₃ F FB-458. H 6-F F F B-459. H 6-CH₃ F F B-460. H 6-OCH₃ F F B-461. F 3-F F FB-462. F 3-CH₃ F F B-463. F 3-OCH₃ F F B-464. F 5-F F F B-465. F 5-CH₃ FF B-466. F 5-OCH₃ F F B-467. F 6-F F F B-468. F 6-CH₃ F F B-469. F6-OCH₃ F F B-470. CH₃ 3-F F F B-471. CH₃ 3-CH₃ F F B-472. CH₃ 3-OCH₃ F FB-473. CH₃ 5-F F F B-474. CH₃ 5-CH₃ F F B-475. CH₃ 5-OCH₃ F F B-476. CH₃6-F F F B-477. CH₃ 6-CH₃ F F B-478. CH₃ 6-OCH₃ F F B-479. OCH₃ 3-F F FB-480. OCH₃ 3-CH₃ F F B-481. OCH₃ 3-OCH₃ F F B-482. OCH₃ 5-F F F B-483.OCH₃ 5-CH₃ F F B-484. OCH₃ 5-OCH₃ F F B-485. OCH₃ 6-F F F B-486. OCH₃6-CH₃ F F B-487. OCH₃ 6-OCH₃ F F B-488. CN 3-F F F B-489. CN 3-CH₃ F FB-490. CN 3-OCH₃ F F B-491. CN 5-F F F B-492. CN 5-CH₃ F F B-493. CN5-OCH₃ F F B-494. CN 6-F F F B-495. CN 6-CH₃ F F B-496. CN 6-OCH₃ F FB-497. CH₂F 3-F F F B-498. CH₂F 3-CH₃ F F B-499. CH₂F 3-OCH₃ F F B-500.CH₂F 5-F F F B-501. CH₂F 5-CH₃ F F B-502. CH₂F 5-OCH₃ F F B-503. CH₂F6-F F F B-504. CH₂F 6-CH₃ F F B-505. CH₂F 6-OCH₃ F F B-506. CHF₂ 3-F F FB-507. CHF₂ 3-CH₃ F F B-508. CHF₂ 3-OCH₃ F F B-509. CHF₂ 5-F F F B-510.CHF₂ 5-CH₃ F F B-511. CHF₂ 5-OCH₃ F F B-512. CHF₂ 6-F F F B-513. CHF₂6-CH₃ F F B-514. CHF₂ 6-OCH₃ F F B-515. CF₃ 3-F F F B-516. CF₃ 3-CH₃ F FB-517. CF₃ 3-OCH₃ F F B-518. CF₃ 5-F F F B-519. CF₃ 5-CH₃ F F B-520. CF₃5-OCH₃ F F B-521. CF₃ 6-F F F B-522. CF₃ 6-CH₃ F F B-523. CF₃ 6-OCH₃ F FB-524. OCH₂F 3-F F F B-525. OCH₂F 3-CH₃ F F B-526. OCH₂F 3-OCH₃ F FB-527. OCH₂F 5-F F F B-528. OCH₂F 5-CH₃ F F B-529. OCH₂F 5-OCH₃ F FB-530. OCH₂F 6-F F F B-531. OCH₂F 6-CH₃ F F B-532. OCH₂F 6-OCH₃ F FB-533. OCHF₂ 3-F F F B-534. OCHF₂ 3-CH₃ F F B-535. OCHF₂ 3-OCH₃ F FB-536. OCHF₂ 5-F F F B-537. OCHF₂ 5-CH₃ F F B-538. OCHF₂ 5-OCH₃ F FB-539. OCHF₂ 6-F F F B-540. OCHF₂ 6-CH₃ F F B-541. OCHF₂ 6-OCH₃ F FB-542. OCF₃ 3-F F F B-543. OCF₃ 3-CH₃ F F B-544. OCF₃ 3-OCH₃ F F B-545.OCF₃ 5-F F F B-546. OCF₃ 5-CH₃ F F B-547. OCF₃ 5-OCH₃ F F B-548. OCF₃6-F F F B-549. OCF₃ 6-CH₃ F F B-550. OCF₃ 6-OCH₃ F F B-551. H H Cl FB-552. F H Cl F B-553. CH₃ H Cl F B-554. OCH₃ H Cl F B-555. CN H Cl FB-556. CH₂F H Cl F B-557. CHF₂ H Cl F B-558. CF₃ H Cl F B-559. OCH₂F HCl F B-560. OCHF₂ H Cl F B-561. OCF₃ H Cl F B-562. H 3-F Cl F B-563. H3-CH₃ Cl F B-564. H 3-OCH₃ Cl F B-565. H 5-F Cl F B-566. H 5-CH₃ Cl FB-567. H 5-OCH₃ Cl F B-568. H 6-F Cl F B-569. H 6-CH₃ Cl F B-570. H6-OCH₃ Cl F B-571. F 3-F Cl F B-572. F 3-CH₃ Cl F B-573. F 3-OCH₃ Cl FB-574. F 5-F Cl F B-575. F 5-CH₃ Cl F B-576. F 5-OCH₃ Cl F B-577. F 6-FCl F B-578. F 6-CH₃ Cl F B-579. F 6-OCH₃ Cl F B-580. CH₃ 3-F Cl F B-581.CH₃ 3-CH₃ Cl F B-582. CH₃ 3-OCH₃ Cl F B-583. CH₃ 5-F Cl F B-584. CH₃5-CH₃ Cl F B-585. CH₃ 5-OCH₃ Cl F B-586. CH₃ 6-F Cl F B-587. CH₃ 6-CH₃Cl F B-588. CH₃ 6-OCH₃ Cl F B-589. OCH₃ 3-F Cl F B-590. OCH₃ 3-CH₃ Cl FB-591. OCH₃ 3-OCH₃ Cl F B-592. OCH₃ 5-F Cl F B-593. OCH₃ 5-CH₃ Cl FB-594. OCH₃ 5-OCH₃ Cl F B-595. OCH₃ 6-F Cl F B-596. OCH₃ 6-CH₃ Cl FB-597. OCH₃ 6-OCH₃ Cl F B-598. CN 3-F Cl F B-599. CN 3-CH₃ Cl F B-600.CN 3-OCH₃ Cl F B-601. CN 5-F Cl F B-602. CN 5-CH₃ Cl F B-603. CN 5-OCH₃Cl F B-604. CN 6-F Cl F B-605. CN 6-CH₃ Cl F B-606. CN 6-OCH₃ Cl FB-607. CH₂F 3-F Cl F B-608. CH₂F 3-CH₃ Cl F B-609. CH₂F 3-OCH₃ Cl FB-610. CH₂F 5-F Cl F B-611. CH₂F 5-CH₃ Cl F B-612. CH₂F 5-OCH₃ Cl FB-613. CH₂F 6-F Cl F B-614. CH₂F 6-CH₃ Cl F B-615. CH₂F 6-OCH₃ Cl FB-616. CHF₂ 3-F Cl F B-617. CHF₂ 3-CH₃ Cl F B-618. CHF₂ 3-OCH₃ Cl FB-619. CHF₂ 5-F Cl F B-620. CHF₂ 5-CH₃ Cl F B-621. CHF₂ 5-OCH₃ Cl FB-622. CHF₂ 6-F Cl F B-623. CHF₂ 6-CH₃ Cl F B-624. CHF₂ 6-OCH₃ Cl FB-625. CF₃ 3-F Cl F B-626. CF₃ 3-CH₃ Cl F B-627. CF₃ 3-OCH₃ Cl F B-628.CF₃ 5-F Cl F B-629. CF₃ 5-CH₃ Cl F B-630. CF₃ 5-OCH₃ Cl F B-631. CF₃ 6-FCl F B-632. CF₃ 6-CH₃ Cl F B-633. CF₃ 6-OCH₃ Cl F B-634. OCH₂F 3-F Cl FB-635. OCH₂F 3-CH₃ Cl F B-636. OCH₂F 3-OCH₃ Cl F B-637. OCH₂F 5-F Cl FB-638. OCH₂F 5-CH₃ Cl F B-639. OCH₂F 5-OCH₃ Cl F B-640. OCH₂F 6-F Cl FB-641. OCH₂F 6-CH₃ Cl F B-642. OCH₂F 6-OCH₃ Cl F B-643. OCHF₂ 3-F Cl FB-644. OCHF₂ 3-CH₃ Cl F B-645. OCHF₂ 3-OCH₃ Cl F B-646. OCHF₂ 5-F Cl FB-647. OCHF₂ 5-CH₃ Cl F B-648. OCHF₂ 5-OCH₃ Cl F B-649. OCHF₂ 6-F Cl FB-650. OCHF₂ 6-CH₃ Cl F B-651. OCHF₂ 6-OCH₃ Cl F B-652. OCF₃ 3-F Cl FB-653. OCF₃ 3-CH₃ Cl F B-654. OCF₃ 3-OCH₃ Cl F B-655. OCF₃ 5-F Cl FB-656. OCF₃ 5-CH₃ Cl F B-657. OCF₃ 5-OCH₃ Cl F B-658. OCF₃ 6-F Cl FB-659. OCF₃ 6-CH₃ Cl F B-660. OCF₃ 6-OCH₃ Cl F

The positions (e.g. 3-/5-/6-) of R³ are relative to the 2- and4-positions of radicals R¹ and R² and to the 1-position of theattachment point of the ring to the SO₂ group.

The preferred compounds among the compounds I.1 to I.40 mentioned aboveare those of the formulae I.1, I.6, I.11, I.16, I.21, I.26, I.31 andI.36, and especially compounds of the formulae I.1, I.6, I.16 and I.21.Particularly preferred are compounds of the formulae I.1 and I.6.

In a specific embodiment, the compounds I are selected from thecompounds specified in the examples, either as a free base or in form ofa pharmaceutically acceptable salt, an N-oxide or a stereoisomer thereofor as their racemate or any other mixture of their stereoisomers.

The compounds I of the invention have a center of chirality in position3 of the 2-oxindole ring. The compounds of the invention may thereforebe in the form of a 1:1 mixture of enantiomers (racemate) or of anonracemic mixture of enantiomers in which one of the two enantiomers,either the enantiomer which rotates the plane of vibration of linearlypolarized light to the left (i.e. minus rotation) (hereinafter (−)enantiomer) or the enantiomer which rotates the plane of vibration oflinearly polarized light to the right (i.e. plus rotation) (hereinafter(+) enantiomer), is enriched, or of substantially enantiopure compounds,that is to say of substantially enantiopure (−) enantiomer or (+)enantiomer. Since the compounds of the invention have a single center ofasymmetry and no axis/plane of chirality, a nonracemic mixture can alsobe defined as a mixture of enantiomers in which either the R or the Senantiomer predominates. Substantially enantiopure compounds canaccordingly also be defined as substantially enantiopure R enantiomer orsubstantially enantiopure S enantiomer.

“Substantially enantiopure compounds” means in the context of thepresent invention those compounds having an enantiomeric excess (ee; %ee=(R−S)/(R+S)×100 or (S−R)/(S+R)×100) of at least 80% ee, preferably atleast 85% ee, more preferably at least 90% ee, even more preferably atleast 95% ee and in particular at least 98% ee.

In one embodiment of the invention, the compounds of the invention arein the form of substantially enantiopure compounds. Particularlypreferred compounds have an enantiomeric excess of at least 85% ee, morepreferably of at least 90% ee, even more preferably of at least 95% eeand in particular of at least 98% ee.

The invention thus relates both to the pure enantiomers and to mixturesthereof, e.g. mixtures in which one enantiomer is present in enrichedform, but also to the racemates. The invention also relates to thepharmaceutically acceptable salts of the pure enantiomers of compoundsI, and the mixtures of enantiomers in the form of the pharmaceuticallyacceptable salts of compounds I.

Preferred embodiments of the invention are compounds of the formula I asdetailed above which are characterized in that they are in opticallyactive form, and the enantiomer of the relevant compound of the formulaI is the S-enantiomer, in the form of a free base, or a pharmaceuticallyacceptable salt thereof.

Particularly preference is given to compounds of the general formula Iand their pharmaceutically acceptable salts as detailed above in whichthe corresponding S-enantiomer is present in an optical purity(enantiomeric excess, ee) of more than 50% ee, particularly preferablyof at least 80% ee, more preferably of at least 90% ee and even morepreferably of at least 95% ee and in particular of at least 98% ee.

Likewise preferred embodiments of the invention are compounds of thegeneral formula I as detailed above which are characterized in that theyare in optically inactive form, i.e. in the form of the racemate, or inthe form of a pharmaceutically acceptable salt of the racemate.

Examples of synthetic routes for preparing the oxindole derivatives ofthe invention are described below.

The compounds of the invention can be prepared by using methodsdescribed in WO 2005/030755, WO 2006/005609 and the other referencesmentioned in the outset for synthesizing analogous compounds, and thepreparation is outlined by way of example in the below synthesisschemes. The variables in these synthetic schemes have the same meaningsas in formula I.

As shown in scheme 1, 3-hydroxy-1,3-dihydroindol-2-ones IV can beobtained by addition of metallated heterocycles III onto the 3-ketogroup of the isatins II. The metallated heterocycles, such as, forexample, the corresponding Grignard (Mg) or organyllithium compound III(M=MgX or Li; X═I or Br), can be obtained in any conventional way fromhalogen or hydrocarbon compounds by reaction with Mg or lithium-organiccompounds. Exemplary methods are described in Houben-Weyl, Methoden derOrganischen Chemie, vol. 13, 1-2, chapter on Mg and Li compounds. Theisatins II are either commercially available or were prepared in analogyto methods described in the literature (Advances in HeterocyclicChemistry, A. R. Katritzky and A. J. Boulton, Academic Press, New York,1975, 18, 2-58; J. Brazil. Chem. Soc. 12, 273-324, 2001).

The 3-hydroxyoxindoles IV can be converted into the compounds V whichhave a leaving group LG′ in position 3, where the leaving group LG′ is aconventional leaving group such as, for example, chlorine or bromide.The intermediate V with for example LG′=Cl can be prepared by treatingthe alcohol IV with thionyl chloride in the pres-presence of a base suchas, for example, pyridine, in a suitable solvent such as, for example,dichloromethane. The compounds V can subsequently be reacted withamines, such as, for example, ammonia, in a substitution reaction togive the amines VI.

In the first variant amines VI are converted into the sulfonylatedproduct VIII by treatment with sulfonyl chlorides VII afterdeprotonation with a strong base such as, for example, potassiumtert-butoxide or sodium hydride in DMF. Sulfonyl chlorides VII employedcan either be purchased or be prepared by known processes (for exampleJ. Med. Chem. 40, 1149 (1997)). Compounds VIII are then reacted withcarbonic acid halide, such as phenyl chloroformate, in the presence of abase such as, for example, pyridine, to give the corresponding carbamateIX (LG=leaving group; in case of using phenyl chloroformate,LG=phenoxy).

As shown in scheme 2, intermediate IX can then be reacted with anappropriate amine X to give directly the compounds of the generalformula I; this conversion can be done at room temperature or elevatedtemperature and with the addition of auxiliary bases such as, forexample, triethylamine or diisopropylethylamine.

In a second variant compounds of the general formula I are prepared fromintermediates IX in a two-step sequence: intermediate IX can be reactedwith an appropriate azetidine-3-one XII or1-(3-azetidinyl)-4-piperidinone XIII employing the same method andconditions as described above to give the corresponding oxo compoundsXIV or XV. Reductive amination of compounds XIV or XV with theappropriate amines XVI or XVII then gives the compounds of the generalformula I. The latter reaction is carried out in the presence of asuitable reduction agent, e.g. boron-based reduction agent, typically aboronic ester, such as sodium triacetoxyhydroborate, orcyanoborohydride; where appropriate a Lewis acid such as e.g. zincchloride or titanium isopropoxide is added to the reaction. Generalexamples for reductive amination are described in the literature, e.g.Comprehensive Organic Transformations 2^(nd) ed, R. Larock, Wiley VCH,835-846.

As shown in scheme 3, in a third variant amines VI are first reactedwith a carbonic acid halide, such as phenyl chloroformate, in thepresence of a base such as, for example, pyridine, to give thecorresponding carbamate XVIII (LG=leaving group; in case of using phenylchloroformate, LG=phenoxy), and then reacted further with an appropriateamine at room temperature or elevated temperature and with the additionof auxiliary bases such as, for example, pyridine, triethylamine ordiisopropylethylamine. to give intermediate XIX. Sulfonylation ofcompounds XIX by treatment with sulfonyl chlorides VII afterdeprotonation with a strong base such as, for example, potassiumtert-butoxide or sodium hydride in DMF, then gives the compounds of thegeneral formula I.

If not indicated otherwise, the above-described reactions are generallycarried out in a solvent at temperatures between room temperature andthe boiling temperature of the solvent employed. Alternatively, theactivation energy which is required for the reaction can be introducedinto the reaction mixture using microwaves, something which has provedto be of value, in particular, in the case of the reactions catalyzed bytransition metals (with regard to reactions using microwaves, seeTetrahedron 2001, 57, p. 9199 ff. p. 9225 ff. and also, in a generalmanner, “Microwaves in Organic Synthesis”, André Loupy (Ed.), Wiley-VCH2002.

The acid addition salts of compounds I are prepared in a customarymanner by mixing the free base with a corresponding acid, whereappropriate in solution in an organic solvent, for example a loweralcohol, such as methanol, ethanol or propanol, an ether, such as methyltert-butyl ether or diisopropyl ether, a ketone, such as acetone ormethyl ethyl ketone, or an ester, such as ethyl acetate.

Routine experimentations, including appropriate manipulation of thereaction conditions, reagents and sequence of the synthetic route,protection of any chemical functionality that may not be compatible withthe reaction conditions, and deprotection at a suitable point in thereaction sequence of the preparation methods are within routinetechniques.

Suitable protecting groups and the methods for protecting anddeprotecting different substituents using such suitable protectinggroups are well known to those skilled in the art; examples of which maybe found in T. Greene and P. Wuts, Protective Groups in OrganicSynthesis (3rd ed.), John Wiley & Sons, NY (1999), which is incorporatedherein by reference in its entirety. Synthesis of the compounds of theinvention may be accomplished by methods analogous to those described inthe synthetic scheme described hereinabove and in specific examples.

Starting materials, if not commercially available, may be prepared byprocedures selected from standard organic chemical techniques,techniques that are analogous to the synthesis of known, structurallysimilar compounds, or techniques that are analogous to the abovedescribed schemes or the procedures described in the synthetic examplessection.

When an optically active form of a compound of the invention isrequired, it may be obtained by carrying out one of the proceduresdescribed herein using an optically active starting material (prepared,for example, by asymmetric induction of a suitable reaction step), or byresolution of a mixture of the stereoisomers of the compound orintermediates using a standard procedure (such as chromatographicseparation, recrystallization or enzymatic resolution).

Similarly, when a pure geometric isomer of a compound of the inventionis required, it may be obtained by carrying out one of the aboveprocedures using a pure geometric isomer as a starting material, or byresolution of a mixture of the geometric isomers of the compound orintermediates using a standard procedure such as chromatographicseparation.

The present invention moreover relates to compounds of formula I asdefined above, wherein at least one of the atoms has been replaced byits stable, non-radioactive isotope (e.g., hydrogen by deuterium, ¹²C by¹³C, ¹⁴N by ¹⁵N, ¹⁶O by ¹⁸O) and preferably wherein at least onehydrogen atom has been replaced by a deuterium atom.

Of course, the compounds according to the invention contain more of therespective isotope than this naturally occurs and thus is anyway presentin the compounds I.

Stable isotopes (e.g., deuterium, ¹³C, ¹⁵N, ¹⁸O) are nonradioactiveisotopes which contain one additional neutron than the normally abundantisotope of the respective atom. Deuterated compounds have been used inpharmaceutical research to investigate the in vivo metabolic fate of thecompounds by evaluation of the mechanism of action and metabolic pathwayof the non deuterated parent compound (Blake et al. J. Pharm. Sci. 64,3, 367-391 (1975)). Such metabolic studies are important in the designof safe, effective therapeutic drugs, either because the in vivo activecompound administered to the patient or because the metabolites producedfrom the parent compound prove to be toxic or carcinogenic (Foster etal., Advances in Drug Research Vol. 14, pp. 2-36, Academic press,London, 1985; Kato et al., J. Labelled Comp. Radiopharmaceut.,36(10):927-932 (1995); Kushner et al., Can. J. Physiol. Pharmacol., 77,79-88 (1999).

Incorporation of a heavy atom, particularly substitution of deuteriumfor hydrogen, can give rise to an isotope effect that could alter thepharmacokinetics of the drug.

Stable isotope labeling of a drug can alter its physico-chemicalproperties such as pKa and lipid solubility. These changes may influencethe fate of the drug at different steps along its passage through thebody. Absorption, distribution, metabolism or excretion can be changed.Absorption and distribution are processes that depend primarily on themolecular size and the lipophilicity of the substance. These effects andalterations can affect the pharmacodynamic response of the drug moleculeif the isotopic substitution affects a region involved in aligand-receptor interaction.

Drug metabolism can give rise to large isotopic effect if the breakingof a chemical bond to a deuterium atom is the rate limiting step in theprocess. While some of the physical properties of a stableisotope-labeled molecule are different from those of the unlabeled one,the chemical and biological properties are the same, with one importantexception: because of the increased mass of the heavy isotope, any bondinvolving the heavy isotope and another atom will be stronger than thesame bond between the light isotope and that atom. In any reaction inwhich the breaking of this bond is the rate limiting step, the reactionwill proceed slower for the molecule with the heavy isotope due to“kinetic isotope effect”. A reaction involving breaking a C-D bond canbe up to 700 percent slower than a similar reaction involving breaking aC—H bond. If the C-D bond is not involved in any of the steps leading tothe metabolite, there may not be any effect to alter the behavior of thedrug. If a deuterium is placed at a site involved in the metabolism of adrug, an isotope effect will be observed only if breaking of the C-Dbond is the rate limiting step. There is evidence to suggest thatwhenever cleavage of an aliphatic C—H bond occurs, usually by oxidationcatalyzed by a mixed-function oxidase, replacement of the hydrogen bydeuterium will lead to observable isotope effect. It is also importantto understand that the incorporation of deuterium at the site ofmetabolism slows its rate to the point where another metabolite producedby attack at a carbon atom not substituted by deuterium becomes themajor pathway a process called “metabolic switching”.

Deuterium tracers, such as deuterium-labeled drugs and doses, in somecases repeatedly, of thousands of milligrams of deuterated water, arealso used in healthy humans of all ages, including neonates and pregnantwomen, without reported incident (e.g. Pons G and Rey E, Pediatrics 1999104: 633; Coward W A et al., Lancet 1979 7: 13; Schwarcz H P, Control.Clin. Trials 1984 5(4 Suppl): 573; Rodewald L E et al., J. Pediatr. 1989114: 885; Butte N F et al. Br. J. Nutr. 1991 65: 3; MacLennan A H et al.Am. J. Obstet Gynecol. 1981 139: 948). Thus, it is clear that anydeuterium released, for instance, during the metabolism of compounds ofthis invention poses no health risk.

The weight percentage of hydrogen in a mammal (approximately 9%) andnatural abundance of deuterium (approximately 0.015%) indicates that a70 kg human normally contains nearly a gram of deuterium. Furthermore,replacement of up to about 15% of normal hydrogen with deuterium hasbeen effected and maintained for a period of days to weeks in mammals,including rodents and dogs, with minimal observed adverse effects(Czajka D M and Finkel A J, Ann. N.Y. Acad. Sci. 1960 84: 770; Thomson JF, Ann. New York Acad. Sci 1960 84: 736; Czakja D M et al., Am. J.Physiol. 1961 201: 357). Higher deuterium concentrations, usually inexcess of 20%, can be toxic in animals. However, acute replacement of ashigh as 15%-23% of the hydrogen in humans' fluids with deuterium wasfound not to cause toxicity (Blagojevic N et al. in “Dosimetry &Treatment Planning for Neutron Capture Therapy”, Zamenhof R, Solares Gand Harling O Eds. 1994. Advanced Medical Publishing, Madison Wis. pp.125-134; Diabetes Metab. 23: 251 (1997)).

Increasing the amount of deuterium present in a compound above itsnatural abundance is called enrichment or deuterium-enrichment. Examplesof the amount of enrichment include from about 0.5, 1, 2, 3, 4, 5, 6, 7,8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71,75, 79, 84, 88, 92, 96, to about 100 mol %.

The hydrogens present on a particular organic compound have differentcapacities for exchange with deuterium. Certain hydrogen atoms areeasily exchangeable under physiological conditions and, if replaced bydeuterium atoms, it is expected that they will readily exchange forprotons after administration to a patient. Certain hydrogen atoms may beexchanged for deuterium atoms by the action of a deuteric acid such asD₂SO₄/D₂O. Alternatively, deuterium atoms may be incorporated in variouscombinations during the synthesis of compounds of the invention. Certainhydrogen atoms are not easily exchangeable for deuterium atoms. However,deuterium atoms at the remaining positions may be incorporated by theuse of deuterated starting materials or intermediates during theconstruction of compounds of the invention.

Deuterated and deuterium-enriched compounds of the invention can beprepared by using known methods described in the literature. Suchmethods can be carried out utilizing corresponding deuterated andoptionally, other isotope-containing reagents and/or intermediates tosynthesize the compounds delineated herein, or invoking standardsynthetic protocols known in the art for introducing isotopic atoms to achemical structure. Relevant procedures and intermediates are disclosed,for instance in Lizondo, J et al., Drugs Fut, 21(11), 1116 (1996);Brickner, S J et al., J Med Chem, 39(3), 673 (1996); Mallesham, B etal., Org Lett, 5(7), 963 (2003); PCT publications WO1997010223,WO2005099353, WO1995007271, WO2006008754; U.S. Pat. Nos. 7,538,189;7,534,814; 7,531,685; 7,528,131; 7,521,421; 7,514,068; 7,511,013; and USPatent Application Publication Nos. 20090137457; 20090131485;20090131363; 20090118238; 20090111840; 20090105338; 20090105307;20090105147; 20090093422; 20090088416; 20090082471, the methods arehereby incorporated by reference.

A further aspect of the present invention relates to a pharmaceuticalcomposition comprising at least one compound of the general formula Iand/or an N-oxide, a stereoisomer or a pharmaceutically acceptable saltthereof as detailed above, and a pharmaceutically acceptable carrier; orcomprising at least one compound I wherein at least one of the atoms hasbeen replaced by its stable, non-radioactive isotope, preferably whereinat least one hydrogen atom has been replaced by a deuterium atom, incombination with at least one pharmaceutically acceptable carrier and/orauxiliary substance. Suitable carriers depend inter alia on the dosageform of the composition and are known in principle to the skilledworker. Some suitable carriers are described hereinafter.

The present invention furthermore relates to a compound I as definedabove or an N-oxide, a stereoisomer or a pharmaceutically acceptablesalt thereof for use as a medicament. The present invention also relatesto a compound I as defined above or an N-oxide, a stereoisomer or apharmaceutically acceptable salt thereof for the treatment ofvasopressin-related diseases, especially of disorders which respond tothe modulation of the vasopressin receptor and in particular of the V1breceptor.

A further aspect of the present invention relates to the use ofcompounds of the formula I and/or of an N-oxide, a stereoisomer or ofpharmaceutically acceptable salts thereof for the manufacture of amedicament for the treatment and/or prophylaxis of vasopressin-relateddiseases, especially of disorders which respond to the modulation of thevasopressin receptor and in particular of the V1b receptor.

Vasopressin-related diseases are those in which the progress of thedisease is at least partly dependent on vasopressin, i.e. diseases whichshow an elevated vasopressin level which may contribute directly orindirectly to the pathological condition. In other words,vasopressin-related diseases are those which can be influenced bymodulating the vasopressin receptor, for example by administration of avasopressin receptor ligand (agonist, antagonist, partialantagonist/agonist, inverse agonist etc.).

In a preferred embodiment, the present invention relates to the use ofcompounds of the invention of the formula I or of an N-oxide, astereoisomer or of pharmaceutically acceptable salts thereof for themanufacture of a medicament for the treatment and/or prophylaxis ofdiseases selected from diabetes, insulin resistance, nocturnal enuresis,incontinence and diseases in which impairments of blood clotting occur,and/or for delaying micturition. The term “diabetes” means all types ofdiabetes, especially diabetes mellitus (including type I and especiallytype II), diabetes renalis and in particular diabetes insipidus. Thetypes of diabetes are preferably diabetes mellitus of type II (withinsulin resistance) or diabetes insipidus.

In a further preferred embodiment, the present invention relates to theuse of compounds of the invention of the formula I or of an N-oxide, astereoisomer or of pharmaceutically acceptable salts thereof for themanufacture of a medicament for the treatment and/or prophylaxis ofdiseases selected from hypertension, pulmonary hypertension, heartfailure, myocardial infarction, coronary spasm, unstable angina, PTCA(percutaneous transluminal coronary angioplasty), ischemias of theheart, impairments of the renal system, edemas, renal vasospasm,necrosis of the renal cortex, hyponatremia, hypokalemia,Schwartz-Bartter syndrome, impairments of the gastrointestinal tract,gastritic vasospasm, hepatocirrhosis, gastric and intestinal ulcers,emesis, emesis occurring during chemotherapy, and travel sickness.

The compounds of the invention of the formula I or their N-oxides,stereoisomers or pharmaceutically acceptable salts or the pharmaceuticalcomposition of the invention can also be used for the treatment ofvarious vasopressin-related complaints which have central nervous causesor alterations in the HPA axis (hypothalamic pituitary adrenal axis),for example for affective disorders such as depressive disorders andanxiety disorders. Depressive disorders include for example dysthymicdisorders, major depression, seasonal depression, treatment-resistantdepression disorders, bipolar disorders, or childhood onset mooddisorders. Anxiety disorders include for example phobias, post-traumaticstress disorders, general anxiety disorders, panic disorders, drugwithdrawal-induced anxiety disorders, and obsessive-compulsivedisorders.

Vasopressin-related complaints which have central nervous causes oralterations in the HPA axis are further cognitive disorders such asAlzheimer's disease, MCI (Mild Cognitive Impairment) and CIAS (CognitiveImpairment Associated with Schizophrenia).

The compounds of the invention of the formula I and their N-oxides, astereoisomers or pharmaceutically acceptable salts or the pharmaceuticalcomposition of the invention can likewise be employed for the treatmentof anxiety disorders and stress-dependent anxiety disorders, such as,for example, generalized anxiety disorders, phobias, post-traumaticanxiety disorders, panic anxiety disorders, obsessive-compulsive anxietydisorders, acute stress-dependent anxiety disorders, drugwithdrawal-induced anxiety disorders and social phobia.

The compounds of the invention of the formula I and their N-oxides,stereoisomers or pharmaceutically acceptable salts or the pharmaceuticalcomposition of the invention can likewise be employed for the treatmentand/or prophylaxis of social impairment, such as autism or socialimpairment related with schizophrenia.

The compounds of the invention of the formula I and their N-oxides,stereoisomers or pharmaceutically acceptable salts or the pharmaceuticalcomposition of the invention can likewise be employed for the treatmentand/or prophylaxis of increased aggression in conditions such asAlzheimer's disease and schizophrenia.

The compounds of the invention can furthermore also be employed for thetreatment of memory impairments, Alzheimer's disease, psychoses,psychotic disorders, sleep disorders and/or Cushing's syndrome, and allstress-dependent diseases.

Accordingly, a further preferred embodiment of the present inventionrelates to the use of compounds of the invention of the formula I or ofan N-oxide, a stereoisomer or pharmaceutically acceptable salts thereoffor the manufacture of a medicament for the treatment of affectivedisorders.

In a further preferred embodiment, the present invention relates to theuse of compounds of the invention of the formula I or of an N-oxide, astereoisomer or pharmaceutically acceptable salts thereof for themanufacture of a medicament for the treatment of anxiety disordersand/or stress-dependent anxiety disorders.

In a further preferred embodiment, the present invention relates to theuse of compounds of the invention of the formula I or of an N-oxide, astereoisomer or pharmaceutically acceptable salts thereof for themanufacture of a medicament for the treatment of memory impairmentsand/or Alzheimer's disease.

In a further preferred embodiment, the present invention relates to theuse of compounds of the invention of the formula I or of an N-oxide, astereoisomer or pharmaceutically acceptable salts thereof for themanufacture of a medicament for the treatment of psychoses and/orpsychotic disorders.

In a further preferred embodiment, the present invention relates to theuse of compounds of the invention of the formula I or of an N-oxide, astereoisomer or pharmaceutically acceptable salts thereof for themanufacture of a medicament for the treatment of Cushing's syndrome orother stress-dependent diseases.

In a further preferred embodiment, the present invention relates to theuse of compounds of the invention of the formula I or of an N-oxide, astereoisomer or pharmaceutically acceptable salts thereof for themanufacture of a medicament for the treatment of sleep disorders.

In a further preferred embodiment, the present invention relates to theuse of compounds of the invention of the formula I or of an N-oxide, astereoisomer or pharmaceutically acceptable salts thereof for themanufacture of a medicament for the treatment of depressive disorders.In the case of depressive disorders, specific mention is to be made ofchildhood onset mood disorders, i.e. depressive moods having their onsetin childhood, but also of major depression, seasonal depression, bipolardisorders and dysthymic disorders, and especially of major depressionand seasonal depression as well as of the depressive phases of bipolardisorders. The invention also relates to compounds of the formula I orN-oxides, stereoisomers or pharmaceutically acceptable salts thereof forthe manufacture of a medicament for the treatment of treatment-resistantdepression disorders and for the use in an add-on therapy of depressivedisorders.

In a further preferred embodiment, the present invention relates to theuse of compounds of the invention of the formula I or of an N-oxide, astereoisomer or pharmaceutically acceptable salts thereof for themanufacture of a medicament for the treatment of vasomotor symptomsand/or thermoregulatory dysfunctions such as, for example, the hot flushsymptom.

In a further preferred embodiment, the present invention relates to theuse of compounds of the invention of the formula I or of an N-oxide, astereoisomer or pharmaceutically acceptable salts thereof for themanufacture of a medicament for the treatment and/or prophylaxis of drugor pharmaceutical dependencies and/or dependencies mediated by otherfactors, for the treatment of drug-use disorders, for the treatmentand/or prophylaxis of stress caused by withdrawal of one or more factorsmediating the dependence and/or for the treatment and/or prophylaxis ofstress-induced relapses into drug or pharmaceutical dependencies and/ordependencies mediated by other factors. To be more precise, the presentinvention relates to the use of compounds of the invention of theformula I or of an N-oxide, a stereoisomer or pharmaceuticallyacceptable salts thereof for the manufacture of a medicament for thetreatment and/or prophylaxis of substance-related and addictivedisorders such as substance use disorder, substance-induced disorder,alcohol use disorder, alcohol intoxication, alcohol withdrawal,unspecified alcohol-related disorder, caffeine intoxication, caffeinewithdrawal, unspecified caffeine disorder, cannabis use disorder,cannabis withdrawal, unspecified cannabis-related disorder,phencyclidine use disorder, other hallucinogen use disorders,phencyclidine intoxication, other hallucinogen disorders, hallucinogenpersisting perception disorder, unspecified phencyclidine disorder,inhalant use disorder, inhalant intoxication, opioid use disorder,opioid withdrawal, sedative, hypnotic or anxiolytic use disorder,sedative, hypnotic or anxiolytic withdrawal, stimu-stimulant usedisorder, stimulant intoxication, stimulant withdrawal, tobacco usedisorder, tobacco withdrawal, unspecified tobacco-related disorder,other (or unknown) substance use disorders, other (or unknown) substanceintoxication, other (or unknown) substance withdrawal, other (orunknown) substance related disorder and gambling disorder; as well as tocompounds of the invention of the formula I or of an N-oxide, astereoisomer or of pharmaceutically acceptable salts thereof for thetreatment and/or prophylaxis of the above-listed diseases.

In a further preferred embodiment, the present invention relates to theuse of compounds of the invention of the formula I or of an N-oxide, astereoisomer or pharmaceutically acceptable salts thereof for themanufacture of a medicament for the treatment and/or prophylaxis ofschizophrenia and/or psychosis.

In a further preferred embodiment, the present invention relates to theuse of compounds of the invention of the formula I or of an N-oxide, astereoisomer or pharmaceutically acceptable salts thereof for themanufacture of a medicament for the treatment and/or prophylaxis ofpain, e.g. acute or chronic pain, preferably chronic pain, especiallyneuropathic pain. Chronic pain may be a complex regional pain syndrome,pain arising from peripheral neuropathies, post-operative pain, chronicfatigue syndrome pain, tension-type headache, pain arising frommechanical nerve injury and severe pain associated with diseases such ascancer, metabolic disease, neurotropic viral disease, neurotoxicity,inflammation, multiple sclerosis or any pain arising as a consequence ofor associated with stress or depressive illness.

A further aspect of the invention relates to a compound I orpharmaceutically acceptable salts thereof for use as a medicament, andto a compound I or an N-oxide, a stereoisomer or pharmaceuticallyacceptable salts thereof for the manufacture of a medicament for thetreatment and/or prophylaxis of the above-defined diseases.

A further aspect of the invention relates to a method for the treatmentand/or prophylaxis of vasopressin-related diseases, in which aneffective amount of at least one compound of the invention of theformula I or of an N-oxide, a stereoisomer or of at least onepharmaceutically acceptable salt thereof or of a pharmaceuticalcomposition of the invention is administered to a patient.

Concerning the definition of vasopressin-related diseases, reference ismade to the above statements.

In a preferred embodiment of the invention, the method of the inventionserves for the treatment and/or prophylaxis of disorders selected fromdiabetes, insulin resistance, nocturnal enuresis, incontinence anddiseases in which impairments of blood clotting occur, and/or fordelaying micturition. Concerning the definition of diabetes, referenceis made to the above statements.

In a further preferred embodiment, the method of the invention servesfor the treatment and/or prophylaxis of disorders selected fromhypertension, pulmonary hypertension, heart failure, myocardialinfarction, coronary spasm, unstable angina, PTCA (percutaneoustransluminal coronary angioplasty), ischemias of the heart, impairmentsof the renal system, edemas, renal vasospasm, necrosis of the renalcortex, hyponatremia, hypokalemia, Schwartz-Bartter syndrome,impairments of the gastrointestinal tract, gastritic vasospasm,hepatocirrhosis, gastric and intestinal ulcers, emesis, emesis occurringduring chemotherapy, and travel sickness.

In a further preferred embodiment, the method of the invention servesfor the treatment and/or prophylaxis of affective disorders.

In a further preferred embodiment, the method of the invention servesfor the treatment and/or prophylaxis of anxiety disorders and/orstress-dependent anxiety disorders.

In a further preferred embodiment, the method of the invention servesfor the treatment and/or prophylaxis of memory impairments and/orAlzheimer's disease.

In a further preferred embodiment, the method of the invention servesfor the treatment and/or prophylaxis of psychoses and/or psychoticdisorders.

In a further preferred embodiment, the method of the invention servesfor the treatment and/or prophylaxis of Cushing's syndrome.

In a further preferred embodiment, the method of the invention servesfor the treatment and/or prophylaxis of sleep disorders in a patient.

In a further preferred embodiment, the method of the invention servesfor the treatment and/or prophylaxis of depressive disorders. In thecase of depressive disorders, specific mention is to be made of majordepression, seasonal depression, bipolar disorders, dysthymic disordersand childhood onset mood disorders, i.e. depressive moods having theironset in childhood, and especially of major depression and seasonaldepression as well as of the depressive phases of bipolar disorders. Themethod of the invention also serves for the treatment oftreatment-resistant depression disorders and as an add-on therapy ofdepressive disorders.

In a further preferred embodiment, the method of the invention servesfor the treatment and/or prophylaxis of vasomotor symptoms and/orthermoregulatory dysfunctions, such as, for example, the hot flushsymptom.

In a further preferred embodiment, the method of the invention servesfor the treatment and/or prophylaxis of drug or pharmaceuticaldependencies and/or dependencies mediated by other factors, for thetreatment of drug-use disorders, for the treatment and/or prophylaxis ofstress caused by withdrawal of one or more factors mediating thedependence, and/or for the treatment and/or prophylaxis ofstress-induced relapses into drug or pharmaceutical dependencies and/ordependencies mediated by other factors.

In a further preferred embodiment, the method of the invention servesfor the treatment and/or prophylaxis of schizophrenia and/or psychosis.

In a further preferred embodiment, the method of the invention servesfor the treatment and/or prophylaxis of pain, e.g. acute or chronicpain, preferably chronic pain, especially neuropathic pain.

The patient to be treated prophylactically or therapeutically with themethod of the invention is preferably a mammal, for example a human or anonhuman mammal or a nonhuman transgenic mammal. Specifically it is ahuman.

The compounds of the general formula I and their pharmaceuticallyacceptable salts as detailed above can be prepared by a skilled workerwith knowledge of the technical teaching of the invention inimplementing and/or in analogous implementation of process steps knownper se.

The compounds I and/or their pharmaceutically acceptable salts, N-oxidesand their stereoisomers are distinguished by having a selectivity forthe vasopressin V1b receptor subtype vis-à-vis at least one of theclosely related vasopressin/oxytocin receptor subtypes (for examplevasopressin V1a, vasopressin V2 and/or oxytocin).

Alternatively, or preferably in addition, the compounds I and/or theirpharmaceutically acceptable salts, N-oxides and a stereoisomers aredistinguished by having an improved metabolic stability.

The metabolic stability of a compound can be measured for example byincubating a solution of this compound with liver microsomes fromparticular species (for example rat, dog or human) and determining thehalf-life of the compound under these conditions (R S Obach, Curr OpinDrug Discov Devel. 2001, 4, 36-44). It is possible in this connection toconclude from an observed longer half-life that the metabolic stabilityof the compound is improved. The stability in the presence of humanliver microsomes is of particular interest because it makes it possibleto predict the metabolic degradation of the compound in the human liver.Compounds with increased metabolic stability (measured in the livermicrosome test) are therefore probably also degraded more slowly in theliver. The slower metabolic degradation in the liver may lead to higherand/or longer-lasting concentrations (active levels) of the compound inthe body, so that the elimination half-life of the compounds of theinvention is increased. Increased and/or longer-lasting active levelsmay lead to a better activity of the compound in the treatment orprophylaxis of various vasopressin-related diseases. In addition, animproved metabolic stability may lead to an increased bioavailabilityafter oral administration, because the compound is subject, afterabsorption in the intestine, to less metabolic degradation in the liver(so-called first pass effect). An increased oral bioavailability may,owing to an increased concentration (active level) of the compound, leadto a better activity of the compound after oral administration.

The compounds of the invention are effective after administration byvarious routes. Possible examples are intravenous, intramuscular,subcutaneous, topical, intratracheal, intranasal, transdermal, vaginal,rectal, sublingual, buccal or oral administration, and administration isfrequently intravenous, intramuscular or, in particular, oral.

The present invention also relates to pharmaceutical compositions whichcomprise an effective dose of a compound I of the invention and/or anN-oxide, a stereoisomer and/or a pharmaceutically acceptable saltthereof and suitable pharmaceutical carriers (drug carriers).

These drug carriers are chosen according to the pharmaceutical form andthe desired mode of administration and are known in principle to theskilled worker.

The compounds of the invention of the formula I, their N-oxides,stereoisomers or optionally suitable salts of these compounds can beused to produce pharmaceutical compositions for oral, sublingual,buccal, subcutaneous, intramuscular, intravenous, topical,intratracheal, intranasal, transdermal, vaginal or rectaladministration, and be administered to animals or humans in uniformadministration forms, mixed with conventional pharmaceutical carriers,for the prophylaxis or treatment of the above disorders or diseases.

The suitable administration forms (dose units) include forms for oraladministration such as tablets, gelatin capsules, powders, granules andsolutions or suspensions for oral intake, forms for sublingual, buccal,intratracheal or intranasal administration, aerosols, implants, forms ofsubcutaneous, intramuscular or intravenous administration and forms ofrectal administration.

The compounds of the invention can be used in creams, ointments orlotions for topical administration.

In order to achieve the desired prophylactic or therapeutic effect, thedose of the active ingredient can vary between 0.01 and 50 mg per kg ofbody weight and per day.

Each unit dose may comprise from 0.05 to 5000 mg, preferably 1 to 1000mg, of the active ingredient in combination with a pharmaceuticalcarrier. This unit dose can be administered once to 5 times a day, sothat a daily dose of from 0.5 to 25 000 mg, preferably 1 to 5000 mg, isadministered.

If a solid composition is prepared in the form of tablets, the activeingredient is mixed with a solid pharmaceutical carrier such as gelatin,starch, lactose, magnesium stearate, talc, silicon dioxide or the like.

The tablets can be coated with sucrose, a cellulose derivative oranother suitable substance or be treated otherwise in order to display asustained or delayed activity and to release a predetermined amount ofthe active ingredient continuously.

A preparation in the form of gelatin capsules is obtained by mixing theactive ingredient with an extender and including the resulting mixturein soft or hard gelatin capsules.

A preparation in the form of a syrup or elixir or for administration inthe form of drops may contain active ingredients together with asweetener, which is preferably calorie-free, methylparaben orpropylparaben as antiseptics, a flavoring and a suitable coloringsubstance.

Water-dispersible powders or granules may comprise the activeingredients mixed with dispersants, wetting agents or suspending agents,such as polyvinylpyrrolidones, and sweeteners or masking flavors.

Rectal or vaginal administration is achieved by using suppositorieswhich are prepared with binders which melt at rectal temperature, forexample cocoa butter or polyethylene glycols. Parenteral administrationis effected by using aqueous suspensions, isotonic saline solutions orsterile and injectable solutions which comprise pharmacologicallyacceptable dispersants and/or wetting agents, for example propyleneglycol or polyethylene glycol.

The active ingredient may also be formulated as microcapsules orcentrosomes, if suitable with one or more carriers or additives.

The compositions of the invention may, in addition to the compounds ofthe invention, comprise other active ingredients which may be beneficialfor the treatment of the disorders or diseases indicated above.

The present invention thus further relates to pharmaceuticalcompositions in which a plurality of active ingredients are presenttogether, where at least one of these is a compound I of the invention,or salt thereof.

The invention is explained in more detail below by means of examples,but the examples are not to be understood to be restrictive.

The compounds of the invention can be prepared by various syntheticroutes. The methods mentioned, as described accordingly in synthesisschemes 1, 2 and 3, are explained in greater detail merely by way ofexample using the given examples without being exclusively restricted tosynthesis route 1, 2 or 3 or analogous methods.

EXPERIMENTAL SECTION

Abbreviations Used:

Et₃N: Triethylamine

THF: Tetrahydrofuran

DMF: N,N-Dimethylformamide

DMSO: Dimethyl sulfoxide

TFA: Trifluoroacetic acid

RT room temperature

p: pseudo (for example pt pseudo triplet)

b: broad (for example bs broad singlet)

s: singlet

d: doublet

t: triplet

m: multiplet

dd: doublet of doublets

dt: doublet of triplets

tt: triplet of triplets

I. Preparation of the Starting Compounds

1.)(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide

To a solution of (S)-phenyl(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)carbamate(425 mg, 0,691 mmol) and azetidin-3-one hydrochloride (80 mg, 0,744mmol) in DMF (6 ml) Et3N (1 ml, 7.17 mmol) was added and the mixturestirred over night at room temperature. Subsequently 40 ml of water and10 ml NaHCO₃-solution were added and the mixture extracted twice withethyl acetate. The combined organic layers were washed 3× with brine,dried over MgSO₄, filtered off and evaporated to give 430 mg of a yellowsolid.

Flash chromatography (silica gel/gradient from 0 to 5% methanol indichloromethane) yielded 330 mg of the title compound as white solid.

ESI-MS [M+H⁺]=592.2

2.)(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide

To a solution of (S)-phenyl(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)carbamate(1 g, 1,665 mmol) and azetidin-3-one hydrochloride (220 mg, 2,046 mmol)in 10 ml of DMF Et₃N (1.5 ml, 10.76 mmol) was added and the mixturestirred over night at room temperature. 70 ml of water and 10 ml of 10%NaHCO₃-solution were added, the mixture extracted twice with ethylacetate, the combined organic layers washed twice with brine, dried overMgSO₄, filtered and concentrated to leave 1.3 g of the crude product asyellow oil. Flash chromatography (silica gel/gradient from 0 to 5%methanol in dichloromethane) yielded 610 mg of the title compound as anoff-white solid.

ESI-MS [M+H⁺]=578.1

3.)(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-oxopiperidin-1-yl)azetidine-1-carboxamide

To a solution of (S)-phenyl(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)carbamate(1.3 g, 2,009 mmol) and 1-(3-azetidinyl)-4-piperidinone (0.37 g, 2,399mmol) in DMF (9 ml) Et₃N (2 ml, 14.35 mmol) was added and the mixturestirred over night at room temperature. Water (80 ml) was added,stirring continued for 30 min, the precipitated solid filtered off,subsequently washed with water and n-pentane, and dried under vacuum togive 705 mg of a solid. The aqueous layers were re-extracted twice withethyl acetate, the combined organic layers washed with brine, dried overMgSO₄, filtered and evaporated to leave 360 mg of yellow oil. Flashchromatography (silica gel/gradient from 0 to 5% methanol indichloromethane) of the combined crude product yielded 500 mg of thetitle compound as white solid.

ESI-MS [M+H⁺]=675.2.

Following the procedures as described for intermediates 1 and 2 andusing the appropriate starting material were prepared:

4.)(S)—N-(1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-5,6-difluoro-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide

ESI-MS [M+H⁺]=603.1.

5.)(S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-6-fluoro-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide

ESI-MS [M+H⁺]=610.1.

6.)(S)—N-(5-chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide

ESI-MS [M+H⁺]=602.1.

7.)(S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-oxopiperidin-1-yl)azetidine-1-carboxamide

ESI-MS [M+H⁺]=661.2.

8.)(S)—N-(5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

a) To a solution of(S)-3-amino-3-(2-ethoxypyridin-3-yl)-2-oxoindoline-5-carbonitrile (9 g,30.6 mmol) in dichloromethane (150 ml) at 5° C. were added subsequentlypyridine (20 ml) and then dropwise phenyl chloroformate (4.5 ml, 35.8mmol), and stirring was continued for 1.5 hr. Dichloromethane (220 ml)and water (60 ml) were added, the mixture was stirred for 20 min, theorganic layer washed subsequently with water and brine, dried overMgSO₄, filtered and concentrated to give 18.7 g of a brown oil. Flashchromatography of the crude product (silica gel/gradient from 0 to 30%methanol in dichloromethane) yielded 12.1 g of the title compound asamorphous solid; ESI-MS [M+H⁺]=415.0.

b) To a solution of (S)-phenyl(5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)carbamate (2.6 g,5.65 mmol) and 4-(1-(azetidin-3-yl)piperidin-4-yl)morpholine×3TFA (3.3g, 5.82 mmol) in acetonitrile (80 ml) at 5° C. Et₃N (5.5 ml, 39.5 mmol)was added and then stirred over night at room temperature. The mixturethen was concentrated, treated with 100 ml of ice water, digested 3×with dichloromethane, the combined organic layers washed with brine,dried over MgSO₄, filtered and evaporated to give 3.0 g of a yellow oil.Flash chromatography of the crude product (silica gel/gradient from 0 to50% methanol in dichloromethane) yielded 1.2 g of the title compound asamorphous solid; ESI-MS [M+H+]=546.2.

9.)(S)—N—(C-cyano-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

Synthesis according to procedure as described for intermediate 8.

ESI-MS [M+H⁺]=532.2.

10.) (S)-Phenyl(5-Cyano-3-(2,5-dimethoxyphenyl)-1-((2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)carbamate

To a solution of(S)-3-amino-3-(2,5-dimethoxyphenyl)-2-oxoindoline-5-carbonitrile (425mg, 1,374 mmol) DMF (10 ml) at 5° C. first sodium hydride (60%: 77 mg,1,924 mmol) and after stirring for 20 min 2,4-dimethoxybenzenesulfonylchloride (358 mg, 1,511 mmol) was added, and stirring continued for 30min. Then 40 ml of water and 10 ml of 10% NaHCO₃-solution were added,extracted twice with ethyl acetate, the combined organic layers washedwith brine, dried over MgSO₄, filtered and evaporated to give 730 mg ofa yellow solid.

The crude product was dissolved in dichloromethane (20 ml), pyridine(0,834 ml, 10.32 mmol) and phenyl chloroformate (0,194 ml, 1,547 mmol)were added at 5° C. and stirred 1 for h at 5° C. The mixture was dilutedwith 120 ml of water, the organic layer washed 3× with water, dried overMgSO₄, filtered and evaporated to leave 966 mg of a yellow solid, whichwas treated with 50 ml of methyl-tert-butylether/diisopropylether 1:5 togive 630 mg of the title compound as white solid.

ESI-MS [M+H+]=630.0

11) N-Methyl-N-(oxetan-3-yl)piperidin-4-amine×2TFA

To a solution of 1-Boc-4-methylaminopiperidine (500 mg, 2,333 mmol) inTHF (10 ml) 3-oxetanone (235 mg, 3.27 mmol) was added and the mixturestirred over night at room temperature. Then subsequently sodiumcyanoborohydride (176 mg, 2.80 mmol) and acetic acid (0.27 ml, 4.72mmol) were added and stirring continued for 3 days at room temperature.The mixture was concentrated under vacuum, the obtained residue dilutedwith 20 ml of and 10 ml of 10% NaHCO₃-solution, extracted 2× withdichloromethane, the combined organic layers dried over MgSO₄, filteredoff and evaporated to leave 700 mg of the crude product. Flashchromatography (silica gel/gradient from 0 to 10% methanol indichloromethane) gave 230 mg of a clear oil, which was treated with TFA(2 ml, 26.0 mmol) for 1 hr. The mixture was concentrated, diluted with20 ml of methyl-tert-butylether, the precipitate filtered off, washedwith 10 ml of methyl-tert-butyl ether and dried to yield 340 mg of thetitle compound as white solid;

ESI-MS [M+H+]=171.2.

12) N-Ethyl-N-(oxetan-3-yl)piperidin-4-amine×2TFA

To a solution of 1-Boc-4-piperidinone (0.6 g, 3.01 mmol) andN-ethyloxetan-3-amine (0.38 g, 3.76 mmol) in methanol (5 ml) were addedzinc chloride (1,231 g, 9.03 mmol), and then after 10 min stirringsodium cyanoborohydride (0,473 g, 7.53 mmol), and the mixture stirredover night at room temperature. For work-up 2 ml of 10% NaHCO₃-solutionwere added, the mixture concentrated, diluted with 80 ml of water,extracted 3× with ethyl acetate, the combined organic layers washedtwice with brine, dried over MgSO₄, filtered and evaporated to give 730mg of a clear oil. The Boc-protected amine was treated with 2 ml of TFAfor 1 hr, concentrated, and the obtained residue digested with 20 mlmethyl-tert-butylether. Filtering off the precipitate, washing anddrying gave 690 mg of the title compound as white solid.

ESI-MS [M+H⁺]=185.2.

13) N-Cyclopropyl-N-(oxetan-3-yl)piperidin-4-amine×2TFA

To a solution of 1-tert-butoxycarbonyl-4-(cyclopropylamino)piperidine (2g, 8.32 mmol) and 3-oxetanone (0,840 g, 11.65 mmol) in methanol (25 ml)subsequently zinc chloride (2,155 g, 15.81 mmol)—and after stirring for10 min—sodium cyanoborohydride (0,994 g, 15.81 mmol) were added and themixture was stirred over night. 20 ml of a 10% NaHCO₃-solution wereadded to the reaction mixture and concentrated under vacuum. Afteraddition of 60 ml of water, 10 ml of 10% NaHCO₃-solution and 30 ml ofdichloromethane the formed solid was filtered off, washed with 10 ml ofwater and 10 ml of dichloromethane, the aqueous layer digested againwith dichloromethane, and the combined organic layers then washed withwater, dried over MgSO₄, filtered and evaporated to leave 2.29 g of ayellow oil. Hash chromatography (silica gel/gradient from 0 to 15%methanol in dichloromethane) yielded 1.57 g of a clear oil, which wasdissolved in dichloromethane (1 ml) and treated with TFA (4 ml) for 15min. The mixture was concentrated, 40 ml of methyl-tert-butylether addedand stirred for 2 hr. The precipitate was filtered off, washed and driedto give 1.9 g of the title compound as white solid.

ESI-MS [M+H⁺]=197.2

14) 1-(Azetidin-3-yl)-N-methyl-N-(oxetan-3-yl)piperidin-4-amine×3TFA

a. To a solution of 1-Boc-4-methylaminopiperidine (5.5 g, 25.7 mmol) and3-oxetanone (3 g, 41.6 mmol) in methanol (50 ml) and THF (40 ml)subsequently were added zinc chloride—and after stirring for 10min—sodium cyanoborohydride (2.3 g, 36.6 mmol), and the mixture stirredover night at room temperature. The mixture was concentrated, 30 ml of10% NaHCO₃-solution, 100 ml of water and 70 ml of dichloromethane added,filtered, and the aqueous layer digested with dichloromethane. Thecombined organic layers were washed with brine, dried over MgSO₄,filtered and evaporated to leave 6.78 g of a pale yellow oil. The crudeproduct was treated with TFA (15 ml) in dichloromethane (40 ml) at 5° C.over night, the mixture concentrated, diluted with 150 ml ofmethyl-tert-butylether, stirred for 2 hr, the precipitated solid wasfiltered off, washed again with 50 ml methyl-tert-butylether and driedto give 9.63 g of the amine 2TFA salt as white solid.

c. Reductive amination tert-butyl 3-oxoazetidine-1-carboxylate (3 g,17.52 mmol) with N-methyl-N-(oxetan-3-yl)piperidin-4-amine×2TFA (8 g,20.09 mmol) following the procedure as described for step a and followedby BOC-cleavage using TFA gave 19.5 g of a yellow oil, which was treatedwith 150 ml of methyl-tert-butylether for 2 hr, the precipitated solidfiltered off, washed and dried to give 8.5 g of the title compound aswhite solid.

ESI-MS [M+H+]=171.2

15) 4-(1-(Azetidin-3-yl)piperidin-4-yl)morpholine×3TFA

Reductive amination of 1-Boc-azetidinone (5 g, 29.2 mmol) and4-(piperidin-4-yl)-morpholine (5.97 g, 35.0 mmol) as described forintermediate 13 and subsequent cleavage of Boc yielded 12.1 g of thetitle compound as white solid.

ESI-MS [M+H+]=226.2

II. Preparation of the Compounds of the Formula I

Enantiomers of the compounds I were prepared by using enantiomericallypure starting compounds.

Example 1(S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom theyare bound to, form morpholin-4-yl)

(S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide(400 mg, 0,676 mmol) and 4-(piperidin-4-yl)-morpholine (400 mg, 2.35mmol) were stirred in THF (15 ml) over night at room temperature. Sodiumcyanoborohydride (70 mg, 1,114 mmol) and acetic acid (250 μl, 4.37 mmol)were added and the mixture was stirred for 2 hr. Subsequently 40 ml ofwater and 10 ml of a 10% NaHCO₃-solution were added, extracted twicewith ethyl acetate, the combined organic layers washed with brine, driedover MgSO₄, filtered off and evaporated to give 620 mg as white solid.Flash chromatography of the crude product (silica gel/gradient from 0 to10% methanol in dichloromethane) yielded 336 mg of the title compound aswhite solid.

ESI-MS [M+H⁺]=746.3

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.14 (dd, 1H), 7.88 (dd, 1H), 7.83 (m,3H), 7.66 (s, 1H), 7.55 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.65 (d,1H), 4.08 (q, 2H), 3.86 (s, 3H), 3.79 (m broad, 2H), 3.65-3.50 (m, 6H),3.46 (s, 3H), 2.95 (m, 1H), 2.71 (m, 2H), 2.39 (m, 4H), 2.08 (m, 1H),1.71 (4H), 1.34 (m, 2H), 0.95 (t, 3H).

Example 2(S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

To a solution of(S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide(250 mg, 0,423 mmol) and N-methyl-N-(oxetan-3-yl)piperidin-4-amineTFA-salt (200 mg, 0,502 mmol) in methanol (5 ml) zinc chloride (115 mg,0,844 mmol) was added and stirred for 10 min. Sodium cyanoborohydride(55 mg, 0,875 mmol) was added and the mixture stirred over night. Then 2ml of 10% NaHCO₃-solution were added, the mixture was concentrated undervacuum, 60 ml of water and 20 ml of dichloromethane were added, and thesolid was filtered off and washed with 10 ml of water and 10 ml ofdichloromethane. The aqueous layer was separated and extracted withdichloromethane, and the combined organic layers were washed with water,dried over MgSO₄, filtered and concentrated to give 350 mg of a clearoil. Flash chromatography of the crude product (silica gel/gradient from0 to 10% methanol in dichloromethane) afforded 123 mg of the titlecompound as white solid.

ESI-MS [M+H⁺]=746.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.14 (dd, 1H), 7.88 (dd, 1H), 7.83 (m,3H), 7.66 (s, 1H), 7.55 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d,1H), 4.46 (m, 4H), 4.07 (q, 2H), 3.85 (s, 3H), 3.78 (m broad, 3H), 3.55(m broad, 2H), 3.46 (s, 3H), 2.93 (m, 1H), 2.71 (m, 2H), 2.20 (m, 1H),2.08 (s, 3H), 1.67 (m, 2H), 1.51 (m, 2H), 1.36 (m, 2H), 0.95 (t, 3H).

Example 3(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom theyare bound to, form morpholin-4-yl)

To a solution of(S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide(80 mg, 0,139 mmol) and 4-(piperidin-4-yl)-morpholine (50 mg, 0,294mmol) in ethanol (5 ml) and THF (5 ml) titanium isopropoxide (2000,0,672 mmol) was added, the mixture then stirred over night at roomtemperature and then for 50 min. at 60° C. The mixture was then cooledto 25° C., sodium cyanoborohydride (25 mg, 0,398 mmol) was added andstirring continued for 30 min. For work-up 2 ml of water and 2 ml of 10%NaHCO₃-solution were added, the mixture concentrated under vacuum, theobtained residue di-diluted with 20 ml of water and 20 mldichloromethane, filtered over celite, washed with 20 ml ofdichloromethane, the organic layer separated and dried over MgSO₄, toleave 80 mg of a yellow solid. Flash chromatography of the crude product(silica gel/gradient from 0 to 10% methanol in dichloromethane) afforded17.7 mg of the title compound as white solid.

ESI-MS [M+H⁺]=732.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.15 (dd, 1H), 7.91 (d, 1H), 7.86 (d,1H), 7.80 (dd, 1H), 7.78 (dd, 1H), 7.70 (m, 1H), 7.64 (s broad, 1H),7.06 (dd, 1H), 6.72 (dd, 1H), 6.68 (dd, 1H), 3.87 (s, 3H), 3.70 (s, 3H),3.65-3.55 (m, 6H), 3.51 (s, 3H), 2.96 (m, 1H), 2.74 (m, 2H), 2.55-2.40(m, overlapped with DMSO), 2.1 (m, 1H), 1.75 (m, 4H), 1.37 (m, 2H).

Example 4(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

To a solution of(S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-oxoazetidine-1-carboxamide(225 mg, 0,390 mmol) and N-methyl-N-(oxetan-3-yl)piperidin-4-amineTFA-salt (220 mg, 0,552 mmol) in methanol (3 ml) and THF (6 ml) zincchloride (200 mg, 1,468 mmol) was added and the mixture stirred for 10min. The sodium cyanoborohydride (100 mg, 1,591 mmol) was added andstirring continued over night at room temperature. Then 6 ml of 10%NaHCO₃-solution were added, concentrated under vacuum, 50 ml of waterand 20 ml of ethyl acetate, the aqueous layer extracted again with ethylacetate, and the combined organic layers washed twice with brine, driedover MgSO₄, filtered and evaporated to leave 235 mg of a yellow solid.Flash chromatography of the crude product (silica gel/gradient from 0 to10% methanol in dichloromethane) afforded 108 mg of the title compoundas white solid.

ESI-MS [M+H⁺]=732.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.15 (dd, 1H), 7.90 (d, 1H), 7.82 (d,1H), 7.81 (dd, 1H), 7.79 (dd, 1H), 7.70 (m, 1H), 7.58 (s broad, 1H),7.06 (dd, 1H), 6.72 (dd, 1H), 6.68 (dd, 1H), 4.46 (m, 4H), 3.86 (s, 3H),3.80-3.70 (m broad, 3H), 3.65 (s, 3H), 3.60-3.52 (m broad, 2H), 3.50 (s,3H), 2.92 (m, 1H), 2.71 (d, 2H), 2.19 (m, 2H), 2.19 (m, 1H), 1.67 (m,2H), 1.51 (m, 2H), 1.36 (m, 2H).

The following compounds were obtained according to the proceduresdescribed for examples 1-4 using the appropriate starting materials.

Example 5(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(ethyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, R⁸ is ethyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=760.6.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.14 (dd, 1H), 7.88 (d, 1H), 7.86-7.80(m, 3H), 7.66 (s, 1H), 7.55 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66(d, 1H), 4.47 (dt, 4H), 4.15-3.99 (m, 3H), 3.86 (s, 1H), 3.77 (m broad,1H), 3.54 (m broad, 1H), 3.46 (s, 3H), 2.93 (m, 1H), 2.70 (t, 2H), 2.58(m, 2H), 2.37 (m, 1H), 1.68 (m, 2H), 1.51 (m, 2H), 1.29 (m, 2H), 0.94(dt, 6H).

Example 6(S)-3-(4-(2-Oxa-7-Azaspiro[3.5]nonan-7-yl)piperidin-1-yl)-N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom theyare bound to, form 2-oxa-7-aza-spiro[3.5]non-7-yl)

ESI-MS [M+H+]=786.30.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.13 (dd, 1H), 7.88 (d, 1H), 7.84-7.80(m, 3H), 7.66 (s, 1H), 7.54 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66(d, 1H), 4.24 (s, 4H), 4.09 (q, 2H), 3.86 (s, 3H), 3.80 and 3.62 (each mbroad, 2H), 3.46 (s, 3H), 2.93 (m, 1H), 2.71 (m, 2H), 2.40-2.30 (m, 4H),2.15 (m, 1H), 1.85-1.65 (m, 8H), 1.38 (m, 2H), 0.95 (t, 3H).

Example 7N-[(3S)-5-Cyano-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-ethoxy-3-pyridyl)-2-oxoindolin-3-yl]-3-[4-[cyclopropyl(oxetan-3-yl)amino]-1-piperidyl]azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, R⁸ is cyclopropyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=772.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.14 (dd, 1H), 7.89 (d, 1H), 7.83 (dd,3H), 7.66 (s, 1H), 7.55 (s, 1H), 7.05 (dd, 1H), 6.71 (dd, 1H), 6.66 (d,1H), 4.67 (m, 2H), 4.43 (m, 2H), 4.18 (m, 1H), 4.09 (q, 2H), 3.86 (s,3H), 3.73 (m broad, 2H), 3.60 (m broad, 2H), 3.46 (s, 3H), 2.93 (m, 1H),2.72 (t, 2H), 2.48 (m, overlapped with DMSO), 1.94 (m, 1H), 1.67 (m,2H), 1.56 (m, 2H), 1.45 (m, 2H), 0.95 (t, 3H), 0.50 (m, 2H), 0.30 (m,2H).

Example 8(S)—N-(1-((2,4-Dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-5,6-difluoro-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is F, R⁷ is F, and R⁸ and R⁹, together with the nitrogen atom theyare bound to, form morpholin-4-yl)

ESI-MS [M+H+]=757.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.13 (dd, 1H), 7.89 (d, 1H), 7.74 (dd,1H), 7.62 (dd, 1H), 7.48 (s, 1H), 7.34 (m, 1H), 7.02 (dd, 1H), 6.70 (dd,1H), 6.67 (d, 1H), 4.11 (q, 2H), 3.86 (s, 3H), 3.80-3.70 (m broad, 2H),3.67-3.52 (m, 6H), 3.50 (s, 3H), 2.94 (m, 1H), 2.70 (m, 2H), 2.42 (m,4H), 2.08 (m, 1H), 1.71 (m, 4H), 1.35 (m, 2H), 1.01 (t, 3H).

Example 9

(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-6-fluoro-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is F, and R⁸ and R⁹, together with the nitrogen atom theyare bound to, form morpholin-4-yl)

ESI-MS [M+H+]=764.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.15 (dd, 1H), 7.89 (s, 1H), 7.88 (s,1H), 7.71 (d, 1H), 7.68 (d, 1H), 7.56 (s, 1H), 7.07 (dd, 1H), 6.71 (dd,1H), 6.67 (d, 1H), 4.10 (q, 2H), 3.86 (s, 3H), 3.84-3.70 (m broad, 2H),3.68-3.53 (m, 6H), 3.52 (s, 3H), 2.94 (m, 1H), 2.71 (m, 2H), 2.42 (m,4H), 2.08 (m, 1H), 1.72 (m, 4H), 1.34 (m, 2H), 0.99 (t, 3H).

Example 10(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-6-fluoro-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is F, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=764.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.15 (dd, 1H), 7.88 (m, 1H), 7.69 (dd,1H), 7.56 (s, 1H), 7.07 (dd, 1H), 6.71 (dd, 1H), 6.67 (d, 1H), 4.53-4.38(m, 4H), 4.09 (q, 2H), 3.84 (m broad, 2H), 3.58 (m broad, 2H), 3.51 (s,3H), 2.93 (m, 1H), 2.71 (m, 2H), 2.19 (m, 1H), 1.67 (m, 2H), 1.51 (m,2H), 1.36 (m, 2H), 0.99 (t, 3H).

Example 11N-[(3S)-1-[(2,4-Dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-5,6-difluoro-2-oxo-2,3-dihydro-1H-indol-3-yl]-3-{4-[methyl(oxetan-3-yl)amino]piperidin-1-yl}azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is F, R⁷ is F, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=757.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.13 (dd, 1H), 7.89 (d, 1H), 7.73 (dd,1H), 7.62 (dd, 1H), 7.48 (s, 1H), 7.34 (m, 1H), 7.02 (dd, 1H), 6.71 (dd1H), 6.67 (d, 1H), 4.46 (m, 4H), 4.10 (q, 2H), 3.85 (s, 3H), 3.75 (mbroad, 3H), 3.55 (m broad, 2H), 3.50 (s, 3H), 2.93 (m, 1H), 2.71 (m,2H), 2.19 (m, 1H), 2.11 (s, 3H), 1.67 (m, 2H), 1.51 (m, 2H), 1.36 (m,2H), 1.01 (t, 3H).

Example 12(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(cyclopropyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, R⁸ is cyclopropyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=758.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.15 (dd, 1H), 7.90 (d, 1H), 7.86 (d,1H), 7.81 (m, 2H), 7.70 (d, 1H), 7.59 (s, 1H), 7.06 (dd, 1H), 6.72 (dd,1H), 6.68 (d, 1H), 4.67 (m 2H), 4.43 (m 2H), 4.18 (1H), 3.87 s, 3H),3.77 (m broad, 2H), 3.65 (s, 3H), 3.58 (m broad, 2H), 3.52 (s, 3H), 2.94(m, 1H), 2.71 (m, 2H), 2.61 (m, 2H), 2.39 (m, 1H), 1.68 (m, 2H), 1.52(m, 2H), 1.29 (m, 2H), 0.93 (t, 3H).

Example 13(S)—N-(5-Chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is Cl, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom theyare bound to, form morpholin-4-yl)

ESI-MS [M+H+]=756.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.12 (dd, 1H), 7.88 (d, 1H), 7.69 (dd,1H), 7.66 (d, 1H), 7.49 (s, 1H), 7.38 (dd, 1H), 7.33 (d, 1H), 7.01 (dd,1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.11 (q, 2H), 3.86 (s, 3H), 3.79 (mbroad, 2H), 3.68-3.50 (m, 6H), 3.47 (s, 3H), 2.95 (m, 1H), 2.73 (m, 2H),2.09 (m, 1H), 1.72 (m, 4H), 1.35 (m, 2H), 1.0 (t, 3H).

Example 14(S)—N-(5-Chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is Cl, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=756.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.12 (dd, 1H), 7.88 (d, 1H), 7.69 (d,1H), 7.66 (d, 1H), 7.49 (s, 1H), 7.38 (dd, 1H), 7.33 (d, 1H), 7.01 (dd,1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.45 (m, 4H), 4.11 (q, 2H), 3.88 (s,3H), 3.80 (m broad, 2H), 3.57 (m broad, 3H), 3.46 (s, 3H), 2.92 (m, 1H),2.71 (m, 2H), 2.20 (m, 1H), 2.08 (s, 3H), 1.67 (m, 2H), 1.51 (m, 2H),1.36 (m, 2H), 1.00 (t, 3H).

Example 15(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-((2-methoxyethyl)(methyl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, R⁸ is methyl and R⁹ is 2-methoxyethyl)

To a solution of(S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-oxopiperidin-1-yl)azetidine-1-carboxamide(60 mg, 0,089 mmol) and N-(2-methoxyethyl)methylamine (10 mg, 0,112mmol) in a 1:1 mixture of methanol and THF (3 ml) first zinc chloride(20 mg, 0,147 mmol), and after stirring for 10 min, sodiumcyanoborohydride (15 mg, 0,239 mmol) was added and stirring continuedover night. For work-up 5 ml of 10% NaHCO3-solution were added, themixture concentrated, diluted with 50 ml of water and 20 ml of ethylacetate, separated and the aqueous layer re-extracted with ethylacetate. The combined organic layers then were washed with brine, driedover MgSO4, filtered and evaporated to leave 70 mg of a white solid.Flash chromatography of the crude product (silica gel/gradient from 0 to10% methanol in dichloromethane) yielded 45 mg of the title compound aswhite solid.

ESI-MS [M+H+]=748.3.

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.14 (dd, 1H), 7.88 (d, 1H), 7.83 (m,3H), 7.66 (s, 1H), 7.55 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d,1H), 4.09 (q, 2H), 3.86 (s, 3H), 3.77 (m broad, 2H), 3.58 (m broad, 2H),3.46 (s, 3H), 3.22 (s, 3H), 2.94 (m, 1H), 2.72 (m, 2H), 2.52 (moverlapped with DMSO), 2.28 (m, 1H), 2.17 (s, 3H), 1.70 (m, 2H), 1.63(m, 2H), 1.38 (m, 2H), 0.95 (t, 3H).

Example 16(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methoxy(methyl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is methoxy)

ESI-MS [M+H+]=720.3

Example 17(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(isoxazolidin-2-yl)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom theyare bound to, form isoxazolidin-2-yl)

ESI-MS [M+H+]=732.3

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.14 (dd, 1H), 7.89 (d, 1H), 7.83 (m,3H), 7.67 (s, 1H), 7.54 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d,1H), 4.09 (q, 2H), 3.86 (s, 3H), 3.76 (m, 3H), 3.62 (m, 3H), 3.47 (s,3H), 3.03 (m, 1H), 2.96 (m, 1H), 2.65 (m, 2H), 2.55 (m, 1H), 2.36 (m,1H), 2.13 (m, 2H), 2.13 (m, 1H), 1.92 (m, 1H), 1.77 (m, 2H), 1.64 (m,1H), 1.35 (m, 2H), 0.94 (t, 3H).

Example 18(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(3-(oxetan-3-yl)azetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom theyare bound to, form 3-(oxetan-3-yl)-azetidin-1-yl)

ESI-MS [M+H+]=772.3

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.13 (dd, 1H), 7.88 (d, 1H), 7.84 (m,3H), 7.66 (s, 1H), 7.54 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d,1H), 4.63 (dd, 2H), 4.27 (dd, 2H), 4.09 (q, 2H), 3.86 (s, 3H), 3.72 (mbroad, 2H), 3.53 (m broad, 2H), 3.46 (s, 3H), 3.22 (m, 2H), 3.11 (m,1H), 2.95 (m, 1H), 2.76 (m, 2H), 2.62 (m, 1H), 2.53 (m overlapped withDMSO), 1.96 (m, 1H), 1.79 (m, 2H), 1.57 (m, 2H), 1.10 (m, 2H), 0.95 (t,3H).

Example 19(S)-3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-yl)piperidin-1-yl)-N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom theyare bound to, form 2-oxa-6-aza-spiro[3.3]hept-6-yl)

ESI-MS [M+H+]=758.3

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.13 (dd, 1H), 7.88 (d, 1H), 7.83 (m,3H), 7.66 (s, 1H), 7.53 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.65 (d,1H), 4.57 (s, 4H), 4.08 (q, 2H), 3.85 (s, 3H), 3.78 (m broad, 2H), 3.58(m broad, 2H), 3.46 (s, 3H), 3.19 (s, 3H), 2.94 (m, 1H), 2.54(overlapped with DMSO), 1.86 (m, 1H), 1.75 (m, 2H), 1.54 (m, 2H), 1.09(m, 2H), 0.94 (t, 3H).

Example 20(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(oxetan-3-ylamino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, R⁸ is hydrogen, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=718.3

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.15 (dd, 1H), 7.91 (d, 1H), 7.86 (d,1H), 7.82 (d, 1H), 7.80 (dd, 1H), 7.70 (d, 1H), 7.57 (s, 1H), 7.06 (dd,1H), 6.71 (dd, 1H), 6.68 (d, 1H), 4.60 (m, 2H), 4.28 (m, 2H), 3.91 (m,1H), 3.85 (s, 3H), 3.75 (m broad, 2H), 3.65 (s, 3H), 3.59 (m broad, 3H),3.53 (s, 3H), 2.93 (m, 1H), 2.61 (m, 2H), 2.30 (m, 1H), 1.72 (m, 2H),1.60 (m, 2H), 1.17 (m, 2H).

Example 21(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(tetrahydro-2H-pyran-4-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is tetrahydropyran-4-yl)

ESI-MS [M+H+]=760.3

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.15 (dd, 1H), 7.91 (d, 1H), 7.86 (d,1H), 7.82 (d, 1H), 7.80 (m, 2H), 7.70 (d, 1H), 7.58 (s, 1H), 7.06 (dd,1H), 6.72 (dd, 1H), 6.68 (d, 1H), 3.85 (s, 3H), 3.80 (m, 3H), 3.75 (m,2H), 3.65 (s, 3H), 3.60 (m, 2H), 3.51 (s, 3H), 3.27 (m, 2H), 2.93 (m,1H), 2.74-2.64 (m, 3H), 1.72 (m, 2H), 1.58 (m, 4H), 1.43 (m, 4H).

Example 22(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(oxetan-3-yl(propyl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, R⁸ is propyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=760.3

¹H-NMR (600 MHz DMSO), δ [ppm]: 8.13 (dd, 1H), 7.89 (d, 1H), 7.73 (dd,1H), 7.62 (dd, 1H), 7.48 (s, 1H), 7.34 (m, 1H), 7.02 (dd, 1H), 6.70 (dd,1H), 6.67 (d, 1H), 4.46 (m, 4H), 4.11 (q, 2H), 3.86 (s, 3H), 3.78 (mbroad, 2H), 3.57 (m broad, 2H), 3.50 (s, 3H), 2.93 (m, 1H), 2.71 (m,2H), 2.54 (m, overlapped with DMSO), 2.19 (m, 1H), 2.08 (s, 3H), 1.67(m, 2H), 1.51 (m, 2H), 1.36 (m, 2H), 1.01 (t, 3H).

Example 23(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(ethyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, R⁸ is ethyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=746.3

¹H NMR (600 MHz, DMSO) δ 8.15 (dd, 1H), 7.90 (d, 1H), 7.86 (d, 1H), 7.80(m, 2H), 7.69 (d, 1H), 7.58 (s, 1H), 7.06 (dd, 1H), 6.72 (dd, 1H), 6.68(d, 1H), 4.47 (dt, 4H), 4.04 (m, 1H), 3.87 (s, 3H), 3.85 (m broad, 2H),3.65 (m, 3H), 3.56 (m broad, 2H), 3.53 (s, 3H), 2.94 (m, 1H), 2.71 (m,2H), 2.60 (m, 2H), 2.39 (m, 1H), 1.68 (m, 2H), 1.52 (m, 2H), 1.29 (m,2H), 0.93 (t, 3H).

Example 24(S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is5-F (relative to the 2- and 4-positions of R¹ and R²), R⁶ is CN, R⁷ isH, and R⁸ and R⁹, together with the nitrogen atom they are bound to,form morpholin-4-yl)

a. To a solution of(S)-3-amino-3-(2-ethoxypyridin-3-yl)-2-oxoindoline-5-carbonitrile (1.0g, 3.40 mmol) in DMF (12 ml) at 5° C. sodium hydride (55%: 0.22 g, 5.04mmol) was added. After stirring for 20 min5-fluoro-2,4-dimethoxybenzene-1-sulfonyl chloride (1.0 g, 3.93 mmol) wasadded and stirring continued for 1 hr at 5° C. After completion of thereaction 30 ml of water were added dropwise, the mixture digested 3×with dichloromethane, the combined organic layers washed with brine,dried over MgSO₄, filtered and concentrated to leave a brown oil, whichwas purified by flash chromatography (silica gel/gradient from 0 to 15%methanol in dichloromethane) to yield 1.5 g; ESI-MS [M+H+]=513.2.

b. To a solution of(S)-3-amino-3-(2-ethoxypyridin-3-yl)-1-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-2-oxoindoline-5-carbonitrile(1.5 g, 2.63 mmol) in dichloromethane (50 ml) at 5° C. were addeddropwise pyridine (2.3 ml, 28.4 mmol) and phenylchloroformate (0.8 ml,6.37 mmol), and the mixture stirred over night at room temperature. Themixture was diluted with dichloromethane, digested twice with water, theorganic layer washed subsequently with 10% NaHCO3-solution and brine,dried over MgSO4, filtered and concentrated to give 2.1 g of a yellowoil, which was further purified by flash chromatography (silicagel/gradient from 0 to 15% methanol in dichloromethane) to give 0.7 g ofa yellow amorphous solid; ESI-MS [M+H+]=633.9.

c. To a solution of (S)-phenyl(5-cyano-3-(2-ethoxypyridin-3-yl)-1-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)carbamate(80 mg, 0,126 mmol) and4-(1-(azetidin-3-yl)piperidin-4-yl)morpholine×3TFA (70 mg, 0,123 mmol)in DMF (3 ml) at 5° C. Et3N (120 μl, 0,861 mmol) was added and thenstirred for 4 h at room temperature. The mixture was concentrated,diluted with dichloromethane, washed with water and brine, dried overMgSO₄, filtered and evaporated to leave 210 mg of a brown oil. Flashchromatography (silica gel/gradient from 0 to 20% methanol indichloromethane) yielded 52 mg of the title compound as white solid.

ESI-MS [M+H+]=764.3.

¹H NMR (600 MHz, DMSO) δ 8.13 (dd, 1H), 7.89 (d, 1H), 7.74 (dd, 1H),7.62 (dd, 1H), 7.48 (s, 1H), 7.34 (m, 1H), 7.02 (dd, 1H), 6.70 (dd, 1H),6.67 (d, 1H), 4.11 (q, 2H), 3.86 (s, 3H), 3.75 (m broad, 2H), 3.70-3.55(m, 6H), 3.50 (s, 3H), 2.94 (m, 1H), 2.71 (m, 2H), 2.42 (m, 4H), 2.08(m, 1H), 1.71 (m, 4H), 1.34 (m, 2H), 1.01 (t, 3H).

Example 25(S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-((4-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is H, R² is methoxy, R³ is H, R⁶ isCN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they arebound to, form morpholin-4-yl)

Prepared according to the procedure described for EXAMPLE 25:

ESI-MS [M+H+]=716.3.

Example 26(S)—N-(5-Cyano-1-((2,4-difluorophenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I. 1, wherein R¹ is F, R² is F, R³ is H, R⁶ is CN,R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they are boundto, form morpholin-4-yl)

To a solution of(S)—N-(5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide(200 mg, 0,367 mmol) in THF (3 ml) at 5° C. potassium tert-butoxide (60mg, 0,535 mmol) and after 30 min 2,4-diflurobenzenesulfonylchloride (90mg, 0,423 mmol) were added, and the mixture stirred over night at roomtemperature. The mixture was diluted with 20 ml of water, digested 3×with dichloromethane, and the combined organic layers washed with brine,dried over MgSO4, filtered and concentrated to give 300 mg of a clearoil. Flash chromatography (silica gel/gradient from 0 to 20% methanol indichloromethane) yielded 115 mg of the title compound as white solid.

ESI-MS [M+H+]=716.3.

¹H NMR (600 MHz, DMSO) δ 8.30 (dd, 1H), 8.10 (m, 2H), 7.88 (m, 2H), 7.57(s, 2H), 7.50 (m, 1H), 7.34 (m, 1H), 7.12 (dd, 1H), 4.09 (q, 2H),3.80-3.50 (m, 7H), 2.93 (m, 1H), 2.71 (m, 2H), 2.39 (m, 4H), 2.08 (m,1H), 1.71 (m, 4H), 1.4 (m, 2H), 0.98 (t, 3H).

The following compounds were prepared according to the procedure asdescribed for EXAMPLE 27

Example 27(S)—N-(5-cyano-3-(2-ethoxypyridin-3-yl)-1-((2-fluoro-4-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is F, R² is methoxy, R³ is H, R⁶ isCN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they arebound to, form morpholin-4-yl)

ESI-MS [M+H+]=734.3.

¹H NMR (600 MHz, DMSO) δ 8.14 (dd, 1H), 8.01 (dd, 1H), 7.94 (t, 1H),7.85 (m, 2H), 7.61 (s, 1H), 7.58 (s, 1H), 7.10 (dd, 1H), 7.05 (dd, 1H),6.98 (dd, 1H), 4.05 (m, 2H), 3.86 (s, 3H), 3.75 (m broad, 2H), 3.60-3.50(m, 5H), 2.93 (m, 1H), 2.71 (m, 2H), 2.39 (m, 4H), 2.09 (m, 1H), 1.72(m, 4H), 1.35 (m, 2H), 0.93 (t, 3H).

Example 28(S)—N-(5-cyano-3-(2-ethoxypyridin-3-yl)-1-((4-fluoro-2-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is F, R³ is H, R⁶ isCN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they arebound to, form morpholin-4-yl)

ESI-MS [M+H+]=734.3.

1H NMR (600 MHz, DMSO) δ 8.14 (dd, 1H), 8.01 (dd, 1H), 7.94 (dd, 1H),7.86 (m, 2H), 7.64 (s, 1H), 7.56 (s, 1H), 7.15 (dd, 1H), 7.09 (dd, 1H),6.98 (td, 1H), 4.10 (m, 2H), 3.74 (m broad, 2H), 3.62-3.50 (m, 6H), 3.49(s, 3H), 2.94 (m, 1H), 2.71 (m, 2H), 2.39 (m, 4H), 2.08 (m, 1H), 1.71(m, 4H), 1.34 (m, 2H), 0.98 (t, 3H).

Example 29(S)—N-(5-Cyano-1-((2-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is H, R³ is H, R⁶ isCN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=702.2.

¹H NMR (600 MHz, DMSO) δ 8.13 (dd, 1H), 7.98 (d, 1H), 7.87 (d, 1H), 7.82(m, 2H), 7.71 (m, 2H), 7.69 (s, 1H), 7.24 (d, 1H), 7.16 (m, 1H), 7.06(m, 1H), 4.44 (m, 4H), 3.84 (q, 2H), 3.75 (m broad, 2H), 3.63 (s, 3H),3.54 (s, 3H, overlapped with m broad, 2H), 2.92 (m, 1H), 2.69 (m, 2H),2.19 (m, 1H), 1.66 (m, 2H), 1.49 (m, 2H), 1.37 (m, 2H).

Example 30(S)—N-(5-Cyano-1-((4-fluoro-2-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is F, R³ is H, R⁶ isCN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=720.2.

¹H NMR (600 MHz, DMSO) δ 8.16 (dd, 1H), 8.04 (dd, 1H), 7.91 (dd, 1H),7.87 (d, 1H), 7.83 (dd, 1H), 7.69 (d, 1H), 7.60 (s, 3H), 7.17 (dd, 1H),7.10 (dd, 1H), 7.00 (td, 1H), 4.45 (m, 4H), 3.83-3.50 (m broad, 5H)overlapped with 3.65 (s, 3H), 2.92 (m, 1H), 2.71 (m, 2H), 2.19 (m, 1H),1.66 (m, 2H), 1.50 (m, 2H), 1.36 (m, 2H).

Example 31(S)—N-(5-Cyano-1-((4-fluorophenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is H, R² is F, R³ is H, R⁶ is CN,R⁷ is H, R⁸ is methyl and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=690.2.

¹H NMR (600 MHz, DMSO) δ 8.16 (m, 3H), 8.05 (dd, 1H), 7.88 (d, 1H), 7.83(dd, 1H), 7.65 (d, 2H), 7.53 (m, 2H), 7.13 (dd, 1H), 4.45 (m, 4H),3.92-3.47 (m, 5H), 3.42 (s, 3H), 2.93 (m, 1H), 2.72 (m, 2H), 2.20 (m,1H), 2.06 (s, 3H), 1.67 (m, 2H), 1.51 (m, 2H), 1.36 (m, 2H).

Example 32(S)—N-(5-Cyano-1-((2-fluoro-4-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is F, R² is methoxy, R³ is H, R⁶ isCN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=720.3.

¹H NMR (600 MHz, DMSO) δ 8.16 (dd, 1H), 8.0 (m, 1H), 7.98 (m, 1H), 7.85(m, 2H), 7.67 (s, 1H), 7.62 (s, 1H), 7.11 (m 2H), 7.0 (dd, 1H), 4.46 (m,4H), 3.87 (s, 3H), 3.79-3.60 (m, 5H), 3.57 (s, 3H), 2.92 (m, 1H), 2.71(m, 2H), 2.20 (m, 1H), 2.10 (s, 3H), 1.67 (m, 2H), 1.51 (m, 2H), 1.36(m, 2H).

Example 33(S)—N-(5-Cyano-1-((2,4-difluorophenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is F, R² is F, R³ is H, R⁶ is CN,R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=708.2.

¹H NMR (600 MHz, DMSO) δ 8.17 (dd, 1H), 8.14 (m, 1H), 8.06 (dd, 1H),7.86 (m, 2H), 7.68 (s, 1H), 7.65 (s, 1H), 7.60 (m, 1H), 7.37 (m, 1H),7.14 (dd, 1H), 4.46 (m, 4H), 3.90-3.55 (m, 5H), overlapped with 3.60 (s,3H), 2.932 (m, 1H), 2.70 (m, 2H), 2.19 (m, 1H), 2.19 (s, 3H), 1.67 (m,2H), 1.51 (m, 2H), 1.35 (m, 2H).

Example 34(S)—N-(5-Cyano-1-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is5-F (relative to the 2- and 4-positions of R¹ and R²), R⁶ is CN, R⁷ isH, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=750.3.

¹H NMR (600 MHz, DMSO) δ 8.16 (dd, 1H), 7.87 (m, 2H), 7.82 (dd, 1H),7.75 (dd, 1H), 7.70 (d, 1H), 7.62 (s, 1H), 7.09 (dd, 1H), 6.92 (d, 1H),4.46 (m, 4H), 3.96 (s, 3H), 3.85 (m broad, 2H), 3.66 and 3.58 (each s,3H) overlapped with 3.70-3.50 (m, 3H), 2.93 (m, 1H), 2.71 (m, 2H), 2.20(m, 1H), 2.15 (s, 3H), 1.67 (m, 2H), 1.51 (m, 2H), 1.36 (m, 2H).

Example 35(S)—N-(5-cyano-1-((4-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is H, R² is methoxy, R³ is H, R⁶ isCN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=702.3.

¹H NMR (600 MHz, DMSO) δ 8.14 (dd, 1H), 8.00 (dd, 1H), 7.85 (d, 1H),7.82 (dd, 1H), 7.63 (m, 2H), 7.18 (m, 2H), 7.10 (dd, 1H), 4.45 (m, 4H),3.86 (s, 3H), 3.75-3.65 (m, 3H), 3.59 (m broad, 2H), 2.93 (m, 1H), 2.72(m, 2H), 2.20 (m, 1H), 2.09 (s, 3H), 1.68 (m, 2H), 1.52 (m, 2H), 1.37(m, 2H).

Example 36(S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-((5-methoxypyridin-2-yl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide×TFA

(compound of formula I.21, wherein R² is methoxy, R³ is H, R⁶ is CN, R⁷is H, and R⁸ and R⁹, together with the nitrogen atom they are bound to,form morpholin-4-yl)

ESI-MS [M+H+]=717.3.

Example 37(S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-((2-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is H, R³ is H, R⁶ isCN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom they arebound to, form morpholin-4-yl)

ESI-MS [M+H+]=716.3

¹H NMR (600 MHz, DMSO) δ 8.14 (dd, 1H), 7.97 (dd, 1H), 7.85 (m, 3H),7.71 (m, 1H), 7.67 (s, 1H), 7.56 (s, 1H), 7.20 (d, 1H), 7.14 (m, 1H),7.06 (dd, 1H), 4.08 (q, 2H), 3.81 (m broad, 2H), 3.75-3.50 (m, 5H), 3.49(s, 1H), 2.93 (m, 1H), 2.70 (m, 2H), 2.40 (m, 4H), 2.08 (m, 1H), 1.71(m, 4H), 1.34 (m, 2H), 0.94 (t, 3H).

Example 38(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(isopropyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.6, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, R⁸ is isopropyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=760.3

¹H NMR (600 MHz, DMSO) δ 8.15 (dd, 1H), 7.91 (d, 1H), 7.86 (d, 1H), 7.81(m, 2H), 7.69 (d, 1H), 7.58 (s, 1H), 7.06 (dd, 1H), 6.72 (dd, 1H), 6.68(d, 1H), 4.47 (m, 4H), 4.23 (m, 1H), 3.87 (s, 4H), 3.75 (m broad, 2H),3.65 (s, 3H), 3.58 (m broad, 2H) 3.53 (s, 3H), 3.03 (m, 1H), 2.93 (m,1H), 2.71 (m, 2H), 2.59 (m, 1H), 1.74 (m, 2H), 1.42 (m, 4H), 0.94 (d,3H), 0.93 (d, 3H).

Example 39(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(3,3-difluoroazetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom theyare bound to, form 3,3-difluoroazetidin-1-yl)

ESI-MS [M+H+]=752.3

¹H NMR (600 MHz, DMSO) δ 8.13 (dd, 1H), 7.88 (d, 1H), 7.86-7.80 (m, 3H),7.66 (s, 1H), 7.54 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H),4.09 (q, 2H), 3.86 (s, 4H), 3.78 (m broad, 2H), 3.66-3.53 (m, 6H), 3.52(s, 3H), 2.98 (m, 1H), 2.57 (m, 2H), 2.16 (d, 1H), 1.83 (d, 2H), 1.62(d, 2H), 1.19 (m, 2H), 0.95 (t, 3H).

Example 40(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4,4-difluoro-[1,4′-bipiperidin]-1′-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom theyare bound to, form 4,4-difluoropiperidin-1-yl)

ESI-MS [M+H+]=780.3

¹H NMR (600 MHz, DMSO) δ 8.14 (dd, 1H), 7.88 (d, 1H), 7.83 (m, 3H), 7.66(s, 1H), 7.55 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.09(q, 2H), 3.86 (s, 3H), 3.73 (m broad, 2H), 3.58 (m broad, 2H), 3.46 (s,3H), 2.95 (m, 1H), 2.73 (m, 2H), 2.55 (m, 4H), 2.32 (m, 1H), 1.90 (m,4H), 1.68 (m, 4H), 1.42 (m, 2H), 0.95 (t, 3H).

Example 41(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(3-methoxyazetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom theyare bound to, form 3-methoxyazetidin-1-yl)

ESI-MS [M+H+]=746.3

¹H NMR (600 MHz, DMSO) δ 8.13 (dd, 1H), 7.88 (d, 1H), 7.83 (m, 3H), 7.66(s, 1H), 7.54 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.07(q, 2H), 3.89 (m, 1H), 3.86 (s, 3H), 3.76 (m broad, 2H), 3.58 (m broad,2H), 3.46 (s, 3H), 3.42 (m, 2H), 3.13 (s, 3H), 2.95 (m, 1H), 2.69 (m,2H), 2.51 (m, overlapped with DMSO, 2H), 1.94 (m, 1H), 1.79 (m, 2H),1.59 (d, 2H), 1.14 (m, 2H), 0.95 (t, 3H).

Example 42(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-methoxy-[1,4′-bipiperidin]-1′-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom theyare bound to, form 4-methoxypiperidin-1-yl)

ESI-MS [M+H+]=774.3

¹H NMR (600 MHz, DMSO) δ 8.14 (dd, 1H), 7.88 (d, 1H), 7.83 (m, 3H), 7.66(s, 1H), 7.54 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.09(q, 2H), 3.86 (s, 3H), 3.76 (m broad, 2H), 3.58 (m broad, 2H), 3.46 (s,3H), 3.20 (s, 3H), 3.10 (m, 1H), 2.93 (m, 1H), 2.70 (m, 4H), 2.17 (m,3H), 1.80 (m, 2H), 1.68 (m, 4H), 1.37 (m, 4H), 0.95 (t, 3H).

Example 43(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(3-hydroxyazetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom theyare bound to, form 3-hydroxyazetidin-1-yl)

ESI-MS [M+H+]=732.3

¹H NMR (600 MHz, DMSO) δ 8.13 (dd, 1H), 7.87 (d, J=11.1 Hz, 1H), 7.83(m, 3H), 7.66 (s, 1H), 7.53 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66(d, 1H), 5.23 (d, 1H), 4.09 (q, 2H), 3.86 (s, 3H), 3.76 (m broad, 2H),3.58 (m broad, 2H), 3.45 (s, 3H), 3.41 (m, 3H), 2.95 (m, 1H), 2.60 (m,2H), 2.52 (m overlapped with DMSO), 1.91 (m, 1H), 1.78 (s, 2H), 1.58 (m,2H), 1.11 (m, 2H), 0.95 (t, 3H).

Example 44(S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-hydroxy-[1,4′-bipiperidin]-1′-yl)azetidine-1-carboxamide

(compound of formula I.1, wherein R¹ is methoxy, R² is methoxy, R³ is H,R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atom theyare bound to, form 4-hydroxypiperidin-1-yl)

ESI-MS [M+H+]=760.3

¹H NMR (600 MHz, DMSO) δ 8.13 (dd, 1H), 7.88 (d, 1H), 7.83 (m, 3H), 7.66(s, 1H), 7.54 (s, 1H), 7.05 (dd, 1H), 6.70 (dd, 1H), 6.66 (d, 1H), 4.51(d, 1H), 4.08 (q, 2H), 3.86 (s, 3H), 3.73 (m broad, 2H), 3.54 (m broad,2H), 3.46 (s, 3H), 3.40 (m, overlapped with DMSO), 2.93 (m, 1H), 2.71(m, 4H), 2.14 (m, 3H), 1.67 (m, 6H), 1.33 (m, 4H), 0.95 (t, 3H).

Example 45(S)—N-(5-Cyano-3-(2,5-dimethoxyphenyl)-1-((2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.16, wherein R¹ is methoxy, R² is methoxy, R³ isH, R⁶ is CN, R⁷ is H, and R⁸ and R⁹, together with the nitrogen atomthey are bound to, form morpholin-4-yl)

ESI-MS [M+H+]=761.2

¹H NMR (600 MHz, DMSO) δ 7.90 (d, 1H), 7.84 (d, 1H), 7.77 (dd, 1H), 7.69(d, 1H), 7.48 (s, 1H), 7.07 (d, 1H), 6.95-6.86 (m, 2H), 6.70 (dd, 1H),6.66 (d, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.70-3.55 (m, 11H), 3.50 (s,3H), 2.90 (m, 1H), 2.70 (m, 2H), 2.40 (m, 4H), 2.07 (m, 1H), 1.70 (m,4H), 1.35 (m, 2H).

Example 46(S)—N-(5-Cyano-3-(2,5-dimethoxyphenyl)-1-((2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide

(compound of formula I.16, wherein R¹ is methoxy, R² is methoxy, R³ isH, R⁶ is CN, R⁷ is H, R⁸ is methyl, and R⁹ is oxetan-3-yl)

ESI-MS [M+H+]=761.3

¹H NMR (600 MHz, DMSO) δ 7.90 (d, 1H), 7.84 (d, 1H), 7.77 (dd, 1H), 7.68(d, 1H), 7.48 (s, 1H), 7.07 (d, 1H), 6.96-6.87 (m, 2H), 6.69 (m, 1H),6.66 (d, 1H), 4.53-4.41 (m, 4H), 3.90-3.81 (m, 5H), 3.74 (s, 3H),3.64-3.56 (m, 3H), 3.53 (s, 3H), 3.49 (s, 3H), 2.91 (m, 1H), 2.70 (m,2H), 2.19 (m, 1H), 2.08 (s, 3H), 1.66 (m, 2H), 1.50 (m, 2H), 1.35 (m,2H).

III. Determination of the Biological Activity

1. Vasopressin V1b Receptor Binding Assay:

Substances:

The test substances were dissolved in a concentration of 5 mM in 100%DMSO and further diluted to 5×10⁻⁴M to 5×10⁻⁹ M. These serial DMSOpredilutions were diluted 1:10 with assay buffer. The substanceconcentration was further diluted 1:5 in the assay mixture resulting in2% DMSO in the mixture. All dilutions were performed in a Biomek NXautomation workstation (Beckman)

Membrane Preparation:

CHO-K1 cells with stably expressed human vasopressin V1b receptor (clone3H2) were harvested and homogenized in 50 mM Tris-HCl and in thepresence of protease inhibitors (Roche complete Mini #1836170) using aPolytron homogenizer at intermediate setting for 2×10 seconds, andsubsequently centrifuged at 40 000×g for 1 h. The membrane pellet wasagain homogenized and centrifuged as described and subsequently taken upin 50 mM Tris-HCl, pH 7.4, homogenized and stored in aliquots frozen inliquid nitrogen at −190° C.

Binding Assay:

The binding assay was carried out by the method based on that of Taharaet al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).

The incubation buffer was: 50 mM Tris, 10 mM MgCl₂, 0.1% BSA, pH 7.4.

In the assay mixture (2000), membranes (26 μg protein in incubationbuffer) from CHO-K1 cells with stably expressed human V1b receptors(cell line hV1b_3H2_CHO) were incubated with 1.5 nM ³H-AVP(8-Arg-vasopressin, PerkinElmer, NET 800) in incubation buffer (50 mMTris, 10 mM MgCl₂, 0.1% BSA, pH 7.4) (total binding) or additionallywith increasing concentrations of test substance (displacementexperiment). The nonspecific binding was determined with 1 μM AVP (Fluka94836). All determinations were carried out as duplicate determinations.After incubation (60 minutes at room temperature), the free radioligandwas filtered off by vacuum filtration (Tomtec Mach III) through WathmanGF/B glass fiber filter plates (UniFilter, PerkinElmer 6005177). Theliquid scintillation measurement took place in a Microbeta TriLux 12(Wallac).

Analysis:

The binding parameters were calculated by nonlinear regression in SAS.The algorithms of the program operate in analogy to the LIGAND analysisprogram (Munson P T and Rodbard D, Analytical Biochem. 107, 220-239(1980)). The Kd of ³H-AVP for the recombinant human V1b receptors is 0.4nM and was used to determine the Ki.

2. Vasopressin V1a Receptor Binding Assay:

Substances:

The test substances were dissolved in a concentration of 5 mM M in DMSO.Further dilution of these DMSO solutions took place as described forV1b.

Membrane Preparation:

CHO-K1 cells with stably expressed human vasopressin V1a receptor (clone5) were harvested and homogenized in 50 mM Tris-HCl and in the presenceof protease inhibitors (Roche complete Mini #1836170) using a Polytronhomogenizer at intermediate setting for 2×10 seconds, and subsequentlycentrifuged at 40 000×g for 1 h. The membrane pellet was againhomogenized in a High-Pressure-Homogenizer, Polytec 50K at 1500 PSI(Heinemann, Germany) and subsequently taken up in 50 mM Tris-HCl, pH7.4, homogenized and stored in aliquots frozen in liquid nitrogen at−190° C.

Binding Assay:

The binding assay was carried out by the method based on that of Taharaet al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).

The incubation buffer was: 50 mM Tris, 10 mM MgCl₂, 0.1% BSA, pH 7.4.

In the assay mixture (200 μl), membranes (40 μg protein in incubationbuffer) from CHO-K1 cells with stably expressed human V1a receptors(cell line hV1a_5_CHO) were incubated with 0.04 nM ¹²⁵I-AVP(8-Arg-vasopressin, PerkinElmer NEX 128) in incubation buffer (50 mMTris, 10 mM MgCl₂, 0.1% BSA, pH 7.4) (total binding) or additionallywith increasing concentrations of test substance (displacementexperiment). The nonspecific binding was determined with 1 μM AVP (Fluka94836). Duplicate determinations were carried out.

After incubation (60 minutes at room temperature), the samples wereprocessed as described for V1b.

Analysis:

The binding parameters were calculated by nonlinear regression in SAS.The algorithms of the program operate in analogy to the LIGAND analysisprogram (Munson P J and Rodbard D, Analytical Biochem. 107, 220-239(1980)). The Kd of ¹²⁵I-AVP for the recombinant hV1a receptors wasdetermined in saturation experiments. A Kd of 1.33 nM was used todetermine the Ki.

3. Oxytocin Receptor Binding Assay

Substances:

The substances were dissolved in a concentration of 5 mM in DMSO anddiluted further as described for V1b.

Membrane Preparation:

Confluent HEK-293 cells with transiently expressing recombinant humanoxytocin receptors were harvested and centrifuged at 750×g at roomtemperature for 5 minutes. The pellet was taken up in ice-cold lysisbuffer (50 mM Tris-HCl, 10% glycerol, pH 7.4 and Roche complete proteaseinhibitor) and thereby subjected to an osmotic shock at 4° C. for 20minutes. Lysed cells were then centrifuged at 750×g at 4° C. for 20minutes, the pellet was taken up in incubation buffer (50 mM Tris, 10 mMMgCl₂, 0.1% BSA, pH 7.4), and aliquots corresponding to 10⁷ cells/mlwere prepared. The aliquots were frozen at −80° C. until use.

Binding Assay:

On the day of the experiment, the cell lysate was thawed, homogenized,and diluted with incubation buffer (50 mM Tris, 10 mM MgCl₂, 0.1% BSA,pH 7.4) to the desired concentration. The reaction mixture of 0.200 mlwas composed of cell lysate corresponding to 5×10⁴ cells (HEK-293 cellsexpressing transiently human OT receptors) and 1 nM 3H-oxytocin(PerkinElmer NET858) in the presence of test substance (displacementexperiment) or incubation buffer only (total binding). The nonspecificbinding was determined in the presence of 1 μM oxytocin (Bachem AG,H2510). Determinations were carried out in duplicates. After 60 minutesincubation at room temperature, bound and free radioligand wereseparated by filtration under vacuum on GF/B UniFilter plates (PerkinElmer #6005177) pre-incubated with 0.3% PEI. The bound radioactivity wasdetermined by liquid scintillation measurement in a Microbeta (PerkinElmer) plate counter.

Analysis:

The binding parameters were calculated by nonlinear regression analysis(SAS) in analogy to the LIGAND program of Munson and Rodbard (AnalyticalBiochem 1980; 107: 220-239). The Kd of ³H-oxytocin for the recombinanthOT receptors was 7.6 nM and was used to calculate the Ki fromcompetition binding experiments.

4. Determination of the Microsomal Half-Life:

The metabolic stability of the compounds of the invention was determinedin the following assay.

The test substances were incubated in a concentration of 0.5 μM asfollows: 0.5 μM test substance are preincubated together with livermicrosomes from different species (from rat, human or other species)(0.25 mg of microsomal protein/ml) in 0.05 M potassium phosphate bufferof pH 7.4 in microtiter plates at 37° C. for 5 min. The reaction isstarted by adding NADPH (1 mg/mL). After 0, 5, 10, 15, 20 and 30 min, 50μl aliquots are removed, and the reaction is immediately stopped andcooled with the same volume of acetonitrile. The samples are frozenuntil analyzed. The remaining concentration of undegraded test substanceis determined by MSMS. The half-life (T½) is determined from thegradient of the signal of test substance/unit time plot, it beingpossible to calculate the half-life of the test substance, assumingfirst order kinetics, from the decrease in the concentration of thecompound with time. The microsomal clearance (mCl) is calculated frommCl=ln 2/T½/(content of microsomal protein in mg/ml)×1000 [ml/min/mg](modified from references: Di, The Society for Biomoleculur Screening,2003, 453-462; Obach, D M D, 1999 vol 27. N 11, 1350-1359).

5. Methods for In Vitro Determination of the Cytochrome P450 (CYP)Inhibition

Luminescent Substrates for 2C9 and 3A4:

0.4 mg/ml human liver microsomes are preincubated with the testsubstances to be investigated (0-20 μM), the CYP-specific substrates, in0.05 M potassium phosphate buffer of pH 7.4 at 37° C. for 10 min. TheCyp-specific substrate for CYP 2C9 is lucifer-luciferin H, and for CYP3A4 is luciferin BE. The reaction is started by adding NADPH. Afterincubation at RT for 30 min, the luciferin detection reagent is added,and the resulting luminescence signal is measured (modified fromreference: Promega, Technical Bulletin P450-GLO™ Assays).

Midazolam CYP 3A4 Time-Dependent Inhibition

The assay consists of 2 parts. Firstly, the test substance ispreincubated with the liver microsomes (with NADPH=preincubation, thenaddition of the substrate; in the second part the substrate and the testsubstance are added simultaneously=coincubation.

Preincubation:

0.05 mg/ml microsomal protein (human liver microsomes) are preincubatedwith 0-10 μM (or 50 μM) test substance in 50 mM potassium phosphatebuffer for 5 min. The reaction is started with NADPH. After 30 min 4 μMmidazolam (final concentration) are added, and incubation is continuedfor 10 min. 75 μl of the reaction solution are removed after 10 min, andstopped with 150 μl of acetonitrile solution.

Coincubation:

0.05 mg/ml microsomal protein (human liver microsomes) are preincubatedwith 4 μm midazolam (final concentration) and 0-10 μM (or 50 0\4) testsubstance in 50 mM potassium phosphate buffer for 5 min. The reaction isstarted with NADPH. 75 μl of the reaction solution are removed after 10min and stopped with 150 μl of acetonitrile solution. The samples arefrozen until the MSMS analysis (modified from references: Obdach,Journal of Pharmacology & Experimental Therapeutics, Vol 316, 1,336-348, 2006; Walsky, Drug Metabolism and Disposition Vol 32, 6,647-660, 2004).

6. Method for Determining the Solubility in Water (in Mg/Ml)

The solubility in water of the compounds of the invention can bedetermined for example by the so-called shake flask method (as specifiedin ASTM International: E 1148-02, Standard test methods for measurementof aqueous solubility, Book of Standards Volume 11.05.). This entails anexcess of the solid compound being put into a buffer solution with aparticular pH (for example phosphate buffer of pH 7.4), and theresulting mixture being shaken or stirred until equilibrium has been setup (typically 24 or 48 hours, sometimes even up to 7 days). Theundissolved solid is then removed by filtration or centrifugation, andthe concentration of the dissolved compound is determined by UVspectroscopy or high pressure liquid chromatography (HPLC) by means ofan appropriate calibration plot.

7. Results

The results of the receptor binding investigations are expressed asreceptor binding constants [K_(i)(V1b)] or selectivities[K_(i)(V1a)/K_(i)(V1b)]. The results of the investigation of themetabolic stability are indicated as microsomal clearance (mCl).

The compounds of the invention show very high affinities for the V1breceptor in these assays (maximally 100 nM, or maximally 10 nM,frequently <1 nM). The compounds also show high selectivities vis-à-visthe V1a receptor and a good metabolic stability, measured as microsomalclearance.

The results are listed in table C. The numbers of the compounds refer tothe synthesis examples.

TABLE C Example K_(i)(h-V1b)* [nM] K_(i)(h-V1a)/Ki(h-V1b) 1 +++ +++ 2+++ +++ 3 +++ +++ 4 ++ +++ 5 ++ +++ 6 ++ +++ 8 +++ ++ 9 +++ ++ 10 ++++++ 11 ++ ++ 13 +++ +++ 14 +++ ++ 15 ++ +++ 17 + +++ 18 +++ +++ 19 ++++++ 20 ++ + 21 +++ + 23 ++ ++ 24 ++ +++ 25 +++ ++ 26 ++ +++ 27 +++ +++28 ++ +++ 29 ++ + 30 ++ + 31 ++ + 32 ++ + 33 + + 35 ++ ++ 36 ++ + 37 +++++ 38 + + 39 + +++ 40 +++ +++ 41 ++ +++ 42 ++ +++ 43 ++ +++ 44 +++ +++45 +++ + 46 +++ ++ * h = human Key: K_(i)(h-V1b)K_(i)(h-V1a)/K_(i)(h-V1b) + >10-100 nM 10-<25 ++ 1-10 nM 25-75 +++ <1 nM>75

The invention claimed is:
 1. A compound of formula (I)

wherein X¹ is N or CH; X² is C—R¹ or N; R¹ and R², independently of each other, are selected from the group consisting of hydrogen, halogen, cyano, C₁-C₃-alkyl, fluorinated C₁-C₃-alkyl, C₁-C₃-hydroxyalkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy; R³ is selected from the group consisting of hydrogen, halogen, cyano, hydroxyl, C₁-C₃-alkyl, fluorinated C₁-C₃-alkyl, C₁-C₃-hydroxyalkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy; R⁴ is C₁-C₃-alkoxy; R⁵ is selected from the group consisting of hydrogen and C₁-C₃-alkoxy; R⁶ is selected from the group consisting of cyano and halogen; R⁷ is selected from the group consisting of hydrogen, halogen and cyano; R⁸ is selected from the group consisting of hydrogen, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₃-C₇-cycloalkyl, C₃-C₇-halocycloalkyl and phenyl which may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; R⁹ is selected from the group consisting of C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₇-cycloalkoxy, C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkylthio, C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl, C₁-C₄-alkylsulfonyl, C₁-C₄-haloalkylsulfonyl, phenoxy, wherein the phenyl moiety may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; and a 3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; or R⁸ and R⁹, together with the nitrogen atom they are bound to, form a 3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring, wherein the heterocyclic ring may contain 1 or 2 further heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, and wherein the heterocyclic ring may carry 1 or 2 substituents R¹² and/or 1 or 2 substituents R¹³; wherein in case that the heterocyclic ring does not contain 1 or 2 further heteroatoms or heteroatom groups as ring members, the heterocyclic ring carries 1 or 2 substituents R¹² and optionally 1 or 2 substituents R¹³; R¹⁰ and R¹¹, independently of each other and independently of each occurrence, are selected from the group consisting of halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy, with the proviso that R¹⁰ and R¹¹ are not halogen, C₁-C₄-alkoxy or C₁-C₄-haloalkoxy if they are bound to a carbon atom in α-position to a nitrogen ring atom; or two non-geminal radicals R¹⁰ form together a group —(CH₂)_(n)—, wherein n is 1, 2, 3 or 4, wherein 1 or 2 hydrogen atoms in this group may be replaced a methyl group; or two non-geminal radicals R¹¹ form together a group —(CH₂)_(n)—, wherein n is 1, 2, 3 or 4, wherein 1 or 2 hydrogen atoms in this group may be replaced a methyl group; each R¹² is independently selected from the group consisting of halogen, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₇-cycloalkoxy, C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkylthio, C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl, C₁-C₄-alkylsulfonyl, C₁-C₄-haloalkylsulfonyl, phenoxy, benzyloxy, wherein the phenyl moiety in the two last-mentioned radicals may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; and a 3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; or two radicals R¹², together with the atom(s) they are bound to, form a 3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; each R¹³ is independently selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₃-C₇-cycloalkyl, C₃-C₇-halocycloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₇-cycloalkoxy, C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkylthio, C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl, C₁-C₄-alkylsulfonyl, C₁-C₄-haloalkylsulfonyl, C₁-C₄-alkylcarbonyl, C₁-C₄-haloalkylcarbonyl, phenyl, phenoxy and a 3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, wherein the phenyl moieties or the heterocyclic ring may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; a is 0, 1 or 2; and b is 0, 1, 2, 3 or 4; or a N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof; or the above compound, wherein at least one of the atoms has been replaced by its stable, non-radioactive isotope.
 2. The compound of claim 1, wherein at least one hydrogen atom has been replaced by a deuterium atom.
 3. The compound of claim 1, wherein X² is C—R¹ and R¹, R² and R³, independently of each other, are selected from the group consisting of hydrogen, halogen, C₁-C₃-alkyl, fluorinated C₁-C₃-alkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy.
 4. The compound of claim 3, wherein R¹, R² and R³, independently of each other, are selected from the group consisting of hydrogen, fluorine and methoxy.
 5. The compound of claim 4, wherein R¹ is selected from the group consisting of hydrogen, fluorine and methoxy.
 6. The compound of claim 4, wherein R² is selected from the group consisting of hydrogen, fluorine and methoxy.
 7. The compound of claim 4, wherein R³ is hydrogen or fluorine.
 8. The compound of claim 1, wherein X² is N and R² and R³, independently of each other, are selected from the group consisting of hydrogen, halogen, C₁-C₃-alkyl, fluorinated C₁-C₃-alkyl, C₁-C₃-alkoxy and fluorinated C₁-C₃-alkoxy.
 9. The compound of claim 8, wherein R² is selected from the group consisting of hydrogen, fluorine and methoxy.
 10. The compound of claim 8, wherein R³ is selected from the group consisting of hydrogen, fluorine and methoxy.
 11. The compound of claim 1, wherein R⁴ is selected from the group consisting of methoxy and ethoxy.
 12. The compound of claim 1, wherein R⁵ is hydrogen or methoxy.
 13. The compound of claim 1, wherein R⁶ is selected from the group consisting of cyano, fluorine and chlorine.
 14. The compound of claim 1, wherein R⁷ is hydrogen or fluorine.
 15. The compound of claim 1, wherein R⁸ is selected from the group consisting of hydrogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₃-C₆-cycloalkyl and C₃-C₆-halocycloalkyl; R⁹ is selected from the group consisting of C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₆-cycloalkoxy, C₃-C₆-halocycloalkoxy, and a 3-, 4-, 5- or 6-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; or R⁸ and R⁹, together with the nitrogen atom they are bound to, form a 3-, 4-, 5- or 6-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring, wherein the heterocyclic ring may contain 1 or 2 further heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, and wherein the heterocyclic ring may carry 1 or 2 substituents R¹² and/or 1 substituent R¹³; wherein in case that the heterocyclic ring does not contain 1 or 2 further heteroatoms or heteroatom groups as ring members, the heterocyclic ring carries 1 or 2 substituents R¹² and optionally 1 substituent R¹³; each R¹² is independently selected from the group consisting of halogen, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₆-cycloalkoxy, C₃-C₆-halocycloalkoxy, and a 3-, 4-, 5- or 6-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; or two radicals R¹², together with the atom(s) they are bound to, form a 3-, 4-, 5- or 6-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; and R¹³ is selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₃-C₆-cycloalkyl, C₃-C₆-halocycloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₇-cycloalkoxy, C₃-C₇-halocycloalkoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkylthio, C₁-C₄-alkylsulfinyl, C₁-C₄-haloalkylsulfinyl, C₁-C₄-alkylsulfonyl, C₁-C₄-haloalkylsulfonyl, C₁-C₄-alkylcarbonyl, C₁-C₄-haloalkylcarbonyl, phenyl, phenoxy and a 3-, 4-, 5- or 6-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1, 2 or 3 heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, wherein the phenyl moieties or the heterocyclic ring may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy.
 16. The compound of claim 15, wherein R⁸ is selected from the group consisting of hydrogen, C₁-C₄-alkyl, fluorinated C₁-C₄-alkyl, C₃-C₆-cycloalkyl and fluorinated C₃-C₆-cycloalkyl; R⁹ is selected from the group consisting of C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; or R⁸ and R⁹, together with the nitrogen atom they are bound to, form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring, wherein the heterocyclic ring may contain 1 or 2 further heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, and wherein the heterocyclic ring may carry 1 or 2 substituents and/or 1 substituent R¹³; wherein in case that the heterocyclic ring does not contain 1 or 2 further heteroatoms or heteroatom groups as ring members, the heterocyclic ring carries 1 or 2 substituents R¹² and optionally 1 substituent R¹³; each R¹² is independently selected from the group consisting of halogen, hydroxyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; or two radicals R¹², together with the atom(s) they are bound to, form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; and R¹³ is selected from the group consisting of halogen, hydroxyl, cyano, fluorinated C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated C₁-C₄-alkoxy-C₁-C₄-alkyl, C₃-C₆-cycloalkyl, fluorinated C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring containing 1 or 2 heteroatoms or heteroatom groups selected from the group consisting of O, N, S, NO, SO and SO₂ as ring members, wherein the heterocyclic ring may carry 1, 2 or 3 substituents selected from the group consisting of halogen, hydroxyl, cyano, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy.
 17. The compound of claim 16, wherein R⁸ is selected from the group consisting of hydrogen, C₁-C₄-alkyl and C₃-C₆-cycloalkyl; R⁹ is selected from the group consisting of C₁-C₄-alkoxy-C₁-C₄-alkyl, fluorinated C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, fluorinated C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring containing 1 oxygen atom as ring member; or R⁸ and R⁹, together with the nitrogen atom they are bound to form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring, wherein the heterocyclic ring contains 1 further oxygen atom as ring member, and wherein the heterocyclic ring may carry 1 or 2 substituents R¹²; or form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring which carries 1 or 2 substituents R¹²; and each R¹² is independently selected from the group consisting of halogen, hydroxyl, C₁-C₄-alkoxy, and a 3-, 4-, 5- or 6-membered saturated heterocyclic ring containing 1 oxygen atom as ring member; or two radicals R¹² bound to the same carbon ring atom, together with this carbon atom they are bound to, form a 3-, 4-, 5- or 6-membered saturated heterocyclic ring containing 1 oxygen atom as ring member.
 18. The compound of claim 17, wherein the saturated heterocyclic ring formed by R⁸ and R⁹ together with the nitrogen atom they are bound to is selected from the group consisting of azetidin-1-yl carrying in the 3-position (relative to the 1-position of the nitrogen ring atom) 1 or 2 substituents isoxazolidin-2-yl, piperidin-1-yl carrying in the 4-position (relative to the 1-position of the nitrogen ring atom) 1 or 2 substituents R¹²; and morpholin-1-yl.
 19. The compound of claim 17, wherein two radicals R¹² bound to the same carbon ring atom together form a group —CH₂—O—CH₂— (i.e. together with the carbon atom they are bound to form a spiro-bound oxetan-3-yl ring).
 20. The compound of claim 1, wherein each R¹⁰ is independently selected from the group consisting of halogen and C₁-C₄-alkyl with the proviso that R¹⁰ is not halogen if it is bound to a carbon atom in α-position to a nitrogen ring atom.
 21. The compound of claim 1, wherein each R¹¹ is independently selected from the group consisting of halogen and C₁-C₄-alkyl with the proviso that R¹¹ is not halogen if it is bound to a carbon atom in α-position to a nitrogen ring atom; or two non-geminal radicals R¹¹ form together a group —CH₂—.
 22. The compound of claim 1, wherein X¹ is N.
 23. The compound of claim 1, wherein X¹ is CH.
 24. The compound of claim 1, wherein X² is C—R¹.
 25. The compound of claim 1, wherein X² is N.
 26. The compound of claim 1, wherein a is 0 or
 1. 27. The compound of claim 1, wherein b is 0, 1 or
 2. 28. A compound selected from the group consisting of (S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(ethyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)-3-(4-(2-Oxa-7-Azaspiro[3.5]nonan-7-yl)piperidin-1-yl)-N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)azetidine-1-carboxamide; N-[(3S)-5-Cyano-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-ethoxy-3-pyridyl)-2-oxo-indolin-3-yl]-3-[4-[cyclopropyl(oxetan-3-yl)amino]-1-piperidyl]azetidine-1-carboxamide; (S)—N-(1-((2,4-Dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-5,6-difluoro-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-6-fluoro-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-6-fluoro-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; N-[(3S)-1-[(2,4-Dimethoxyphenyl)sulfonyl]-3-(2-ethoxypyridin-3-yl)-5,6-difluoro-2-oxo-2,3-dihydro-1H-indol-3-yl]-3-{4-[methyl(oxetan-3-yl)amino]piperidin-1-yl}azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(cyclopropyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-((2-methoxyethyl)(methyl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methoxy(methyl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(isoxazolidin-2-yl)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(3-(oxetan-3-yl)azetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide; (S)-3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-yl)piperidin-1-yl)-N-(5-cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(oxetan-3-ylamino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(tetrahydro-2H-pyran-4-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(oxetan-3-yl(propyl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(ethyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-((4-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-difluorophenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-cyano-3-(2-ethoxypyridin-3-yl)-1-((2-fluoro-4-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-cyano-3-(2-ethoxypyridin-3-yl)-1-((4-fluoro-2-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((4-fluoro-2-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((4-fluorophenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2-fluoro-4-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-difluorophenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((5-fluoro-2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-cyano-1-((4-methoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-((5-methoxypyridin-2-yl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-3-(2-ethoxypyridin-3-yl)-1-((2-methoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(isopropyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(3,3-difluoroazetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4,4-difluoro-[1,4′-bipiperidin]-1′-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-((3-methoxyazetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-methoxy-[1,4′-bipiperidin]-1′-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-(3-hydroxyazetidin-1-yl)piperidin-1-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-3-(4-hydroxy-[1,4′-bipiperidin]-1′-yl)azetidine-1-carboxamide; (S)—N-(5-Cyano-3-(2, 5-dimethoxyphenyl)-1-((2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-morpholinopiperidin-1-yl)azetidine-1-carboxamide; and (S)—N-(5-Cyano-3-(2, 5-dimethoxyphenyl)-1-((2,4-dimethoxyphenyl)sulfonyl)-2-oxoindolin-3-yl)-3-(4-(methyl(oxetan-3-yl)amino)piperidin-1-yl)azetidine-1-carboxamide; or a N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof; or the above compound, wherein at least one of the atoms has been replaced by its stable, non-radioactive isotope.
 29. A pharmaceutical composition comprising a compound of claim 1 or an N-oxide, a stereoisomer, or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier. 